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Platform chemicals are essential to industrial processes. Used as starting materials for the manufacture 
of diverse products, their cheap availability and efficient sourcing are an industrial requirement. 
Increasing concerns about the depletion of natural resources and growing environmental 
consciousness have led to a focus on the economics and ecological viability of biobased platform 
chemical production. Biobased strategies such as fermentation still have limitations that restrict their 
large scale industrial application. Current microbial biomanufacturing is hindered by the limitations 
caused by cells, as synthetic pathways and their optimizations are restricted by the physiological limits 
of the cellular production system. Cell-free metabolic engineering is pushing the boundaries of 
traditional bioengineering models by focusing on the use of in vitro combinations of catalytic enzymes 
prepared from purified proteins or crude lysates from cells, assembled in artificial cascades, for 
production of target commodities. 
This thesis describes a cofactor balanced, cell-free, 5 enzyme biosystem for the sustainable production 
of malic acid from glucose, whereby 5 thermophilic proteins (glucose dehydrogenase, dihydroxy-acid 
dehydratase, 2-keto-3-deoxygluconate aldolase, glyceraldehyde dehydrogenase and malate 
dehydrogenase) were successfully expressed, purified and demonstrated to display enzyme activity. 
Enzyme immobilization has been used by many researchers to overcome instability problems and 
facilitate the repetitive use of enzymes. Recombinant glucose dehydrogenase from S. solfataricus was 
successfully purified and immobilized onto novel supports and demonstrated great potential for 
gluconic acid production from glucose, as well as bread waste hydrolysate in a sustainable production 
approach. Coupling of cofactor recycling enzymes (glucose dehydrogenase and malate 
dehydrogenase) was also explored and successfully demonstrated the simultaneous production of 
chemicals and cofactor recycling capabilities. The experimental work also identified potential 
bottlenecks affecting the feasibility of the cell-free biosystem and paves the way for optimized 
characterization of enzymes in the cascade, in the free-state, individually immobilized and co-
immobilized.  
Key words: Cell-free metabolic engineering, multienzyme cascades, sustainable chemical 






To my parents, for always telling me anything was possible 
To my husband, for making everything possible 






























An enormously special thank you to my supervisor, Professor Roslyn Bill for the constant guidance, 
support and encouragement (scientific and otherwise) throughout the length of my PhD. An equally 
special thank you to Dr Pinar Karagoz, for being one of the best scientists I know, and an even better 
friend. A big thanks to all current and past group members for all their help, especially Dr Michelle 
Clare and Dr John Simms for their valuable troubleshooting expertise. Thank you to my industrial 
supervisor, Gavin Stephenson for his outstanding teaching, support and guidance throughout the 






























Abbreviations ................................................................................................................................... 11 
List of figures .................................................................................................................................... 12 
List of tables ..................................................................................................................................... 17 
1. Introduction ................................................................................................................................. 20 
1.1 Biobased production of platform chemicals ............................................................................. 20 
1.2 Industrial production of malic acid........................................................................................... 22 
1.3 Biobased/biochemical production of malic acid ....................................................................... 22 
1.3.1 Using yeast for production of malic acid ........................................................................... 24 
1.3.2 Using bacteria for production of malic acid ....................................................................... 26 
1.3.3 Other methods of malic acid production ........................................................................... 27 
1.4 Improving biobased strategies of malic acid production .......................................................... 28 
1.5 Cell-free metabolic engineering ............................................................................................... 30 
1.5.1 Purified enzymes cell-free cascade systems ...................................................................... 30 
1.6 Applications of thermophiles in CFME ..................................................................................... 33 
1.6.1 Exploiting unique metabolic enzymes found in thermophiles ............................................ 34 
1.7 Cofactor balance ..................................................................................................................... 36 
1.8 Spatial organization ................................................................................................................. 37 
1.9 Spatial organization - a focus on immobilization strategies   .................................................... 38 
1.9.1 Immobilization support materials ..................................................................................... 39 
1.9.2 Types of immobilization techniques .................................................................................. 40 
1.9.3 Support properties for immobilization .............................................................................. 41 
1.10 Challenges and opportunities associated with immobilization ............................................... 41 
1.11 Project aim and objectives ..................................................................................................... 42 
2. Materials and methods ................................................................................................................ 43 
2.1 Reagents ................................................................................................................................. 43 
2.2 Vector generation ................................................................................................................... 43 
2.2.1 E.coli competent cells ....................................................................................................... 43 
2.2.2 Bacterial media................................................................................................................. 44 
     2.2.2.1 Antibiotics ................................................................................................................. 44 
2.2.3 Transformation of E.coli for vector quantification ............................................................. 44 
     2.2.3.1 Restriction digest....................................................................................................... 44 
     2.2.3.2 Agarose gel electrophoresis....................................................................................... 45 
2.3 Protein expression ................................................................................................................... 45 
2.3.1 Bacterial media and stock solutions .................................................................................. 45 
6 
 
2.3.2 Transformation of E.coli for protein expression ................................................................ 45 
     2.3.2.1 Bacterial glycerol stocks ............................................................................................ 45 
2.3.3 Expression of recombinant proteins ................................................................................. 46 
2.4 Recombinant protein extraction .............................................................................................. 46 
2.4.1 Stock solutions ................................................................................................................. 46 
2.4.2 Soluble protein extraction ................................................................................................ 47 
     2.4.2.1 Resuspension buffer .................................................................................................. 47 
     2.4.2.2 Cell lysis and extraction of crude lysates .................................................................... 47 
2.5 Protein purification ................................................................................................................. 47 
2.5.1 Purification buffers ........................................................................................................... 47 
2.5.2 SDS-PAGE and Western blot ............................................................................................. 48 
     2.5.2.1 Buffers and reagents ................................................................................................. 48 
     2.5.2.2 SDS-PAGE preparation ............................................................................................... 48 
     2.5.2.3 Western blot preparation .......................................................................................... 49 
2.5.3 Bicinchoninic acid (BCA) protein assay .............................................................................. 50 
2.5.4 Protein purification- Ni-NTA affinity chromatography ....................................................... 50 
2.5.5 Protein purification- ÄKTA ................................................................................................ 50 
2.5.6 Protein purification- Anion exchange ................................................................................ 51 
2.5.7 Protein purification- Inclusion bodies extraction, resolubilisation and purification ............ 51 
     2.5.7.1 Buffers and reagents ................................................................................................. 51 
     2.5.7.2 Inclusion bodies extraction, resolubilisation and purification protocol ....................... 52 
2.6 Enzyme assays ......................................................................................................................... 53 
2.6.1 GDH experimental conditions ........................................................................................... 53 
     2.6.1.1 GDH activity assay ..................................................................................................... 53 
     2.6.1.2 Determination of kinetic constants ............................................................................ 53 
     2.6.1.3 Support materials ...................................................................................................... 54 
     2.6.1.4 Immobilization of GDH .............................................................................................. 54 
     2.6.1.5 Thermal stability of free-state and immobilized GDH ................................................. 55 
     2.6.1.6 Reusability of immobilized GDH................................................................................. 55 
     2.6.1.7 Effect of immobilization on storage stability .............................................................. 55 
     2.6.1.8 Determination of optimum temperature and pH ....................................................... 55 
     2.6.1.9 Preparation of Bread Waste Hydrolysate (BWH) ........................................................ 55 
     2.6.1.10 SEM analysis ............................................................................................................ 56 
    2.6.2 DHAD experimental conditions ......................................................................................... 56 
             2.6.2.1 DHAD activity assay .................................................................................................... 56 
     2.6.2.2 Activation of DHAD using β-mercaptoethanol ........................................................... 57 
7 
 
     2.6.2.3 Determination of kinetic constants ............................................................................ 57 
     2.6.2.4 Effect of storage on DHAD activity ............................................................................. 57 
2.6.3 KDGA experimental conditions ......................................................................................... 57 
     2.6.3.1 KDGA activity assay ................................................................................................... 57 
     2.6.3.2 Determination of kinetic constants ............................................................................ 57 
2.6.4 AIDH experimental conditions .......................................................................................... 57 
     2.6.4.1 AIDH activity assay .................................................................................................... 57 
2.6.5 MDH experimental conditions .......................................................................................... 58 
     2.6.5.1 MDH activity assay .................................................................................................... 58 
     2.6.5.2 Determination of kinetic conditions........................................................................... 58 
2.7 Standard curves ....................................................................................................................... 58 
2.7.1 NADH standard curve ....................................................................................................... 58 
2.7.2 IC standard curves ............................................................................................................ 59 
3. Cascade design to facilitate the conversion of glucose to malic acid  ........................................... 62 
4. Using glucose dehydrogenase from Sulfolobus solfataricus to catalyse the first reaction step and 
produce gluconate from glucose ...................................................................................................... 64 
4.1 Transformation of GDH vector DNA into BL21-DE3 competent cells......................................... 64 
4.2 Small scale GDH protein expression and purification in LB and AI media  ................................. 65 
4.3 Establishing enzymatic activity with crude GDH fraction  ......................................................... 65 
4.4 Ni-NTA affinity chromatography of crude GDH  ....................................................................... 66 
4.5 Size-exclusion chromatography and protein identification of GDH to determine presence of 
oligomers  ..................................................................................................................................... 67 
4.6 Testing enzymatic activity of purified GDH via NADH absorbance assay at 340nm  .................. 68 
4.7 Analysis of gluconate formation in GDH assays carried out in section 4.6 via IC ....................... 70 
4.8 GDH activity analysis via NADH absorbance assay at 340nm and IC to determine efficiency of 
methods of analysis  ...................................................................................................................... 71 
4.9 Immobilization of purified GDH  .............................................................................................. 73 
4.9.1 Support materials and immobilization of GDH  ................................................................. 73 
4.10 Exploring thermal stability of free-state and immobilized GDH  ............................................. 77 
4.11 Reusability of immobilized GDH  ............................................................................................ 78 
4.12 Storage stability of immobilized GDH  .................................................................................... 79 
4.13 Establishing kinetic parameters of free state and immobilized GDH  ...................................... 80 
4.14 Establishing optimum conditions for GDH immobilized on macro-meso structured SBA 
supports ........................................................................................................................................ 81 
4.15 Conversion of Bread waste hydrolysate (BWH) ...................................................................... 83 
5. Dihydroxy-acid dehydratase as a key enzyme in the conversion of multiple intermediates in 
artificial cascades ............................................................................................................................. 86 
8 
 
5.1 Transformation of DHAD vector DNA into BL21-DE3 competent cells ...................................... 86 
5.2 Small scale DHAD protein expression and purification in LB and AI media  ............................... 87 
5.3 Anion exchange of DHAD as a secondary purification step to improve purity  .......................... 89 
5.4 Size-exclusion chromatography and protein identification of DHAD to determine presence of 
oligomers  ..................................................................................................................................... 90 
5.5 DHAD initial activity analysis via IC (ion chromatography)  ....................................................... 92 
5.6 Large scale expression of DHAD in AI media followed by purification via Ni-NTA   .................... 93 
5.7 IC analysis of DHAD activity with a range of enzyme concentrations   ...................................... 95 
5.8 DHAD activity analysis using gluconate assay kit  ..................................................................... 96 
5.8.1 Optimizing assay and control dilution factors for compatibility with kit  ............................ 96 
5.8.2 Retesting DHAD 0.01mg/ml, all timed conditions with gluconate assay kit and optimized 
dilution factor  .......................................................................................................................... 98 
5.9 Exploiting substrate promiscuity of DHAD to confirm activity via pyruvic acid assay kit  ........... 99 
5.10 Increased DHAD concentration activity analysis using gluconate assay kit  ........................... 100 
5.11 Testing activation of DHAD using 2-Mercaptoethanol (2-ME) to improve activity  ................ 100 
5.12 Activating crude DHAD to establish improved enzyme activity instead of purified DHAD  .... 101 
5.12.1 Analysis of activated crude DHAD activity using gluconic acid assay kit  ........................ 102 
5.12.2 Analysis of activated crude DHAD activity using IC  ....................................................... 102 
5.13 Testing crude DHAD activity under different substrate and enzyme concentrations  ............ 103 
5.13.1 2mM gluconic acid assays with range of enzyme concentrations and time points analysed 
with gluconic acid assay kit  ..................................................................................................... 103 
5.13.2 20mM gluconic acid assays with range of enzyme concentrations and time points 
analysed with gluconic acid assay kit  ...................................................................................... 104 
5.13.3 2mM gluconic acid assays with range of enzyme concentrations and time points analysed 
via IC  ...................................................................................................................................... 105 
5.13.4 20mM gluconic acid assays with range of enzyme concentrations and time points 
analysed via IC  ........................................................................................................................ 106 
5.14 Establishing DHAD enzyme kinetics  ..................................................................................... 107 
5.15 Effect of storage on DHAD enzymatic activity  ..................................................................... 110 
6. 2-keto-3-deoxy-gluconate aldolase catalyses the aldol cleavage of 2-keto-3-deoxy-gluconate to 
form pyruvate and glyceraldehyde  ................................................................................................ 112 
6.1 Transformation of KDGA vector DNA into BL21-DE3 competent cells  .................................... 112 
6.2 Small scale KDGA protein expression and purification in AI media  ........................................ 113 
6.3 Ni-NTA affinity chromatography of crude KDGA   ................................................................... 113 
6.4 Size-exclusion chromatography and protein identification of KDGA to determine presence of 
oligomers  ................................................................................................................................... 115 
6.5 Producing 2-keto-3-deoxygluconate for use as substrate with KDGA  .................................... 117 
6.6 Testing KDGA activity using 2-keto-3-deoxygluconate present with gluconic acid in solution  118 
9 
 
6.7 Testing reverse catalysed reaction of KDHA to form 2-keto-3-deoxygluconate from pyruvate 
and glyceraldehyde  .................................................................................................................... 120 
6.8 Preliminary pilot studies to establish best assay conditions for KDGA kinetic studies  ............ 122 
6.8.1 1mM glyceraldehyde and 2mM pyruvate assay with 0.5, 1 and 2.5mg/ml KDGA at 3 time 
points  ..................................................................................................................................... 122 
6.8.2 10mM glyceraldehyde and 20mM pyruvate assay with 0.5, 1 and 2.5mg/ml KDGA at 3 time 
points  ..................................................................................................................................... 123 
6.9 Exploring the effect of glyceraldehyde and pyruvate concentration ratios on the production of 
2-keto-3-deoxygluconate  ........................................................................................................... 125 
6.10 Establishing KDGA enzyme kinetics  ..................................................................................... 126 
7. Using glyceraldehyde dehydrogenase to shift reaction equilibrium towards production of desired 
intermediate-pyruvate  .................................................................................................................. 129 
7.1 Transformation of AIDH vector DNA into BL21-DE3 competent cells  ..................................... 129 
7.2 AIDH protein expression in AI media  ..................................................................................... 130 
7.2.1 AIDH soluble fraction preparation and purification with Ni-NTA ..................................... 130 
7.2.2 AIDH insoluble fraction preparation and purification with Ni-NTA  .................................. 131 
     7.2.2.1 Refolding of denatured AIDH in GdnHCl with Ni-NTA  .............................................. 132 
     7.2.2.2 Refolding of denatured AIDH in GdnHCl via dialysis  ................................................ 133 
     7.2.2.3 Comparing methods of refolding denatured AIDH with Ni-NTA or via dialysis  ......... 135 
7.3 Testing enzymatic functionality of soluble AIDH obtained from refolding of denatured AIDH 
with Ni-NTA  ................................................................................................................................ 136 
7.4 Exploring AIDH assay components to explore the cause of increasing absorbance values in 
control conditions  ...................................................................................................................... 137 
7.5 Optimizing the extraction and purification protocol of soluble AIDH from inclusion bodies.... 139 
7.6 Attempt 1 of utilising modified protocol for extraction and purification protocol of soluble AIDH 
from AIDH inclusion bodies  ........................................................................................................ 141 
7.7 Attempt 2 at extraction and purification of soluble AIDH from inclusion bodies using Ni-NTA 143 
7.8 Attempt 3 at extraction and purification of soluble AIDH from AIDH inclusion bodies using Ni-
NTA via changes in buffer components   ...................................................................................... 150 
7.9 Attempt 4 at extraction and purification of soluble AIDH from AIDH inclusion bodies using Ni-
NTA via changes in buffer components   ...................................................................................... 153 
7.10 Change of denaturant from GdnHCl to urea  ........................................................................ 155 
7.11 Western blots to confirm functionality of His10 tag   ............................................................. 156 
7.12 Replicating original attempt of AIDH inclusion bodies extraction and purification  ............... 158 
7.13 Examining AIDH expression protocol to determine contribution to successful protein yield . 161 
8. Engineered malate dehydrogenase for improved malate production  ....................................... 163 
8.1 Transformation of MDH vector DNA into BL21-DE3 competent cells  ..................................... 163 
8.2 Small scale MDH protein expression and purification in AI media  ......................................... 164 
10 
 
8.3 Large scale expression of MDH in AI media and purification with the aid of EDTA to minimize 
aggregation  ................................................................................................................................ 164 
8.4 Size-exclusion chromatography and protein identification of MDH to determine presence of 
oligomers  ................................................................................................................................... 165 
8.5 Initial activity analysis of engineered MDH for malate production via IC  ............................... 167 
8.6 IC activity analysis of MDH assays at 2 different enzyme concentrations by equilibrating assay 
conditions in 5% CO2 incubator  ................................................................................................... 170 
8.7 IC activity analysis of MDH assays at 4 different enzyme concentrations and 2 NADH 
concentrations by bubbling CO2 through samples  ....................................................................... 171 
8.8 MDH 0.003mg/ml activity analysis with 0.5 and 1mM NADH at 340nm  ................................. 173 
8.9 Investigating MDH assay components ................................................................................... 174 
8.10 Sixteen hour MDH activity test  ........................................................................................... 176 
8.11 Utilization of atmospheric control unit to measure activity of MDH  .................................... 177 
8.12 Effect of atmospheric conditions on the activity of purified MDH enzyme ........................... 177 
8.13 Establishing enzyme kinetics of MDH  .................................................................................. 182 
8.14 Coupling MDH with GDH for cofactor recycling  ................................................................... 183 
8.14.1 Effect of buffer components of GDH on the activity of MDH  ........................................ 183 
8.14.2 Effect of atmospheric conditions required by MDH on the activity of GDH  ................... 184 
8.14.3  Effect of MDH assay buffer components on the activity of GDH  .................................. 185 
8.14.4 Exploring pyruvate inhibition  ....................................................................................... 186 
8.14.5 Coupling MDH and GDH for cofactor recycling enzyme system  .................................... 187 
9. Discussion ................................................................................................................................... 189 
9.1 Enzymatic cascade design for the conversion of glucose to malate  ....................................... 189 
9.2 Production, purification, characterization and immobilization of GDH  .................................. 190 
9.3 Production, purification and characterization of DHAD  ......................................................... 194 
9.4 Production, purification and characterization of KDGA  ......................................................... 201 
9.5 Improving yields of refolded AIDH from inclusion bodies  ...................................................... 203 
9.6 Production, purification and characterization of MDH, coupled with GDH  ............................ 208 
9.7 Overall conclusions  ............................................................................................................... 211 
10. References ................................................................................................................................ 213 









2-ME  β-mercaptoethanol 
AI  Auto-induction 
AIDH  Glyceraldehyde dehydrogenase 
BCA  Bicinchoninic acid 
BSA  Bovine serum albumin 
BWH  Bread waste hydrolysate 
dd  Double distilled   
DHAD  Dihydroxy-acid dehydratase 
DTT  Dithiothreitol 
E. coli  Escherichia coli 
EDTA  Ethylenediaminetetraacetic acid 
ES  Enzyme support solution 
GDH  Glucose dehydrogenase 
GdnHCl  Guanidine hydrochloride 
IC  Ion chromatography 
IPTG  Isopropyl β-D-1-thiogalactopyranoside 
KDGA  2-keto-3-deoxygluconate aldolase 
LB  Luria-Bertani 
MDH  Malate dehydrogenase 
Ni-NTA  Nickel nitrilotriacetic acid 
OD  Optical density 
PAGE  Polyacrylamide gel electrophoresis  
PBS  Phosphate buffered saline 
pH  Negative logarithm of the hydrogen ion concentration 
SDS  Sodium dodecyl sulfate 
TAE  Tris-acetate-EDTA 
TEMED  N,N,N',N'-tetramethylethane-1,2-diamine 
Tween 20 Polyoxyethylenesorbitan monolaurate  
 
Units   
°C  Celsius    
g  Gram 
g  Gravitational force 
kDa  Kilo Dalton 
L  Litre 
µg  Microgram 
mg  Milligram 
µl   Microlitre 
min  Minute 
ml  Millilitre 
mM  Millimole 
M  Mole 
nm  Nanometre 
Rpm  Revolutions per minute 
U  Units 
V  Volts 




List of Figures 
Chapter 1                      Page 
Figure 1.1. Figure based on the 2004 US Department of Energy report   22  
Figure 1.2.  Schematic representation of the tricarboxylic acid (TCA) cycle   23 
Figure 1.3.  Four possible pathways for production of malate in S. cerevisiae   25 
Figure 1.4.  Artificial synthetic pathway designed for the conversion of glucose to malate 27 
Figure 1.5.  Cell free systems developed for the production of isobutanol and ethanol 32 
Figure 1.6.  Overview of the non-phosphorylative Entner-Doudoroff pathway  35 
Chapter 2 
Figure 2.1.  NADH absorbance standard curve      58 
Figure 2.2.  Gluconic acid standards as analysed via IC     59 
Figure 2.3.  2-keto-3-deoxygluconate standards as analysed via IC    60 
Figure 2.4.  Pyruvic acid standards as analysed via IC     60 
Figure 2.5.  Malic acid standards as analysed via IC      61 
Figure 2.6.  Lactic acid standards as analysed via IC      61 
Chapter 3 
Figure 3.1.  Cell-free minimised enzymatic reaction cascade for the production of malate  
from glucose         62 
Chapter 4 
Figure 4.1  Transformation of GDH into competent BL21-DE3 cells on LB kanamycin plate 65 
Figure 4.2  SDS-PAGE analysis of Ni-NTA purification attempt of GDH   67 
Figure 4.3  Size exclusion chromatography of GDH      68 
Figure 4.4 GDH assay measured at 340nm       69 
Figure 4.5 Schematic representation of the synthesis of the SiO2 framework  75 
Figure 4.6 SEM of hierarchical structured MM-SBA-15-300 and MM-SBA-15-200  76 
13 
 
Figure 4.7  Thermal stability of free-state and immobilized GDH    78 
Figure 4.8  Re-usability of immobilized enzyme      79 
Figure 4.9  Effect of the immobilization and support material on the activity of GDH  80 
Figure 4.10 Effect of temperature and pH on the activity of GDH    82 
Figure 4.11 Re-usability of immobilized GDH      84 
Chapter 5 
Figure 5.1  Transformation of DHAD into competent BL21-DE3 cells on LB kanamycin plate 86 
Figure 5.2 SDS-PAGE analysis of DHAD (LB broth)      87 
Figure 5.3 SDS-PAGE analysis of DHAD (AI media)      88 
Figure 5.4  DHAD desalted fractions following purification and filtration   89 
Figure 5.5 Anion exchange of DHAD       90 
Figure 5.6  Size exclusion chromatography of DHAD     91 
Figure 5.7 SDS-PAGE analysis of DHAD following size exclusion chromatography  92 
Figure 5.8 SDS-PAGE analysis of DHAD following Ni-NTA purification    94 
Figure 5.9 Dialysis of imidazole elution from Ni-NTA purified fractions of DHAD  94 
Figure 5.10  D-gluconate standards        97 
Figure 5.11 Pyruvate standards        99 
Figure 5.12 IC activity analysis of 2mM gluconic acid assays      106 
Figure 5.13 IC activity analysis of 20mM gluconic acid assays    107 
Figure 5.14 2-keto-3-deoxygluconate production using DHAD with 1-20mM gluconic acid 109 
Figure 5.15 Initial activity of DHAD at various gluconic acid concentrations   110 
Figure 5.16 IC activity analysis of DHAD stored at 4°C over the course of 50 days  111 
Chapter 6 
Figure 6.1  Transformation of KDGA into competent BL21-DE3 cells on LB kanamycin plate 112 
Figure 6.2 SDS-PAGE analysis of Ni-NTA purification attempt of KDGA   114 
14 
 
Figure 6.3 Size exclusion chromatography of KDGA      116 
Figure 6.4 SDS-PAGE analysis of KDGA following size exclusion chromatography  117 
Figure 6.5 IC analysis of 0.01mg/ml KDGA 120min assay     119 
Figure 6.6 IC chromatogram peaks of reverse catalysed reaction of KDGA   121 
Figure 6.7 IC analysis of KDGA activity assay-1mM glyceraldehyde and 2mM pyruvate 122 
Figure 6.8 IC analysis of KDGA activity assay-10mM glyceraldehyde and 20mM pyruvate 123 
Figure 6.9 Time point IC analysis of KDGA assay with 10mM glyceraldehyde and 20mM  
pyruvate          124  
Figure 6.10 2-keto-3-doxygluconate production with glyceraldehyde (1-20mM) and  
pyruvate (2-40mM)        127 
Figure 6.11  Initial activity of KDGA at various gluconic acid concentrations   128 
Chapter 7 
Figure 7.1  Transformation of AIDH into competent BL21-DE3 cells on LB kanamycin plate 130 
Figure 7.2 SDS-PAGE analysis of soluble AIDH fraction     131 
Figure 7.3 SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies 132 
Figure 7.4 Dialysis of unfolded AIDH in denaturation buffer     134 
Figure 7.5 SDS-PAGE analysis of supernatant obtained from the centrifugation of  
AIDH aggregates        134 
Figure 7.6 AIDH enzymatic activity analysis via absorbance at 340nm   136 
Figure 7.7 Testing effect of AIDH assay components     138 
Figure 7.8 Samples from the homogenization and centrifugation of cell pellets   142 
Figure 7.9 Dialysis of AIDH inclusion bodies      143 
Figure 7.10 Samples from the homogenization and centrifugation of cell pellets  144 
Figure 7.11 SDS-PAGE analysis of supernatants removed following the homogenization  
and centrifugation        145 
15 
 
Figure 7.12 AIDH inclusion bodies pellet       146 
Figure 7.13 SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies 147 
Figure 7.14 SDS-PAGE analysis of supernatants and pellets from washes   148 
Figure 7.15 Dialysis of aggregated AIDH homogenized in extraction buffer   149 
Figure 7.16 SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies 152 
Figure 7.17 SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies 154 
Figure 7.18 SDS-PAGE analysis of AIDH samples obtained from 3 different conditions 157 
Figure 7.19 Western blot analysis of AIDH samples obtained from 3 different conditions 157 
Figure 7.20 SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies 159 
Figure 7.21 SDS-PAGE analysis of soluble fraction of AIDH     160 
Chapter 8 
Figure 8.1  Transformation of MDH into competent BL21-DE3 cells on LB kanamycin plate 163 
Figure 8.2 SDS-PAGE analysis of MDH expressed in AI media    164 
Figure 8.3 SDS-PAGE analysis of MDH expressed in AI media    165 
Figure 8.4 Size exclusion chromatography of MDH      166 
Figure 8.5 SDS-PAGE analysis of MDH following size exclusion chromatography  167 
Figure 8.6 IC chromatogram of the peaks obtained from MDH activity assays  169 
Figure 8.7 Reaction control with 30mM pyruvic acid and 5mM NADH   170 
Figure 8.8 Reaction control with 30mM pyruvic acid without any assay reagents  172 
Figure 8.9 Reaction control with 1mM malic acid without any assay reagents  172 
Figure 8.10 Reaction control with 1mM malic acid with assay reagents   173 
Figure 8.11 Testing 0.003mg/ml MDH activity with 0.5 and 1mM of NADH   174 
Figure 8.12 Analysis of assay components without bubbling through CO2   175 
Figure 8.13 Analysis of assay components with bubbling through CO2   175 
Figure 8.14 16 hour activity analysis of 0.003mg/ml MDH with 1mM NADH   176 
16 
 
Figure 8.15 Effect of atmospheric conditions and the reaction temperature on the  
initial rate of MDH        181 
Figure 8.16 Initial activity of MDH at different pyruvate concentrations   182 
Figure 8.17 Effect of GDH assay components on the activity of MDH    184 
Figure 8.18 Activity of GDH under aerobic and 15% CO2 and 5% O2 atmospheric condition 184 
Figure 8.19 Effect of MDH assay components on the activity of GDH    185 
Figure 8.20 Effect of pyruvate concentration on activity of GDH    186 
Figure 8.21 Effect of pyruvate concentration on the NADH production profile of GDH 186 



















List of Tables 
Chapter 1                      Page 
Table 1.1 Examples of platform chemicals, their formulas, structures and final uses 21 
Table 1.2 Comparisons of cell and cell-free systems     29 
Chapter 2 
Table 2.1 List of enzymes utilized in the cascade      43 
Chapter 4 
Table 4.1 IC analysis of gluconic acid production via crude GDH    66 
Table 4.2 End point NADH absorbance reading of GDH assays at 6 enzyme concentrations 70 
Table 4.3 IC analysis of samples from GDH assays at 6 enzyme concentrations  70 
Table 4.4 End point NADH absorbance reading of GDH assays at 2 enzyme concentrations 72 
Table 4.5  IC analysis of samples from GDH assays at 2 enzyme concentrations  72 
Table 4.6 Specification of support materials and their immobilization efficiencies  74 
Table 4.7 Effect of the storage period and the support material on GDH leakage  80 
Table 4.8 Kinetic parameters for free-state and immobilized GDH    81 
Table 4.9 Effect of enzyme/support ratio on enzyme immobilization efficiency and activity 83 
Table 4.10 Bio-catalytic productivity of immobilized and free-state GDH on bread  
waste hydrolysate        84 
Chapter 5 
Table 5.1 IC analysis of DHAD assays        93 
Table 5.2 Analysis of known gluconic acid concentrations via IC     95 
Table 5.3  DHAD 5mg/ml activity analysis via IC      96 
Table 5.4  Establishing dilution factors for use with gluconic acid assay kit   97 
Table 5.5 Testing DHAD 0.01mg/ml activity via gluconate detection kit at 15-120 min 98 
Table 5.6 Analysis of pyruvate production using pyruvic acid assay kit   99 
18 
 
Table 5.7 Testing activity of DHAD 0.05mg/ml and 0.1mg/ml via gluconate detection kit 100 
Table 5.8 Testing activity of 2-ME activated and non-activated DHAD   101 
Table 5.9  Testing activity of 2-ME activated and non-activated crude DHAD  102 
Table 5.10 IC activity analysis of 2-ME activated and non-activated crude DHAD  103 
Table 5.11 Testing activity of crude DHAD with 2mM gluconic acid    104 
Table 5.12  Testing activity of crude DHAD with 20mM gluconic acid    104 
Table 5.13 IC activity analysis of 2mM gluconic acid assays     105 
Table 5.14 IC activity analysis of 20mM gluconic acid assays    106 
Table 5.15  IC analysis of negative assay controls      108 
Table 5.16 IC activity analysis of production of 2-keto-3-doxygluconate with 1mg/ml DHAD 108 
Chapter 6 
Table 6.1 IC analysis of DHAD reaction mix to produce 2-keto-3-deoxygluconate  118 
Table 6.2  IC analysis of the assays and controls of reverse activity analysis of KDGA  120 
Table 6.3 IC analysis of KDGA activity assay (1mM glyceraldehyde and 2mM pyruvate) 122 
Table 6.4 IC analysis of KDGA activity assay (10mM glyceraldehyde and 20mM pyruvate) 123 
Table 6.5 IC KDGA activity analysis with 3 ratios of glyceraldehyde and pyruvate  125 
Table 6.6 IC analysis of negative assay controls      126 
Table 6.7 IC activity analysis of production of 2-keto-3-doxygluconate with 1mg/ml KDGA 127 
Chapter 7 
Table 7.1 Summary of inclusion bodies extraction and purification attempts with modified 
protocol         162 
Chapter 8 
Table 8.1 IC activity analysis of 2 different MDH concentrations    168 
Table 8.2 IC activity analysis of malic acid production from 4 enzyme concentrations 171 
Table 8.3 Atmospheric conditions independent variables and their values   177 
19 
 
Table 8.4 Box-Behnken design for 3 factors with 3 centre points    178 
Table 8.5 Experimental conditions and initial rates of MDH    179 
Table 8.6 Initial rate of MDH experimentally calculated under optimum conditions  180 
Table 8.7  Standard assay conditions for GDH and MDH     183 
Table 8.8 Change in kinetic parameters of MDH in the presence pyruvate   187 
Table 8.9 Coupling GDH and MDH for co-factor recycling     188 
Chapter 9 
























The objective for this research project was to design a cell-free biosystem consisting of purified 
enzymes to facilitate the conversion of glucose derived from waste products into malic acid. 
Immobilization of the purified enzymes was also explored to aid enzyme recycling. 
1.1 Biobased production of platform chemicals 
The term platform chemical is given to the chemical intermediates/building blocks/precursors derived 
from fossil resources, to make a variety of industrially-valuable chemicals and materials (Jang et al. 
2012). A high percentage of today’s platform chemicals and subsequent materials are derived from 
fossil fuels and their products, and historically the petrochemical industry has focused on 7 low cost, 
high volume commodity chemicals (methanol, ethylene, propene, butadiene, benzene, toluene and 
xylene), which are then used to manufacture nearly all other commodities (Dudley et al. 2015). Given 
that fossil fuels are a finite resource, their limited supply demands the development of renewable 
alternatives to petrochemically-derived products. There have been advances towards this, for 
example, the process of producing polylactide and polyethylene from lactic acid and ethylene has 
reached the stage of being industrially produced from biomass-derived lactic acid (Singhvi and Gokhale 
2013). However, other commercial platform chemicals are still mass produced via petrochemical 
processes which utilize fossil fuels as the starting raw materials (Erickson et al. 2012). In recent years, 
increasing attention has shifted towards the sustainable production of chemicals given global concerns 
on the environment, limited resources and high oil prices (Dudley et al. 2015, Guterl and Sieber 2013).  
One such platform chemical in high global demand is malic acid. Malic acid, along with other four 
carbon diacids such as succinic and fumaric acid, was reported as one of the top value-added chemicals 
from biomass in a 2004 US Department of Energy report (Bozell and Petersen 2010). The four carbon 
diacids can be converted into 1,4-butanediol (BDO) which can be further converted into high-value 
commodities (Figure 1.1). Oil prices, climate change concerns and advances in the field of metabolic 
engineering have renewed interest in bio-based production of chemicals including malic acid (Rollin et 
al. 2013). The petrochemical paradigm will not be replaced in a hurry, advances in engineering 
however, can develop access to novel chemicals and materials based on richer building blocks than 




Table 1.1. Examples of some platform chemicals, their formulas, structures and final products/uses in multiple 
industries such as, transportation, textiles, safe food supply, environmental, communication, housing, recreation 
and health and hygiene. All platform chemicals listed in the table have the potential to be produced from biomass 
feedstocks.  
 
Biomass can be defined broadly as all matter on the earth’s surface of biological origin and includes 
plant materials such as trees, grasses, agricultural crops, algal biomass and organic waste such as 
animal manure (Sengupta and Pike 2012). Biomass feedstocks replacing fossil feedstocks offer 
sustainable alternatives to the production of chemicals. Biomass degradation can be achieved in 
various ways such as enzymatic hydrolysis and chemical hydrolysis. Enzymatic hydrolytic processes 
offer an advantage in the sense that the hydrolysis of the biomass can be done simultaneously with 
the subsequent use of the hydrolysis products (Straathof 2014). Present strategies for obtaining 
chemicals from biomass feedstocks (Figure 1.1) focus greatly on the established fermentation 
techniques which involves the use of metabolic pathways of a living microbial cell (wild type or 
engineered) in a fermentation process. An alternative to using microbial cells for production of high 
value chemicals from biomass, is to use cell-free synthetic enzymatic pathways for which enzymes can 







Figure 1.1. Figure based on the 2004 US Department of Energy report, model of a bio-based product flow-chart 
for biomass feedstocks, concentrating on the 4-carbon acid, malic acid. 
 
1.2 Industrial production of malic acid 
Malic acid, also known as 2-hydroxybutanedioic acid (C4H6O5), is widely used in a range of industries. 
Malic acid along with succinic and fumaric acid are naturally occurring building blocks found as 
metabolic intermediates in most prokaryotic and eukaryotic microorganisms (Jang et al. 2012). Malic 
acid has commercially-diverse applications in the pharmaceutical, agricultural, food, synthetic resin 
and polymer industries (Deng et al. 2016, Zeikus et al. 1999). Malic acid is currently estimated to have 
a global market of $182.6 million, with increasing demand from the food and beverage industries for 
the use of malic acid as a flavour enhancer, forecasting industrial growth in the future. Commercial 
production of racemic malic acid is achieved by hydration of maleic anhydride and production was 
stated at 5000 tons/annum in the US (Miltenberger 2000). Maleic anhydride itself is produced 
petrochemically by vapour-phase oxidation of n-butane and has large scale applications in coatings 
and polymers. (S)-malic acid is also obtained in industry through the biocatalytic hydration of fumaric 
acid using fumarase for the production of pharmaceuticals (Takata and Tosa 1993). However, both of 
the production strategies utilise non-renewable sources and given the global demand of malic acid, it 
is only sensible that renewable alternatives should be sought after for large scale production of malic 
acid utilising renewable sources.  
1.3 Biobased/biochemical production of malic acid 
Malic acid alongside other C4 acids, succinic and fumaric, are naturally occurring intermediates in the 
tricarboxylic acid (TCA) cycle and are naturally produced by many organisms (Figure 1.2).  
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Figure 1.2. Schematic representation of the tricarboxylic acid (TCA) cycle with major intermediates and the 
enzymes catalysing these reactions. (Cofactors are not shown for simplicity).  
When comparing the methods of production for malic acid, its bio-based production is superior to its 
chemical synthesis in terms of stereo-selectivity whereby the current chemical process produces a 
racemic mixture (Jang et al. 2012). The first patent for the production of l-malic acid via fermentation 
was filed in 1960 (Abe et al. 1962). An Aspergillus flavus strain was selected to be the best natural 
producer and optimization of the fermentation process resulted in final titres of 58.4g/litre after 9 days 
of fermentation. Later studies using the same strain reported that de novo enzyme synthesis during 
nitrogen starvation increased malate synthesis (Peleg et al. 1988). Carbon-13 nuclear magnetic 
resonance analysis of the products in the same study identified that the majority of the malic acid was 
produced via the reductive TCA cycle branch (pyruvate via oxaloacetate to malate) (Figure 1.2). Later 
optimizations with A. flavus have been reported to produce 113g/litre l-malic acid (Battat et al. 1991). 
Despite achieving high yields and titres, natural high capacity malic acid producers like the A. flavus 
have been disqualified from use in industrial production due to aflatoxin (carcinogen) production 
and/or special growth requirements, thereby well-characterized microorganisms such as yeast and E. 
coli are of more interest to researchers to produce malic acid (Jang et al. 2012). Aspergillus oryzae is a 
close relative or even an ecotype of the A. flavus and it was speculated that the former’s high malic 
producing capability, which is generally regarded safe, can be paired with existing large scale 
fermentation (Payne et al. 2006). The yields achieved with A. oryzae are comparable to those of highly 
engineered Escherichia coli and exceed those of Saccharomyces cerevisiae. Further study explored the 
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possible use of A. oryzae on an industrial scale and predicted metabolic engineering targets to increase 
yields such as the over expression of pyruvate carboxylase (Knuf et al. 2013). 
1.3.1 Using yeast for production of malic acid 
Malic acid in fermented products derived from various fruit juices has been early knowledge and it had 
been generally supposed this was exclusively derived from preformed malic acid in the fruit. However, 
in 1924 it was established that l-malic acid is a product of fermentation when carrying out pure sugar 
solution fermentation by pure yeast cultures (Dakin 1924). Fermentative production of malic acid has 
since been successfully demonstrated in other organisms. One notable example is S. cerevisiae where 
a high yield of 12g/litre through the overexpression of cytosolic malate dehydrogenase was achieved 
(Pines et al. 1997). Another yeast strain to have demonstrated malic acid yield of up to 75g/litre is a 
natural isolate of Zygosaccharomyces rouxii under the optimum conditions of 30% glucose, initial pH 
5.0 and 25°C incubation temperature. Acid precursors such as glutamic, malic and succinic aid the 
production of malic acid whereas this is not the case for another four carbon acid, succinic acid (Taing 
and Taing 2007).  
There are four metabolic pathways for the production of malic acid in S. cerevisiae from glucose as 
represented in Figure 1.3 (Zelle et al. 2008): 
1. Carboxylation of pyruvate to oxaloacetate, followed by the direct reduction of oxaloacetate to 
malate. Given that the pyruvate is end product of glycolysis, this nonoxidative pathway is ATP 
neutral and involves net fixation of CO2.  
2. Condensation of oxaloacetate and acetyl-coenzyme A to citric acid, followed by its oxidation 
to malate via the tricarboxylic acid cycle.  
3. Formation of malate from 2 molecules of acetyl-CoA via the glyoxylate pathway. 





Figure 1.3. Four possible pathways for production of malate in S. cerevisiae as adapted from ‘Malic acid 
production by Saccharomyces cerevisiae: Engineering of pyruvate carboxylation, oxaloacetate reduction, and 
malate export’ (Zelle et al. 2008). All possibilities represent oxaloacetate and/or acetyl CoA as starting points. 1. 
Direct reduction of oxaloacetate to malate. 2. Condensation of oxaloacetate and acetyl-coenzyme A to citric acid, 
followed by its oxidation to malate via the tricarboxylic acid cycle. 3. Formation of malate from 2 molecules of 
acetyl-CoA via the cyclic glyoxylate pathway. 4. Noncyclic pathway utilizing glyoxylate cycle enzymes, but 
oxaloacetate is replenished by pyruvate carboxylation. 
S. cerevisiae requires metabolic engineering for high production of organic acids such as malic due to 
the necessity to eliminate alcohol fermentation, which in this strain takes place even under full aerobic 
conditions given the presence of high sugar concentrations (Postma et al. 1989). The obstruction of 
metabolic redirection towards fermentation can be prevented by deletion of the 3 S. cerevisiae 
pyruvate decarboxylase genes (PDC1, PDC5 and PDC6). Deletion of either PDC1 or PDC5 genes has little 
or no effect on the enzyme activity, however deletion of both PDC1 and PDC5 leads to undetectable 
enzyme activity in mutants. Product of PDC6 on the other hand, does not seem to be required for wild-
type enzyme activity in glucose medium (Hohmann 1991). Pyruvate decarboxylase-negative (Pdc_) 
strains seem to offer the perfect platform for metabolic engineering to direct reaction towards higher 
malate producing strains, however, C2 compound auxotrophy and intolerance to high glucose 
concentrations hinder developments. Furthermore growth in synthetic medium in glucose limited 
chemostat cultures requires addition of ethanol or acetate and even in the presence of C2 compound, 
these strains cannot grow (Flikweert et al. 1999). Application of evolutionary engineering in batch and 
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chemostat cultures identified a glucose tolerant, C2-independent Pdc_ S. cerevisiae strain. Under 
aerobic conditions, this strain demonstrated a high production of pyruvate, 135g/litre, a vital 
intermediate to malate production (van Maris et al. 2004). Keeping with all these factors, a favourable 
pathway for efficient malate production in yeast proceeds via carboxylation of pyruvate, followed by 
reduction of oxaloacetate to malate with a theoretical maximum yield of 2 mol malate/mol glucose. 
Introduction of 3 genetic modifications into an engineered glucose tolerant, C2-independent Pdc_ S. 
cerevisiae strain was used to explore the effect of these modifications. The modification was as follows: 
1. Overexpression of native pyruvate carboxylase encoded by PYC2. 
2. High level expression of an allele of malate dehydrogenase gene (MDH3) of which the encoded 
gene was retargeted to the cytosol via the deletion of the C-terminal peroxisomal targeting 
sequence. 
3. Functional expression of the Schizosaccharomyces pombe malate transporter gene SpMAE1.  
This research identified that the simultaneous introduction of all of the above modifications led to the 
highest malate yields and titres. In glucose growth batch cultures, malate production at titres of up to 
59g/litre were achieved (Zelle et al. 2008).  
1.3.2 Using bacteria for production of malic acid 
E. coli is an excellent established biocatalytic platform for metabolic engineering. Variations of E. coli 
have been modified for the production of a four carbon acid, succinic acid (Jantama et al. 2008). A 
previously-engineered E. coli strain optimized for succinate production by increasing expression of 
pyruvate carboxykinase, includes malate as an intermediate in the process, requiring only a single 
reducing equivalent for synthesis from phosphoenolpyruvate. Mutation in fumarate reductase was 
sufficient to redirect reaction to malate. Using a two stage production system of aerobic cell growth 
and anaerobic malate production, the final strain (XZ658) was able to produce malate yields of 
34g/litre, which at the time was equal or better than those of other known biocatalysts (Zhang et al. 
2011).  
E.coli serves as a key component in the biobased production of chemicals as synthetic metabolic 
engineering enables the construction of in vitro synthetic pathways through heat-treatment of the 
recombinant mesophiles having thermophilic enzymes. A key study constructed a synthetic pathway 
capable of direct conversion of glucose to malate (glucose + 2HCO3- +2H  2 malate + 2H2O). The key 
enzyme in this pathway carrying out the reversible carboxylation of pyruvate is the malic enzyme 
derived from Thermococcus kodakarensis. This enzyme was coupled with a non-ATP-forming Embden-
Meyerhof pathway to establish balance and regeneration of cofactors. T. kodakarensis malic enzyme 
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exhibits both malate forming (pyruvate carboxylation) and lactate forming (pyruvate reduction) 
activities, coupled with the concomitant oxidation of NAD(P)H to NAD(P)+ and the concomitant 
reduction of NAD(P)+ to NAD(P)H respectively. The coupling of the malic enzyme with 
thermodynamically favourable NAD(P)H regeneration enzymes theoretically shifts the equilibrium 
towards malate production (Figure 1.4). This CO2 reduction mediated by the malic enzyme has been 
explored more in depth in recent years as it offers a promising approach to the greenhouse gas fixation 
and the production of useful commodities. The study was able to achieve a direct conversion of glucose 
to malate with a molar yield of 60% (Ye et al. 2013).  
Figure 1.4. Schematic representation of artificial synthetic pathway designed for the direct conversion of glucose 
to malate, adapted from ‘Direct conversion of glucose to malate by synthetic metabolic engineering’ (Ye et al. 
2013) All enzymes employed were sourced from thermotolerant sources: 7 glycolytic enzymes from Thermus 
thermophilus, cofactor-independent phosphoglycerate mutase from Pyrococcus horikoshii, non-phosphorylating 
glyceraldehyde-3-phosphate dehydrogenase and Malic enzyme from Thermococcus kodakarensis.  
1.3.3 Other methods of malic acid production 
Malic enzyme has been the focus of other studies in order to improve production of malic acid. As the 
general forward thermodynamically favourable reaction of malic enzymes is converting malate to 
pyruvate, reverse reaction of the enzyme is required. Malic enzyme of Pseudomonas diminuta IFO 
13182 was used in a reverse reaction for HCO3- fixation into pyruvic acid to produce l-malic acid with 
cofactor regeneration (NADH). Glucose-6-phosphate dehydrogenase obtained from Leuconostoc 
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mesenteroides was used for the cofactor regeneration resulting in the production ratio of 38% after 24 
hours of incubation at 30°C (Ohno et al. 2008). Similarly in an experiment carried out using malic 
enzyme of Brevundimonas diminuta IF013182 coupled with the electrochemical regeneration of NADH 
on an enzyme-mediator-immobilized electrode, resulted in the production of nearly 1.1mmol of 
malate from 12.5mmol of pyruvate and 2.5mmol of NaHCO3 in 48 hours (Zheng et al. 2009). 
1.4 Improving biobased strategies of malic acid production 
Biobased strategies such as fermentation have limitations that restrict their large-scale industrial 
applications. Current microbial biomanufacturing is hindered by the limitations caused by cells, as 
synthetic pathways and their optimizations are restricted by the physiological limits of the cellular 
production system (Dudley et al. 2015). A key challenge is the requirement to control a cell’s multiple 
metabolic pathways that lead to formation of unwanted intermediates (Guterl et al. 2012), thereby 
reducing conversion efficiencies. Moreover, construction of artificially-engineered pathways in living 
organisms leads to competition with the natural metabolic pathways of the cell for intermediates and 
cofactors which results in unsatisfactory yields of the actual product of interest. Furthermore, yields 
of target molecules are limited to non-toxic levels only (Matsuda et al. 2013). Ultimately, engineering 
synthetic pathways in cells leads to a competition between the cellular physiological and evolutionary 
objects and the process aims (Dudley et al. 2015, Kwok 2010).  
There is a key idea that can be adapted to overcome the issues discussed above in biobased production 
of commodities including malic acid, called cell-free metabolic engineering (CFME). In a nutshell, the 
founding idea of CFME is the synthesis of complex biomolecular commodities without using intact 
cellular systems (Swartz 2012), but instead using purified enzyme systems or crude cell lysates (Dudley 
et al. 2015). CFME is orchestrated in a  strategy which involves avoiding using living microorganisms 
and uses only enzymes involved in the synthetic pathways (Ninh et al. 2015). Although engineering on 
microbial hosts and single enzyme systems have been in use for some time now, developing cascades 
consisting of multiple enzymes in cell-free pathways is a recent development in comparison (Petroll et 
al. 2019) However, the practical applications of using enzymatic production systems has not been paid 
much attention owing to the economical unprofitability of processes involving enzyme purification 
which tends to be time and cost consuming. Hence, it is a critical issue hindering the possible 
industrialisation of these systems. Enzymatic production systems need to address the crucial factors 
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Table 1.2. Comparisons of cell and cell-free systems are shown with relevant advantages and disadvantages 
within various subfields as highlighted in ‘Cell-free metabolic engineering: Biomanufacturing beyond the cell’ 




1.5 Cell-free metabolic engineering 
 
CFME is pushing the boundaries of traditional bioengineering models by focusing on the use of in vitro 
combinations of catalytic proteins prepared from purified enzymes or crude lysates of cells for 
production of target commodities. In recent years, developments in the engineering foundations of 
cell-free systems have been inspired and have led to the establishment of long enzymatic pathways, 
near theoretical conversion yields and new directions in protein purification, spatial organisation and 
enzymatic stability (Dudley et al. 2015). Various examples have also demonstrated that avoiding the 
cell barrier gives more control on the metabolism leading to efficient and broader production of 
metabolites (Rollin et al. 2013, Swartz 2018). One of the biggest potential applications of cell-free 
systems over microbial fermentation is the ability to catalyse biotransformations that cannot be done 
by microbes or chemical catalysts (Rollin et al. 2013) 
Using enzymes commercially has traditionally been limited to single reactions or very short pathways 
(Straathof 2014). In the context of engineering, CFME has two approaches, purified enzymes or crude 
extracts. CFME research has largely focused on the use of individually purified enzymes that have been 
recombined to assemble the pathway of interest. These pathways can be precisely controlled as 
component variables, such as concentration and activity, are largely known. However, major challenge 
comes in the form of cofactor cost and regeneration (Rollin et al. 2013). Crude lysates or cell extracts 
on the other hand offer advantages in applications where lower costs and complex metabolic systems 
are required as they are cheaply generated and can contain a lot of proteins naturally present in cell 
metabolism (Swartz 2018). This can either be an advantage or disadvantage as the native metabolism 
if unwanted, can be difficult to eliminate or model. A further advantage offered by cell-free systems is 
that absence of substrate toxicity constraints (Takors 2012) and the potential handling of otherwise 
toxic/unstable intermediates (Schrittwieser et al. 2018). Other factors such as lower DNA synthesis 
prices, improved engineering and expression technologies have contributed to better access to 
enzymes utilized in cascade reactions (France et al. 2017).  
1.5.1 Purified enzymes cell-free cascade systems 
One of the early examples of cell-free systems was the production of ethanol from isolated yeast 
glycolytic enzymes (Welch and Scopes 1985) and since then a range of purified enzyme systems have 
been explored. Their development has brought to light a set of general rules in order to achieve high 
productivities and these guidelines closely mimic the vital properties of the in vivo state of growing 
cells, which is suggested to be the key to successful applications of CFME (Dudley et al. 2015) 
1. Stable and robust enzymes. 
2. Enzyme ratios and substrate/cofactor/buffer concentrations. 
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3. Providing a thermodynamic push towards product of interest (i.e. cofactor regeneration, 
product removal, substrate feeding). 
Artificial metabolic pathways are becoming well explored approaches for biotransformation of 
industrial chemicals, however due to the separate preparation and purification required for this, the 
practical applications are limited. A study addressing this key challenge took genes encoding 9 
thermophilic enzymes involved a non-ATP-forming chimeric glycolytic pathway and assembled them 
in an artificial operon and co-expression all of them in a single recombinant E. coli strain. The gene 
expression levels of the enzymes were controlled by their sequential order in the artificial operon. 
Interestingly, the study identified that the specific activities of the enzymes in the cell-free extract of 
the multiple-gene-expression E. coli were 5.0-1,370 times higher than those of an enzyme cocktail 
obtained from over expressed single-gene-expression strains. The purification strategy employed here 
consisted of the multiple-gene-expression cells being heat treated leading to indigenous protein 
denaturation. By coupling the heat-treated extract with other thermophilic enzymes such as H2O 
forming NADH oxidase or lactate/malate dehydrogenase, one pot conversion of glucose to pyruvate 
or lactate respectively, was achieved (Ninh et al. 2015). 
A key paper in the field of purified enzyme systems accomplished the conversion of glucose to ethanol 
and isobutanol using 6 and 9 enzymes respectively (Figure 1.5). The ubiquitous Embden-Meyerhof-
Parnas pathway was shortened by using enzymes from hyperthermophilic archaea in a modified non-
phosphorylative Entner-Doudoroff pathway. The crucial factor of cofactor balance was demonstrated 
in this paper as glucose was converted to pyruvate, generating 2 NADH in the process which were then 
recycled in the later step of conversion to isobutanol. This reaction produced a 57% molar yield of 
ethanol from glucose, which remains one of the best reported examples to date (Guterl et al. 2012). 
This study demonstrated the possibilities for constructing enzymes in artificial non-natural cascades, 
rather than 10 enzymes required by yeast cells to convert glucose to pyruvate, this minimized cascade 
used only 4. This minimized production is possible due to the intermediates not being required for the 
complicated cellular metabolic associated with whole cell approaches (Sperl and Sieber 2018). In 
another example, using the same first 4 enzymes in pathway design as the cascade by Guterl et al 5 
thermophilic enzymes were utilized in a NADH balanced system to facilitate the conversion of glucose 




Figure 1.5. Schematic representation of cell free systems developed for the production of isobutanol and ethanol 
from glucose adapted from ‘Cell-free metabolic engineering: production of chemicals by minimized reaction 
cascades’ (Guterl et al. 2012). GDH, glucose dehydrogenase; DHAD, dihydroxy-acid dehydratase; KDGA, 2-keto-
3-deoxygluconate aldolase; AIDH, glyceraldehyde dehydrogenase; PDC, pyruvate decarboxylase; ADH, alcohol 
dehydrogenase; ALS, Acetolactate synthase; KARI, ketolacid reductoisomerase; KDC, 2-ketoacid decarboxylase. 
 
Artificial enzymatic cascades are fundamentally renewable alternatives to petrochemicals, but their 
appeal is further amplified as some systems have been designed to use by-products of other reactions 
as substrates or intermediates in further downstream processing. Glycerol is a by-product of 
bioethanol and biodiesel production, for example, during the industrial production of bioethanol, the 
fermentation of sugars by yeast is accompanied by significant production of glycerol (Rausch and 
Belyea 2006). At the time of publication, it was estimated that the world production of glycerol would 
reach 4200,000 tonnes by 2020 (Viana et al. 2014). However, the current industry glycerol applications 
require approximately a quarter of the total production, thus encouraging any developments of new 
processes that can facilitate the conversion of glycerol to high value goods.  
Heterogeneous or homogeneous catalysis can be used with glycerol to obtain high value goods but 
biocatalysis is preferred as glycerol can be usually incompatible with chemical transformations due to 
its availability in dilute aqueous solutions. Despite this, conversion efficiencies are plagued by the 
ubiquitous issue of unwanted intermediates due to the multitude of cellular pathways. A cell-free 
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biosystem seems like the perfect answer but if production were to be approached in the natural 
metabolic pathways of glycerol metabolism, an excess of 8 enzymes are required to form pyruvate 
which is a central key intermediate. Gao et al addressed these exact issues and developed an artificial 
system facilitating the conversion of glycerol into pyruvic acid using only 3 enzymes, eliminating any 
need for additional cofactors. 9.3mM pyruvic acid was produced from 10mM glycerol and pyruvate 
was further converted to another useful four carbon commodity, acetoin, using two additional 
enzymes in a cell free environment as well. This cell-free system focuses on the production of pyruvate 
and since that is a key intermediate, this synthetic pathway has potential to be developed as a versatile 
bio-production system (Gao et al. 2015). 
Hydrogen is a future energy carrier and a strong chemical commodity and currently can be produced 
via chemical/biocatalysis/combination of both (Zhang 2010). Hydrogen-producing microbes give a 
theoretical maximum yield of 4 hydrogen molecules per glucose, and to increase this yield, a non-
natural synthetic pathway consisting of 13 enzymes was reported to demonstrate the feasibility of 
almost 12 hydrogen molecules per glucose from starch (Zhang et al. 2007). Further experimental work 
was able to expand the substrate range to include multiple glucan sources (Ye et al. 2009), leading to 
demonstration of sustainable approaches from using biomass feedstocks and stepping back from 
reliance on non-renewable feedstocks. Sustainable development of the corn starch industry was also 
addressed in a study where an enzymatic system with multiple enzymatic cascades was developed for 
formation of valuable platform chemicals from lactate separated from corn steep water. Pyruvate was 
produced as an important intermediate followed by conversion into acetaldehyde and acetoin which 
are further valuable platform chemicals (Li et al. 2017).   
In recent years, the number of enzymatic cascades published for synthesis of commodities is growing 
steadily, however CFME has its own set of challenges, working with non-optimized catalysts can make 
defining operational windows difficult. Therefore, the enzymes to be employed must demonstrate 
excellent process stabilities as well as being available at low costs and large scale. Cofactor 
stability/regeneration also has to be taken into account in this context and enzyme recyclability and 
reusability are also of vital importance for economic analysis (Guterl and Sieber 2013). The following 
sections outline the challenges associated with designing efficient enzyme cascade systems and the 
solutions used to overcome them. 
1.6 Applications of thermophiles in CFME 
As previously highlighted, the stability and purification of enzymes to be utilized in enzymatic cascades 
have to be considered for achieving a feasible system. Display of stability at extreme temperatures by 
thermophiles can be accompanied by additional properties such as low water activity and high 
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hydrostatic pressure. The environments colonised by thermophiles include hot springs, fumaroles, 
submarine hydrothermal vents and oil reservoirs, and thermophiles are mainly archaea with some 
having been classified as eubacteria (Sellek and Chaudhuri 1999). Thermophilic enzyme production can 
be expressed in a native thermophilic host; however cultivation of any extremophile is not easy. It 
requires specialist equipment and faces slow growths and low yields, meaning heterologous gene 
expression using a common host such as E. coli is much preferred. The nutritional requirements for 
these thermophiles vary and therefore they are host to a wide variety of useful enzymes (Sellek and 
Chaudhuri 1999). The enzymatic cascade examples given in the previous section have already stated 
how some examples have utilized enzymes of thermophilic origin to design artificial reaction pathways. 
This is due to application of thermotolerant enzymes mitigating some of the major challenges facing 
CFME approaches. Despite the potential advantages of cell-free systems, there are four key challenges 
that require optimization if commercial application of these systems is to be tackled. These are: low-
cost enzyme production, prolonged enzyme stability, enzyme/cofactor engineering and pathway 
optimization/modelling (Rollin et al. 2013). In response to tackling the first two challenges, heat 
treatment of recombinant mesophiles results in a one-step preparation of an enzyme cocktail avoiding 
costly purification strategies and the high operational stability of enzymes of thermophilic origin 
mitigate the challenges of protein synthesis and renewal (Ninh et al. 2015). For most approaches to 
tackling enzyme stability issues, using thermotolerant enzymes is usually a fair starting point, and if 
there is no thermotolerant enzyme available for the mesophilic enzyme equivalent, enzyme 
engineering can be next explored (Zhang 2015).  
1.6.1 Exploiting unique metabolic enzymes found in thermophiles 
Not only do thermophilic enzymes offer the advantages in low-cost enzyme production and long-term 
enzyme stability, unique metabolic pathways found in hyperthermophilic archaea contain unique 
metabolic enzymes with applications in enzymatic cascades. The Entner-Doudoroff pathway was first 
discovered in 1952 in Pseudomonas saccharophila and has been viewed as an alternative to the 
Embden-Meyerhof-Parnas glycolytic pathway (Conway 1992). Archaea have a complicated 
carbohydrate metabolism and utilize glucose via modifications of the classic Embden-Meyerhof-Parnas 
and the Entner-Doudoroff pathways. In the thermophilic aerobic archaeon Sulfolobus solfataricus, 
glucose degradation occurs via a branched Entner-Doudoroff pathways with a semi-phosphorylative 
and a non-phosphorylative branch (Siebers and Schonheit 2005, Ahmed et al. 2005). Due to the lack of 
a functional phosphofructokinase, the Embden-Meyerhof-Parnas is supposed to function for 
gluconeogenic purposes only (Kouril et al. 2013). The classical branch (phosphorylative) of the Entner-
Doudoroff pathway seem to be only found in bacteria, however modifications such as the semi-
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phosphorylative and a non-phosphorylative branches have been reported in all 3 domains of life: 
archaea, bacteria and eukarya (Conway 1992).  
 
Figure 1.6. Overview of the non-phosphorylative Entner-Doudoroff pathway, with enzymes and characteristic 
phosphorylation level indicated (orange).  
 
In both of the branches (semi-phosphorylative and non-phosphorylative), glucose is oxidized to 
gluconate by glucose dehydrogenase (Milburn et al. 2006), followed by dehydration of gluconate to 2-
keto-3-deoxygluconate by dihydroxy-acid dehydratase (also referred to as gluconate dehydratase in 
literature) (Kim and Lee 2006). After these first two reactions the branches have the following 
reactions.  In the semi-phosphorylative branch, 2-keto-3-deoxygluconate is phosphorylated by 2-keto-
3-deoxygluconate kinase into 2-keto-3-deoxy-6-phosphogluconate. This is followed by the latter’s 
cleavage by 2-keto-3-deoxygluconate aldolase into one molecule of glyceraldehyde-3-phosphate and 
pyruvate (Lamble et al. 2005). Glyceraldehyde-3-phosphate is degraded further by a NADP+ dependent 
non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase forming 3-phosphoglycerate and 
NAD(P)H and H+ (Ettema et al. 2008). The resulting 3-phosphoglycerate can then be metabolized in the 
lower Embden-Meyerhof-Parnas pathway to yield the second pyruvate molecule. In the non-
phosphorylative branch of the Entner-Doudoroff pathway, the 2-keto-3-deoxygluconate formed is not 
phosphorylated but undergoes cleavage via the same 2-keto-3-deoxygluconate aldolase into one 
36 
 
molecule of glyceraldehyde and pyruvate (Kouril et al. 2013). Glyceraldehyde is then oxidized into 
glycerate via aldehyde oxidoreductase followed by the conversion of glycerate into 2-
phosphoglycerate via glycerate kinase (Kardinahl et al. 1999). Similarly to the semi-phosphorylative 
branch, the resulting 2-phosphoglycerate can then be metabolized in the lower Embden-Meyerhof-
Parnas pathway to yield the second pyruvate molecule. The physiological significance and regulation 
of the semi-phosphorylative and non-phosphorylative branches are not clearly understood, however 
it has been suggested that the presence of 2 branches have a role in thermoadaptation of organisms 
growing at high temperatures (Ahmed et al. 2005), and the different pathways in vivo and their 
selection has been suggested to depend on the energy demands of the cell (Ahmed et al. 2005). 
There are two key enzymes associated with the Entner-Doudoroff pathway, dihydroxy-acid 
dehydratase which catalyses the dehydration of gluconate to form 2-keto-3-deoxygluconate, and 2-
keto-3-deoxygluconate aldolase which catalyses the cleavage of 2-keto-3-deoxygluconate to form 
pyruvate and glyceraldehyde. Given the unique metabolic pathways these enzymes are involved with 
the added benefit of unique reaction parameters (substrate promiscuities and specificities), enzymes 
of the thermophilic origin offer advantages in enzyme stability and ease of purification if incorporated 
into the pathway design of cell-free cascades, as well as non-natural pathway design construction via 
combinations of mesophilic and thermophilic proteins.  
1.7 Cofactor balance 
Many proof-of-concept pathways have been successfully demonstrated at the lab scale but it is still 
uncertain to what extent CFME systems can serve as commercial production systems. Another key 
barrier presents itself in the form of cofactor regeneration. Purified enzyme systems are required to 
supplement the reaction with the necessary cofactors. The nicotinamide nucleotides NAD+ and NADP+ 
are used by most redox enzymes and their balance is crucial in cell-free enzymatic pathways which lack 
metabolic regulation from living cells (Dudley et al. 2015). Co-factor balance needs to be crucially 
maintained as unbalance can lead to the disruption of the entire cascade. Cofactor costs and instability 
has led to developments in the design of cell-free systems that are not only cofactor balanced but 
attention is paid to ensure cofactor regeneration in the cascade, furthermore, to be economically 
viable, cofactor regeneration methods must be able to recycle the cofactor at least 100 to 106 times 
(Chenault et al. 1988). Cofactors cost countering solutions have been proposed in the form of 
biomimetic nicotinamide derivatives, whereby molecules such as 1-benzyl-1,4-dihydropyridine-3-
carboxamide are structurally less complex than NAD(P)H and easier to synthesize but enzymatic 
methods for regeneration of reduced form and not adaptable to these cofactors (Nowak et al. 2017). 
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Furthermore, the general applications of these artificial cofactors require enzyme engineering to adapt 
enzymatic binding and conversion (Zhang et al. 2011).  
Achieving the cofactor balance requirements has meant that the cofactor preference for certain 
enzymes has been engineered to alter preferences. A NADH-dependent pathway was constructed 
using engineered enzymes where the cofactor preference had been altered from NADPH to NADH for 
production of isobutanol. This aided in the development of economically competitive aerobic 
production conditions over the native anaerobic NADPH requiring conditions. Moreover, it was 
demonstrated that the engineered NADH-dependent pathway enables isobutanol production at 100% 
theoretical yield than the native NADPH-dependent pathway (Bastian et al. 2011), thus demonstrating 
how engineering cofactor preferences can be a competent solution to the critical issue of cell-free 
system commercialisation. Vice-versa, cofactor engineering has also been applied to shift preference 
from NADH to NADPH (Campbell et al. 2010) or has relaxed/boarded the cofactor specificity 
altogether. 
Cofactor engineering has been split into three major approaches: rational design, swapping modules 
or directed evolution (Rollin et al. 2013). Module swapping refers to the technique of replacing an 
entire enzyme domain in order to alter cofactor specificity. This was performed successfully in a 
thermophilic bacterium where the specificity of isocitrate dehydrogenase was altered from NADP+ to 
NAD+. The mutant isocitrate dehydrogenase was found to be stable as the original wildtype enzyme 
(Yaoi et al. 1996). Directed evolution consists of using error-prone PCR to introduce mutations into a 
gene of interest and then screening the mutant library for transformants with the desired activity. This 
approach was employed with the thermotolerant NADPH dependent malic enzyme from T. 
kodakarensis to alter its preference from NADPH to NADH. It was serendipitously found that this 
cofactor preference also altered the reaction specificity of the enzyme. The native malic enzyme in this 
case catalyses the conversion of malate to pyruvate and the reverse reaction is thermodynamically 
unfavourable and yet is the one with productive appeal in the renewable production of malic acid. The 
shift in cofactor preference not only allows for the more thermally stable NAD+/NADH to replace 
NADP+/NADPH as the preferred cofactors, it also shifted the reaction towards malate production. The 
mutant enzyme with NADH as a cofactor gave 1.2 times higher concentration of malate than the 
wildtype enzyme with NADPH (Morimoto et al. 2014).  
1.8 Spatial organisation 
Cells have evolved to spatially organise pathways which are specialised in handling metabolic pathways 
with overlapping intermediates and to isolate them from any toxic intermediates, moreover enzymes 
have evolved to have the maximal activity in in vivo crowded macromolecular surroundings (Zhang 
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2015). Cell-free systems employing crude lysates tend to have enzymatic concentrations of around 1-
10mg/ml (Jewett and Swartz 2004), this concentration is considerably lower for purified enzyme cell-
free systems. In comparison to these figures, total cytoplasmic protein concentrations tend be 
approximately 200mg/ml (Jandt et al. 2013). Evolutionary design enables enzymes to have excellent 
activity, specificity and selectivity, all under physiological requirements, which do not always align with 
industrial requirements, and industrial application of enzymes may be prone to inhibition and have 
low stability (dos Santos et al. 2015). For these reasons, it is only reasonable that approaches to mimic 
optimal intracellular environments such as, compartmentalisation, scaffolding and immobilization, are 
explored (Rollin et al. 2013).  
Immobilization of enzymes is a technique that is fast becoming a sought after solution to overcome 
some of the challenges faced by cell-free biosystems. Immobilization as a tool, is being used by 
researchers to improve enzyme features like activity selectivity, selectivity, specificity and inhibition 
resistance (dos Santos et al. 2015). It is a common industrial practice to increase enzyme life via 
immobilization but this is sometimes achieved at the expense of enzyme activity, inactivation of a 
percentage of immobilized enzymes, mass transfer limitations and slow reaction rates (Zhang et al. 
2011). Despite the potential drawbacks, progress is being made to overcome limitations and many 
immobilization techniques have been proposed such as adsorption, covalent binding, entrapment, 
encapsulation, crosslinking and nanoparticle immobilization (Dudley et al. 2015).  
1.9 Spatial organisation - a focus on immobilization strategies 
Immobilization of enzymes is the attachment of the biocatalysts to a solid support that is insoluble in 
the reaction mixture (Jesionowski et al. 2014). It has been shown to substantially improve the stability 
of enzymes and provide a method of reusability of biocatalysts over catalytic cycles. Immobilization 
also changes the catalysts from a homogeneous form to a heterogenous form, allowing for the ease of 
separation of biocatalytic units from the reaction mix and reducing downstream purification strategies 
(Zdarta et al. 2018). For instance, cell-free production of isobutanol is an alternative to the cellular 
production, given the toxic effects of higher order alcohols on cells. Isobutanol production has been 
demonstrated successfully using 9 purified enzymes and isolating the enzymes directly responsible for 
the production of desired product is better than optimizing a complex full live cell system (Guterl et al. 
2012). An immobilized cascade for production of isobutanol would also simplify alcohol/water 





1.9.1 Immobilization support materials 
Immobilization strategies can be applied in various techniques, and the difference between these 
techniques is that the different types of interactions formed and the type of support materials used. 
Therefore, deciding which immobilization technique and materials to employ requires knowing the 
reaction type and conditions as well the type of biocatalyst (Guzik et al. 2014). Support materials for 
immobilization are available in a variety and can be divided into 2 main groups, classic and new 
materials (Zdarta et al. 2018).  
Classic materials are available in large varieties and can be classified as inorganic or organic materials 
(Zdarta et al. 2018). One of the most frequently used inorganic support material for immobilization is 
silica, it has wide practical applications and has high thermal and chemical resistance as well as offering 
high surface area and pore size for sorption applications (Jesionowski and Krysztafkiewicz 2002). Silica 
also provides benefits in the applications with multiple enzyme catalytic classes as it can be used in 
many forms (fumed silica, silica nanoparticles and silica gel) (Zucca and Sanjust 2014). Silica materials 
are also highly hydrophilic due to the presence of multiple hydroxyl groups on their surface, thereby 
improving enzyme immobilization (Zdarta et al. 2018). Mineral materials of mainly clay (bentonite, 
halloysite) are also used as supports for enzymatic biosystems. These materials have great economical 
appeal as they are sourced easily given their abundance in nature, are cheap and require no extensive 
treatment before application (Ghiaci et al. 2009). The inorganic materials classically used for 
immobilization purposes have some limitations such as limited biocompatibility, low affinity to 
biomolecules, and furthermore, cross linking agents may be needed to create covalent bonds between 
the enzyme and support. For this reason, some organic materials are also used for immobilization 
purposes and these can be either synthetic materials (polymers) or biopolymers (naturally sourced 
renewable materials) (Zdarta et al. 2018). The biggest advantage offered by organic materials is that 
they can form linkages between the enzyme and the support without the need for cross-linking agents 
which is a disadvantage posed by using inorganic materials for immobilization (Zdarta et al. 2018).  
New materials are continually being reported to facilitate novel practical applications of immobilized 
enzymes and again, these materials can be inorganic or organic in their origin. One of the novel 
supports with wide potential applications are mesoporous supports (Zdarta et al. 2018). These are 
distinguished from other materials used for immobilization purposes as the properties of the support 
can be tailored to the enzyme via adjustment of synthesis conditions leading to matrices with desired 
pore structures (Matuszek et al. 2016). Overall, the new materials are highly tailorable with regards to 




1.9.2 Types of immobilization techniques 
The main methods of immobilization of enzyme is divided into 4 categories (Mohamad et al. 2015):  
1. Physical adsorption 
2. Entrapment/Encapsulation 
3. Cross-linking  
4. Covalent bonding 
1. Binding the enzyme to supports (typically synthetic resins, biopolymers or inorganic solids such as 
silicas) can be achieved via adsorption. Being the oldest and easiest immobilization technique, 
adsorption is the interaction between the enzyme and support through weak forces physical such as 
hydrogen bonds, hydrophobic, van der Waals, or ionic interactions (Jesionowski et al. 2014). These 
interactions can least withstand the rigorous conditions often imposed by industrial processes, 
whereby the physical binding would be too weak to retain enzyme on support leading to enzyme 
leaching (Sheldon and van Pelt 2013). This technique is reversible and enzymes can be detached from 
the support, a highly useful strategy when support is in need of reloading with fresh enzyme 
(Mohamad et al. 2015) as novel supports can be recycled with extended lifetimes.  
2. Entrapment is the technique in which enzymes are irreversibly immobilized/entrapped inside 
polymer networks, this allows the substrates/products to pass but it retains enzyme inside. This 
entrapment is also not fully sufficient to completely prevent leakage so additional covalent linking is 
often required (Nisha et al. 2012, Sheldon and van Pelt 2013). 
3. Cross-linking is also an irreversible immobilization technique whereby a carrier/support is not 
required (unlike the adsorption and entrapment techniques) to prevent enzyme loss into the reaction 
mix (Honda et al. 2005). Due to this, this method is also known as carrier-free immobilization. It is 
carried out by forming intermolecular cross-linkage between the enzymes using a cross-linking reagent 
such as glutaraldehyde (Sheldon 2007).  
4. Covalent binding is another irreversible conventional method better at retaining the enzyme on 
support. The attachment between the enzyme and the support is achieved either through direct linking 
or through a spacer arm which can provide a great degree of mobility to the linked enzyme and these 
enzyme shave been reported to show higher activities in comparison to those attached directly (Nisha 
et al. 2012).  However covalent interactions may irreversibly deactivate the enzyme leading to reaction 




1.9.3 Support properties for immobilization 
Given the different types of immobilization protocols and materials available for immobilization, 
adequate selection of the protocol and support are crucial for an efficient system. The particle size in 
a support for immobilization plays a crucial role in handling of the supports, whereby too small 
particles will pose problems in handling of the particles in industrial applications (dos Santos et al. 
2015). Larger particles can cause problems in efficient diffusion, in a given instance if the substrate 
diffusion rate is slower than the substrate consumption rate, the enzymes immobilized in the centre 
of the support material might not receive any substrate at all, reducing observed biocatalytic activity 
(Bortone et al. 2014). In general, the best support should have a high loading capacity as a larger 
amount of enzyme will be immobilized with a lower volume of support (dos Santos et al. 2015). The 
pore diameter is recommended to be 4-5 fold larger than the larger enzyme diameter to: (i) ensure 
the pore closing is avoided and new enzyme molecules can still enter after the initial enzymes have 
immobilized onto the support and (ii) the full surface of the support can be coated by the enzyme 
(Hudson et al. 2008).  
1.10 Challenges and opportunities associated with immobilization 
Despite the advances made in analysis of suitable support materials and immobilization techniques, 
one of the most common issues with immobilized enzymes is their display of diminished activities, this 
can be tackled via molecular engineering to improve activity and stability. Any engineering efforts 
require a detailed understanding between protein structure and function and this information is not 
always available. One possible way around this is using highly stable soluble proteins like folded green 
fluorescent protein and stabilised maltose binding domain, the coupling of these with enzymes of 
interest can increase solubility and possibly lessen protein-protein self-interactions (Magliery et al. 
2011). This approach was applied to stabilise immobilized keto-acid decarboxylase and retain its 
activity. This was then further developed into a production scheme based on CFME to produce 
isobutanol. Two immobilized enzymes, keto-acid decarboxylase and alcohol dehydrogenase were 
immobilized on methacrylate resin with formate dehydrogenase in solution to aid cofactor recycling. 
This system produced isobutanol titres 8-20 times higher than the highest reported titres with S. 
cerevisiae on a mol/mol basis. Without in situ product removal, 55% conversion of ketoisovaleric acid 
to isobutanol was achieved and therefore increasing titre can be explored by continuous removal of 
the isobutanol (Grimaldi et al. 2016). 
Immobilization strategies have also been focused on biocatalytically relevant cofactor recycling 
enzymes such as glucose dehydrogenase (GDH) and NADH oxidase (NOD). GDH belongs to the 
oxidoreductases family of enzymes which make up one quarter of all known enzymes and require 
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costly nicotinamide cofactors. Immobilization of the enzymes utilising expensive cofactors would 
therefore assist in the cost management as the cofactor could be reused and recycled in biosystems. 
Enzymes belonging to the oxidoreductases family have not been so well explored in immobilization, 
possibly owing to denaturation that comes with immobilization of multimeric enzymes leading to 
activity loss (Betancor et al. 2003). In a particular study, immobilization was explored in microspheres 
developed by ReSyn™ Biosciences (South Africa). Three variants of the aldehyde functional polymer 
microspheres were explored which varied only in their functional group densities. Immobilization of 
GDH resulted in the maintenance of approximately 40% of the activity, furthermore the immobilized 
GDH displayed improved activity in the acidic pH range (Twala, Sewell, & Jordaan, 2012). 
1.11 Project aim and objectives 
With biobased production of malic acid heavily dependent on microbial fermentation processes, 
alternatives are being sought to increase yields and cut costs. Cell free metabolic engineering provides 
a competitive answer given that the restrictions imposed by physiological limits of cellular production 
systems are overcome to an extent. Designing an artificial enzymatic cascade using enzymes 
exclusively from thermophiles mitigates the issue of time and cost consuming purification strategies, 
and cofactor balance can be achieved with the incorporation of additional biocatalytically relevant 
enzymes or they can be a part of the original cascade resulting in a reaction intermediate. Mimicking 
intracellular environments with the aid of enzyme immobilization can further enhance the appeal of 
cell-free system for the sustainable production of malic acid.  
The objectives of this project were therefore to: 
1. Design an enzymatic cascade to convert glucose to malic acid. 
2. Produce and purify the recombinant enzymes of the cascade. 
3. Characterize the activity of the produced enzymes. 









2. Materials and Methods 
2.1 Reagents 
All chemicals and consumables unless otherwise stated, were purchased in analytical grade from the 
following suppliers: Appleton Woods, Clontech, Bio-Rad, Cambio, Expedeon, Formedium, GE, 
GenScript, GeneFlow, Merck, Molekula, NEB, Qiagen, Sigma-Aldrich, StarLabs and Thermo Fisher 
Scientific.  
2.2 Vector generation 
Plasmids used in this study are listed in Table 2.1.  




GDH Sulfolobus solfataricus CAA09918.1 
Dihydroxy-acid 
dehydratase 











Malate dehydrogenase MDH Thermococcus 
kodakarensis  
BAE47514.1 
Table 2.1. List of enzymes utilized in the cascade.  
 
All plasmids were synthesised and cloned into pET-30a via NdeI and BamHI as the 5’ and 3’ restriction 
sites respectively. All protein sequences were designed with a N-terminal His10 tag followed by a 6 
glycine-serine linker. Among these, GDH, DHAD, KDGA and AIDH are wild-type sequences whereas 
MDH sequence has 3 mutations (R221G, K228R and I310V). These mutations were reported to alter 
the cofactor preference of MDH and also shift reaction specificity towards malate production 
(Morimoto et al. 2013). Gene synthesis was carried out by GenScript (New Jersey, United States) and 
plasmids were supplied as a concentrated miniprep of ~4µg of DNA.  
2.2.1 E.coli competent cells 
One Shot® TOP10 and One Shot® BL21(DE3) chemically competent E. coli cells were purchased from 





2.2.2 Bacterial media  
For liquid Luria-Bertani (LB) broth, 20g/L LB was dissolved completely in water and autoclaved prior to 
use. For LB agar, 20g/L LB and 20g/L agar were dissolved in water, autoclaved and sufficiently cooled 
before pouring into sterile petri dishes. Antibiotic was added (kanamycin at 50µg/ml) to media at 
around 40°C.  
2.2.2.1 Antibiotics 
Stock solutions of 100mg/ml kanamycin were prepared by completely dissolving 1g of kanamycin 
powder into 10ml of double distilled (dd) water. The solution was then sterilized by filtering through a 
0.2µm syringe filter and stored at -20°C. Kanamycin was used at a working concentration of 50µg/ml.  
2.2.3 Transformation of E.coli for vector quantification 
In order to amplify vector DNA (Table 2.1) for protein expression purposes, E. coli TOP10 competent 
cells were transformed and minipreps were performed to isolate each vector. 50µl aliquot of TOP10 
cells was thawed on ice, and 2µl of vector DNA (~200ng/µl) was added before incubating on ice for 30 
minutes. This was followed by heat shocking the tubes containing the competent bacterial cells and 
vector DNA for 30 seconds at 42°C. The tubes were immediately put back on ice for a further 2 minutes. 
400µl of LB broth was added to the tube and incubated at 37°C, 220rpm for 1 hour. Following the 
incubation, 200µl of the sample was added to LB-agar kanamycin plates and incubated overnight at 
37°C for no more than ~18 hours followed by storage at 4°C. When required, single bacterial colonies 
were picked from the plate, added to LB broth supplemented with kanamycin and incubated overnight 
at 37°C, 220rpm. Following overnight growth, the cultures were taken, centrifuged and vectors were 
isolated using a GeneJet Plasmid Miniprep kit (Thermo Scientific) according to the manufacturer’s 
protocol. Vector DNA recovered was quantified using a NanoDrop, aliquoted and stored at -80°C until 
use.  
2.2.3.1 Restriction digest 
To verify the correct insert size, restriction digests were performed on the vector DNA obtained in 
Section 2.2.3. NdeI (NEB R0111S) and BamHI-High fidelity (NEB R3136S) were used in 1µl quantities 
with 5µl of CutSmart buffer (NEB) and 2µl of vector DNA made up to a final volume of 25µl using ultra-
pure water from a Type 1 Milli-Q Synthesis A10 water purification system. The digest was then 
incubated at 37°C for an hour and NdeI was then heat deactivated at 65°C for 20 minutes before adding 




2.2.3.2 Agarose gel electrophoresis  
1% agarose gels were prepared using 1g of agarose to every 100ml of 1x TAE (Tris-acetate-EDTA) 
buffer. Stock 50x TAE (Thermo Fisher Scientific B49) was used to make up 1x TAE buffer and gels were 
run at 100V to confirm correct insert sizes. 
2.3 Protein expression 
2.3.1 Bacterial media and stock solutions 
LB broth (liquid/agar) was prepared as detailed in Section 2.2.2.  
Kanamycin stock was prepared as detailed in Section 2.2.2.1.  
Liquid Auto-induction (AI) media (Formedium AIMLB0210) was prepared by dissolving 34.85g/L AI 
media in water and autoclaving prior to use. 
1M isopropyl β-D-1-thiogalactopyranoside (IPTG) was prepared by dissolving 2.38g of IPTG in a final 
volume of 10ml dd water, the solution was filtered sterilized with 0.2µm syringe filter and stored at -
20°C. The working concentration of IPTG was 1mM.  
2.3.2 Transformation of E.coli for protein expression 
For protein expression purposes, E. coli BL21-DE3 competent cells were transformed. A 50µl aliquot of 
BL21-DE3 cells was thawed on ice, and 2µl of vector DNA (~200ng/µl) was added before incubating on 
ice for 30 minutes. This was followed by heat shocking the tubes containing the competent bacterial 
cells and vector DNA for 30 seconds at 42°C. The tubes were immediately put back on ice for a further 
2 minutes. 400µl of LB broth was added to the tube and incubated at 37°C, 220rpm for 1 hour. 
Following the incubation, 200µl of the sample was added to LB-agar kanamycin plates and incubated 
overnight at 37°C for no more than ~18 hours followed by storage at 4°C.  
2.3.2.1 Bacterial glycerol stocks 
For long term storage of bacterial cultures, glycerol stocks were prepared for each protein. Following 
a transformation protocol (Section 2.3.2), single bacterial colonies were picked from the plate, added 
to LB broth supplemented with kanamycin and incubated overnight at 37°C, 220rpm. After overnight 
growth, 500µl culture was added to 500µl 50% glycerol, gently resuspended and stored at -80°C for 
long term storage. To recover bacteria from the plate, a sterile loop was used to scrape some of the 
frozen suspension on an LB agar kanamycin plate, ensuring the glycerol stock did not thaw. The 




2.3.3 Expression of recombinant proteins 
Expression in LB broth- 
For small scale expression of GDH, DHAD, KDGA, AIDH or MDH, single colonies from LB agar kanamycin 
plates were picked into 10ml LB broth supplemented with kanamycin and grown at 37°C, 220rpm in 
small baffled flasks until OD600 of >0.6. This was used as a pre-culture and 10ml was added to 1L LB 
broth (in 2L shake flasks) supplemented with kanamycin and grown at 37°C for 3-4 hours. OD600 was 
monitored until an absorbance 0.4-0.6 was achieved. This was followed by induction with 1mM IPTG 
and overnight incubation at room temperature, 220rpm (OD600 of ~7-10). Concentrated cell pellets 
were obtained by centrifugation and LB broth removed.  
Expression in AI media- 
For small scale expression of GDH, DHAD, KDGA, AIDH and MDH, single colonies from LB agar 
kanamycin plates were picked into 10ml AI media supplemented with kanamycin and grown at 37°C, 
220rpm in small baffled flasks until OD600 of >0.6. This was used as a pre-culture and 10ml was added 
to 1L AI media (in 2L shake flasks) supplemented with kanamycin and grown overnight at room 
temperature, 220rpm (OD600 of ~8-12). Concentrated cell pellets were obtained by centrifugation and 
AI media removed.  
2.4 Recombinant protein extraction 
2.4.1 Stock solutions 
1M HEPES buffer, pH 7.5 was prepared by dissolving 238.3g of HEPES powder in ~800ml of dd water, 
the pH adjusted to 7.5 with sodium hydroxide (NaOH). The final volume was made up to 1L with 
additional dd water and the solution was filtered sterilized with a 0.2µm bottle top filter unit (StarLabs) 
and stored at room temperature.  
2M magnesium chloride (MgCl2) was prepared by dissolving 95.2g of MgCl2 into a final volume of 500ml 
dd water, the solution was filtered sterilized with 0.2µm bottle top filter unit and stored at room 
temperature. 
50% glycerol was prepared by mixing 500ml dd water with 500ml 100% glycerol. The solution was 
sterilized either by filtration or autoclaved, and stored at room temperature.  




EDTA-free protease inhibitor cocktail was purchased in tablet form from Sigma-Aldrich (4693132001) 
used as per the manufacturer’s instructions. 
2.4.2 Soluble protein extraction 
2.4.2.1 Resuspension buffer 
100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol, DNase I solution and protease inhibitor tablets.   
2.4.2.2 Cell lysis and extraction of crude lysates 
Cell pellets obtained following expression of recombinant proteins (Section 2.3.3) were resuspended 
in resuspension buffer until completely homogenised. Cell lysates were prepared using a Bandelin 
sonuplus cell disruptor system on ice at 75% power for 20 minutes with 40 second sonication and 20 
second pause pulses. Cell debris was removed by centrifugation at 80,000xg for 30 minutes at 4°C 
(Beckman Coulter Optima L-80 XP ultracentrifuge, 70.1 Ti rotor). The supernatant was heat treated (30 
min at 70°C) and the centrifugation step repeated. The supernatant (referred to as crude 
enzyme/protein) achieved from this step was either used directly as an enzyme solution in assay 
conditions or purified further.  
2.5 Protein purification 
2.5.1 Purification buffers 
Stock solutions are described in Section 2.4.1. 
1M Tris-HCl buffer pH 7.5 was purchased from Thermo Fisher Scientific. 
1M sodium chloride (NaCl) was prepared by dissolving 58.44g NaCl in 1L of dd water. The solution was 
filtered sterilized with 0.2µm bottle top filter unit and stored at room temperature. 
1M imidazole solution purchased from Sigma-Aldrich (68268). 
1M ethylenediaminetetraacetic acid (EDTA) pH 8 was prepared by adding 93g of EDTA to ~200ml of dd 
water, adding NaOH to aid full dissolving and dd water to make a final volume of 250ml. The solution 
was filtered sterilized with a 0.2µm bottle top filter unit and stored at room temperature. 
Ni-NTA wash buffer- 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol. 
Ni-NTA elution buffer- 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol with an imidazole gradient 
of 50-1000mM. Where applicable, 100mM working concentration of EDTA was added to the collection 
tubes of elution buffer to avoid leeching of nickel  
Anion exchange wash buffer- 20mM Tris-HCl pH 7.5, 5% glycerol. 
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Anion exchange elution buffer- 20mM Tris-HCl pH 7.5, 5% glycerol with NaCl gradient of 50-1,000mM. 
2.5.2 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot 
2.5.2.1 Buffers and reagents 
5x Laemmli sample buffer was prepared using 1.25ml 0.5M Tris-HCl pH 6.8, 2ml 50% glycerol, 2ml 10% 
SDS (sodium dodecyl sulfate), 0.5ml β-mercaptoethanol (2-ME), 10µl bromophenol blue and 2.25ml 
dd water. 
SDS Tris buffer was prepared using 100ml 10x SDS Tris buffer (Geneflow) and 900ml dd water. 
Western Tris buffer was prepared using 100ml 10x Tris buffer (Geneflow), 200ml methanol and 700ml 
dd water.  
Phosphate buffered saline (PBS) was prepared with 10 PBS tablets dissolved in dd water to a final 
volume of 1L. 
PBS Tween 20 (Wash buffer) was prepared with 1L PBS and 2ml Tween 2 (0.2%). 
Blocking buffer was prepared by adding 2.5g of dried milk (5%) to 50ml of PBS. 
10% separating gel was prepared using 1.9ml 30% polyacrylamide, 1.5ml 1.5M Tris-HCl pH 8.8, 60 µl 
10% SDS, 2.15ml water, 20µl 20% ammonium persulfate and 4.5 µl TEMED 
(tetramethylethylenediamine). 
12% separating gel was prepared using 2.3ml 30% polyacrylamide, 1.5ml 1.5M Tris-HCl pH 8.8, 60 µl 
10% SDS, 1.8ml water, 20µl 20% ammonium persulfate and 4.5 µl TEMED.  
4% stacking gel was prepared using 0.3ml 30% polyacrylamide, 0.6ml 0.5M Tris-HCl pH 6.8, 25µl 10% 
SDS, 1.5ml water, 10µl 20% ammonium persulfate and 2.5µl TEMED.  
Antibodies used for western blot analysis:  
• Primary- 6x-His Tag Monoclonal antibody (Clontech 631212) 
• Secondary- Anti-mouse IgG HRP-linked antibody (NEB 7076S). 
2.5.2.2 SDS-PAGE preparation 
Glass plates were cleaned with 70% ethanol, allowed to dry and then inserted into clamps. The 10% 
separating gel was poured between the plates to approximately ¾ height. dd water was layered on top 
allowing the gel to set level. The water was poured off, the stacking gel was poured into the plates and 
a comb was then inserted before allowing the gel to set. The comb was removed when the gel 
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solidified. PageRuler plus prestained Protein ladder (Thermo Fisher Scientific 26619) was used for 
molecular weight reference. Samples to be loaded were prepared by mixing 20µl of sample with 5µl 
of 6x Laemmli sample buffer. Gels were then placed in a gel tank (Bio-Rad Protean 3 cell) and filled 
with SDS Tris buffer, loaded and run for 1.5 hours at 100V. The gel was then analysed by using a 
Coomassie protein stain for polyacrylamide gels (Expedeon ISB1L). 
2.5.2.3 Western blot preparation 
For western blot analysis, the SDS-PAGE was carried out as outlined in section 2.5.2.2, with the 
exception of adding the protein stain. Following SDS-PAGE, the stacking gel was removed from the 
separating gel and discarded. Fibre pads and filter papers (Whatman 3mm chromatography paper) 
were soaked in Western Tris buffer for 5 minutes. The PVDF (Polyvinylidene difluoride) (Bio-Rad 
1620177) membrane was soaked in methanol for 5 minutes before assembly as follows: 
• 1 Fibre pad 
• 3 filter papers 
• Gel 
• PVDF membrane 
• 3 filter pads 
• 1 fibre pad 
The cassette was placed into an electrical module after confirming the correct orientation. An ice block 
was placed into the tank and it was filled to just below the top of the cassette with the western running 
buffer. This was run for precisely an hour at 100V. Once the transfer was complete, the PVDF 
membrane was removed and placed into a plastic container. 50ml blocking buffer was added to it and 
left to block overnight covered in foil. The following day, 10µl primary antibody was added directly to 
the membrane in the blocking buffer at 1:5,000 dilution. This was then placed on rocker for 1 hour at 
30rpm at room temperature. After an hour, 3 washes were carried out with PBS Tween on a rocker for 
3-4 minutes per wash. 50ml fresh blocking buffer were then added to the membrane with 10µl 
secondary antibody at 1:5,000 dilution and rocked for an additional hour at 30rpm. 3 washes with PBS 
Tween were then repeated. An EZ-ECL chemiluminescence detection kit (Geneflow) was used to detect 
His-tagged protein bands according to the manufacturer’s protocol. The membrane was visualised 




2.5.3 Bicinchoninic acid (BCA) protein assay  
Protein concentrations were determined using 1mg/ml bovine serum albumin (BSA) as standard in a 
96-well plate. BSA standards were prepared at 0, 0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2mg/ml. All 
standards were loaded in a final volume of 10µl in triplicate. Unknown samples were also added in a 
final volume of 10µl at range of different concentrations, to ensure a sample falling within the linear 
range of the standard curve. 200µl BCA reagent (50:1 ratio (v/v) between BCA solution and 4% (w/v) 
copper II sulfate solution) was added to each well of standards and unknowns. The 96-well plate was 
incubated at 37°C for no more than 30 minutes. Absorbance values were measured at 562nm in a 
Multiskan™ FC Microplate Photometer (Thermo Fisher Scientific). A standard curve was generated and 
the unknown sample concentrations were calculated in mg/ml.  
2.5.4 Protein purification- Ni-NTA (nickel-nitrilotriacetic acid) affinity chromatography 
The crude protein extracts obtained (Section 2.4.2.2) were resuspended with Ni-NTA resin (Qiagen) 
and incubated to bind (magnetic stirrer) either at 4°C or room temperature overnight. Following this, 
the resuspension was added to a polypropylene column (GE) and the flow through was collected. This 
was followed by 5 column volume washes of the resin. The His-tagged protein was then eluted from 
the resin using an imidazole gradient. Samples from each stage were collected to detect proteins by 
SDS-PAGE, following which the samples of interest were isolated. If required, the protein samples were 
concentrated further using  an ultrafiltration unit, Vivaspin 20 centrifugal concentrators (molecular 
weight cut off 10kDa) by centrifugation at 3,900xg at 4°C. To ensure the PES (polyethersulfone) 
membranes of the concentrators did not get saturated and to prevent protein aggregation, the protein 
samples were not centrifuged for more than 10 minutes at a time and were resuspended by pipetting. 
The protein concentration was determined via bicinchoninic acid assay (BCA) and/or a NanoDrop. 
Confirmation of functional His-tagged protein was determined by western blot.  
2.5.5 Protein purification- ÄKTA 
Size exclusion chromatography was carried out on an ÄKTA pure protein purification system (GE). A 
Superdex 200 column with a 24ml bed column was used with a Unicorn version 7.0 software for 
analysis. The flow rate was set at 0.3ml/min and the fraction line and loop were washed with water 
followed by buffer (100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol). Following washes, 500 µl 
sample to be analysed was injected ensuring no air bubbles were injected into the system. After  the 
sample run had finished, the software-generated chromatogram was used to analyse sample 
compositions. Samples from each automated fraction were collected to detect proteins by SDS-PAGE, 
following which the samples of interest were isolated. If required, the protein samples were 
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concentrated further using concentrators as outlined in Section 2.5.4. The protein concentration was 
determined via bicinchoninic acid assay (BCA) and/or a NanoDrop.  
2.5.6 Protein purification- Anion exchange 
Anion exchange chromatography was employed as a secondary purification strategy whereby protein 
samples purified by Ni-NTA affinity chromatography were put through a secondary purification step in 
an attempt to improve overall purity. The protein sample to be analysed was buffer exchanged from 
100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer to 20mM Tris-HCl pH 7.5, 5% glycerol buffer. 
The anion exchange column was washed with 5 column volumes of wash buffer (20mM Tris-HCl pH 
7.5, 5% glycerol) then with the highest elution buffer (20mM Tris-HCl pH 7.5, 5% glycerol, 1M NaCl) for 
equilibration. The column was then equilibrated with 5 column volumes of wash buffer again. The 
protein sample was then applied to the column and circulated to ensure binding. The column was 
washed again with 5 column volumes of wash buffer or until the flow through appeared clear. 
Following this, elutions were performed with 5 column volumes of each NaCl gradient concentration. 
Samples from each stage were collected to detect proteins by SDS-PAGE, following which the samples 
of interest were isolated. If required, the protein samples were concentrated further using 
concentrators as outlined in Section 2.5.4. The protein concentration was determined via bicinchoninic 
acid assay (BCA) and/or a NanoDrop.  
2.5.7 Protein purification- Inclusion bodies extraction, resolubilisation and purification 
Due to poor recovery of soluble AIDH, cell pellets were treated for extraction, resolubilisation and 
purification of AIDH inclusion bodies.  
2.5.7.1 Buffer and reagents 
1M DL-Dithiothreitol (DTT) solution purchased from Sigma-Aldrich (43816). 
8M buffered guanidine hydrochloride (GdnHCl) solution purchased from Sigma-Aldrich (G7294). 
Triton X-100 purchased from Sigma-Aldrich (T8787).  
Lysis buffer: 






Protease inhibitors  
DNase I  
 
Wash buffer: 
100mM HEPES pH 7.5 
5mM EDTA 
5mM DTT 





100mM HEPES pH 7.5 
5mM EDTA  
6M GdnHCl 
5mM DTT/2mM 2-ME 
2.5.7.2 Inclusion bodies extraction, resolubilisation and purification protocol 
Recombinant AIDH was expressed as outlined previously in Section 2.3.3. The resulting pellet was 
obtained by centrifugation and resuspended into 5ml of freshly prepared lysis buffer per gram wet 
weight of cell. The pellet was resuspended into the buffer with the aid of a homogenizer until 
completely homogenized. Cell lysates were prepared using a Bandelin sonuplus cell disruptor system 
on ice at 75% power for 20 minutes with 40 second sonication and 20 second pause pulses. Cell debris 
was removed by centrifugation at 80,000xg for 30 minutes at 4°C. The supernatant (this soluble 
fraction was purified using Ni-NTA affinity chromatography to recover any soluble AIDH) was poured 
off and the resulting pellet was resuspended in wash buffer (5ml per gram wet weight cells) to ensure 
the washing out of soluble proteins and cellular components (cell wall and outer membrane material). 
GdnHCl or urea both can be utilized in the wash step. If using GdnHCl, SDS is not used as it forms a 
precipitate and was replaced with Triton X-100. SDS use was compatible when using urea. The wash 
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buffer was prepared in two versions, one including all the components as listed in Section 2.5.7.1, and 
one without Triton X-100 and GdnHCl. After adding the pellet to wash buffer, resuspending and 
homogenizing, the suspension was centrifuged at 80,000xg for 30 minutes at 4°C and the supernatant 
discarded. This step was repeated twice, following which the pellet was resuspended in wash buffer 
minus Triton X-100 and GdnHCl, homogenized and centrifuged at 80,000xg for 30 minutes at 4°C. This 
final wash without Triton X-100 and GdnHCl aided the removal of excess Triton X-100. If required, the 
washed pellets were stored at this stage. The pellet was then resuspended in extraction buffer at 1ml 
buffer per gram wet weight of the original cell pellet. The cell suspension was purified one of two ways: 
(i) dialysis into HEPES 100mM pH 7.5, 200mM MgCl2, 10% glycerol buffer with multiple cycles until 
GdnHCl, EDTA and DTT have been dialysed to a negligible amount or (ii) extracted unfolded protein 
refolded straight on the affinity column by binding with Ni-NTA resin and eluting protein with imidazole 
(in which case DTT was substituted with 2mM 2-ME in the extraction buffer).  
2.6 Enzyme assays 
Enzyme solutions (either crude or purified by techniques outlined in Section 2.5) were utilized for 
testing enzymatic activity. Standard assay conditions used for each enzyme are outlined in the sections 
below. Where the concentrations of enzyme or cofactor are subject to alteration depending on the 
experiment objectives, the actual assay conditions are mentioned in the respective results sections 
(Chapters 3-8). 
2.6.1 GDH experimental conditions 
2.6.1.1 GDH activity assay 
The activity of GDH was assayed in 100 mM HEPES pH 7.4, 2.5% glycerol, 30mM MgCl2, 100mM glucose, 
5mM NAD+. Unless otherwise stated, the activity assay for both immobilized and free-state GDH was 
conducted in a water bath at 55°C for 3 hours. At the end of the assay, samples were placed into pre-
cooled racks and supernatants were filtered through 0.2 µm filters. The activity of GDH was detected 
by measuring the NADH concentrations of the supernatants with a plate reader at 340 nm. The enzyme 
concentration was measured using the BCA method.  
2.6.1.2 Determination of kinetic constants  
The kinetic constants for free-state and immobilized GDH were determined by measuring the reaction 
rates at regular time intervals and different substrate concentrations (0, 0.1, 0.5, 1, 2.5, 5, 10, 25, 50, 




2.6.1.3 Support materials 
To immobilize GDH, three different commercial enzyme supports; methacrylate-based ECR8309F, 
styrene-based ECR1090M and methacrylate/divinylbenzene-based ECR1030M were purchased from 
Purolite, UK. Meso-macroporous SBA-15 (MM-SBA-15) was synthesised by Dr Jinesh Cherukkattu 
Manayil via a modified true liquid crystal templated (TLCT) SBA-15 synthesis (Parlett et al. 2013) which 
included a hard macropore template of polystyrene spheres. Polystyrene spheres were synthesised as 
reported elsewhere (Manayil et al. 2017). The structure-directing template (Pluronic P123l; 2 ml) was 
mixed with hydrochloric acid acidified water (~pH 2, 2.1ml) and sonicated at 40°C to produce a 
homogeneous gel. The sol-gel exhibited a hexagonal mesophase. 6g polystyrene were added to the 
sol-gel with stirring, resulting in the formation of a viscous solution. Tetramethoxysilane (4ml) was 
added and mixed with stirring to form a homogeneous liquid at 40°C. The evolved methanol was 
removed under a light vacuum (0.12 bar) at 40°C to form a viscous gel overnight. The gel was exposed 
to the atmosphere at room temperature for 24 hours to complete condensation before calcination at 
500°C for 6 hours in air (ramp rate 2°C/min). The products were designated MM-SBA-15-300 and MM-
SBA-15-200, 300 and 200 according to the size of the polystyrene beads used in the synthesis. Low 
angle XRD patterns were recorded on a Bruker D8 Advance diffractometer fitted with an X’celerator 
detector and Cu Kα (1.54 Å) source over the range 2θ = 0.3-10°. Nitrogen porosimetry was measured 
on a Quantachrome Nova 4000 porosimeter and analysed with NovaWin software. Samples were 
degassed at 120 °C overnight prior to analysis at -196 °C. Brunauer-Emmett-Teller (BET) surface areas 
were calculated in the relative pressure range of 0.01−0.2. The Barret-Joyner-Halenda (BJH) method 
was used to calculate pore diameters and pore volumes in the desorption isotherm for relative 
pressures >0.35. The polystyrene bead size and morphology of synthesised MM-SBA-15-200 and MM-
SBA-15-300 were evidenced using Scanning Electron Microscope (SEM).  
2.6.1.4 Immobilization of GDH  
The immobilization of recombinant GDH onto different support materials was done by gently mixing 
the enzyme and the support material with enzyme support solution (ES- 100mM HEPES pH 7.4, 2.5% 
glycerol, 50 mM MgCl2) at room temperature for 10 min. Unless otherwise stated, 0.03 mg GDH and 
0.01 g support material were mixed with 1 ml ES. Following this, mixtures were stored at 4°C overnight. 
The amount of immobilized enzyme was detected by measuring the protein concentration before and 
after immobilization. Immobilization yield (%) was calculated using the equation below.  






Where C0 and CS denote the amount of enzyme before and after immobilization (mg), respectively (in 
collaboration with Dr Pinar Karagoz). 
2.6.1.5 Thermal stability of free-state and immobilized GDH  
The thermal stability of free-state and immobilized GDH was investigated at 55, 65 and 80°C after 1, 3, 
18 and 24 hours. 0.03 mg free-state or immobilized GDH in 500 µl ES were incubated as required, 
instantly cooled down on ice for 2 min and stored at 4°C for 20 min. Cooled samples were gently mixed 
with assay mixture and the activities of free and immobilized GDH were evaluated as described in 
Section 2.6.1.1 (in collaboration with Dr Pinar Karagoz). 
2.6.1.6 Reusability of immobilized GDH  
To detect the reusability of GDH immobilized onto different supports, the immobilized enzyme was 
washed with ES after each use and stored at 4°C overnight and then re-suspended in fresh assay 
mixture to determine remaining activity. This procedure was repeated 10 times. The activity of the 
enzyme in the first cycle was defined as 100% and the remaining activities were calculated as follows:  




where a1 and aX2….10 denote the enzyme activity at the end of the first and subsequent cycles, 
respectively (in collaboration with Dr Pinar Karagoz). 
2.6.1.7 Effect of immobilization on storage stability  
The free-state and immobilized GDH were stored at 4°C to detect the effect of the support material 
and immobilization on their storage stability. The activity of the GDH was determined at 4-week time 
intervals (in collaboration with Dr Pinar Karagoz). 
2.6.1.8 Determination of optimum temperature and pH  
The activity profiles were studied at different temperatures (30-80°C) and pH ranges (5.0-10.5). The 
pH of the GDH assay buffer was adjusted using 3M HCl, 1M and 100mM NaOH (in collaboration with 
Dr Pinar Karagoz). 
2.6.1.9 Preparation of Bread Waste Hydrolysate (BWH)  
Sliced, soft white packaged bread (Warburton) was used as a feedstock. According to the 
manufacturer’s nutritional information, one slice of bread (wet weight 28.8g) contained 13.1g 
carbohydrate (of which 0.8g were sugars), 2.6g protein and 0.6g fat. Slices were dried at 37°C overnight 
and broken into small pieces by hand.  Pieces from 1 slice of bread were transferred into 250 ml 
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Erlenmeyer flasks, 100 ml water was added and the flask was placed in a shaking incubator at 60°C, 
200 rpm for 1 hour. As previously described (Benabda et al. 2018), 5mg α-amylase from Aspergillus 
oryzae (Sigma-Aldrich 10065) and 7mg amyloglucosidase from Rhizopus sp. (Sigma-Aldrich A9228) 
were added to each flask and incubated at 60°C for 1.5 hours. Solid particles were separated by 
centrifugation for 20min, at 4100×g and 4°C. The supernatant was transferred into a flask and 
autoclaved at 121°C for 15 min. The glucose concentration of the hydrolysate and utilization of glucose 
by GDH was measured using glucose assay (Sigma-Aldrich GAGO20S) and gluconic acid assay (Sigma-
Aldrich MAK279) kits. To investigate the activity and stability of free-state and immobilized GDH, BWH 
was used as the sole glucose source. The glucose concentration of the reaction mixture was set to 
100mM using BWH liquor.  Free and immobilized GDH were tested in 10ml reactions in 50ml sterile 
Falcon tubes placed in an orbital shaker at 200rpm and 55°C. Samples were taken during 3 hour 
reactions.  Before measuring NADH, glucose and gluconic acid concentrations, samples were filtered 
through 0.2 µm filters and deproteinized using 10 kDa cut-off spin filters. As previously described, after 
3 hours the supernatant was removed and the supports with immobilized enzymes were kept in ES 
overnight at 4°C and re-used in a new BWH-containing reaction mixture 10 times (Dr Pinar Karagoz). 
2.6.1.10 SEM analysis  
Scanning electron microscopy (SEM) images were taken with Dr Jinesh Cherukkattu Manayil using a 
JEOL JSM-7800F instrument equipped with EDX and operating at 10 kV. The samples were mounted 
using carbon tape on a sample holder. The images were also taken before and after enzyme 
immobilization to check the distribution of enzyme on the supports and to confirm their structural 
integrity. 
2.6.2 DHAD experimental conditions 
2.6.2.1 DHAD activity assay 
As standard, the activity of DHAD was assayed in 100 mM HEPES pH 7.5, 2.5mM MgCl2, 10mM gluconic 
acid or 10mM glyceric acid. Unless otherwise stated, the activity assay for DHAD was conducted in a 
shaking heat block at 55°C, 300rpm for 2 hours. At the end of the assay, samples were placed into pre-
cooled racks and supernatants were filtered through 0.2 µm filters. The activity of DHAD was detected 
either by ion chromatography (IC), gluconic acid assay (MAK279-1KT) kits and/or pyruvic acid assay 






2.6.2.2 Activation of DHAD using β-mercaptoethanol 
Activation of purified and crude DHAD was carried out as described elsewhere (Carsten et al. 2015). 
DHAD enzyme solution was incubated with 100mM HEPES pH 7.5 and 98mM 2-ME at 70°C for 45 
minutes. Any precipitated proteins were removed via centrifugation at 18,000xg and the solution was 
buffer exchanged into 100mM HEPES pH 7.5 buffer.  
2.6.2.3 Determination of kinetic constants  
The kinetic constants for DHAD were determined by measuring the reaction rates at regular time 
intervals and different substrate concentrations (1, 2, 4, 6, 8, 10, 15, 20mM). Km and Vmax values were 
calculated from Lineweaver-Burk plots.  
2.6.2.4 Effect of storage on DHAD activity  
DHAD stock solution was tested for activity under the same assay conditions over a 50 day period.  
2.6.3 KDGA experimental conditions 
2.6.3.1 KDGA activity assay 
As standard, the activity of KDGA was assayed in 100 mM HEPES pH 7.5, 20mM glyceraldehyde and 
40mM pyruvate. Unless otherwise stated, the activity assay for KDGA was conducted in a shaking heat 
block at 55°C, 300rpm for 2 hours. At the end of the assay, samples were placed into pre-cooled racks 
and supernatants were filtered through 0.2 µm filters. The activity of KDGA was detected by IC.  
2.6.3.2 Determination of kinetic constants 
The kinetic constants for KDGA were determined by measuring the reaction rates at regular time 
intervals and different substrate concentrations (0.5, 1, 3, 5, 10, 20mM glyceraldehyde and 1, 2, 6, 10, 
20, 40mM pyruvate in each condition respectively). Km and Vmax values were calculated from 
Lineweaver-Burk plots.  
2.6.4 AIDH experimental conditions  
2.6.4.1 AIDH activity assay 
As standard, the activity of AIDH was assayed in 100 mM HEPES pH 7.5, 100mM glyceraldehyde and 
5mM NAD+. Unless otherwise stated, the activity assay for AIDH was conducted in 96 well plates in a  





2.6.5 MDH experimental conditions 
2.6.5.1 MDH activity assay 
As standard, the activity of MDH was assayed in 500mM HEPES pH 7.5, 5mM NH4Cl, 0.5mM MnCl2, 
30mM pyruvate, 85mM NaHCO3 and 1mM NADH. Unless otherwise stated, the activity assay for MDH 
was conducted in 96 well plates in a FLUOstar Omega Microplate Reader fitted with an atmospheric 
control unit at 55°C for 2 hours at 15% CO2 and 5% O2. The activity of GDH was detected by monitoring 
the timely NAD+ concentrations of the supernatants with a plate reader at 340 nm.  
2.6.5.2 Determination of kinetic constants 
The kinetic constants for MDH were determined by measuring the reaction rates at regular time 
intervals and different substrate levels (0-75mM). Km and Vmax values were calculated from Lineweaver-
Burk plots.  
2.7 Standard curves 
2.7.1 NADH standard curve 
For the reaction using NAD+/NADH as cofactor, the reaction progression can be followed by monitoring 
the reaction at 340nm. The concomitant formation/reduction in NADH levels were used to measure 
the concentration of product formed. 
 
Figure 2.1. NADH absorbance standard curve. Concentrations of 0-1mM of NADH were assayed in triplicate and 
their absorbance was measured at 340nm at 55°C for 30 minutes. No significant change was observed in the 























2.7.2 IC standard curves 
For enzymatic analysis via IC, known standard concentrations of enzymatic substrates/products were 
analysed via IC to produce standard curves. These standard curves were then used to calculate the 
unknown concentrations of chemicals of interest.  All samples analysed via IC were performed in a 
Dionex™ Integrion™ HPIC™ System (Thermo Fisher Scientific). Unless otherwise stated all samples 
were diluted x10 and detected under reaction conditions of 5mM eluent at 30°C at 0.38ml/min flow 
rate.  
 























Figure 2.3. 2-keto-3-deoxygluconate standards as analysed via IC, each data point is an average of triplicate 



































































































3. Cascade design to facilitate the conversion of glucose to malic acid 
 
As per the main objective for the basis of this thesis, a synthetic cell-free enzymatic biosystem 
consisting of 5 enzymes was designed to facilitate the conversion of glucose to malic acid (Figure 3.1). 
The conversion of glucose to the key intermediate pyruvate was achieved via a modified non-
phosphorylative branch of the Entner-Doudoroff pathway modelled on hyperthermophilic archaea 
(Ahmed et al. 2005). Pathway design takes into account the requirements of an efficient cell-free 
system as it is designed to minimise unwanted intermediates and is cofactor balanced. Cutting down 
time and cost consuming purification of enzymes has been mitigating by employing thermophilic 
enzymes which provide the option of one step heat denaturation preparation of enzyme solutions.  
 
Figure 3.1. Schematic representation of artificial cell-free minimised enzymatic reaction cascade designed to 
produce malic acid (malate) from glucose. Dihydroxy-acid dehydratase being an enzyme with dual function, 
catalyses 2 reactions; gluconate to 2-keto-3-deoxygluconate, and is later responsible for the redirection of 
undesirable intermediate glyceraldehyde into pyruvate. Molecules of CO2 and H2O used or released in the 
individual reaction steps are not shown. 
 
Previous research into cell-free production of malic acid has been successfully demonstrated as 
outlined in Chapter 1, Section 1.3.2 (Ye et al. 2013), however the number of enzymes employed in the 
synthetic cascade have been in excess of 10. This is economically unfavourable as increasing the 
number of enzymes in the cascade leads to a higher number of intermediates which can affect final 
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yields of the product of interest (Dudley et al. 2015) Use of enzymes from thermophilic sources not 
only offers ease of purification, their unique metabolic pathways also offer shorter routes to key 
metabolic intermediates such as pyruvate (Conway 1992). This was adapted successfully into the 
design and the number of enzymes employed in the cascade is 5, with added redirection of unwanted 
intermediates into key intermediates (Figure 3.1). 
The enzymes used in the cascade design have all been employed from thermophilic organisms due to 
the thermostable advantages offered (Ninh et al. 2015, Zhang 2015) including one step heat 
denaturation purification. The Glucose dehydrogenase (GDH) and dihydroxy acid dehydratase (DHAD) 
gene sequences were obtained from Sulfolobus solfataricus, 2-keto-3-deoxygluconate aldolase (KDGA) 
from Sulfolobus acidocaldarius, glyceraldehyde dehydrogenase (AIDH) from Thermoplasma 
acidophilum and NADP (H)-dependent malic enzyme (MDH) was obtained from Thermococcus 
kodakarensis (gene sequences in appendix). To avoid phosphorylation and dephosphorylation steps in 
the pathway design, promiscuity of S. solfataricus DHAD has been exploited (Kim and Lee 2006), which 
is key to catalysing the transformation of both gluconate to 2-keto-3-deoxygluconate and glycerate to 
pyruvate, the latter transformation being the redirection of an unwanted intermediate into one that 
can be actively used in the cascade design. Employing AIDH aids with the reaction dynamic shift 
towards pyruvate formation as well as maintaining cofactor balance. Using NADH as the only electron 
carrier further minimizes reaction complexity (Guterl at al. 2012). Exploiting enzymes from the Entner-
Doudoroff pathway has formed the basis of some cell-free biosystems as outlined in Chapter 1. The 
unique coupling of enzymes from the Entner-Doudoroff pathway and an engineered malate 
dehydrogenase with altered reaction specificity to produce malate from glucose was explored here in 
an artificial cascade, as well as investigating immobilization strategies. Thermodynamically, this 
reaction cascade is considered to be favourable as it is adapted from enzymes in the naturally occurring 
Entner-Doudoroff pathway as outlined in Figure 1.6. Taking into consideration the general rules for 









4. Using glucose dehydrogenase from Sulfolobus solfataricus to catalyse the first reaction step and 
produce gluconate from glucose 
 
Glucose dehydrogenase (GDH) from the thermoacidophilic archaebacterium Sulfolobus solfataricus 
utilises a unique non-phosphorylative Entner-Doudoroff pathway to metabolise both glucose and 
galactose (Theodossis et al. 2005). Not only does it catalyse the oxidation of glucose to gluconate, it 
has been cited to show activity with a wide range of sugar substrates to further include xylose and L-
arabinose (Milburn et al. 2006). These properties make GDH an attractive enzyme to catalyse the initial 
breakdown to sugars in multiple cascade systems. For the purpose of the cascade discussed in this 
thesis, GDH was used to catalyse the following reaction: 
Glucose + NAD+  Gluconate +  NADH 
This chapter discusses the protein expression, purification and characterization of GDH. The key 
challenges faced in finding suitable methods of successful large-scale protein production are also 
explored. Immobilization has been used by many researchers to overcome instability problems and 
facilitate the repetitive use of enzymes, furthermore, it has the possibility to improve enzymatic 
efficiencies due to the increase of local enzyme concentration (Ahmed et al. 2017). Two novel, 
hierarchically-structured silica-based supports were developed for this purpose and the activity of 
free-state and immobilized GDH were compared under different pH and temperature conditions to 
assess their activity. This chapter also explores the stability, long-term storage and the re-use of 
immobilized GDH. To study the potential of an enzymatic approach to waste valorisation, the 
generation of gluconate from bread waste hydrolysate (BWH) using immobilized GDH was also 
analysed.   
4.1 Transformation of GDH vector DNA into BL21-DE3 competent cells 
Synthesised pET30a vectors containing GDH sequence arrived as a concentrated miniprep of ~4µg of 
DNA from GenScript (sequence in appendix). The original vector sample was archived and 
transformation of vector into DH5α competent cells was done followed by a miniprep to obtain 50µl 
of quantified vector DNA. GDH was transformed into BL21-DE3 cells as they have favourable 
characteristics for recombinant protein production such as protease deficiency, low acetate 
production under high glucose conditions and high permeability. Following successful transformation, 
single colonies were used to initiate protein expression. LB agar kanamycin plates with the successful 
transformation of vector DNA into BL21-DE3 were also used to prepare glycerol stocks for storage at -




Figure 4.1. Quantified vector DNA obtained following miniprep was transformed into competent BL21-DE3 cells, 
successful transformation is shown by the presence of bacterial colonies on LB kanamycin plate. 
 
4.2 Small scale GDH protein expression and purification in LB and AI media 
Following the successful transformation of GDH vector DNA, protein expression and purification was 
initially carried out in a 1L final volume. Initial GDH expression was carried out in AI media with a final 
concentration of kanamycin at 50µg/ml at room temperature overnight. The cell pellet obtained from 
the cultures were resuspended, sonicated and heat treated as outlined in the methods sections. All 
resuspension, sonication, heat treatment and centrifugation steps were carried out in a 100mM HEPES 
pH 7.5, 50mM MgCl2, 10% glycerol buffer unless otherwise stated. The suspension obtained following 
cell lysis, heat treatment at 70°C to denature host cellular components and centrifugation to remove 
cell debris, was used as GDH crude enzyme fraction. This crude GDH fraction was used to confirm 
enzyme activity before purification with Ni-NTA affinity chromatography.  
4.3 Establishing enzymatic activity with crude GDH fraction 
Before purifying the crude GDH fraction obtained in section 4.2, the crude fraction was assayed for 
activity by assaying GDH for catalysing the conversion of glucose to gluconate. The concentration of 
GDH in the crude fraction was not determined and 1ml of crude GDH was used in a 6ml reaction volume 
with the sole purpose of detecting any gluconate present. Any gluconate formed was detected via 
analysis with IC as outlined in the methods section. 50mM of glucose was used as substrate with 5mM 
of the cofactor, NAD+. The reaction was set up in triplicate with 4 reaction controls as well, control1 of 
5mM gluconic acid as a positive control for the IC, control2 without any glucose, control3 without any 
66 
 
NAD+ and control4 without any crude GDH. All assay conditions and control conditions were incubated 
at 60°C for 1.5 hours before deproteinizing all samples that contained crude GDH followed by analysis 
via IC. A gluconic acid standard curve (Figure 2.1) was used to calculate the concentration of gluconate 












Gluconic acid (mM) 6.20 5.12 N/D N/D N/D 
Table 4.1. IC analysis of gluconic acid production via crude GDH assayed with 50mM glucose and 5mM NAD+ as 
substrate and cofactor respectively. Standard deviation for assay conditions= <0.134. N/D=None detected. 
 
Positive enzymatic activity was successfully established via the crude GDH assay. 6.2mM of gluconate 
was detected via IC in the assay conditions, with the overestimation attributed to error associated with 
the standard curve. The positive control for the IC analysis also matched to what was expected, 5mM 
of known gluconic acid was loaded onto the IC as calculated using the peak area and gluconic acid 
standard curve and was calculated to be 5.12mM which is a slight over estimation by 0.12mM, but still 
within range. As expected, no peaks corresponding to gluconic acid were seen in controls 2, 3 and 4 as 
these conditions were missing either the substrate (glucose), cofactor (NAD+), or crude GDH 
respectively. The retention time for all peaks corresponding to gluconic acid were all observed to be 
similar. Following on from positive confirmation of enzymatic activity in crude GDH, the crude fraction 
was then purified via Ni-NTA chromatography in the following section.  
4.4 Ni-NTA affinity chromatography of crude GDH  
The crude fraction of GDH (50ml in 100mM HEPES pH 7.5, 50mM MgCl2, 10% glycerol buffer) obtained 
from small scale expression of GDH as outlined in section 4.2, was bound to 5ml of Ni-NTA overnight 
at room temperature. Following this, the suspension was transferred to polypropylene column and the 
flow through was collected and the Ni-NTA resin washed with 100mM HEPES pH 7.5, 50mM MgCl2, 
10% glycerol buffer. A gradient consisting of 50mM-1M imidazole in 100mM HEPES pH 7.5, 50mM 
MgCl2, 10% glycerol buffer was then used to elute off bound protein. All samples collected from Ni-
NTA affinity chromatography were analysed via SDS-PAGE (Figure 4.2). GDH binding to Ni-NTA via the 
His10 tag was successful as evident from comparing samples in Lane 2 and 3 of Figure 4.2. Crude GHD 
sample in Lane 2 presents a thick band at around 43kDa which is the size of the GDH monomer. As 
seen in Lane 3 of Figure 4.2, after binding the crude fraction with Ni-NTA and collecting the flow 
through, the intensity of the band at size 43kDa was considerably less indicating the GDH in the crude 
fraction had successfully bound to the Ni-NTA resin. 400-600mM imidazole was indicated to the 




Figure 4.2. SDS-PAGE analysis of Ni-NTA purification attempt of GDH. Samples in all lanes, except Lane 2, are 
from elutions obtained from the column following Ni-NTA affinity chromatography. Lane 2 contains sample of 
crude GDH prior to binding with Ni-NTA resin. Lane 3 contains the flow through collected from column and Lane 
4 contains the HEPES buffer washes (100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2). Lanes 6, 7, 8, 9, 10, 11 
and 12 contain HEPES buffer imidazole elutions with 50, 100, 200, 400, 600, 800 and 1000mM imidazole 
respectively.  
 
Fractions from Lanes 9, 10 and 11 of Figure 4.2 containing the highest amount of GDH eluted were 
pooled (30ml final volume). 100mM final concentration of EDTA was also added to the sample to aid 
dialysis. Previous attempts of purification of an unrelated glucose dehydrogenase had highlighted the 
idea of using EDTA to stop protein aggregation during dialysis. Previous attempts of purifying another 
GDH had run into multiple instances of protein aggregation during the dialysis stage. A solution to this 
was explored via the addition of 100mM final concentration of EDTA to the dialysis tubing. The elution 
of bound protein with imidazole also leads to leached nickel ions from the column and into the 
collection tubing. During Ni-NTA affinity chromatography, both imidazole and the His10 tag chelate the 
nickel, and the removal of just imidazole during dialysis can result in the sample being insoluble. The 
addition of EDTA assists successful dialysis as it is assumed to chelate the nickel ions and thereby 
prevents protein-protein self-interactions and a successful dialysis cycle. The 30ml of GDH solution was 
successfully put through 3 cycles of dialysis until the imidazole and EDTA were dialysed out and their 
respective concentrations in the solution were negligible. The GDH sample was then concentrated 
down in volume and its protein concentration was determined via BCA to be 4.42mg/ml. 
4.5 Size-exclusion chromatography and protein identification of GDH to determine presence of 
oligomers 
The small scale expression of GDH gave a single band on the SDS-PAGE matching the expected size of 
the GDH monomer (Figure 4.2, Lane 9), however there are other non-specific bands. To confirm the 
ratio of protein of interest versus non-specific proteins in the eluted fractions, GDH from section 4.4 
was diluted down to 1mg/ml and loaded onto the ÄKTA system and, as size-exclusion chromatography 
separates molecules in solution based on their molecular weight, the peaks on a chromatogram are 
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indicative of the different size proteins in the sample. The chromatogram obtained from the size-
exclusion of GDH (Figure 4.3) automatically identified 2 peaks and aliquoted them into a collection 
plate as different fractions.  
 
B 
Peak Retention (ml) Area (ml*mAU) Area % Fractions Volume (ml) 
a 0.17 0.77 0.17 A1 0.5 
b 13.45 447.9 99.83 C2-C11 5 
Figure 4.3. Size exclusion chromatography of GDH. Figure 4.3A displays the chromatogram obtained from the 
software. The blue trace represents the UV absorbance at 280nm and the 3 peaks are indicative of the quantity 
of protein detected. The brown trace reflects the conductivity monitor which measures conductivity of buffer 
and samples for online monitoring of the true gradient. The green trace is applied if there is another buffer being 
used, since this sample was run in one buffer only, the trace has a value of 0. Figure 4.3B lists the retention time 
of each peak as well as the final volume collected of all fractions.  
 
The samples corresponding to those in peak B were determined to be GDH via SDS-PAGE. As this peak 
made up more than 99% of the total sample loaded, the sample was taken to be 100% GDH.  
4.6 Testing enzymatic activity of purified GDH via NADH absorbance assay at 340nm 
Following the purification of crude GDH via Ni-NTA affinity chromatography, a 4.42mg/ml enzyme 
stock was obtained. This purified stock was tested for functional activity to catalyse the conversion of 
glucose to gluconate. As this reaction uses a cofactor in the form of NAD+, the primary catalysed 
reaction can be indirectly followed by the formation of NADH. NADH shows absorption at 340nm while 
NAD+ does not, hence any increase in absorbance as measured at 340nm can be correlated to the 
formation of gluconate as NADH forms a secondary by-product from this reaction as the reaction ratios 




The activity of purified GDH was tested at 6 different enzyme concentrations, 0.003, 0.015, 0.03, 0.06, 
0.15 and 0.3mg/ml. All conditions were done in triplicates with 3 reaction controls, control1 without 
any GDH, control2 without any cofactor, NAD+, and control3 without any substrate, glucose. The assay 
conditions were 100mM HEPES pH 7.5, 50mM MgCl2, 10% glycerol, 50mM glucose and 5mM NAD+ as 
outlined in the methods. The assay conditions were consistent through all conditions and the only 
different variable was the protein concentration of GDH added. The assay and control conditions 
reagents were loaded into 96 well plates, followed by the addition of the relevant concentration of 
GDH to each corresponding condition before immediately starting absorbance readings at 340nm for 
120 minutes at 60°C. Reaction control 1 was used the background absorbance value and this was 
deducted from the absorbance values of all the assay condition (Figure 4.4). 
  
Figure 4.4. NADH absorbance curves at 340nm from 6 different GDH assay conditions with 6 enzyme 
concentrations at 0.003, 0.015, 0.03, 0.06, 0.15 and 0.3mg/ml GDH. Standard deviations for all GDH assay 
conditions: 0.003mg/ml= <0.088, 0.015 mg/ml= <0.22, 0.03 mg/ml= <0.21, 0.06 mg/ml= <0.19, 0.15 mg/ml= 
<0.196 and 0.3 mg/ml= <0.22.  
 
NADH standard curve (Figure 2.1) was used to calculate the final concentration of NADH formed in all 
reaction conditions, however this posed an issue. As seen in Figure 4.4, all conditions upon reaching 



















0.003mg/ml GDH 0.015mg/ml GDH 0.03mg/ml GDH
0.06mg/ml GDH 0.15mg/ml GDH 0.3mg/ml GDH
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absorbance values getting out of absorbance range for the plate reader. Only the 0.003mg/ml GDH 
condition had an end absorbance 340nm that that fell within the range of the standard curve after the 









2.21 3.06 3.02 2.97 2.98 2.98 
NADH (mM) 0.83 1.15 1.14 1.12 1.12 1.12 
Table 4.2. End point NADH absorbance readings of GDH assays at 6 enzyme concentrations, 0.003, 0.015, 0.03, 
0.06, 0.15 and 0.3mg/ml GDH, after 120 minutes. NADH standard curve (y= 2.6583x, R²= 0.9975) was used to 
calculate the NADH mM formed. Only the 0.003mg/ml had an end point reading which fell within the range of 
the NADH standard curve, remaining 5 assay conditions (grey, italics) had end values outside the range of the 
curve, thereby the NADH concentration calculated are not reliable.  
 
Following the failure to accurately calculate the concentration of NADH formed in 5 assay conditions, 
all assay conditions were analysed via IC and concentration of gluconate measured via the peak formed 
and gluconic acid standard curve (Figure 2.2). 
4.7 Analysis of gluconate formation in GDH assays carried out in section 4.6 via IC 
Samples from the assays in section 4.6 were deproteinized after the assay was completed at 120 
minutes. Following these, the samples were analysed via IC for gluconate formation as outlined in the 
methods section. As mentioned at the end of the previous section, the gluconic acid standard curve 
was used to calculate the concentration of gluconate formed in all assay conditions (Table 4.3). Control 
1, without any GDH, was also loaded for comparative purposes and no peak was seen at the retention 




0.003 0.015 0.03 0.06 0.15 0.3 
Gluconic acid (mM) 2.92 3.24 4.59 5.08 5.50 5.56 
Table 4.3. IC analysis of samples from GDH assays at 6 enzyme concentrations, 0.003, 0.015, 0.03, 0.06, 0.15 and 
0.3mg/ml GDH, after 120 minutes, deproteinized and analysed for gluconate formation. All calculated gluconic 
acid mM concentrations are from gluconic acid standard curve (y = 1.2304x, R²= 0.9967).  
 
Following the analysis of these samples via IC, the 0.003mg/ml GDH sample analysed via NADH assay 
as outlined in Table 4.2 was directly comparable to the 0.003mg/ml GDH sample analysed via IC as in 
Table 4.3. As mentioned previously, the conversion of glucose to gluconate as catalysed by GDH, uses 
of a cofactor in the form of NAD+. The primary catalysed reaction can be indirectly followed by the 
formation of NADH. NADH shows absorption at 340nm while NAD+ does not, hence any increase in 
71 
 
absorbance as measured at 340nm can be correlated to the formation of gluconate as NADH forms a 
secondary by-product from this reaction. As the reaction ratios are 1:1, 1mM of NADH formed should 
theoretically equate to 1mM of gluconate. Therefore, the NADH mM concentration calculated in Table 
4.2 should be similar in value to the gluconic acid concentration calculated from analysis via IC. These 
values, however showed a big difference between the amount of gluconate as calculated via NADH 
absorbance assay (0.83mM) and that calculated via IC (2.92mM), so there was a considerable 
discrepancy with data for which the expectations for both methods of analysis are to obtain similar 
values. This discrepancy could have been caused due to the experimental design of the NADH 
absorbance assay (Figure 4.4). End point readings were not reliable in this experiment and in spite of 
the end value of the 0.003mg/ml condition was within the range of the NADH standard curve, it was 
near the highest end where the values begin to fall out of the linear range, by this analogy the end 
point value of even the 0.003mg/ml GDH assay condition cannot be taken in full confidence. The 
discrepancy was explored further by repeating GDH with selected enzyme concentrations and time 
points. 
4.8 GDH activity analysis via NADH absorbance assay at 340nm and IC to determine efficiency of 
methods of analysis 
Following the inconsistency between in the gluconic acid concentrations calculated via NADH 
absorbance assay at 340nm and IC analysis, a new set of experiments were performed to determine if 
both methods of analysis are able to provide similar concentrations of gluconic acid at the end points. 
The same experiment as outlined in section 4.6 was set up again with the following changes as these 
conditions offer intermediate initial rates of reactions as seen in Figure 4.4. The activity of purified GDH 
was tested at only 2 enzyme concentrations, 0.03 and 0.06mg/ml. All conditions were done in 
triplicates with a reaction control without any GDH. The assay conditions were 100mM HEPES pH 7.5, 
50mM MgCl2, 10% glycerol, 50mM glucose and 5mM NAD+ as outlined in the methods. The assay and 
control conditions were loaded into 96 well plates, followed by the addition of the relevant 
concentration of GDH to each condition before immediately starting absorbance readings at 340nm 
for either 10 or 20 minutes at 60°C. 2 time points were tested as the absorbance curve in Figure 4.4 
indicates the absorbance values around these time points for the 2 GDH concentrations tested, fall in 
the middle of the NADH standard curve, thereby omitting reliability issues with any data obtained.  
Reaction control 1 was used the background absorbance value and this was deducted from the 
absorbance values of all the assay conditions. Following the completion of the 2 reaction conditions at 
10 and 20 minutes, the end point value was converted to the amount of NADH formed via the NADH 




0.03mg/ml GDH 0.06mg/ml GDH 
Reaction time (min) 10 20 10 20 
Absorbance 340nm 
after 120 minutes 
1.06 2.07 1.83 2.74 
NADH (mM) 0.80 1.56 1.38 2.06 
Table 4.4. End point NADH absorbance readings of GDH assays at 2 enzyme concentrations, 0.03 and 0.06mg/ml 
GDH, after 10 and 20 minutes. NADH standard curve (y= 2.6583x, R²= 0.9975) was used to calculate the NADH 
mM formed. 
 
Samples from the GDH assays performed above were deproteinized after the assays was completed at 
10 and 20 minutes. Following this, the samples were analysed via IC for gluconate formation as 
outlined in the methods section. A gluconic acid standard curve was used to calculate the 
concentration of gluconate formed in all assay conditions (Table 4.5). Control 1, without any GDH, was 
also loaded for comparative purposes and no peak was seen at the retention time of gluconic acid in 
the control sample.  
 
0.03mg/ml GDH 0.06mg/ml GDH 
Reaction time (min) 10 20 10 20 
Gluconic acid (mM) 0.96 1.61 1.50 2.46 
Table 4.5. IC analysis of samples from GDH assays at 2 enzyme concentrations, 0.03 and 0.06mg/ml GDH, after 
10 and 20 minutes, deproteinized and analysed for gluconate formation. All calculated gluconic acid mM 
concentrations are from gluconic acid standard curve (y = 1.2304x, R²= 0.9967). 
 
After analysing samples from the 2 GDH enzyme and time conditions with 2 different methods of 
quantification, the data obtained displayed similar values as expected. The 0.03mg/ml GDH assay at 
10 minutes was calculated to have formed 0.8mM gluconate via NADH absorbance assay whereby 
analysis via IC calculated gluconate concentration to be 0.96mM. At 20 minutes the values calculated 
were different by 0.05mM only as the 0.03mg/ml GDH assay at 20 minutes was calculated to have 
formed 1.56mM gluconate via NADH absorbance assay whereby analysis via IC calculated gluconate 
concentration to be 1.61mM. For the 0.06mg/ml GDH assay at 10 minutes, 1.38Mm gluconate was 
calculated via the NADH absorbance assay and 1.50mM via IC, and at 20 minutes, 2.06mM gluconate 
calculated via NADH absorbance assay and 2.46mM via IC. The trend in values was much closer here 







The following work was done in collaboration with Dr Pinar Karagoz and Dr Jinesh Cherukkattu 
Manayil.  
4.9 Immobilization of purified GDH 
Immobilization has been used by many researchers to overcome instability problems and facilitate the 
repetitive use of enzymes (dos Santos et al. 2015). Furthermore, it has the possibility to improve 
enzymatic efficiencies due to the increase of local enzyme concentration (Ahmed et al. 2017). The 
successful development of an immobilized enzyme process depends on the properties of the enzyme, 
the specific immobilization process and the properties of the support, including its morphology, 
composition, particle size, pore structure, specific surface area, surface functional groups and rigidity 
(Hartmann and Kostrov 2013) . Due to their robust surface chemistry and tuneable morphology, 
porous silica supports have been extensively studied for enzyme immobilization. Following the positive 
confirmation of activity displayed by the purified GDH as outlined in the previous section, large scale 
enzyme preparation was carried out and purified as mentioned in section 4.4. This batch of purified 
GDH was immobilized onto support materials (2 novel and 3 commercially available) and the activity 
of free-state and immobilized GDH were compared under various conditions to and their activity was 
assessed. 
4.9.1 Support materials and immobilization of GDH 
To immobilize GDH, three different commercial enzyme supports; methacrylate-based ECR8309F, 
styrene-based ECR1090M and methacrylate/divinylbenzene-based ECR1030M were purchased from 
Purolite, UK. Novel supports designated as MM-SBA-15-300 and MM-SBA-15-200 were produced as 
outlined in the methods section by Dr Jinesh Cherukkattu Manayil. The characteristics of all support 








Type of support Surface 
functional 
group 








ECR8309F Amino C2 Methacrylate NH2 (short 
spacer) 
Covalent or ionic 150-300 70-220 60-120 59±10 
ECR1090M Macroporous styrene None Adsorption/hydrophobic 
interaction 
300-700 750-850 90-110 76±16 
ECR1030M DVB/Methacrylate None Adsorption/hydrophobic 
interaction 
300-700 80-120 20-30 73±11 
MM-SBA-15-
300 









Table 4.6. Specification of support materials and their immobilization efficiencies. *Particle size determined by SEM analysis **Mesopores determined from N2 porosimetry 









Purified GDH was immobilized onto the different support materials listed in Table 4.6 without the use 
of cross-linking agents. Due to the presence of hydroxyl groups that facilitate enzyme binding, silica-
based materials are efficient and attractive supports for enzyme immobilization. The hierarchical 
structure of macro-meso-porous structured silica-based materials used in this study is shown 
schematically in Figure 4.5. 
 
Figure 4.5. Schematic representation of the synthesis of the SiO2 framework containing polystyrene templates 






With the introduction of macroporosity into mesoporous SBA-15 using polystyrene beads, a well-
defined interconnected macro-meso network of SBA-15 is formed. The SEM analysis confirmed the 





Figure 4.6. SEM of hierarchical structured (a) MM-SBA-15-300, (b) MM-SBA-15-200, (c) GDH immobilized onto 
MM-SBA-15-300 and (d) MM-SBA-15-200. 
 
The macropore diameter was consistent with the size of the polystyrene bead used in the synthesis. 
Mesoporous generation was further confirmed by N2 porosimetry and both MMSBA-15 samples 
possessed surface areas of ~300 ± 50 m2/g. The values were comparable with the commercial 
macroporous polymer support, ECR8309F, which has a slightly lower surface area of 70-220 m2/g. The 
other commercial supports have significantly higher (~700 ± 50 m2/g, ECR1090M) or lower (~100 ± 20 
m2/g) surface areas (Table 4.6).  The pore diameters of macro-meso-porous structured MM-SBA-15-





ECR1030M). In addition, the large surface areas of MM-SBA-15-300 and MM-SBA15-200 are 
comparable with those of commercial supports. Under the same immobilization conditions, 3mg GDH 
was immobilized onto 1 g support. Table 4.6 shows that the immobilization efficiency of macro-meso-
porous structured silica-based MM-SBA-15-300 and MM-SBA-15-200 were significantly higher than 
that of all three-commercial support materials.  98% of the GDH was successfully immobilized onto 
MM-SBA-15 supports. SEM of immobilized GDH onto these hierarchical silica supports is shown in 
Figure 4.6. The macropore provides a dimension for effective entrapment of enzyme molecules. As a 
result of its smaller pore diameter, higher amounts of immobilized enzyme were visible on the surface 
of MM-SBA-15-200 than MM-SBA-15-300 (Figure 4.6d and c respectively). 
4.10 Exploring thermal stability of free-state and immobilized GDH 
To understand the stability of GDH under non-physiological conditions, free-state and immobilized 
GDH were assayed to investigate thermal stability at 55, 65 and 80°C after 1, 3, 18 and 24 hours. 
0.03mg free-state or immobilized GDH in 500µl enzyme support solution (100mM HEPES pH 7.4, 2.5% 
glycerol, 50 mM MgCl2) was incubated as required, instantly cooled down on ice for 2 minutes and 
stored at 4°C for 20 minutes as outlined in the methods section. Cooled samples were gently mixed 
with assay mixture consisting of 100 mM HEPES pH 7.4, 2.5% glycerol, 30 mM MgCl2, 100 mM glucose, 
5 mM NAD+. Unless otherwise stated, the activity assay for both immobilized and free-state GDH was 
conducted in a water bath at 55°C for 3 hours. At the end of the assay, samples were placed into pre-
cooled racks and supernatants were filtered through 0.2 µm filters. The activity of GDH was detected 
by measuring the NADH concentrations of the supernatants via a plate reader at 340 nm.  
The free-state and immobilized GDH were thermostable at 55 and 65°C, since no significant activity 
loss was detected (data not shown). However, the samples heated at 80°C for 18 hours lost all activity. 
Figure 4.7 shows that the thermal stability of GDH immobilized onto ECR8309F, an amino methacrylate 
support, was significantly higher than the stability of free-state GDH over 60 minutes. However, the 
thermal stability of GDH immobilized onto ECR1090M and ECR1030M was not significantly increased. 
The thermal stability of GDH immobilized onto macro-meso-structured MM-SBA-15 supports was 




Figure 4.7. Thermal stability of free-state and immobilized GDH on commercial (ECR8309F, ECR1090M, 
ECR1030M) and hierarchical (MM-SBA-15-300 and MM-SBA-15-200) support materials at 80°C. 
 
4.11 Reusability of immobilized GDH 
As free-state enzymes are difficult to recover and re-use (Li et al. 2018), immobilization of enzymes 
allows cost-effective re-use in a repeated batch or continuously-running processes (Yu et al.2017). In 
this section, the re-usability of GDH was studied over 10 cycles as outlined in the methods section. 
During the first 5 cycles, the activity of GDH immobilized on macro-meso-structured MM-SBA15-300 
and MM-SBA15-200 was significantly more stable than when it was immobilized on commercial 
supports (Figure 4.8). At the end of the 5th cycle, GDH immobilized on MM-SBA-15-300 and MM-SBA-
15-200 retained 55% and 49% of its initial activity, respectively. The activity of GDH immobilized on 
ECR1090M, ECR1030M and ECR8309M were 35, 22, and 17% of initial activity, respectively. The 
reduction of enzymatic activity after each cycle is likely caused by the leakage of unbound enzyme 
and/or accumulated reaction product on the surface of the material, thereby limiting the diffusion of 

























Figure 4.8. Re-usability of immobilized enzyme on commercial and hierarchical supports and their loss of activity 
after each re-use. 
4.12 Storage stability of immobilized GDH 
To determine storage stability, free-state and immobilized GDH were stored at 4°C in enzyme support 
solution (100mM HEPES pH 7.4, 2.5% glycerol, 50 mM MgCl2) for 12 weeks and the enzymatic activity 
was measured at various time points. Figure 4.9 shows that the catalytic properties of free-state GDH 
were well preserved in enzyme support solution at 4°C, with 90% activity being retained at the end of 
the 12-week storage period. However, the activity of GDH immobilized on commercial supports was 
significantly reduced with increasing storage time. This might be due to pore blockage or hindered 
accessibility to the enzyme active site, and the amount of enzyme leaking from the supports increased 
with time. After 8 weeks, 24.7-36.1% of the initial protein loading had leaked from the supports and 
at the end of the 12-week storage period, the amount of leaked protein increased to 30-43% (Table 
4.7). At the end of the 12-week storage period, the remaining activity of GDH immobilized onto MM-
SBA-15 supports was 60% higher than that of GDH immobilized onto commercial support materials. In 
addition, during the 12-week storage period, the remaining activity of GDH immobilized onto silica 

























Figure 4.9. Effect of the immobilization and the nature of the support material on the activity of free-state or 
immobilized GDH stored at 4°C for 12 weeks. 
 




Protein leakage (%) 
after 8-week 
storage 
24±7 31±1 36±3 35±1 36±1 
Protein leakage (%) 
after 12-week 
storage 
30±2 30±1 34±1 40±1 43±3 
Table 4.7. Effect of the storage period and the support material on GDH leakage. 
 
4.13 Establishing kinetic parameters of free state and immobilized GDH 
The Michaelis-Menten model was used to calculate the apparent Vmax and Km values of free-state GDH 
and GDH immobilized onto MM-SBA-15 supports (Table 4.8). The apparent Vmax and Km values of free 
state GDH were 5.91 U/mg and 0.87 mM, respectively. After immobilization, the Vmax values of the 
GDH immobilized onto MM-SBA-15-300 and MM-SBA-15-200 reduced to 0.83 and 1.14 U/mg, 
respectively. Overall, when GDH was immobilized onto hierarchical supports, there was a 5–7-fold 
decrease in Vmax. Compared with free-state GDH, the Km values of GDH immobilized onto MM-SBA-15-
300 and MM-SBA-15-200 increased from 0.87 to 1.88 and 1.22 mM, respectively. Compared to the 
free-state enzyme and the enzyme immobilized onto MM-SBA-15-200, higher Km values were observed 
























Kinetic parameters  Free-state MM-SBA-15-300 MM-SBA-15-200 
Vmax (U/mg) 5.91 0.83 1.13 
Km (mM) 0.87 1.88 1.22 
kcat (1/s) 3.94 0.55 0.76 
Table 4.8. Kinetic parameters for free-state and immobilized GDH. 
 
4.14 Establishing optimum conditions for GDH immobilized on macro-meso structured SBA supports 
The activity of GDH immobilized onto MM-SBA-15-300 and MM-SBA-15-200 were investigated at 
different temperature and pH conditions. The effect of temperature on the activity of free-state and 
immobilized GDH was investigated from 30-80°C at pH 7.4. Free and immobilized enzyme showed 
optimum activity at 50°C (Figure 4.10a). At temperatures higher than 50°C, immobilized GDH showed 
better relative activity than the free-state enzyme. As shown in Figure 4.10a, GDH immobilized on MM-
SBA-15-300 and MM-SBA-15-200 showed similar characteristics at all temperatures. Figure 4.10b 
shows the effect of pH on the activity of free and immobilized GDH. The optimum pH for immobilized 
and free state GDH was pH 7.8. Even at high pH conditions, the activity of GDH was retained, with 
higher activity remaining for immobilized GDH. At pH 9.6, the residual activity of free-state GDH was 
78.8%, while the activity of GDH immobilized onto MM-SBA-15-300 and MM-SBA-15-200 was 93.7% 
and 95.0, respectively. When the pH was adjusted to 10.5, immobilized GDH retained half its activity, 











Figure 4.10. Effect of (a) temperature and (b) pH on the activity of GDH when it is in a free-state or immobilized 













































The effect of enzyme/support ratio on GDH immobilization onto macro-meso structured silica supports 
was investigated by increasing the amount of protein during the immobilization process. Table 4.9 
shows the immobilization efficiency and relative activity of the immobilized GDH at different enzyme 
loadings. As shown in Table 4.9, almost 100% of the GDH was successfully immobilized when the 
GDH/support ratio was between 1/1 and 5/1. After this point, immobilization efficiency slightly 
decreased to 98% and 82% for MM-SBA-15-300 and MM-SBA-15-200, respectively. However, the 
relative activity of the immobilized GDH increased until the GDH/support ratio reached 5/1. When the 
MM-SBA-15-300 was used as a support, suitable GDH/support ratios were between 3/1 and 25/1, 
which achieved high relative activity and high immobilization efficiency. Similarly, for MM-SBA-15-200, 
suitable GDH/support ratios were between 3/1 and 10/1. 





100±0 100±0 99±1 96±4 98±1 98±1 
MM-SBA-15-
200 





89±7 91±3 93±1 95±1 98±1 99±1 
MM-SBA-15-
200 
64±4 86±5 98±2 99±1 99±1 99±1 
Table 4.9. Effect of enzyme/support ratio on enzyme immobilization efficiency and activity. 
 
4.15 Conversion of Bread waste hydrolysate (BWH)  
To investigate the stability and activity of free-state and immobilized GDH on waste-based sugars, BWH 
was used. BWH was prepared as described previously and the glucose concentration of BWH was 
63.1±3.3 g/L. This sugar-rich liquor was used as the sole glucose source in the reaction mixture. The 
final glucose concentration was adjusted to 100 mM using BWH. Figure 4.11 shows the remaining 
activity after each use of immobilized GDH. After 7 cycles, the remaining activities of immobilized GDH 
were 64 and 55% on MM-SBA-15-300 and MM-SBA-15-200, respectively. After this point, further use 
of immobilized enzymes reduced the activity to more than 50% of its initial activity. After 10 cycles, 
the remaining activities of GDH immobilized onto MM-SBA-15-300 and MM-SBA-15-200 were reduced 




Figure 4.11. Re-usability of GDH immobilized on MM-SBA-15-300 or MM-SBA-15-200 in BWH and the loss of 
activity after each re-use cycle. 
 
As can be seen from Table 4.10, 45% of the glucose in BWH was converted by free-state GDH. A 2-fold 
decrease in the conversion yield was observed when immobilized GDH was used. GA production 
efficiencies by free-state GDH and GDH immobilized onto MM-SBA-15-300 and MM-SBA-15-200 were 
calculated as 47, 32 and 35 gGA/gGDH, respectively. In every cycle, the GA production efficiency of the 
GDH immobilized onto MM-SBA-15-200 was higher than MM-SBA-15-300 and after the 10th cycle, the 





























glucose in BWH (%) 
45±8 23±2 25±2 21±4 23±3 25±2 22±2 
Gluconic acid (GA) 
production from 
BWH (gGA/gGDH) 
47±1 32±1 35±1 31±1 38±2 12±1 25±3 



























This chapter has discussed the production of recombinant GDH from S. solfataricus and its successful 
purification and immobilization onto different supports, commercial and novel. GDH immobilized onto 
a novel, hierarchically-structured macroporous-mesoporous silica support showed great potential for 
gluconic acid production from glucose as well as BWH. Hierarchically porous MM-SBA-15 showed 
better immobilization efficiency than commercial supports. Moreover, GDH immobilized onto these 
materials showed excellent reusability. The use of GDH immobilized onto hierarchically-structured 
supports has the potential to be incorporated into next generation bio-refineries and waste 





















5. Dihydroxy-acid dehydratase as a key enzyme in the conversion of multiple intermediates in 
artificial cascades 
 
Dihydroxy-acid dehydratase (DHAD)  is a key enzyme in the Entner-Doudoroff pathway, which itself is 
an alternative series of reactions to catalyse glucose into pyruvate. DHAD plays its role following the 
initial conversion of glucose to gluconate via glucose dehydrogenase (GDH), by facilitating the 
conversion of gluconate to 2-keto-3-deoxygluconate. The substrate promiscuity displayed by DHAD 
makes it an attractive enzyme to utilise in artificial enzyme cascades. For the purpose of this project, 
DHAD promiscuity has been exploited at a further step in the cascade to catalyse the reaction of 
glycerate into pyruvate.  
Gluconate  2-keto-3-deoxygluconate 
Glycerate  Pyruvate 
 
This chapter discusses the protein expression, purification and characterization of DHAD. The key 
challenges faced in finding suitable methods of optimizing and detecting enzyme activity are also 
reviewed.    
5.1 Transformation of DHAD vector DNA into BL21-DE3 competent cells 
Synthesised pET30a vectors containing DHAD sequence arrived as a concentrated miniprep of ~4µg 
of DNA from GenScript (sequence in appendix). The original vector samples were archived and 
transformation of each vector into DH5α competent cells was done followed by a miniprep to obtain 
50µl of quantified vector DNA. DHAD was transformed into E. coli BL21-DE3 cells and single colonies 
were used to initiate protein expression. LB agar kanamycin plates with the successful 
transformation of vector DNA into BL21-DE3 were also used to prepare glycerol stocks for storage at 
-80°C for future applications.  
 
Figure 5.1. Quantified vector DNA obtained following miniprep was transformed into competent E. coli BL21-DE3 




5.2 Small scale DHAD protein expression and purification in LB and AI media 
Following the successful transformation of DHAD vector DNA, protein expression and purification was 
initially carried out in a 2L final volume of LB broth. Initial DHAD expression was carried out in LB broth 
with a final concentration of kanamycin at 50µg/ml. The final OD600 was an average of 3.94 across both 
1L flasks. The cell pellets obtained from the cultures by centrifugation were resuspended, sonicated 
and heat treated as outlined in the methods sections. The crude protein fraction obtained from the 
prior steps was purified using 5 ml of Ni-NTA resin as outlined in the methods chapter. All resuspension, 
sonication, heat treatment and purification steps were carried out in a 100mM HEPES pH 7.5, 200mM 
MgCl2, 10% glycerol buffer unless otherwise stated.  
 
Figure 5.2. SDS-PAGE analysis of DHAD expressed in E. coli BL21-DE3 and LB broth. Lane 2 contains crude protein 
prior to binding with Ni-NTA. Lanes 2 and 3 contain the flow through from the column and HEPES buffer washes 
(100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol) respectively. Lane 5 contains HEPES buffer with 50mM 
imidazole. Lanes 6-10 contain HEPES buffer with 600mM imidazole elutions. 
 
Fractions 7 and 8 from the above purification were pooled and the total 4ml fraction was buffer 
exchanged into the HEPES buffer (100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol) using a protein 
concentrator, and the imidazole was removed by washing the protein with excess buffer. A final 
protein concentration of 0.5mg/ml was obtained in a 1.5ml volume and no issues of protein 
aggregation were encountered in this attempt.  
Following successful expression and purification of DHAD in LB broth, AI media was also tested as it 
allows for a higher cell density growth followed by automatic induction of protein expression from lac 
promoters. 2L of AI media was used to grow cultures of DHAD overnight and the final OD600 was an 
average of 8.96 across both flasks. As with the cultures grown in LB broth, the subsequent steps carried 




Figure 5.3. SDS-PAGE analysis of DHAD expressed in E. coli BL21 (DE3) and AI media. Lane 2 contains the flow 
through from the column, lane 3 and 4 contain HEPES buffer washes (100mM HEPES pH 7.5, 200mM MgCl2, 10% 
glycerol), lanes 5, 6, 7, 8 contain HEPES buffer and imidazole elutions at the concentrations of 20, 40, 60 and 
80mM respectively. Lane 9 is HEPES buffer and imidazole elution at 600mM and lane 10 is 1M imidazole elution.  
 
Given the final OD600 of the cultures obtained from AI media was over twice as high as those from LB 
broth, a higher protein yield was anticipated. With the previous attempt, an imidazole gradient was 
not tested and the protein was all eluted off with a single 600mM elution, collected in five 2ml fractions 
(Figure 5.2). As seen in Figure 5.2, there were a lot of other protein bands which are not desired as 
they diminish the purity of the final protein sample. For this reason, the DHAD protein produced from 
the AI media cultures were eluted off using a protein gradient in an attempt to get rid of non-desired 
proteins before eluting off the product of interest (Figure 5.3). Lanes 5-8 contain HEPES buffer and 
imidazole washes at 20, 40, 60 and 80mM imidazole respectively. The 600mM imidazole elution 
followed these, however, as it can be seen from Figures 5.2 and 5.3, the additional imidazole washes 
were not entirely effective at eluting off non-desired proteins. Presumably due to the higher protein 
yield obtained, DHAD was eluted off in the lower concentration imidazole washes as well (Figure 5.3, 
lanes 7 and 8). Two fractions containing the highest amount of protein as determined by the SDS-PAGE 
were taken forward for further processing (Figure 5.3, lanes 9 and 10), and they were desalted using 
PD-10 columns. At this stage, both of the desalted fractions were noticed to display signs of protein 
aggregation. This could be attributed to the high levels of protein overexpression which upon desalting 
and thereby removal of any leached nickel and imidazole would increase protein-protein self-
interactions and increase chances of protein aggregation. The two fractions were filtered through a 
sterile 0.2µm filter straight after the desalting step to remove the protein aggregates and prevent any 
further aggregation from taking place. Although protein yield was sacrificed in doing so, further protein 
aggregation downstream was not observed in these samples. Figure 5.4 shows the  samples before 




Figure 5.4. DHAD desalted fractions following purification with Ni-NTA. Fractions prior to filtration displaying 
signs of protein aggregates (A), fractions following filtration and aggregates removal (B). 
 
Following concentration of both fractions, their individual protein concentrations were determined 
with a BCA, DHAD 600mM imidazole fraction was concentrated down to 8.79mg/ml and DHAD 1M 
imidazole fraction was concentrated down to 1.34mg/ml.  
5.3 Anion exchange of DHAD as a secondary purification step to improve purity 
From the initial expression of DHAD as discussed in section 5.2, it was evident that the first cycle of 
purification is not specific enough to give a protein sample of high purity. Therefore, anion exchange 
of DHAD was performed as an attempt at a secondary purification step. The DHAD fraction obtained 
from the Ni-NTA purification at a concentration of 1.34mg/ml (as discussed in section 5.2) was used as 
the sample for anion exchange. 5ml of this sample was buffer exchanged into 20mM Tris HCl pH 7.5, 
5% glycerol buffer which was applied to the column before eluting fractions off with a NaCl gradient 
ranging from 50mM to 1M. All the final elutions were loaded onto a SDS-PAGE to analyse the 
effectiveness of the secondary purification step (Figure 5.5). The 50-200mM NaCl elutions were 
effective at eluting off the protein at the highest purity with only very faint bands for non-specific 
proteins as seen in the SDS-PAGE. However, 300 and 400mM NaCl elutions produced a similar SDS-
PAGE band profile as previously seen in gels from LB broth and AI media purifications. There is an 
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intense band around the 70kDa, indicative of the DHAD monomer which is 64kDa. Bands were 
consistently seen around the 130kDa and 250kDa mark which would be consistent with the presence 
of oligomers (Figure 5.5). 
  
Figure 5.5. Anion exchange of DHAD as a secondary purification step. Lane 2 contains the DHAD sample after 
buffer exchange into 20mM Tris-HCl, pH 7.5, 5% glycerol buffer; followed by flow through from the column in 
lane 3, and 5x column wash in lane 4. Lane 5, 6 and 7 contain 20mM Tris-HCl, pH 7.5, 5% glycerol buffer with 50, 
100 and 200mM NaCl elutions respectively. Lanes 9, 10, 11, 12 and 13 contain 300, 400, 500, 750mM and 1M 
NaCl elution, respectively.  
 
Fractions from lanes 5, 6 and 7 were pooled and hereby referred to as sample 1 and fractions from 
lane 9 and 10 and were pooled hereby referred to as sample 2, both of these fractions were 
concentrated down a final volume of 1ml and buffer exchanged back into the HEPES buffer as 
mentioned in 5.2. BCA determined the final concentrations of sample 1 to be 0.1mg/ml and sample 2 
to be 1.2mg/ml. As multiple purification steps were applied to DHAD, protein yield was compromised 
with each added step. For characterization studies to follow, a highly concentrated yield of DHAD in a 
larger volume was required and therefore, the protocol had to be adjusted in an attempt to achieve 
these requirements.  
5.4 Size-exclusion chromatography and protein identification of DHAD to determine presence of 
oligomers 
As mentioned in section 5.3, bands were consistently seen around the 130kDa and 250kDa mark on 
the SDS-PAGE which would be consistent with the presence of oligomers. To determine this, a fresh 
batch of DHAD was purified using Ni-NTA as previously described in section 5.2. The final concentration 
of this batch as determined by BCA was 5.2mg/ml. As size-exclusion chromatography separates 
molecules in solution based on their molecular weight, the peaks on a chromatogram are indicative of 
the different size proteins in the sample. The chromatogram obtained from the size-exclusion of DHAD 
(Figure 5.6) automatically identified 3 peaks and aliquoted them into a collection plate as different 
fractions. Multiple samples from each identified peak, a, b and c, were loaded onto a SDS-PAGE in 
order to visualise their composition. The SDS-PAGE obtained from the samples (Figure 5.7) shows the 
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composition is exactly the same in all samples loaded, confirming the presence of oligomers. Despite 
being identified as different peaks, the only difference between them is the quantity of protein 
present. A concentrated protein sample has been previously observed to elute off in multiple peaks in 
size-exclusion chromatography and it would seem that this is the case here. In Figure 5.7, samples in 
lanes 2 and 3 are from peak a, samples in lane 4 and 5 are from peak b and lastly, samples in lane 5 
and 6 are from peak c (Figure 5.6A). It is evident from the gel in Figure 5.7 that the same bands are 
constantly seen in all the samples, differing only in their intensities, which correlates with the different 
concentrations of protein present in the different fractions. Following the SDS-PAGE, as a further 
confirmation of oligomers, the DHAD bands indicated in Figure 5.7 were excised from the gel and were 




Peak Retention (ml) Area (ml*mAU) Area % Fractions Volume (ml) 
a 11.82 40.89 17.18 B5-B12 7.80 
b 13.52 193.9 81.49 C2-D1 7.79 
c 19.67 3.16 1.33 D4-D5 7.68 
Figure 5.6. Size exclusion chromatography of DHAD. Figure 5.6A displays the chromatogram obtained from the 
software. The blue trace represents the UV absorbance at 280nm and the 3 peaks are indicative of the quantity 
of protein detected. The brown trace reflects the conductivity monitor which measures conductivity of buffer 
and samples for online monitoring of the true gradient. The green trace is applied if there is another buffer being 
used, since this sample was run in one buffer only, the trace has a value of 0. Figure 5.6B lists the retention time 







Figure 5.7. SDS-PAGE analysis of DHAD following size exclusion chromatography. Lane 2 and 3 contain samples 
from peak a, taken from fractions B8 and B12 respectively. Lane 4 and 5 contain samples from peak b, taken from 
fractions C5 and C10 respectively. Lane 6 contains sample from peak c, taken from fraction D4. The bands 
indicated in the figure were excised for mass spectrometry analysis.  
 
Mass spectrometry analysis of the bands shown in Figure 5.7 positively identified all 3 bands as being 
DHAD. Using ImageJ scientific image analysis, the confirmed DHAD bands were calculated as a 
percentage of the total protein concentration. Using this method allowed for the actual concentration 
of DHAD to be determined in a sample with other non-specific proteins purified during Ni-NTA 
purification in future experiments.  
5.5 DHAD initial activity analysis via IC (ion chromatography) 
Following the size exclusion analysis of DHAD in section 5.4 and positive identification of oligomers 
with mass spectrometry, a purified enzyme stock of 1mg/ml was used to test enzyme activity in a 1ml 
final reaction volume with a final concentration of 0.1mg DHAD and 10mM gluconic acid. Gluconic acid 
serves as one of the substrates for DHAD whereby it is converted to 2-keto-3-deoxygluconate. The 
assay was set up with a reaction time of 20 hours on a shaking heat block at 60°C, 300rpm. The assay 
samples were analysed via IC. A known range of concentrations for both gluconic acid and 2-keto-3-
deoxygluconate were run on the IC and standard curves were generated (Figure 2.2 and 2.3). These 
standard curves were then used to calculate the amount of substrate consumed and product formed 
from the enzyme reaction. Following the 20-hour incubation for the assay, the samples were 
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Table 5.1. IC analysis of assay samples. Assay controls determined gluconic acid concentration via IC standard 
curve to be 10.15mM. Assay run in duplicate, values obtained from both samples are shown.  
 
The IC analysis of the DHAD initial reaction determined that the purified protein produced is active and 
is successful at converting the substrate into the desired product. Reaction parameters could now be 
optimized, and in order to test multiple reaction conditions, a larger batch of DHAD expression protein 
purification was attempted.  
5.6 Large scale expression of DHAD in AI media followed by purification via Ni-NTA  
Following successful confirmation of activity displayed by DHAD, large scale expression and purification 
of DHAD was attempted. Several attempts were made whereby the expression, sonication, heat 
treatment and subsequent binding and purification using Ni-NTA were successful. However, removing 
the imidazole from the eluted fractions proved to be challenging. Since these attempts at purification 
were large scale and the final fractions requiring imidazole removal were too large in volume to 
efficiently buffer exchange using spin columns, dialysis was the most efficient solution for buffer 
exchange of these samples. During dialysis however, a persistent problem was faced with sample 
precipitating out of solution on numerous attempts. Attempts were made by changing the ratio of 
volumes however the problem still persisted. A solution was provided in the addition of EDTA to the 
imidazole eluted fractions to be dialysed. This was tested by preparing a large scale DHAD expression 
(4L), the resulting cell pellet being resuspended in 100ml 100mM HEPES pH 7.5, 200mM MgCl2, 10% 
glycerol buffer. Following sonication, heat treatment and centrifugation to obtain crude DHAD protein 
fraction, the soluble protein fraction was bound to 10ml of Ni-NTA overnight. The Ni-NTA bound 
soluble fraction was split into 2 polypropylene columns hence all elutions were obtained in duplicates. 




Figure 5.8. SDS-PAGE analysis of DHAD following Ni-NTA purification done in duplicate. Lane 2 contains flow 
through, lane 3 contains HEPES buffer wash and lanes 4-9 contain HEPES buffer and imidazole elutions at 
concentration of 50, 100, 200 400 600 and 1000mM respectively.  
 
The HEPES buffer imidazole elutions were collected in 10ml fractions, fractions from lanes 6 and 7 from 
the purification replicates were pooled (20ml total). One 20ml fraction was dialysed without any added 
EDTA against 1L of 100ml 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer. The second 
fraction had EDTA added at a final concentration of 100mM and was dialysed against 1L of 100ml 
100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer as well, both dialysis carried out overnight 
at 4°C. Overnight dialysis was found to have been effective only in the fraction which had EDTA added 
to it (Figure 5.9), the fraction without EDTA as seen in Figure 5.9 has precipitated out in the dialysis 
tubing.  
 
Figure 5.9. Dialysis of imidazole elution from Ni-NTA purified fractions of DHAD. Dialysis is only effective in the 
replicate with the addition of 100mM EDTA. The fraction without EDTA can be observed to have precipitated out 




Establishing the effectiveness of EDTA at reducing protein precipitation during the first cycle of dialysis, 
2 more cycles of dialysis were carried out without any additional EDTA. The latter 2 cycles were 
calculated to have diluted the imidazole and EDTA concentrations to a negligible concentration so the 
final DHAD fraction was stored in a 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer for 
further downstream analysis. This fraction was concentrated and its protein concentration was 
determined to be 3.31mg/ml via BCA.  
5.7 IC analysis of DHAD activity with a range of enzyme concentrations  
Solving the problem of DHAD precipitating out during large scale preparation with the aid of EDTA in 
section 5.6, further DHAD stocks were obtained in a sufficient amount to perform further enzyme 
characterization experiments. 6-reaction conditions were set up in 1ml volumes. 5mg/ml DHAD stock 
was added in final volumes of 2.5, 5, 10, 20, 50 and 100µl to each condition with 50mM gluconic acid. 
End point conversion efficiencies were tested after incubation at 55°C for 2 hours, followed by 
deproteinizing samples and loading onto the IC for analysis alongside the control condition. Due to 
technical issues with low range of values in the standard curve for 2-keto-3-deoxygluconate at the time 
of the experiment, the analysis from these assay conditions was only analysed by the consumption of 
gluconic acid.  
A new standard curve for gluconic acid was also generated to accommodate a higher range of 
concentrations, the standards were diluted by a factor of 10. Using the equation generated from the 
standard curve, the concentration of each standard was calculated back to check the error factor 
(Table 5.2). The highest overestimation in calculated concentration was of 0.47mM and lowest 
















2.5 10 3.59 3.68 3.66 2.97 
10 3.59 3.62 
5 10 3.62 6.57 6.47 5.26 
10 3.61 6.38 
7.5 10 3.63 9.20 9.25 7.51 
10 3.63 9.29 
10 10 3.66 11.81 11.99 9.74 
10 3.69 12.16 
Table 5.2. Analysis of known gluconic acid concentrations via IC. The known concentrations are recalculated using 
the standard curve to determine possible error factor. 
 
To fit within the range of the standard curve, all assay samples were diluted by a factor 100 before 
loading onto the IC (final dilution factor of 10 on account of standard curve being at a dilution factor 
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of 10 previously) The control samples without any DHAD were also analysed via IC and using the 
standard curve for gluconic acid and factoring in the dilution factor, the gluconic acid concentration 
calculated was an average of 68.55mM (standard deviation = 0.068). This was an overestimation by 
18.55mM as originally 50mM of gluconic acid had been added to all assay conditions. Regardless, the 
gluconic acid consumption was calculated by subtracting the gluconic acid remaining in each assay 
condition from 68.55mM (3). Despite the overestimation issue, the original objective for this 
experiment was considered achieved as the general data trend as seen in Table 5.3 showed the assay 
conditions with higher DHAD concentrations also consumed increasing gluconic acid over the reaction 
period.  
  DHAD 5mg/ml stock volume added (µl) 




5.67 5.43 5.3 5.29 5.27 4.75 
*10 for 
dilution factor 
56.73 54.32 52.99 52.88 52.70 47.53 
Gluconic acid  
consumption 
(mM) 
11.82 14.23 15.55 15.67 15.85 21.02 
Table 5.3. DHAD activity analysis via IC. Control with no DHAD and 50mM gluconic acid was also analysed via IC 
(data not shown in table). Standard deviation for all conditions= <0.49 
 
The enzymatic activity analysis of DHAD carried out as described until this point were all with fresh 
purified batches of DHAD. These experiments led to positive confirmation of enzyme activity and 
following this, DHAD enzyme kinetics were explored. Batches of DHAD were therefore produced and 
snap frozen for long term storage at -80°C to be thawed out and used as required. Unless stated 
otherwise, the following experiments were carried out with DHAD stocks thawed out from storage at 
-80°C. 
5.8 DHAD activity analysis using gluconate assay kit 
5.8.1 Optimizing assay and control dilution factors for compatibility with kit 
The next set of experiments to follow were pilot experiments to optimize the reaction conditions for 
enzyme kinetics. Unlike the experimental setup in section 5.7, the objective for the set of experiments 
discussed in this section was to establish DHAD activity at lower enzyme concentration and various 
time points. 3 final enzyme concentrations were tested, 0.1µg/ml, 1µg/ml and 10µg/ml, each at time 
intervals of 15, 30, 60 and 120 minutes with 20mM gluconic acid as substrate. All reaction conditions 
were carried out with controls included, with incubation at 55°C and 220rpm. Following the end of the 
desired incubation period, all samples were deproteinized straight away before analysis with gluconic 
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acid assay kit. Gluconic acid assay kits were used as they offer an advantage in sensitivity. With lower 
enzyme concentrations being employed in shorter assay times, the IC analysis is not sensitive for 
accurate detection. As this was an initial test, the detection kit was only used to assay the depletion of 
gluconic acid in the 10µg/ml 120 minutes assay condition, on the basis that this condition would display 
the highest levels of gluconic acid depletion. Sensitivity levels for the detection kit was <2µM 
gluconate, therefore all samples to be analysed had to be diluted by a suitable dilution factor to be 
within the detection range of the kit. For this initial test, a range of dilutions were tested to determine 
which one fits best within the range, for both the assay samples and controls. Gluconate standard was 
provided in the kit and a range of standards were run alongside each assay (Figure 5.10) on the same 
96 well plate. 
 
Figure 5.10. D-gluconate standards. Standard deviation for all conditions= <0.03. 
 
Initially, the deproteinized 10µg/ml 120 minutes assay condition samples and controls were diluted by 
a factor of 2000 and 1000 on the same 96 well plate as the gluconate standards (Figure 5.10), however 
the final absorbance readings for these were far too low to fit within the range of the standard curve 
(Table 5.4). A further 2 dilution factors, 500 and 250, were then tested, without running a gluconate 
standard curve alongside, to estimate if either of these dilution factor was a better fit for the range 
(Table 5.4).  
 
DHAD 1µg/ml 120 min assay Control 20mM gluconic acid (no DHAD) 
Dilution factor 2000 1000 500 250 2000 1000 500 250 
Absorbance 
450nm 
0.04 0.09 0.13 0.26 0.02 0.17 0.26 0.43 
Table 5.4. Testing a range of dilutions for assay and control conditions via gluconate detection kit to determine 

























From Table 5.4, it was evident that dilution of factor of 250 was sufficient for analysis of both assay 
and control condition as it is a suitable fit within the range of the gluconate standard curve obtained 
with the prior set of dilution factor tests. Since the latter two dilution factors of 500 and 250 were 
assayed without their own gluconate standards, the final absorbance readings from the DHAD 10µg/ml 
120 minutes assay condition were not analysed any further to calculate gluconate consumption as it 
would not be reliable data. Although this experiment was intended as a pilot study to optimize enzyme 
kinetic experiments for DHAD, the requirement for optimization of assay variables was presented. 
Therefore, the objective altered into identifying the optimum assay conditions which was ultimately 
successfully achieved. Any further assays performed with the gluconic acid kit utilise a dilution factor 
of either 200 or 250 for all samples and controls which gives values that fit well into the range of the 
standard curve.  
5.8.2 Retesting DHAD 0.01mg/ml, all timed conditions with gluconate assay kit and optimized 
dilution factor 
The deproteinized samples from the DHAD 10µg/ml 15, 30, 60 and 120 minute conditions (5.8.1) were 
all stored at 4°C. Following the establishment of the optimum dilution factor to be used with the 
gluconic acid assay kit, all the samples from this condition were analysed with the kit. The objective of 
this experiment was to determine if the assay times need to be adjusted for enzyme activity. All 
samples and controls were diluted by a factor of 200 and alongside a fresh set of gluconate standards 
(R2=0.9), were all analysed as per manufacturer’s instructions for the gluconic acid assay kit. The final 
absorbance readings obtained for the 4 timed conditions and control are shown in Table 5.5, from 
which it can be concluded that there is no significant difference between the assay and control 
readings (Control absorbance 450nm=0.406, DHAD 10µg/ml assay 120 min absorbance 450nm=0.405).  
 
DHAD 0.01mg/ml activity assay Control 
no DHAD  
15 min 30 min 60 min 120 min 120 min 
Absorbance 450nm 0.41 0.40 0.39 0.41 0.41 
Table 5.5. Testing all time points of DHAD 0.01mg/ml via gluconate detection kit to monitor gluconic acid 
depletion over time. Control condition with substrate only sampled at final time point of 120 minutes. Standard 
deviation for all conditions= <0.024 
 
As these set of experiments were performed with DHAD stocks thawed from storage at -80°C, possible 
batch degradation of DHAD was considered as a plausible explanation for the apparent lack of activity 





5.9 Exploiting substrate promiscuity of DHAD to confirm activity via pyruvic acid assay kit  
Following on from inconclusive data about activity displayed by DHAD towards gluconate, its substrate 
promiscuity was exploited. Although experimental data from section 5.8 hinted at potential storage 
induced enzyme degradation, this was tested to confirm or deny possible degradation. DHAD also 
facilitates the conversion of glyceric acid to pyruvic acid, and using the pyruvic acid assay kit, 
accumulation of pyruvate can be monitored. Multiple batches of DHAD were tested to ensure the 
results obtained in section 5.8.2 were not due to a single batch anomaly. 3 batches of DHAD were 
tested, DHAD batch 1, which was snap frozen and stored at -80°C, DHAD batch 1a stored at 4°C and 
DHAD batch 2 snap frozen and stored at -80°C. 2 concentrations of DHAD were tested, 0.01mg/ml and 
0.1mg/ml with 20mM glyceric acid as substrate at a reaction time of 1 hour.  All other reaction 
parameters were the same as stated in section 5.8.1. Pyruvic acid assay kit contains pyruvate standards 
which were run alongside assay samples and control containing no DHAD.  
 
Figure 5.11. Pyruvate standards. Standard deviation for all conditions= <0.039. 
  
DHAD batch 1 DHAD batch 1a DHAD batch 2 Control 
no DHAD 
DHAD mg/ml 0.01 0.1 0.01 0.1 0.01 0.1 N/A 
Absorbance 570nm 0.06 0.59 0.01 0.13 0.01 0.09 0.00 
Pyruvate ng/µl 0.93 9.55 0.21 2.04 0.13 1.46 0.05 
Table 5.6. Analysis of pyruvate production using pyruvic acid assay kit from 2 different batches of DHAD and 
storage conditions. Standard deviation for all conditions= <0.02.  
 
Batch 1 of DHAD gave the highest absorbance reading when tested with the pyruvic acid assay kit from 
all the batches tested, calculated amount of pyruvate in this reaction was 9.55ng/µl. As expected, the 
control sample showed the lowest absorbance reading indicating no pyruvate present in sample. The 






















DHAD as the highest enzyme concentration. For the purpose of detecting product with certainty, the 
activity assays conducted in this section for analysis with pyruvic acid assay kit were performed with 
an additional enzyme concentration of 0.1mg/ml. The 10-fold increase in enzyme activity was sufficient 
to detect pyruvate.  
5.10 Increased DHAD concentration activity analysis using gluconate assay kit 
As established from section 5.9, increased enzyme concentration of DHAD in the reaction following 
the conversion of glyceric acid to pyruvate, pyruvate was detected with the pyruvic acid assay kit. 
Following this, increased DHAD concentration was then also used to retest activity using gluconic acid 
as substrate and gluconate assay kit to monitor the consumption of gluconic acid. 0.05mg/ml and 
0.1mg/ml DHAD were tested with 20mM gluconic acid as substrate, all other reaction parameters were 
the same as stated in section 5.8.1. Dilution factor of 200 was applied to all assay and control 
conditions as determined previously in section 5.8.1, and gluconate standards were run alongside 








Absorbance at 450nm 0.40 0.37 0.42 
Table 5.7. Testing activity of DHAD 0.05mg/ml and 0.1mg/ml via gluconate detection kit to monitor gluconic acid 
depletion. Standard deviation for all conditions= <0.007.  
 
The absorbance values obtained for the 0.1mg/ml DHAD and the control (20mM gluconic acid, no 
DHAD) samples were used to calculate the amount of gluconic acid present in each the assay and 
control condition. The control condition was calculated to have 44.41ng/µl of gluconate still present, 
whereas the 0.1mg/ml DHAD condition was calculated to have 39.15ng/µl of gluconate present. There 
was still considerable amount of gluconic acid present in the assay condition, leading to the conclusion 
that gluconic acid levels in the assay have not been depleted and the enzyme is displaying very low 
levels of activity, possibly due to -80°C storage induced degradation. 
5.11 Testing activation of DHAD using 2-Mercaptoethanol (2-ME) to improve activity 
Establishing optimum enzyme activity of DHAD was difficult due to stored batches of purified DHAD 
displaying poor levels of activity even when higher enzyme concentrations were used in assays. 
Literature has been cited to use 2-ME to improve enzyme activity as it was established to be ‘activating’ 
the enzyme (Carsten et al. 2015). An aliquot of DHAD batch 1 (previously used as stated in section 5.9) 
was used for this experiment and the experimental condition contained 1.6mg/ml DHAD in a 100mM 
HEPES pH 7.5 buffer supplemented with 98mM 2-ME. This solution was then ‘activated’ as per 
methodology. The resulting enzyme solution was buffer exchanged into 100mM HEPES pH 7.5 buffer 
to remove 2-ME. This activated DHAD was assayed under the same conditions using gluconate assay 
101 
 
kit as stated in section 5.10 using DHAD stock sample as a control, in an attempt to determine the 
effect of the ‘activation’ protocol on the activity of DHAD. 
 
Activated DHAD Non-activated DHAD Control 
 
0.05mg/ml 0.1mg/ml 0.05mg/ml 0.1mg/ml No DHAD 
Absorbance 450nm 0.45 0.44 0.56 0.46 0.67 
Table 5.8. Testing activity of 2-ME activated and non-activated DHAD 0.05mg/ml and 0.1mg/ml via gluconate 
detection kit to monitor gluconic acid depletion. Standard deviation for all conditions= <0.19. 
 
The control samples for this experiment gave a mean absorbance value of 0.67. For all previous 
experiments done where the same control was run, the absorbance values have been 0.43, 0.41 and 
0.42 (section 5.8.1, 5.8.2 and 5.10 respectively). This absorbance value from this experiment falls 
outside of the normal range expected from this sample as it has been consistent in the past 
experiments, moreover the value of 0.67 falls outside the range of the gluconate standards (R2= 0.98). 
The absorbance values obtained from the experimental conditions of activated and non-activated 
DHAD are inconclusive as well. In The condition 0.1mg/ml for both conditions gave similar absorbance 
values, indicating that the activation protocol has not had a significant effect on improving the activity 
of the enzyme.  
5.12 Activating crude DHAD to establish improved enzyme activity instead of purified DHAD 
Following unsuccessful experiments to establish higher levels of activity from the purified DHAD, an 
approach was devised to use crude DHAD in an attempt to establish activity instead. From this point 
onwards, unless otherwise stated, fresh DHAD was used for enzymatic activity purposes. As per 
methodology in chapter 2, DHAD was expressed and a final wet weight pellet of 19.43g was obtained. 
Following the heat treatment purification of DHAD, the crude was dialysed into a final buffer of 100mM 
HEPES pH 7. This solution displayed slight aggregation during the dialysis cycle, hence was centrifuged 
to separate out the aggregates, followed by filtration with a 0.2µm syringe filter. The crude fraction 
was analysed via SDS-PAGE and analysed by ImageJ to estimate actual DHAD concentration in the total 
crude sample. The total crude sample was estimated to be consisting of 92% DHAD. The crude fraction 
was concentrated and the DHAD protein concentration was determined to be 31.87mg/ml. Using 2-
ME to activate DHAD in order to increase activity was then reattempted with crude DHAD in an attempt 
to establish if an improved result could be achieved compared to section 5.11. Crude DHAD was 
activated with 2-ME as described elsewhere (Carsten et al. 2015), following centrifugation to get rid of 
any precipitates formed. After buffer exchanging the resulting solution into 100mM HEPES pH 7 to 
remove the 2-ME, the protein solution was concentrated down to a final volume of 1ml. As some of 
the protein had precipitated during the activation procedure, a BCA was performed to determine the 
new protein concentration, which was determined to be 2.82mg/ml. A fraction of the crude DHAD was 
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also diluted down to 2.82mg/ml, this was done in order to run a control of unactivated DHAD alongside 
the activated version to observe any distinguishable differences in activity attributed to activation. 
5.12.1 Analysis of activated crude DHAD activity using gluconic acid assay kit 
For both the activated and unactivated DHAD assay conditions, 2 enzyme concentrations were tested, 
0.1mg/ml and 1mg/ml using 20mM gluconic acid as substrate for 60 minutes at 55°C. Upon completion 
of 60 minutes, all samples were deproteinized before analysis with gluconic acid assay kit. A control 
condition without any DHAD was run alongside and as per standard and a gluconic acid standard curve 
was run alongside all samples (R2= 0.99).  
 
Activated DHAD mg/ml DHAD mg/ml Control  
0.1 1 0.1 1 No DHAD 
Absorbance 450nm 0.37 0.24 0.34 0.25 0.39 
Gluconic acid mM 21.39 14.12 19.68 14.83 22.63 
Table 5.9. Testing activity of 2-ME activated and non-activated crude DHAD 0.1mg/ml and 1mg/ml via gluconate 
detection kit to monitor gluconic acid depletion. Standard deviation for all conditions = <0.037.  
 
The control conditions without any DHAD containing only 20mM gluconic acid substrate has been 
slightly overestimated by the kit to contain 22.63mM gluconic acid, there is certain error factor 
involved when using the detection kit as it is very sensitive, so this was expected. The 1mg/ml DHAD 
conditions for both the activated and unactivated crude DHAD have shown significant depletion of 
gluconic acid as they both have approximately 14mM gluconic acid remaining. However, since the 
objected of this experiment was to establish whether activation improved the activity of DHAD, that 
has not been achieved. From the data it can be deducted that both activated and unactivated crude 
DHAD have consumed the same amount of gluconic acid within the time frame of 60 minutes, 
therefore activation is not adding any value to the preparation of DHAD and so any further activation 
protocols were not performed from here onwards. Only a very small volume of the deproteinized 
samples from this activity assay were needed to do the dilutions in order to run the gluconic acid assay 
kit. The remaining deproteinized samples from the assay conditions and controls were in excess of 
300µl and therefore were also run on the IC to compare both methods of analysis.   
5.12.2 Analysis of activated crude DHAD activity using IC 
The remaining deproteinized samples from the crude DHAD activity assay comparing activated and 
unactivated DHAD were also analysed via IC to establish which method is more effective and if values 
obtained from both correlate. The gluconic acid assay kits are only measuring the depletion of the 
substrate (gluconic acid) and not the formation of product (2-keto-3-deoxygluconate), whereas 
analysis IC shows both of the data. All gluconic acid and 2-keto-3-deoxygluconate concentrations were 




Activated DHAD Unactivated DHAD Control 
 
0.1mg/ml 1mg/ml 0.1mg/ml 1mg/ml No DHAD 




N/D 6.77 N/D 6.545 N/D 
Table 5.10. IC activity analysis of 2-ME activated and non-activated crude DHAD 0.1mg/ml and 1mg/ml to monitor 
gluconic acid depletion and 2-keto-3-deoxygluconate formation. Standard deviation for all conditions = <0.85. 
(N/D=none detected). 
 
Comparing the results from the gluconic acid assay kit for this assay (section 5.12.1) and the IC analysis, 
the data is not consistent. From Table 5.9, it has been calculated using the kit that the final 
concentration of gluconic acid remaining in both the activated and unactivated 1mg/ml DHAD assay 
conditions is 14.12 and 14.83mM respectively. Given that the gluconic acid assay kit estimated the 
control condition’s concentration to be 22.63mM, 8.51 and 7.81mM of gluconic acid has been 
consumed in the activated and unactivated 1mg/ml DHAD conditions respectively (Table 5.9), and 
theoretically been converted to 2-keto-3-deoxygluonate. From the IC analysis data in Table 5.10, 
measuring the exact peaks corresponding to 2-keto-3-deoxygluconate, it has been calculated that 
6.77mM and 6.55mM of 2-keto-3-deoxygluconate has been produced from the activated and 
unactivated 1mg/ml DHAD conditions respectively. The control shows the gluconic acid to have been 
calculated to be 19.59mM (Table 5.10) and considering the original substrate added to all conditions 
was 20mM, the IC analysis has given an estimate much closer to the actual concentration added in 
comparison to the gluconic acid assay kit, which had estimated the concentration to be 22.63mM 
(Table 5.9). The IC however, is not sensitive enough to detect the 2-keto-3-deoxygluconate at low 
concentrations therefore the gluconic acid assay kit is a better option for the analysis of lower enzyme 
concentrations assay conditions.  
5.13 Testing crude DHAD activity under different substrate and enzyme concentrations 
Following the experimental data which established that activation of both purified and crude DHAD 
using 2-ME is not significantly improving the enzyme activity (section 5.11 and 5.12), crude DHAD with 
no activation was used for all further assay condition optimizations. 2 substrate concentrations were 
tested, 2 and 20mM gluconic acid, each with 1, 2.5 or 5mg/ml DHAD enzyme solution. Each condition 
was tested at 3 different time points of 15, 30 and 60 minutes and upon completion of the respective 
time points, all samples were deproteinized and analysed for gluconic acid depletion using gluconic 
acid assay kit.  
5.13.1 2mM gluconic acid assays with range of enzyme concentrations and time points analysed with 
gluconic acid assay kit 
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Gluconic acids standards were run alongside all 2mM assay and control conditions. 
 






















0.05 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 
Gluconic 
acid mM 
1.31 0.98 0.41 0.00 0.00 0.00 0.00 0.00 0.00 
Table 5.11. Testing activity of crude DHAD with 2mM gluconic acid with 3 different enzyme concentration at 3 
different time points. Standard deviation for all conditions= <0.02 
 
In the 2mM gluconic acid assays, after 15 minutes, higher DHAD conditions consumed more gluconic 
acid as there was 1.31, 0.98 and 0.41mM gluconic acid remaining in the 1, 2.5 and 5mg/ml DHAD assays 
respectively. At 30 and 60 minutes, no gluconic acid was detected in any of the assay conditions 
indicating 100% conversion of gluconic acid to 2-keto-3-deoxygluconate. However, the controls for this 
experiment were not as expected. 2mM gluconic acid without DHAD was run as a control with each 
time point, no change is expected in the concentration of gluconic acid. Using the kit however gave 
the final concentration of the controls to be 4.8, 4 and 1.45mM from the 15, 30 and 60 minute 
conditions respectively. 4.8 and 4mM are a gross overestimate from the original 2mM added into the 
controls whereas 1.45mM is an underestimation. There is an substantial error factor when using the 
gluconic acid assay kit as there is a large dilution factor involved and pipetting errors with such small 
volumes are to be expected. Following analysis of 2mM all assay conditions on one 96 well plate, the 
same analysis was repeated for the second assay conditions consisting of 20mM gluconic acid. 
5.13.2 20mM gluconic acid assays with range of enzyme concentrations and time points analysed 
with gluconic acid assay kit 
 





















0.35 0.35 0.30 0.34 0.27 0.22 0.32 0.22 0.1 
Gluconic 
acid mM 
19.39 19.4 16.72 18.6 14.77 11.97 17.6 12.03 5.40 
Table 5.12. Testing activity of crude DHAD with 20mM gluconic acid with 3 different enzyme concentration at 3 
different time points. Standard deviation for all conditions= <0.025.  
 
Similarly to the 2mM gluconic acid assay conditions stated in Table 5.11, after 60 minutes, higher DHAD 
conditions consumed more gluconic acid as there is 17.6, 12.03 and 5.4mM gluconic acid remaining in 
the 1, 2.5 and 5mg/ml DHAD assays respectively. Even after 60 minutes, the highest DHAD 
concentration of 5mg/ml has converted just under 15mM of the total 20mM of gluconic acid. Similarly 
to the 2mM gluconic acid assays, the controls for this experiment were not as expected. 20mM 
gluconic acid without DHAD was run as a control with each time point and therefore no change was 
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expected in the concentration of gluconic acid. Using the kit however, gave the final concentration of 
the controls to be 26.87, 22.33 and 21.29mM from the 15, 30 and 60 minute control conditions 
respectively. All of the control conditions were overestimated in concentration in comparison to the 
original 20mM gluconic acid added into the controls.  
Another set of negative controls were run with the DHAD enzyme solutions at the 3 given 
concentrations without any substrate to check that the enzyme solution itself is not contributing 
towards any absorbance readings. The maximum false positive reading obtained from these controls 
was of 0.68mM gluconic acid. This detection kit uses a coupled enzyme reaction to generate a 
colorimetric signal propionate to the amount of D-gluconate present, other assay components could 
be contributing this false positive and therefore the background absorbance values are not reliable. 
For this reason, use of gluconic acid assay kits was ceased from here onwards. The IC allows for the 
direct selection of 2-keto-3-deoxygluconate peaks formed, therefore all further assays were analysed 
by the direct quantification of the product formed. Only a small volume of deproteinized samples from 
all assay conditions (as outlined in 5.13) were required for the gluconic acid assay kit and therefore, all 
samples from assays carried out in this section were also analysed via IC.  
5.13.3 2mM gluconic acid assays with range of enzyme concentrations and time points analysed via 
IC 
All deproteinized samples from the 2mM gluconic acid assays (5.13) were analysed via IC and the final 
2-keto-3-deoxygluconate concentrations were calculated using a standard curve (Figure 2.3).  
  2-keto-3-deoxygluconate produced (mM) 
Time (min) DHAD 1mg/ml DHAD 2.5mg/ml DHAD 5mg/ml 
0 0 0 0 
15 0.62 1 1.48 
30 1.92 2.7 1.98 
60 2.66 2.49 2.42 
Table 5.13. IC activity analysis of 2mM gluconic acid assays with a range of enzyme concentrations at different 





Figure 5.12. Graphical representation of the IC activity analysis of 2mM gluconic acid assays with a range of 
enzyme concentrations at different time points. Standard deviation for all conditions= <0.44. 
 
A negative control of 2mM was analysed via the IC and using the corresponding standard curve (Figure 
2.2), its concentration was calculated to be 2.54mM, so there was an over estimation by 0.54mM. 
Based on this value, 2.54mM of 2-keto-3-deoxygluconate would be expected as the final product if 
100% conversion of substrate to product had occurred. From Table 5.13 and Figure 5.12, it can be seen 
that the final concentrations of 2-keto-3-deoxygluconate obtained after 60 minutes are in the range 
of 2.42-2.66mM 2-keto-3-deoxygluconate. Given the error factor involved in subjective IC peak 
selection, this is taken to be 100% conversion as there were no peaks seen indicative of any residual 
gluconic acid in the sample.  
5.13.4 20mM gluconic acid assays with range of enzyme concentrations and time points analysed via 
IC 
Following the analysis of 2mM gluconic acid assays, all deproteinized samples from the 20mM gluconic 
acid assays (section 5.13) were analysed via IC as well and the final 2-keto-3-deoxygluconate 
concentrations were calculated using the standard curve (Figure 2.3).  
  2-keto-3-deoxygluconate produced mM 
Time (min) DHAD 1mg/ml DHAD 2.5mg/ml DHAD 5mg/ml 
0 0 0 0 
15 0.52 1.27 2.96 
30 1.27 3.26 6.24 
60 2.48 5.97 11.08 
Table 5.14. IC activity analysis of 20mM gluconic acid assays with a range of enzyme concentrations at different 






























Figure 5.13. Graphical representation of the IC activity analysis of 20mM gluconic acid assays with a range of 
enzyme concentrations at different time points. Standard deviation for all conditions= <2.47.  
 
A negative control of 20mM gluconic acid was analysed via the IC and using the corresponding standard 
curve (Figure 2.2) its concentration was calculated to be 17.18mM, so this was an under estimation by 
2.82mM. Based on this value, 17.18mM of 2-keto-3-deoxygluconate would be expected as the final 
product if 100% conversion of substrate to product had occurred. From Table 5.14 and Figure 5.13, it 
can be seen that the final concentrations of 2-keto-3-deoxygluconate obtained after 60 minutes are in 
the range of 2.48-11.08 mM 2-keto-3-deoxygluconate from the 3 different enzyme concentrations. 
100% conversion was not achieved for any of the conditions after 60 minutes.  
5.14 Establishing DHAD enzyme kinetics 
Following the experimental data obtained in 5.13, 1mg/ml final DHAD concentration was tested with 
a range of gluconic acid concentrations (1-40mM gluconic acid) for enzyme kinetics calculations. All 
conditions were run alongside negative controls to check if the concentration of known standards is 
calculated to be the similar from the standard curves (Table 5.15). The 40mM gluconic acid condition 
was abandoned as the retention time for both gluconic acid and 2-keto-3-deoxygluconate are in the 
same time range and smaller concentrations of 3-keto-3-deoxygluconate are overshadowed by the 



























DHAD 1mg/ml DHAD 2.5mg/ml DHAD 5mg/ml
108 
 
Gluconic acid (mM) Calculated gluconic acid 
concentration from 









Table 5.15. IC analysis of negative assay controls with known concentrations of gluconic acid without addition of 
DHAD. Standard deviation for all conditions = <0.84 
 
Table 5.16 shows production of 2-keto-3-deoxygluconate using 1mg/ml DHAD in assays with gluconic 
acid as substrate at various time points. Given the error factor in the concentration calculations as 
evident from Table 5.15, some conditions are overestimating the amount of 2-keto-3-deoxygluconate 
present as the final value is over the concentration of substrate added to the reaction. This is due to 
the error factor in using the IC to calculate final concentrations. Due to the nature of peak selection, 
this is a factor which cannot be mitigated easily. 
 
2-keto-3-deoxygluconate production mM 
















2 0.05 0.08 0.12 0.17 0.20 0.24 0.34 N/D 
4 0.13 0.17 0.23 0.34 0.39 0.29 0.45 0.79 
6 0.22 0.28 0.47 0.54 0.50 0.51 0.65 0.77 
10 0.41 0.68 0.76 1.00 1.07 1.06 0.91 0.84 
15 0.62 0.99 1.37 1.32 1.49 1.89 1.22 1.16 
30 1.14 1.79 2.42 2.62 2.48 3.53 2.58 1.67 
60 1.32 2.29 3.79 4.22 4.65 4.54 3.99 3.57 
120 1.32 2.64 4.59 5.73 5.84 6.29 5.75 4.30 
300 1.29 2.50 5.26 6.94 7.16 8.60 7.23 5.54 
1440 1.72 2.39 4.87 7.15 9.10 12.12 15.19 13.94 
Table 5.16. IC activity analysis of production of 2-keto-3-doxygluconate under 1mg/ml DHAD assays with gluconic 
acid (GA) as substrate, tested in the range of 1-20mM at various time points. 20mM gluconic acid 2 min condition 
data point missing as 2-keto-3-deoxygluconate peak difficult to isolate. Standard deviation of all conditions= 
<1.57.  
 
For ease of data representation, graphical representation from Table 5.15 has been split between 2 
graphs, Figure 5.14A shows 1-6mM gluconic acid assay conditions, while Figure 5.14B shows 8-20mM 







Figure 5.14. Graphical representation of 2-keto-3-deoxygluconate production using 1mg/ml DHAD with various 
concentrations of gluconic acid. Figure 5.14A represents product formation when using 1-6mM gluconic acid and  
Figure 5.14B represents the same with 8-20mM gluconic acid. Standard deviation of all conditions = <1.57.  
 
Figure 5.15A shows the initial activity of DHAD at different substrate concentrations and Figure 5.15B 
shows the Lineweaver-Burk plot for the kinetics calculation. The Michealis-Menten model was used to 






























































Figure 5.15. Initial activity of DHAD at various gluconic acid concentrations (A), Lineweaver-Burk plot for the 
kinetic analysis (B). 
 
5.15 Effect of storage on DHAD enzymatic activity 
Literature has been cited to advise the use of freshly prepared DHAD whenever possible as activity loss 
has been widely reported when enzymatic solution is stored at 4°C and -80°C. This was also 
demonstrated by the experiments carried out with thawed DHAD stocks, which displayed poor 
activities (section 5.8-5.11). Activity loss of DHAD was therefore tested over the course of 50 days, with 
freshly prepared DHAD stock being tested on day 0 before being stored at 4°C with subsequent activity 
analysis on day 28 and day 50 (Figure 5.16). 6mM gluconic acid was used as substrate and activity was 
tested at 2, 4, 6, 10, 15 and 30 minute time intervals. All reaction conditions were the same outlined 





































that the stock faces degradation while at storage and storage condition at 4°C is not a suitable solution 
to the problem.  
 
Figure 5.16. IC activity analysis of 1mg/ml DHAD stored at 4°C over the course of 50 days using 6mM of gluconic 
acid as substrate (GA). Standard deviation of all conditions= <0.32.  
 
This chapter has outlined the successful expression, purification and quantification techniques 
employed for the production of DHAD. Activity of DHAD has successfully been established and its main 
reaction of interest in the overall cascade has been optimized and characterized. However, there are 
still outstanding issues of optimizing storage conditions and improving enzyme activity without 


































Day 0 6mM GA Day 28 6mM GA Day 50 6mM GA
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6. 2-keto-3-deoxy-gluconate aldolase catalyses the aldol cleavage of 2-keto-3-deoxy-gluconate to 
form pyruvate and glyceraldehyde 
 
The hyperthermophilic archaeon Sulfolobus solfataricus metabolizes glucose via a novel non-
phosphorylated Enter-Doudoroff pathway, whereby the initial reaction is the NAD+-dependent 
dehydrogenation of glucose to gluconate (Chapter 4), which is then dehydrated to form 2-keto-3-
deoxygluconate (Chapter 5), 2-keto-3-deoxygluconate then undergoes a reversible aldol cleavage 
catalysed by 2-keto-3-deoxygluconate aldolase (KDGA) to give pyruvate and glyceraldehyde. 
2-Keto-3-deoxygluconate  Pyruvate + Glyceraldehyde 
KDGA from a thermostable archaeon with its inherent thermostability and ability to utilize non-
phosphorylated substrates can offer multiple advantages over other enzyme systems. This chapter 
discusses the protein expression, purification and characterization of KDGA.  
6.1 Transformation of KDGA vector DNA into BL21-DE3 competent cells 
Synthesised pET30a vectors containing KDGA sequence arrived as a concentrated miniprep of ~4µg of 
DNA from GenScript (sequence in appendix). The original vector sample was archived and 
transformation of vector into DH5α competent cells was done followed by a miniprep to obtain 50µl 
of quantified vector DNA. KDGA vector DNA was transformed into BL21-DE3 cells as they have 
favourable characteristics for recombinant protein production such as protease deficiency, low acetate 
production under high glucose conditions and high permeability. Following successful transformation, 
single colonies were used to initiate protein expression. LB agar kanamycin plates with the successful 
transformation of vector DNA into BL21-DE3 were also used to prepare glycerol stocks for storage at -
80°C for future applications. 
 
Figure 6.1. Quantified vector DNA obtained following miniprep was transformed into competent BL21-DE3 cells, 
successful transformation is shown by the presence of bacterial colonies on LB kanamycin plate. 
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6.2 Small scale KDGA protein expression and purification in AI media 
Following the successful transformation of KDGA vector DNA, protein expression and purification was 
initially carried out in a 2L final volume. Initial KDGA expression was carried out in AI media with a final 
concentration of kanamycin at 50µg/ml at room temperature overnight for which the final OD600 was 
9.61. The cell pellet obtained from the cultures was resuspended, sonicated and heat treated as 
outlined in the methods sections. All resuspension, sonication, heat treatment and centrifugation 
steps were carried out in a 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer unless otherwise 
stated. The suspension obtained following cell lysis, heat treatment to denature host cellular 
components and centrifugation to remove cell debris, was used as the KDGA crude enzyme fraction 
for purification via Ni-NTA affinity chromatography. 
6.3 Ni-NTA affinity chromatography of crude KDGA  
The crude fraction of KDGA (50ml in 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer) 
obtained from small scale expression of KDGA as outlined in section 6.2, was bound to 5ml of Ni-NTA 
resin overnight at room temperature. Following this, the suspension was transferred to a 
polypropylene column, the flow through was collected and the Ni-NTA resin washed with 100mM 
HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer. Three concentrations of imidazole in 100mM HEPES 
pH 7.5, 200mM MgCl2, 10% glycerol buffer were then used to elute off bound protein. All samples 
collected from Ni-NTA affinity chromatography were analysed via SDS-PAGE (Figure 6.2). KDGA binding 
to Ni-NTA via the His10 tag was successful as evident from comparing samples in lanes 2 and 3 of Figure 
6.2. The crude KDGA sample in lane 2 presents a thick band at around 34kDa which is the size of the 
KDGA monomer. As seen in lane 3 of Figure 6.2, after binding the crude fraction with Ni-NTA and 
collecting the flow through, the intensity of the band at 34kDa is very faint, indicating the KDGA in the 
crude fraction has successfully bound to the Ni-NTA. 500mM imidazole was sufficient to elute off KDGA 
(Figure 6.2, lanes 6 and 7). The original elution of KDGA as shown in lane 6 of Figure 6.2 precipitated 
out soon after the elution was collected and the sample loaded into lane 6 was following the 
centrifugation to remove aggregated protein. The removal of protein aggregates did not prevent 
further aggregation, and several aggregation/centrifugation cycles were done after which it was not 





Figure 6.2. SDS-PAGE analysis of Ni-NTA purification attempt of KDGA. Samples in all lanes, except lane 2, are 
from elutions obtained from the column following Ni-NTA affinity chromatography. Lane 2 contains sample of 
crude KDGA prior to binding with Ni-NTA. Lane 3 contains the flow through collected from column and lane 4 
contains the HEPES buffer washes (100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2). Lanes 5, 6, 7 and 8 
contain HEPES buffer imidazole elutions with 100, 500, 500 and 1000mM imidazole respectively. 
 
Fraction from lane 7 containing the highest amount of KDGA eluted was taken forward (10ml final 
volume) and 100mM final concentration of EDTA was also added to the sample to aid dialysis. Previous 
attempts of purification of GDH and DHAD in Chapters 4 and 5 respectively have highlighted the idea 
of using EDTA to stop protein aggregation during dialysis. The elution of bound protein with imidazole 
also leads to leached nickel ions from the column and into the collection tubing. During Ni-NTA affinity 
chromatography, both imidazole the His10 tag chelate the nickel, and the removal of just imidazole 
during dialysis can result in the sample being insoluble. The addition of EDTA assists successful dialysis 
as it is assumed to chelate the nickel ions and thereby prevents protein-protein self-interactions and 
results in a successful dialysis cycle. The 10ml of KDGA solution was successfully put through 2 cycles 
of dialysis until the imidazole and EDTA were dialysed out and their respective concentrations in the 
solution were negligible (<0.01mM). The concentration of MgCl2 was reduced to 100 and 50mM in the 
first and second cycle of dialysis respectively, and the final storage buffer for KDGA was 100mM HEPES 





2 cycles of dialysis were performed: 
1- 10ml elution dialysed in 1L of 100mM HEPES pH 7.5, 10% glycerol, 100mM MgCl2 buffer at a 
dilution factor of 100. 
2- 30ml elution dialysed in 1L of 100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2 buffer at a 
dilution factor of 100. 
The GDH sample was then concentrated down in volume and its protein concentration was determined 
via BCA to be 1.2mg/ml. Large scale preparations of KDGA were purified in further attempts similarly 
as outlined above, and following the determination of protein concentration, the 1ml aliquots were 
snap frozen and stored at -80°C until required.  
6.4 Size-exclusion chromatography and protein identification of KDGA to determine presence of 
oligomers 
The small scale expression of KDGA gave a single band on the SDS-PAGE matching the expected size of 
the KDGA monomer (Figure 6.2, lane 6 and 7), however there is one other main band seen around the 
70kDa position which was suspected to be a KDGA dimer. To confirm the presence of oligomers, KDGA 
purified from section 6.3 was loaded onto the ÄKTA system and as size-exclusion chromatography 
separates molecules in solution based on their molecular weight, the peaks on a chromatogram are 
indicative of the different size proteins in the sample. The chromatogram obtained from the size-
exclusion of KDGA (Figure 6.3) automatically identified 2 peaks and aliquoted them into a collection 







Peak Retention (ml) Area (ml*mAU) Area % Fractions Volume (ml) 
a 13.67 98.21 96.18 B9-C12 8 
b 19.38 2.61 2.55 D2-D5 2 
Figure 6.3. Size exclusion chromatography of KDGA. Figure 6.3A displays the chromatogram obtained from the 
software. The blue trace represents the UV absorbance at 280nm and the 2 peaks are indicative of the quantity 
of protein detected. The brown trace reflects the conductivity monitor which measures conductivity of buffer 
and samples for online monitoring of the true gradient. The green trace is applied if there is another buffer being 
used, since this sample was run in one buffer only, the trace has a value of 0. Figure 6.3B lists the retention time 
of each peak as well as the final volume collected of all fractions.  
 
The chromatogram also identified a peak at retention volume of 0.094ml which comprised a total of 
1.27% of the total area, since this retention volume falls within the range of the void volume, this peak 
and its analysis was disregarded. 2 samples from peak a and one sample from peak b were loaded onto 
a SDS-PAGE gel in order to visualise their composition. The SDS-PAGE obtained from the samples 
(Figure 6.4) shows the composition is exactly the same in all samples loaded, confirming the presence 
of oligomers. No visible bands can be seen in lane 4 which contained the sample taken from peak b, 
however as can be seen on the chromatogram in Figure 6.3A, the peak is very small in comparison to 
peak a, hence very little protein would be expected to be in this elution. In Figure 6.4, the sample in 
lane 2 and 3 is from peak a and sample in lane 4 is from peak b (Figure 6.3A). It is evident from the gel 
in Figure 6.4 that the same bands are constantly seen in all the samples, differing only in their 
intensities, which correlates with the different concentrations of protein present in the different 
fractions. Following the SDS-PAGE, as a further confirmation of oligomers, the KDGA bands indicated 







Figure 6.4. SDS-PAGE analysis of KDGA following size exclusion chromatography. Lane 2 and 3 contains samples 
from peak A, taken from fractions B12 and C5 respectively. Lane 4 contains sample from peak B, taken from 
fraction D3. The bands indicated in the figure were excised for mass spectrometry analysis. 
 
Mass spectrometry analysis of the bands shown in Figure 6.4 positively identified both as being KDGA. 
As peak A comprised 96.18% of the total area and this would have been higher if not for the false peak 
identified at the retention volume of 0.094ml, the composition of the Ni-NTA purified KDGA in this 
instance and the protein concentration determined by the corresponding BCA was taken as the final 
KDGA concentration. For any further attempts at purification, ImageJ scientific image analysis was used 
and the confirmed KDGA bands (via mass spectrometry) were calculated as a percentage of the total 
protein concentration. Using this method allowed for the actual concentration of KDGA to be 
determined in a sample with other non-specific proteins purified during Ni-NTA purification in future 
experiments.  
6.5 Producing 2-keto-3-deoxygluconate for use as substrate with KDGA 
2-Keto-3-deoxygluconate is the product of the following reaction catalysed by DHAD as discussed in 
the previous chapter: 
Gluconate  2-keto-3-deoxygluconate 
The commercial availability of 2-keto-3-deoxygluconate is in very small quantities and as a lithium salt, 
therefore purchasing this substrate for testing functional activity of KDGA was not an economically 
favoured option. Furthermore, additional reaction controls would be required to address the presence 
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of lithium ions in the reaction mixture and reaction parameters would not be the same in the eventual 
testing of the cascade. For these reasons, 2-keto-3-deoxygluconate was attempted to be produced on 
a large scale using DHAD. From the previous chapter, the kinetic parameters of DHAD were established 
and 15mM gluconic acid gave 15mM 2-keto-3-deoxygluconate as analysed via IC (Table 5.16) with very 
little residual gluconic acid remaining. The same reaction with 15mM of gluconic acid was set up to 
obtain 15mM of 2-keto-3-deoxygluconate which was then intended to use to test the functional 
activity of KDGA. 1mg/ml DHAD was used to catalyse the conversion of 15mM gluconic acid in 2x 50ml 
reaction volume and incubated for 1440 minutes at 55°C. Following the end of the reaction incubation 
period, the samples were deproteinized and the conversion efficiency of gluconate to 2-keto-3-
deoxygluconate was analysed via IC.  
 
Gluconic acid mM 2-Keto-3-deoxygluconate mM 
Reaction mix 1 8.07 8.97 
Reaction mix 2 8.33 8.38 
Table 6.1. IC composition analysis of 2x 50ml DHAD reaction mix to produce 2-keto-3-deoxygluconate. 15mM 
gluconic acid was used as substrate for this reaction of which 8.07 and 8.33mM remained in the reaction mixture 
after incubation for 1440 minutes at 55°C.  
 
The DHAD stock used in the reaction mix had been stored at 4°C and was not a fresh stock, the issues 
with DHAD storage and decreasing enzyme activity over time were previously discussed in detail in 
Chapter 5. Only 50% conversion of total gluconic acid was achieved and this was presumed due to the 
DHAD batch used and the loss of activity within the batch. A 100ml final volume solution was obtained 
which contained ~8mM of gluconic acid and ~8mM of 2-keto-3-doxygluconate. Despite it not being 
ideal, the mixture of 50/50 gluconic acid/2-keto-3-deoxygluconate was used as the substrate to test 
functional KDGA activity.  
6.6 Testing KDGA activity using 2-keto-3-deoxygluconate present with gluconic acid in solution 
Since a 100ml deproteinized solution of 50/50 gluconic acid/2-keto-3-deoxygluconate was already 
obtained from the previous section, this was tested as substrate for any activity with KDGA despite the 
presence of gluconic acid in the solution. 3 concentrations of KDGA were tested, 0.0001, 0.001 and 
0.1mg/ml KDGA at 4 different time points of 15, 30, 60 and 120 minutes. All reaction and control 
conditions were set up in triplicate 1ml volumes and incubated at 55°C, 300rpm shaking, before 
deproteinizing and analysis via IC. The final substrate concentration of 2-keto-3-deoxygluconate 
assayed in all conditions was 5mM due to low concentrations of the experimentally produced 2-keto-
3-deoxygluconate stock in section 6.5. Initially only the 0.1mg/ml KDGA assay at 120 minutes and its 
subsequent control was analysed via IC (Figure 6.5). This reaction condition would theoretically display 




Figure 6.5. IC analysis of 0.01mg/ml KDGA 120min assay condition and its subsequent control with no KDGA. For 
overlaying purposes, the trace of the control condition is shifted to the right to allow for direct side by side visual, 
otherwise the retention times are similar for gluconic acid and 2-keto-3-deoxygluconate peaks in both assay and 
control conditions.  
 
As seen in Figure 6.5, the 2-keto-3-deoxygluconate peaks are of a similar area for both the control and 
assay conditions meaning that 2-keto-3-doxygluconate in the assay conditions has not been converted 
to desired products of pyruvate and glyceraldehyde as its concentration largely remaining unchanged.  
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6.7 Testing reverse catalysed reaction of KDHA to form 2-keto-3-deoxygluconate from pyruvate and 
glyceraldehyde 
The IC analysis of the KDGA forward reaction revealed no peaks for the desired products of pyruvate 
and glyceraldehyde as outlined in section 6.6. As the aldol cleavage of 2-keto-3-deoxygluconate is a 
reversible reaction, the reaction parameters were also explored in reverse: 
Pyruvate + Glyceraldehyde  2-Keto-3-deoxygluconate 
Due to ease of commercial availability of pyruvate and glyceraldehyde, the reverse reaction 
parameters were easier to manipulate with variations in concentrations without any restrictions. 
20mM glyceraldehyde and 50mM pyruvate were used as substrates to test the conversion to 2-keto-
3-deoxygluconate by 0.25mg/ml KDGA. Two controls were also run alongside the assay condition 
(Control 1- 20mM glyceraldehyde and 50mM pyruvate, no KDGA and Control 2- no substrates, 
0.25mg/ml KDGA), all in triplicate. The reaction and controls were incubated for 15 minutes at 55°C, 
300rpm shaking before being deproteinized and analysed via IC. The column used for the IC could not 
be used to detect glyceraldehyde, therefore a reduction in the concentration of pyruvate and the 
presence of a peak with the retention time of 2-keto-3-deoxygluconate was used as a positive 
confirmation of the functional activity of KDGA (Table 6.2). 
 
Concentration detected by IC (mM)  
Pyruvate 2-keto-3-deoxygluconate 
Control 1 47.23 N/D 
Control 2 N/D N/D 
Assay 46.87 1.77 
Table 6.2. IC analysis of the assay and control conditions of reverse activity analysis of KDGA to form 2-keto-3-
deoxygluconate from pyruvate and glyceraldehyde. (N/D= none detected).  
 
The pyruvate and 2-keto-3-deoxygluconate peaks were calculated as their respective concentrations 
from the pyruvic acid and 2-keto-3-deoxygluconate standard curves (Figure 2.3 and 2.4) as outlined in 
the Methods chapter. 50mM of pyruvic acid was added into the assay condition and the same was 
added to reaction Control 2. As shown in Table 6.2, the control condition has been calculated to contain 
47.23mM pyruvic acid, this is a slight underestimation from the 50mM added to both assay and control 
conditions. However, this discrepancy was expected as 50mM pyruvic acid was the final value in the 
standard curve, and around these higher concentrations of pyruvic acid, the IC chromatogram peaks 
begin to plateau and widen, indicating the concentration of the solution loaded exceeded the 
analytical limitations of the device. For these reasons, the underestimation of the 50mM pyruvic acid 
to 47.23mM was expected. The presence of the 2-keto-3-doxygluconate peak was taken to be a true 




Figure 6.6. IC chromatogram peaks of reverse catalysed reaction of KDGA to form 2-keto-3-deoxygluconate from 
pyruvate and glyceraldehyde. Panel A contains reaction control 1 with substrates but no KDGA. Panel B is reaction 
control 2 with KDGA but no substrates. Panel C is the assay with 0.25mg/ml KDGA and 20mM glyceraldehyde 
and 50mM pyruvate. 2-Keto-3-deoxygluconate peak was observed in the assay condition confirming functional 
activity of KDGA.  
 
A peak with the expected retention time of 2-keto-3-doxygluconate was identified in the analysis of 
the assay chromatogram (Figure 6.6, Panel C) whereas no such peak was observed in either one of the 
controls (Figure 6.6, Panels A and B). This experiment confirmed a functional KDGA stock and also 




6.8 Preliminary pilot studies to establish best assay conditions for KDGA kinetic studies 
Before establishing KDGA kinetics parameters, pilot experiments were performed where a range of 
enzyme concentrations were tested with 2 substrate concentrations over certain time points. Three 
different KDGA concentrations were tested, 0.5, 1, 2.5mg/ml, firstly with low substrate concentrations 
of 1mM glyceraldehyde and 2mM pyruvate and then with high substrate concentration of 10mM 
glyceraldehyde and 20mM pyruvate. Each assay condition (with relevant controls) as described above 
was tested at 3 time points of 15, 30 and 60 minutes for formation of 2-keto-3-deoxygluconate. 
Analysis was carried out via IC after deproteinizing assay samples. 
6.8.1 1mM glyceraldehyde and 2mM pyruvate assay with 0.5, 1 and 2.5mg/ml KDGA at 3 time points 
Table 6.3 lists the 2-keto-3-deoxygluconate concentrations calculated using 2-keto-3-deoxygluconate 
standard curve (Figure 2.3).  
 
2-Keto-3-deoxygluconate (mM) 
Time (min) 0.5 mg/ml KDGA 1mg/ml KDGA 2.5mg/ml KDGA 
0 0 0 0 
15 0.07 0.15 0.47 
30 0.17 0.28 0.63 
60 0.22 0.31 0.63 
Table 6.3. IC analysis of KDGA activity assay (0.25, 1 and 2.5mg/ml) with 1mM glyceraldehyde and 2mM pyruvate 
as substrates at 15, 30 and 60 minutes, for the formation of 2-keto-3-doxygluconate. Standard deviation of all 
conditions= <0.065.  
 
 
Figure 6.7. Graphical representation of IC analysis of KDGA activity assay (0.25, 1 and 2.5mg/ml) with 1mM 




























0.5 mg/ml KDGA 1mg/ml KDGA 2.5mg/ml KDGA
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The highest concentration of 2-keto-3-deoxygluconate detected from all the assay conditions in the 
low substrate concentration was at 30 minutes with 2.5mg/ml KDGA, whereby 0.63mM of 2-keto-3-
deoxygluconate was detected.  
6.8.2 10mM glyceraldehyde and 20mM pyruvate assay with 0.5, 1 and 2.5mg/ml KDGA at 3 time 
points 
Table 6.4 lists the 2-keto-3-deoxygluconate concentrations as calculated using 2-keto-3-
deoxygluconate standard curve (Figure 2.3).  
 
2-Keto-3-deoxygluconate (mM) 
Time (min) 0.5 mg/ml KDGA 1mg/ml KDGA 2.5mg/ml KDGA 
0 0 0 0 
15 1.4 2.82 5.47 
30 3.51 5.88 8.5 
60 5.22 7.52 8 
Table 6.4. IC analysis of KDGA activity assay (0.25, 1 and 2.5mg/ml) with 10mM glyceraldehyde and 20mM 
pyruvate as substrates at 15, 30 and 60 minutes, for the formation of 2-keto-3-doxygluconate. Standard deviation 
of all conditions= <1.76.  
 
 
Figure 6.8. Graphical representation of IC analysis of KDGA activity assay (0.25, 1 and 2.5mg/ml) with 10mM 
glyceraldehyde and 20mM pyruvate as substrates at 15, 30 and 60 minutes, for the formation of 2-keto-3-
deoxygluconate. 
 
The assay conditions with the high substrate concentrations (10mM glyceraldehyde and 20mM 
pyruvate) produced 8.495 and 7.995mM of 2-keto-3-deoxygluconate at 60 minutes by both 1mg/ml 
and 2.5mg/ml KDGA. Therefore, all further kinetic studies were established to be done with KDGA 

























0.5 mg/ml KDGA 1mg/ml KDGA 2.5mg/ml KDGA
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20mM pyruvate at 15, 30 and 60 minutes is shown in Figure 6.9 as the 2-keto-3-deoxygluconate peak 
can be seen as the incubation time increases, and the pyruvic acid peak can be seen decreasing as it is 
converted into 2-keto-3-deoxygluconate (Figure 6.9).  
 
Figure 6.9. IC analysis of 1mg/ml KDGA assay with 10mM glyceraldehyde and 20mM pyruvate as substrates. 
Panel A is reaction components at 15 minutes, panel B is reaction components at 30 minutes and panel C is 
reaction components at 60 minutes. All samples were deproteinized once their appropriate incubation times 
were completed before loaded onto the IC for analysis. Glyceraldehyde could not be detected on the particular 
column used with the IC. The area of the pyruvate peak is seen to be decreasing over the 60 minutes while the 






6.9 Exploring the effect of glyceraldehyde and pyruvate concentration ratios on the production of 2-
keto-3-deoxygluconate 
Previously performed studies (Wolterink-van Loo et al. 2007) have used 20mM glyceraldehyde and 
50mM pyruvate for any activity measurements of KDGA. The rationale for using this ratio was explored 
as the theoretical yield is 1:1. To test this, three ratios of glyceraldehyde and pyruvate were tested 
under experimental conditions: 
1. 10mM glyceraldehyde + 20mM pyruvate (as previously used for KDGA activity analysis in 
sections 6.7 and 6.8.2 and Buchanan et al. 1999, Wolterink-van Loo et al. 2007) 
2. 20mM glyceraldehyde + 20mM pyruvate (1:1 ratio) 
3. 20mM glyceraldehyde + 10mM pyruvate (reverse ratios of those condition in 1) 
Each condition was run with its own control without any KDGA, all assay and control conditions were 
incubated at 55°C at 300rpm shaking for one hour before deproteinizing and analysis via IC. 2-Keto-3-
deoxygluconate was not detected in any of the control conditions. The pyruvate concentrations in the 
control and assay conditions were calculated using a pyruvic acid standard curve (Figure 2.4), as was 
the 2-keto-3-deoxygluconate concentration formed in the assay conditions from its respective 
standard curve (Figure 2.3). 
 
Pyruvate (mM) 2-Keto-3-deoxygluconate (mM) 
Assay 10mM glyceraldehyde + 20mM pyruvate  11.54 8.34 
Control 10mM glyceraldehyde + 20mM pyruvate  19.35 N/D 
Assay 20mM glyceraldehyde + 20mM pyruvate  6.88 13.1 
Control 20mM glyceraldehyde + 20mM pyruvate  19.2 N/D 
Assay 20mM glyceraldehyde + 10mM pyruvate  2.56 7.9 
Control 20mM glyceraldehyde + 10mM pyruvate  9.52 N/D 
Table 6.5. IC 0.25mg/ml KDGA activity analysis with 3 ratios of glyceraldehyde and pyruvate in the formation of 
2-keto-3-deoxygluconate after 60 minutes. Standard deviation for all assay and control conditions= <0.6. N/D= 
none detected. 
 
No 2-keto-3-deoxygluconate peaks were detected in any of the controls as expected since there is no 
KDGA added to catalyse the conversion of glyceraldehyde and pyruvate to 2-keto-3-deoxygluconate. 
As for the ratios used, the 10mM glyceraldehyde + 20mM pyruvate substrate ratios produced 8.34mM 
2-keto-3-deoxygluconate. The reverse of this condition with opposite substrate ratios, 20mM 
glyceraldehyde and 10mM pyruvate gave slightly lower 2-keto-2-deoxygluconate concentration of 
7.9mM. As for the condition where the concentration of glyceraldehyde used was doubled to 20mM 
from 10mM, the concentration of 2-keto-3-deoxygluconate formed would also expected to be 
doubled. As this was not the case, performing further experiments with an increased concentration of 
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glyceraldehyde would lead to unnecessary addition of substrate without it contributing significantly to 
the yield increase overall, therefore the rationale for using 10mM glyceraldehyde and 20mM pyruvate 
as cited in literature was justified.  
6.10 Establishing KDGA enzyme kinetics 
Following the experimental data obtained in sections 6.82 and 6.9, 1mg/ml final KDGA concentration 
was tested with a range of glyceraldehyde and pyruvate concentrations in which the ratio of 
glyceraldehyde to pyruvate was always kept 1:2 respectively, and the enzyme kinetics experiments 
were performed. All conditions were ran alongside negative controls to check if the concentration of 
known substrate concentrations added to assays (only pyruvate as glyceraldehyde could not be 
detected on the IC column) were calculated to be similar concentrations from the standard curve 
(Table 6.6).  
Pyruvic acid (mM) Calculated pyruvic acid concentration 







Table 6.6. IC analysis of negative assay controls with known concentrations of pyruvic acid without addition of 
KDGA. Standard deviation for all conditions = <2.68 
 
As outlined in Table 6.6, the concentrations of added pyruvic acid to the assay conditions are slightly 
underestimated when they are recalculated using the pyruvic acid standard curve. This is due to the 
error factor in using the IC to calculate final concentrations. Due to the nature of peak selection, this 
is a factor which cannot be mitigated easily. Enzyme kinetics experiments were run and the final 
concentration of 2-keto-3-deoxygluconate obtained from all conditions is outlined in Table 6.7 below 

























2 N/A N/A 0.25 0.53 0.81 1.81 
4 N/A N/A 0.36 0.66 1.30 3.33 
6 N/A N/A 0.48 0.91 1.97 3.93 
10 N/A 0.18 0.66 0.99 3.65 5.78 
15 N/A 0.28 0.79 1.71 4.68 9.29 
30 N/A 0.28 1.24 3.37 7.31 17.70 
Table 6.7. IC activity analysis of production of 2-keto-3-doxygluconate with 1mg/ml KDGA assays with 
glyceraldehyde (GL) and pyruvate (PA) as substrates, tested in the range of 0.5-20mM glyceraldehyde and 1-
40mM pyruvate at various time points. 0.5mM GL 1mM PA and some 1mM GL 2mM PA data points missing as 
2-keto-3-deoxygluconate peak was very difficult to isolate due to surrounding buffer component peaks (N/A). 
Standard deviation of all conditions= <0.94. 
 
The missing data points (N/A) in Table 6.7 are due to surrounding buffer component peaks with very 
similar retention times to that of 2-keto-3-deoxygluconate. They were also seen in each condition 
control and since the initial concentrations of 2-keto-3-deoxygluconate are very small peaks, especially 
when the overall substrate concentrations used in the assay conditions are low, it was very hard to 
objectively isolate the peak associated with 2-keto-3-deoxygluconate.  
 
Figure 6.10. Graphical representation of 2-keto-3-doxygluconate productions with 1mg/ml KDGA using various 
concentrations of glyceraldehyde (GL) and pyruvate (PA) as substrates over a time course of 30 minutes. Standard 
deviation of all conditions= <0.94. 
 
Figure 6.11A shows the initial activity of KDGA at different substrate concentrations and Figure 6.11B 
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calculate the apparent Vmax and Km values of KDGA which was calculated to be 0.287U/mg and 
32.426mM respectively. There are two substrates present in the assay condition (glyceraldehyde and 
pyruvate) and as pyruvate was the only one which could be detected via IC, this was used to calculate 
the enzyme kinetics.  
 
 
Figure 6.11. Initial activity of KDGA at various gluconic acid concentrations (A), Lineweaver-Burk plot for the 
kinetic analysis (B). 
 
 
This chapter has outlined the successful expression, purification and quantification techniques 
employed for the production of KDGA. Activity of KDGA in the reverse direction has successfully been 















































7. Using glyceraldehyde dehydrogenase to shift reaction equilibrium towards production of desired 
intermediate-pyruvate 
 
As outlined in Chapter 6, the prior step in the cascade catalysed by 2-keto-3-deoxygluconate aldolase 
catalyses the cleavage of 2-keto-3-deoxygluconate into pyruvate and glyceraldehyde, with only the 
former product of pyruvate being an intermediate of interest in relation to the cascade design 
discussed in this thesis. Glyceraldehyde is as an unwanted by-product which reduces the theoretical 
yield efficiency of the final product, malic acid. A solution to this was explored with the addition of 
glyceraldehyde dehydrogenase (AIDH) to the cascade design. AIDH catalyses the conversion of 
glyceraldehyde to glycerate and as outlined previously in Chapter 5, substrate promiscuity of DHAD 
can be exploited as it can also catalyse the conversion of  glycerate to pyruvate. This thereby reduces 
the unwanted intermediates formed and pushes the reaction forward in the desired direction. AIDH 
from Thermoplasma acidophilum has been cited to display high substrate specificity towards 
glyceraldehyde (Guterl et al. 2012) and therefore is a suitable option for application in this cascade. 
Previous attempts at expression and purification of AIDH from Thermoplasma acidophilum have 
highlighted issues with purification from inclusion bodies (Steffler and Sieber 2013).  This chapter 
discusses the protein expression, issues with purification from the soluble and insoluble fraction and 
attempts at methods of optimization of AIDH purification and characterization are also explored. 
7.1 Transformation of AIDH vector DNA into BL21-DE3 competent cells 
Synthesised pET30a vectors containing AIDH sequence arrived as a concentrated miniprep of ~4µg of 
DNA from GenScript (sequence in appendix). Original vector sample was archived and transformation 
of vector into DH5α competent cells was done followed by a miniprep to obtain 50µl of quantified 
vector DNA. AIDH was transformed into BL21-DE3 cells as they have favourable characteristics for 
recombinant protein production such as protease deficiency, low acetate production under high 
glucose conditions and high permeability. Following successful transformation, single colonies were 
used to initiate protein expression. LB agar kanamycin plates with the successful transformation of 





Figure 7.1. Quantified vector DNA obtained following miniprep was transformed into competent BL21-DE3 cells, 
successful transformation is shown by the presence of bacterial colonies on LB kanamycin plate. 
 
7.2 AIDH protein expression in AI media 
Following successful transformation of AIDH vector DNA, protein expression for crude protein fraction 
preparation was initially carried out in a 4L final culture volume of AI media with a final concentration 
of kanamycin at 50µg/ml. An average OD600 of 9.055 was read across the 4 flasks.  
7.2.1 AIDH soluble fraction preparation and purification with Ni-NTA 
The cell pellets obtained from the cultures in 7.2 were resuspended, sonicated and heat treated as 
outlined in the methods sections. Following centrifugation of AIDH cultures and isolation of the cell 
pellet, the medium was not discarded as standard but an aliquot was stored to be analysed via SDS-
PAGE. This was done in order to confirm whether or not the protein was being secreted into the AI 
medium itself (Figure 7.2, lane 2).  Regarding the cell pellet obtained, all resuspension, sonication, heat 
treatment and purification steps were carried out in a 100mM HEPES pH 7.5, 10% glycerol buffer unless 
otherwise stated. As this cell pellet was processed with the main goal of downstream processing of 
AIDH inclusion bodies, no MgCl2 was added to the buffer used for resuspension, sonication and heat 
treatment of the cell pellet as presence of salt promotes refolding (Singh et al. 2015) and the inclusion 
bodies protocol was to be done under denaturing conditions to unfold and correctly refold the protein. 
Following resuspension, sonication and heat treatment of cell pellet, 100ml of soluble crude protein 
fraction obtained from this stage was bound to and purified using 5 ml of Ni-NTA as outlined in the 
methods section. This step was carried out to determine if any soluble AIDH is present in the crude 
fraction and if it can be purified using Ni-NTA or whether the majority of the AIDH protein is present 
in the inclusion bodies. Following the Ni-NTA purification protocol as outlined in the methods section, 
one key change was made during this purification protocol. 200mM of MgCl2 was added to the HEPES 
buffer mix (100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2) used for washes and the imidazole 
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elutions. The reintroduction of the MgCl2 into the buffer assists protein stability in the soluble fraction. 
Following buffer washes and imidazole elutions, all elutions obtained were analysed via SDS-PAGE 
(Figure 7.2).  
 
Figure 7.2. SDS-PAGE analysis of soluble AIDH fraction obtained following expression in E. coli BL21-DE3 and AI 
media. Samples in all lanes are from elutions obtained from the column following Ni-NTA affinity 
chromatography. Lane 2 contains AI medium after centrifugation to isolate the cell pellet to check for any 
secreted proteins. Lane 3 is the flow through from the column and lanes 4 and 5 contain HEPES buffer washes 
(100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2). Lane 7, 8, 9, 10, 11, 12 and 13 contain HEPES buffer 
imidazole elutions with 50, 100, 200, 400, 600, 800 and 1000mM imidazole respectively. 
 
AIDH monomer is 57 kDa and as seen in Figure 7.2, lanes 9, 10 and 11 feature strong bands at the 
position correlating to this size. There was a strong band seen around the 230 kDa size as seen in lanes 
9, 10 and 11. This was suspected to be a tetramer of AIDH and along with the AIDH monomer, both of 
these bands were excised from the gel and analysed via mass spectrometry to confirm protein ID. Mass 
spectrometry analysis identified both of these bands to be AIDH from Thermoplasma acidophilum 
(data in appendix). The full fraction of the elution sample loaded in lane 10 was buffer exchanged using 
a protein concentrator spin column until negligible amounts of imidazole remained. Following this, an 
attempt was made to concentrate the protein down to a smaller volume during which the protein 
aggregated and recovery of soluble protein was very poor.  
7.2.2 AIDH insoluble fraction preparation and purification with Ni-NTA 
Cell pellet obtained from the expression of AIDH in AI media was processed as outlined at the beginning 
of section 7.2.1 and the soluble crude fraction was purified using Ni-NTA as shown in Figure 7.2. The 
cell pellet obtained following the sonication, heat treatment and centrifugation during the soluble 
fraction preparation was processed downstream for AIDH inclusion bodies. As mentioned in section 
7.2.1, the resuspension and all subsequent steps carried out with the initial AIDH pellet obtained 
following expression and growth in AI media were carried out in 100mM HEPES pH 7.5, 10% glycerol 
132 
 
buffer without any MgCl2, therefore it contained no traces of salt to promote refolding and was 
suitable to be processed under denaturing conditions. The cell pellet was resuspended in 50ml of 
denaturation buffer consisting of 6M guanidine hydrochloride (GdnHCl), 2mM DTT and 20mM HEPES 
pH 7.5 (as outlined in the materials section) and incubated to denature the protein and unfold it 
completely. The expectation after incubation of the cell pellet with denaturation buffer was to have 
the AIDH completely unfolded in solution which was followed by centrifugation to get rid of cellular 
debris. The 50ml of denaturation buffer containing unfolded AIDH was split into two 25ml fractions.  
7.2.2.1 Refolding of denatured AIDH in GdnHCl with Ni-NTA 
Two different methods to refold the unfolded AIDH were attempted with each 25ml fraction. The first 
method was to bind one 25ml fraction with 2.5ml Ni-NTA before purification using imidazole as 
outlined in the methods and done previously with the soluble fraction in section 7.2.1. The idea behind 
this attempt was that the unfolded AIDH in the GdnHCl, DTT and HEPES buffer solution binds to Ni-
NTA with the aid of the His10 tag. This was followed by affinity chromatography which gradually 
removes the GdnHCl and DTT in the flow through from the column, and the excess HEPES buffer mix 
(100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2) washes remove traces of GdnHCl and DTT from 
the Ni-NTA resin until their concentrations are negligible. Removing AIDH from GdnHCl solution 
promotes refolding and the introduction of MgCl2 and glycerol in the buffer further encourages protein 
refolding and stability (Singh et al. 2015). This was followed by imidazole elutions to elute any bound 
protein from the Ni-NTA. 3 different imidazole concentrations were used to elute any bound protein 
(Figure 7.3).  
 
Figure 7.3. SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies following extraction with 
GdnHCl. Samples in all lanes are from elutions obtained from the column following Ni-NTA affinity 
chromatography. Lane 2 contains flow through of denaturation buffer. Lanes 3 and 4 contain samples from HEPES 
buffer washes (100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2). Lanes 5, 6 and 7 contain HEPES buffer 
imidazole elutions with 100, 500 and 1000mM imidazole respectively.  
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From Figure 7.3, it is evident that binding the unfolded protein under denaturing conditions with Ni-
NTA and then eluting any bound protein off with imidazole was an effective strategy. The HEPES buffer 
washes were effective at removing GdnHCl and DTT as the flow through contains a very high amount 
of GdnHCl and upon addition to the SDS-PAGE, it precipitated resulting in the smear seen in lane 2. A 
negligible amount of GdnHCl in the following washes resulted in the elution of bound AIDH as seen in 
lane 6. As mentioned previously, AIDH monomer is 57 kDa and as seen in Figure 7.3 lane 6 features a 
single band at the position correlating to this size. There was a strong band around 230 kDa as seen in 
lane 6 and faintly in lane 7 as well. This was suspected to be a tetramer of AIDH and along with the 
AIDH monomer, both of these bands were excised from the gel and analysed via mass spectrometry 
to confirm protein ID. Mass spectrometry analysis identified both of these bands to be AIDH from 
Thermoplasma acidophilum (data in appendix). Going forward, refolding of AIDH while carrying out 
affinity chromatography seems an effective strategy and the protocol was to be optimized before 
attempting it again. The full fraction of the elution sample loaded in lane 6 was buffer exchanged using 
a protein concentrator spin column until negligible amounts of imidazole remained. Following this, an 
attempt was made to concentrate the protein down to a smaller volume during which a 1.27mg/ml 
concentrated sample of AIDH was obtained as determined via BCA. This sample was stored before 
analysis for enzymatic activity at a later stage.  
7.2.2.2 Refolding of denatured AIDH in GdnHCl via dialysis 
As mentioned in section 7.2.2, the unfolded AIDH in denaturation buffer was split into two 25ml 
fractions, the first of which was processed as outlined in section 7.2.2.1 with a successful attempt at 
refolding unfolded AIDH using Ni-NTA chromatography. The second 25ml fraction was attempted to 
be refolded using a dialysis technique. The idea behind this attempt was similar to that of the approach 
in section 7.2.2.1 in the sense that gradual removal of GdnHCl from the solution promotes refolding of 
the protein in solution which could then be bound with Ni-NTA to remove any unwanted proteins. The 
25ml fraction was dialysed against 500ml of 100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2 buffer 
overnight. This was not effective as aggregates were seen inside the dialysis tubing (Figure 7.4A). The 
sample from the dialysis tubing was centrifuged to separate the aggregates from the supernatant 







Figure 7.4. Dialysis of 25ml unfolded AIDH in denaturation buffer consisting of 6M GdnHCl, 2mM DTT and 20mM 
HEPES pH 7.5 against 500ml of 100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2. Aggregates are visible inside 
the dialysis tubing (Figure 7.4A). Aggregates from the dialysis tubing were centrifuged at 30,000rpm to separate 
the aggregates from the supernatant (Figure 7.4B). 
 
 
Figure 7.5. SDS-PAGE analysis of supernatant obtained from the centrifugation of aggregates formed in the 
dialysis tubing following the unsuccessful attempt at dialysing the 25ml unfolded AIDH in denaturation buffer 
consisting of  6M GdnHCl, 2mM DTT and 20mM HEPES pH 7.5 against 500ml of 100mM HEPES pH 7.5, 10% 
glycerol, 200mM MgCl2. 
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From the SDS-PAGE analysis of the supernatant it can be seen that in comparison to the method of 
refolding denatured AIDH with Ni-NTA (Figure 7.3), refolding denatured AIDH via dialysis produces a 
lot of non-specific proteins (Figure 7.5) as there was no Ni-NTA to select for the binding of His10 tagged 
AIDH. Following a successful dialysis series to remove GdnHCl and DTT to negligible levels, the 
presumed refolded AIDH still requires Ni-NTA affinity chromatography to remove non-specific 
proteins, for this reason refolding the denatured AIDH via binding with Ni-NTA in the unfolded state 
followed by eluting protein with imidazole presents itself to be a more efficient method. There was 
also a prominent band seen around the ~250kDa marker which has previously also been seen during 
the soluble AIDH fraction Ni-NTA purification (Figure 7.2) as outlined in section 7.2.1 and also during 
the Ni-NTA purification attempt of AIDH inclusion bodies following extraction with GdnHCl (Figure 7.3) 
as outlined in section 7.2.2.1. Both of these bands were suspected AIDH tetramers and have been 
positively identified as AIDH from Thermoplasma acidophilum via mass spectrometry analysis. The 
band seen in Figure 7.5 at around the 250kDa mark could be SDS-induced aggregates or, also be 
correlating to folded subdomains which can presumably associate with complimentary binding 
surfaces in an intermolecular manner to form oligomers and eventually aggregates (Palmer and 
Wingfield 2004).   
7.2.2.3 Comparing methods of refolding denatured AIDH with Ni-NTA or via dialysis 
From sections 7.2.2.1 and 7.2.2.2 it is evident that binding denatured AIDH in a 6M GdnHCl, 2mM DTT 
and 20mM HEPES pH 7.5 buffer with Ni-NTA followed by affinity chromatography and elution of bound 
AIDH with imidazole is an efficient method in comparison to dialysis of denatured AIDH in a 6M 
GdnHCl, 2mM DTT and 20mM HEPES pH 7.5  buffer. As seen in Figure 7.5 lane 2, there are still various 
unwanted bands correlating to other proteins in the sample, hence a secondary step would be required 
to obtain a higher purity AIDH sample regardless. Binding denatured AIDH with Ni-NTA and omitting 
the dialysis eliminates a step and improves efficiency. Moreover, the success of the dialysis step 
depends on establishing optimum dialysis conditions in terms of dialysis buffer volume ratios, 
temperature, buffer components and speed of dialysis etc. The failure of the dialysis refolding attempt 
of AIDH as outlined in section 7.2.2.2 can therefore be attributed to a multitude of factors. The protocol 
developed for use in the preparation and extraction of the AIDH inclusion bodies as outlined in 7.2.2 
was simplified at the time of attempt. Inclusion bodies are typically of a whiteish colour in their 
appearance whereas the cell pellet obtained following the sonication, heat treatment and 
centrifugation during the soluble fraction preparation as outlined in section 7.2.1 and was processed 
downstream for AIDH inclusion bodies was of a brownish appearance. This is indicative of the presence 
of other cellular components and presumably the AIDH inclusion bodies had not been extracted 
efficiently. The denaturation buffer consisting of GdnHCl, DTT and HEPES consisted of basic 
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denaturation buffer components and it was therefore decided to optimize the extraction of inclusion 
bodies further before reattempting refolding of denatured AIDH in GdnHCl with Ni-NTA. The 
experimental data gathered from section 7.2 and all its subsequent subsections successfully 
demonstrated positive protein ID of AIDH and also provided directions in which to optimize the 
extraction and purification of soluble AIDH from AIDH inclusion bodies.  
7.3 Testing enzymatic functionality of soluble AIDH obtained from refolding of denatured AIDH with 
Ni-NTA 
A 1.27mg/ml soluble AIDH stock was obtained following the successful refolding of denatured AIDH in 
GdnHCl with Ni-NTA as outlined in 7.2.2.1. The other attempts of purifying AIDH from the crude soluble 
fraction as outlined in 7.2.1 resulted in protein precipitation during an attempt to concentrate the Ni-
NTA purified protein and gave very poor recovery of AIDH. Refolding of denatured AIDH in GdnHCl via 
dialysis also lead to protein aggregation in the dialysis tubing, hence the only soluble AIDH stock came 
from the successful refolding of denatured AIDH in GdnHCl being bound to Ni-NTA followed by elution 
of bound AIDH with the aid of imidazole. AIDH was assayed for activity and since it uses NAD+ as a 
cofactor, the reaction can easily be followed at 340nm by the concomitant reduction of NAD to NADH. 
Glyceraldehyde + NAD+  Glycerate + NADH 
0.32 mg/ml of AIDH was assayed in triplicates of 200µl volume with 100mM of glyceraldehyde in excess 
and 5mM of NAD+. A control without any AIDH was analysed in triplicate alongside the assay as well 
and this was also used as a blank for assay conditions (Figure 7.6).  
 
Figure 7.6. 0.32mg/ml AIDH enzymatic activity analysis via absorbance at 340nm. All conditions were done in 
triplicates, standard deviation for control= <0.04, standard deviation for assay= <0.197.  
From the initial AIDH activity analysis as seen in Figure 7.6, the control for this experiment did not show 






















conversion of glyceraldehyde to glycerate and thereby theoretically no NADH should be present in the 
assay to contribute to the increase in absorbance values at 340nm. However, as seen in Figure 7.6 
there is a gradual increase in the absorbance values of the control. This made the overall experimental 
design unreliable as the assay condition absorbance readings cannot be confidently attributed to the 
activity of AIDH. This anomaly in the increasing absorbance readings of the control were explored in 
the following section to determine its cause.  
7.4 Exploring AIDH assay components to explore the cause of increasing absorbance values in control 
conditions 
To determine which assay component/s is/are having an absorbance increasing effect on the AIDH 
control condition, different combinations of assay components were compared for their absorbance 
values at 340nm in different combinations. The secondary product of the reaction, NADH was also 
tested with assay conditions to determine if the reaction progression might be contributing to the 
unusual absorbance 340nm readings seen in the control conditions in Figure 7.6. Overall 7 different 
assay conditions were tested, firstly the 3 different concentrations of glyceraldehyde (10, 50 and 
100mM) with 100mM HEPES pH 7.5. Glyceraldehyde and NAD+ were also tested together at 50mM 
glyceraldehyde + 2.5mM NAD+ and 100mM glyceraldehyde and 5mM NAD+ both in 100mM HEPES pH 
7.5. Glyceraldehyde and NADH were also tested with 100mM HEPES pH 7.5 at 50mM glyceraldehyde 
+ 2.5mM NADH and 100mM glyceraldehyde and 5mM NADH. Absorbance readings of all conditions 
over the course of ~180 minutes are shown in Figure 7.7.  Glyceraldehyde on its own at various 
concentrations (10, 50 and 100mM) shows very little fluctuation in readings over the course of the 
assay period.   However, glyceraldehyde + NAD+ display an increase in absorbance values and as 
previous mentioned, glyceraldehyde on its own demonstrated no major changes in absorbance values, 
therefore, even though 2 different concentrations of glyceraldehyde were tested with 2  
concentrations of NAD+, the difference in the increase of absorbance values  for the condition was 
attributed to the higher NAD+ concentration. The conditions of glyceraldehyde at 50 and 100mM 
tested with 2.5 and 5mM of NADH respectively gave absorbance readings as expected. NADH at 
concentrations above 2mM gives absorbance values that fall outside the readable range of the 
spectrophotometer and therefore gives erratic absorbance values similar to those seen in Figure 7.7 
at around 3.5 absorbance 340nm. However, given their consistent values over the course of the assay 
period, it is likely that the progression of the reaction and production of NADH as the secondary 





Figure 7.7. Testing effect of AIDH assay components to determine if any components are contributing to the increased absorbance 340nm as previously seen in the control 
condition. All conditions ran in triplicates and standard deviations are as follows: Glyceraldehyde  10, 50 and 100mM <0.022, glyceraldehyde 50mM + 2.5mM NAD+ <0.035, 
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From the data obtained in Figure 7.7, it was concluded that the increase in absorbance values of the 
AIDH assay control are due to the interaction of glyceraldehyde and NAD+. Some aldehydes can break 
down to carboxylic acids in water/air, and this breakdown could possibly be providing the electrons 
required to form NADH from NAD+ over time, leading to an increase in the control absorbance even in 
the absence of AIDH to catalyse the formation of NADH as a secondary reaction product.  
7.5 Optimizing the extraction and purification protocol of soluble AIDH from AIDH inclusion bodies 
Following the successful attempt of refolding denatured AIDH in section 7.2.2, the method of 
extraction and purification was optimized to improve yield of soluble protein recovered as required 
for experimental purposes. In the earlier attempt (section 7.2.2), it was assumed that inclusion bodies 
were not extracted efficiently, therefore a higher yield of soluble AIDH was not achieved as the 
protocol developed for use in the preparation and extraction of the AIDH inclusion bodies was 
simplified at the time of attempt. Inclusion bodies are typically of a whiteish colour in their appearance 
whereas the cell pellet obtained following the sonication, heat treatment and centrifugation during 
the soluble fraction preparation (section 7.2.1) and was processed downstream for AIDH inclusion 
bodies, was of a brownish appearance. This is indicative of the presence of other cellular components 
and presumably the AIDH inclusion bodies had not been extracted efficiently. This was the main aim 
for this optimization, to extract AIDH inclusion bodies efficiently and purify soluble AIDH to recover 
higher yield of soluble protein for experimental purposes. A modified protocol for the extraction and 
purification of AIDH inclusion bodies was developed as outlined in the methods (section 2.5.7) and 
experimental strategy is described here.   
Following expression of AIDH and isolation of the cell pellet as outlined in section 7.2, no attempt was 
made to purify AIDH from the soluble fraction as previously done in section 7.2.1. Following expression, 
the cell pellet was processed directly for inclusion bodies extraction and purification as the attempt to 
analyse the soluble fraction as previously done in section 7.2.1 resulted in low yields of AIDH, which 
precipitated during concentration, meaning it was not efficient to extract the small amount of soluble 
AIDH expressed. The cell pellet was resuspended in lysis buffer for sonication with the lysis buffer being 
added as 5ml per gram wet weight of cells and prepared fresh prior to use each time. The lysis buffer 
composition was as follows: 
 100mM HEPES pH 7.5 
 5mM EDTA 
 5mM DTT 
 10% Glycerol 
 Protease inhibitors (1 tablet per 50ml) 
 DNase I (5µl per 50mls) 
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No MgCl2 was added to the lysis buffer as it promotes protein refolding (Palmer and Wingfield 2004) 
and the buffer conditions were to be kept in favour of denaturing to allow for maximum recovery of 
protein to be refolded at a later stage.  
Following addition of lysis buffer to pellet, it was homogenized until fully resuspended and then 
sonicated as outlined in the methods. The lysed cell suspension was centrifuged and the supernatant 
was removed from the cell pellet. The cell pellet was then resuspended in wash buffer with the 
intention of washing out soluble proteins and cellular components such as cell wall and outer 
membrane material. Adding detergent such as Triton X-100 or SDS aids the extraction of lipid and 
membrane-associated proteins (Palmer and Wingfield 2004) therefore they form an integral 
component of the wash buffer. GdnHCl or urea are known to be used as part of the wash steps in 
protocols, however GdnHCl is not compatible with SDS as forms a precipitate, therefore if the 
processed protein samples are to be analysed via SDS-PAGE downstream, it is recommended to use 
Triton X-100 instead of SDS as the detergent (Palmer and Wingfield 2004). If urea is being employed 
as the denaturant in the washes and extraction of inclusion bodies then SDS is compatible as the 
detergent. For the purpose of this protocol, GdnHCl was used as the denaturant and Triton X-100 was 
used as the detergent. The wash buffer was added as 5ml of wash buffer per gram wet weight cells 
(pellet obtained following the centrifugation of the lysed cell suspension and removal of supernatant), 
and as with the lysis buffer, also being prepared just prior to use. The wash buffer composition was as 
follows: 
 100mM HEPES pH 7.5 
 5mM EDTA 
 5mM DTT 
 10% Glycerol 
 2% Triton X-100 
 2M GdnHCl 
 
Two versions of the wash buffer were prepared; one as outlined above and another without the 
addition of GdnHCl and Triton X-100. Following addition of cell pellet to wash buffer, it was 
homogenized until fully resuspended and then centrifuged with the supernatant discarded and pellet 
retained for the next wash step. This was then repeated 2 more time or until the supernatant is no 
longer cloudy or coloured. A colourless and clear supernatant is indicative of removal of most cellular 
components, lipids and membrane associate components. When the supernatant is no longer cloudy 
or coloured, the cell pellet is resuspended in the final wash buffer made up without the addition of 
GdnHCl and Triton X-100, which is then centrifuged with the supernatant discarded and cell pellet 
retained for the next step. This final wash without GdnHCl and Triton X-100 aids the removal of Triton 
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X-100 from the cell pellet as Triton X-100 can stick to dialysis membranes. If required, the washed cell 
pellets can also be stored at this stage before further downstream processing.   
The final stage of this protocol involved the suspension of the cell pellet obtained following the wash 
stage into extraction buffer. This extraction buffer was added as 1ml of extraction buffer per gram wet 
weight of the original cells. The extraction buffer composition was as follows: 
 100mM HEPES pH 7.5 
 5mM EDTA 
 6M GdnHCl  
 5mM DTT 
 
If this buffer is cloudy it can be filtered and be stored in the fridge for 1 month without DTT (Palmer 
and Wingfield 2004). Following the resuspension of the cell pellet into the extraction buffer, the cell 
suspension was incubated and stirred for a minimum of 2 hours before processing further. This 
incubation period allowed for the AIDH in the inclusion bodies to homogenize in the denatured state. 
Following the incubation period, the cell suspension could be refolded either by binding with Ni-NTA 
in the denatured state and then eluting refolded protein via affinity chromatography and use of 
imidazole (as previously attempted in section 7.2.2.1). The cell suspension could also be transferred 
into dialysis tubing and dialysed into the required buffer (as previously attempted in section 7.2.2.2) 
with the dialysis cycles being repeated until GdnHCl, EDTA and DTT have been dialysed to a negligible 
amount. If the cell suspension was to be refolded on the affinity column, DTT was omitted from the 
extraction buffer and substituted with 2mM β-mercaptoethanol as DTT is a strong reducing agent and 
will reduce the nickel ions in the Ni-NTA resin (Palmer and Wingfield 2004). In addition, strong chelating 
agent such as EDTA are not recommended as they will strip the nickel ions from the column, 
significantly reducing the binding efficiency of the His tagged protein.  
7.6 Attempt 1 of utilising modified protocol for extraction and purification protocol of soluble AIDH 
from AIDH inclusion bodies 
Having designed a modified protocol for the extraction and purification of AIDH inclusion bodies as 
outlined in section 7.5, it was experimentally tested with a freshly expressed batch of AIDH. 2L of AI 
media were used to grow AIDH cultures where a final OD600 of 5.76 and 5.83 was achieved. 17.7g of 
combined cell pellet was obtained following centrifugation which was resuspended in 90ml of lysis 
buffer made up as detailed in section 7.5. After homogenization, the cell suspension was sonicated as 
outlined in the method section. The lysed cell suspension was centrifuged and the supernatant was 
removed from the cell pellet. 3.3g of cell pellet was obtained following the lysis, sonication and 
centrifugation steps. This cell pellet was then resuspended in 16.5ml of wash buffer until completely 
homogenized before being centrifuged and supernatant removed and pellet retained. This wash step 
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was repeated a total of 3 times and with an additional fourth wash without any GdnHCl and Triton X-
100 for the reasons previously discussed in section 7.5. Wash 4 was observed to have a colourless and 
clear supernatant which is indicative of removal of most cellular components, lipids and membrane 
associated components (Figure 7.8). 
 
Figure 7.8. Supernatants removed following the homogenization and centrifugation of cell pellets with wash 
buffer. Washes 1-3 consists of HEPES, EDTA, DTT, glycerol, Triton X-100 and GdnHCl whereas wash 4 is without 
GdnHCl and Triton X-100.  
 
In this attempt, wash 3 was not completely clear and still retained a colour to it (Figure 7.8), for any 
further replicates, it was noted that an improvement might be to repeat the wash step containing the 
GdnHCl and Triton X-100 until the supernatant is clear and colourless before doing a final wash without 
the addition of GdnHCl and Triton X-100 to ensure all other components have been removed. The 
pellet obtained after the wash steps was observed to be much lighter in appearance in comparison to 
that cell pellet processed for the extraction of inclusion bodies in 7.2.2, however it was not completely 
white in appearance and still had a tinge of colour to it. For any further attempts, it was noted that it 
might be necessary to continue the washes with wash buffer containing GdnHCl and Triton X-100 until 
pellet is white in appearance. Following the wash steps, the cell pellet obtained was stored  at -80°C 
before final step of extraction of inclusion bodies. Extraction buffer was added as 1ml per gram wet 
weight of the original cells. The original cell pellet was 17.7g. This was rounded up to 20g and 20ml of 
extraction buffer was prepared and the pellet was resuspended until completely homogenized with 
the extraction buffer. The suspension was incubated for 2.5 hours at room temperature. Dialysis was 
attempted to remove the extraction buffer components and dialyse the suspension into 100mM HEPES 
pH 7.5, 200mM MgCl2, 10% glycerol buffer. The previous dialysis attempt (section 7.2.2.2) was 
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unsuccessful and this was attributed to the higher presence of contaminating proteins, as the protocol 
did not employ extra wash steps. For the attempt discussed in this section, the modified protocol 
included wash steps to remove soluble proteins and other cellular components, thereby theoretically, 
failure of dialysis due to contaminating proteins was lowered. It is also a quicker alternative to refolding 
on the column. 20ml of extraction buffer suspension was dialysed against 200ml of 100mM HEPES pH 
7.5, 200mM MgCl2, 10% glycerol buffer at dilution factor of 10. This was not successful and the protein 
aggregates could be seen inside the dialysis tubing (Figure 7.9).  
 
Figure 7.9. Dialysis of 20ml AIDH inclusion bodies extracted with HEPES, EDTA, GdnHCl and DTT dialysed against 
200ml of 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer at dilution factor of 10. Dialysis attempt was 
not successful and protein aggregates can be seen in the dialysis tubing.  
 
Following the unsuccessful attempt at dialysis as seen in Figure 7.9, this attempt at extraction of 
soluble AIDH from AIDH inclusion bodies was not successful due to failure at the final stage of dialysis. 
This attempt was therefore abandoned here and purification of soluble AIDH via binding AIDH in its 
denatured state in the extraction buffer was decided to be explored next.   
7.7 Attempt 2 at extraction and purification of soluble AIDH from AIDH inclusion bodies using Ni-
NTA 
Following the unsuccessful dialysis attempt at refolding the denatured AIDH extracted from inclusion 
bodies in section 7.6, refolding the denatured AIDH via binding with Ni-NTA and eluting with imidazole 
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was then explored. Previously stored glycerol stocks were used to streak out a LB agar kanamycin plate 
from which colonies were used to grow 4 precultures. These precultures were used to grow four 1L 
cultures of AIDH in AI media supplemented with 50µg/ml kanamycin of which the average OD600 was 
7.85. 30.6g of cell pellet was obtained following centrifugation which was resuspended in 150ml of 
lysis buffer made up as detailed in 7.5. After homogenization, the cell suspension was sonicated as 
outlined in the methods. The lysed cell suspension was centrifuged and the supernatant was removed 
from the cell pellet. 21.7g of cell pellet was obtained following the lysis, sonication and centrifugation 
steps. This cell pellet was then resuspended in 110ml of wash buffer until completely homogenized 
before being centrifuged and supernatant removed and pellet retained. This wash step was repeated 
a total of 3 times and with an additional fourth wash without any GdnHCl and Triton X-100 for the 
reasons previously discussed in section 7.5. Washes 3 and 4 was observed to have colourless and clear 
supernatant which is indicative of removal of most cellular components, lipids and membrane 
associate components (Figure 7.10). 
 
Figure 7.10. Supernatants removed following the homogenization and centrifugation of cell pellets with wash 
buffer. Washes 1-3 consists of HEPES, EDTA, DTT, glycerol, Triton X-100 and GdnHCl whereas wash 4 is without 
GdnHCl and Triton X-100.  
 
The cell pellet following homogenization and centrifugation was observed to be getting lighter 
following each wash, this is what the expectation would be of an efficiently extracted inclusion bodies 
pellet as they are known to be typically white in appearance. All 4 washes from Figure 7.10 were 





Figure 7.11. SDS-PAGE analysis of supernatants removed following the homogenization and centrifugation of cell 
pellets with wash buffer. Lane 2, 3 and 4 consists of wash buffer with HEPES, EDTA, DTT, glycerol, Triton X-100 
and GdnHCl whereas lane 5 consists of wash buffer HEPES, EDTA, DTT and glycerol only.  
 
Lanes 2, 3 and 4 consist of wash buffer containing HEPES, EDTA, DTT, glycerol, Triton X-100 and GdnHCl 
where the latter is added at a concentration of 2M. The presence of GdnHCl explains the band 
corresponding to AIDH seen at the 57kDa position. The experimental strategy behind these washes 
was to remove other soluble proteins, however with these washes, the protein of interest in the 
inclusion bodies may also be partially extracted and being removed in the washes, as demonstrated 
by the presence of the AIDH bands present on the SDS-PAGE (Figure 7.11). Lane 5 in Figure 7.11 is the 
last wash buffer without any GdnHCl, thereby explaining why there is no band on the SDS-PAGE as 
there is no  GdnHCl in the wash to extract any AIDH. A 5.7g AIDH inclusion bodies pellet was extracted 
following the washes which displayed the typical whiteish appearance associated with inclusion bodies 




Figure 7.12. AIDH inclusion bodies pellet extracted following 4x homogenization and centrifugation with wash 
buffer consisting of HEPES, EDTA, DTT, glycerol, Triton X-100 and GdnHCl where wash 4 is without GdnHCl and 
Triton X-100. 
 
Following the successful isolation of AIDH exclusion bodies, the pellet was stored at -80°C for prior to 
the next stage in the protocol, which is homogenizing the exclusion bodies pellet in extraction buffer 
and incubating to allow AIDH to be in the denatured state. As outlined in section 7.6, previously dialysis 
was attempted to remove the extraction buffer components following incubation and dialyse the 
suspension into 100mM HEPES pH 7.5, 200mM MgCl2, 10% glycerol buffer. This was not successful and 
the protein aggregates could be seen inside the dialysis tubing (Figure 7.9). For this reasoning in this 
attempt, following the homogenization of AIDH inclusion bodies in extraction buffer, the decision was 
made to bind the AIDH in its denatured state to Ni-NTA and elute off bound protein with imidazole via 
affinity chromatography during as discussed in section 7.5. As also previously outlined in section 7.5, 
changes were made to the composition of the extraction buffer because if the cell suspension is to be 
refolded straight on the affinity column, it is recommended that DTT is omitted from the extraction 
buffer and substituted with 2mM β-mercaptoethanol as DTT is a strong reducing agent and will reduce 
the nickel ions in the Ni-NTA resin. In addition, strong chelating agent such as EDTA is also not 
recommended as it will strip the nickel ions from the column, significantly reducing the binding 
efficiency of the His tagged protein. The EDTA was an oversight on this attempt, whereby the DTT was 
replaced with β-mercaptoethanol but the EDTA was added in error which therefore led to the stripping 
of nickel from the column in the eventual attempt to purify the AIDH. The composition of the extraction 
buffer in this attempt was as follows: 
 100mM HEPES pH 7.5 
 5mM EDTA 
 6M GdnHCl  
 2mM β-mercaptoethanol 
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The inclusion bodies pellet isolated from the washes (Figure 7.12) was resuspended into 30ml of 
extraction buffer as it to be added as 1ml per gram wet weight of the original cells (original cell pellet 
weight 30.6g). The 30ml of homogenized extraction buffer was incubated with 5ml of Ni-NTA overnight 
at room temperature to allow for the binding of AIDH in its denatured state to the Ni-NTA. Upon 
addition of the cell suspension to polypropylene columns to collect flow through, the solution was 
viscous which is when the error of the addition of EDTA to the extraction buffer was realised. 
Regardless, Ni-NTA affinity chromatography was proceeded with followed by 3x 50ml washes with 
100mM HEPES pH 7.5, 50mM MgCl2, 10% glycerol buffer to remove any residual GdnHCl, EDTA and β-
mercaptoethanol. During the buffer washes, white residues were noticed inside the polypropylene 
column and in the collection tubes which was presumed to be protein aggregates. The aggregation 
levels were reduced as the number of buffer washes increased, presumably due to the majority of 
aggregates being removed in the first washes. A high yield of AIDH was not expected due to chelation 
of Nickel resulting in insufficient binding, leading to very little protein recovery. Recovery of any soluble 
AIDH bound to Ni-NTA was attempted to be eluted from the column using 2x 500mM imidazole 
100mM HEPES pH 7.5, 50mM MgCl2, 10% glycerol elutions (Figure 7.13). 
 
Figure 7.13. SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies following extraction with 
GdnHCl. Samples in all lanes are from elutions obtained from the column following Ni-NTA affinity 
chromatography. Lane 2 contains flow through of extraction buffer. Lanes 3, 4 and 5 contain samples from HEPES 
buffer washes (100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2). Lanes 6 and 7 contain HEPES buffer imidazole 
elutions with 500mM imidazole and lane 8 contains HEPES buffer imidazole elution with 1M imidazole.  
 
From the analysis of the SDS-PAGE gel, it was theorised that AIDH inclusion bodies purification had 
failed in this attempt due to insufficient binding with Ni-NTA, caused by the chelation of nickel by EDTA 
erroneously present in the extraction buffer. Since inclusion bodies contain very little host protein, the 
concentration of the protein of interest, in this case AIDH, is presumably very high. The extraction 
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buffer provides denaturation conditions under which the unfolded protein is suspended, the addition 
of Ni-NTA to the suspension allows for the binding of AIDH in its unfolded state to the nickel via the 
His10 tag. In this case, EDTA added in error to the extraction buffer chelated the nickel rendering the 
binding of the AIDH to the Ni-NTA insufficient. Thus, the removal of the extraction buffer and its 
denaturing components gradually promotes refolding of the protein in solution, the addition of the 
100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2 buffer further promotes refolding of the protein. 
With the nickel chelated via the EDTA, there is insufficient binding of the AIDH to the Ni-NTA hence 
protein-protein self-interactions could have caused the aggregates observed during the wash buffers. 
This is in part tested by centrifuging the buffer wash (100mM HEPES pH 7.5, 10% glycerol, 50mM 
MgCl2) fractions obtained from the Ni-NTA purification attempt (Figure 7.13, Lanes 3-5) and 
centrifuging out the presumed AIDH protein aggregates and supernatant which should not contain any 
soluble protein. The 3 washes obtained from the column were centrifuged out at 13,000rpm for 5 
minutes, with the pellet being resuspended in water and loaded onto SDS-PAGE for analysis along with 
the supernatant from each corresponding wash.  
 
Figure 7.14. SDS-PAGE analysis of supernatants and pellets obtained from the centrifugation of 3 HEPES buffer 
washes (100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2) collected during the Ni-NTA purification attempt of 
AIDH inclusion bodies. Lane 2, 4 and 6 contains the supernatants from the 3 washes and Lane 3, 5 and 7 contain 
the pellets from the 3 washes. 
 
2 of the most intense bands seen all the pellet samples in lanes 3, 5 and 7 correlate with the size of the 
AIDH monomer (57kDa) and the AIDH tetramer (228kDa). The volume of sample loaded for each 
sample is the same (15µl), the difference observed in the intensity of the bands was noted to be due 
to the concentration of aggregated protein in each wash. Presumably majority of the aggregates were 
removed during the initial buffer wash. Very little soluble AIDH was present in the supernatant 
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obtained following the centrifugation of all the pellets indicating that majority of the protein present 
had aggregated.  
Following this, all the buffer washes from the Ni-NTA purification containing the protein aggregates 
(150ml total) were pooled and centrifuged at 32,000rpm for 1 hour. Following this, the supernatant 
was discarded and the pellet of AIDH aggregated protein retained (0.64g). This pellet was resuspended 
and homogenized into 5ml of extraction buffer overnight at 4°C. An attempt was made to dialyse this 
suspension, therefore DTT was used in the extraction buffer instead of β-mercaptoethanol. Previously 
dialysis buffer has comprised of 100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2, however to aid the 
gradual removal of GdnHCl to avoid protein precipitation, MgCl2 was left out of the buffer. 1M of 
GdnHCl was also added to the dialysis buffer to aid the gradual removal as well. The dialysis buffer 
volume was of 300ml with the final composition of 100mM HEPES pH 7.5, 1M GdnHCl and 10% glycerol. 
Dialysis was then performed for 3 hours at room temperature, however the altered dialysis conditions 
did not work successfully as white aggregates could be seen in the dialysis tubing (Figure 7.15). The 
precipitated suspension was centrifuged and the pellet retained. This attempt was terminated at this 
point and changes were reviewed before attempting extraction and purification of AIDH inclusion 
bodies again.  
 
Figure 7.15. Dialysis of 5ml aggregated AIDH homogenized in extraction buffer consisting of HEPES, EDTA, GdnHCl 
and DTT, dialysed against 300ml of 100mM HEPES pH 7.5, 1M GdnHCl, 10% glycerol buffer at dilution factor of 




7.8 Attempt 3 at extraction and purification of soluble AIDH from AIDH inclusion bodies using Ni-
NTA via changes in buffer components  
The attempt made in section 7.6 had some clear issues which needed to be addressed in order to 
effectively purify AIDH extracted from inclusion bodies. For this attempt, the following changes were 
considered to the AIDH exclusion bodies protocol as outlined in section 7.5. During the buffer wash 
step, as many washes as required were done until the supernatant was no longer cloudy, with the 
wash buffer composition being as follows: 
 100mM HEPES pH 7.5 
 5mM EDTA 
 5mM DTT 
 10% Glycerol 
 2% Triton X-100 
 2M GdnHCl 
 
The final wash buffer is usually made up without the addition of Triton X-100 and GdnHCl, however for 
this attempt, EDTA was also excluded from the final wash buffer. This was to ensure that no residual 
EDTA remained in the pellet to interfere with binding of protein to Ni-NTA downstream. The volume 
of Ni-NTA was also increased in this attempt to allow for sufficient binding. 100mM HEPES pH 7.5, 10% 
glycerol, 50mM MgCl2, 500mM imidazole elutions were employed to elute any AIDH bound to Ni-NTA 
in the attempt outlined in section 7.7 (Figure 7.14). The concentration of MgCl2 included in the elutions 
in this attempt was also increased to 200mM from 50mM to aid refolding and stability of AIDH.  
26g of AIDH cell pellet was obtained following expression of AIDH in 4L of AI media. The cell pellet was 
resuspended in 130ml of lysis buffer made up as detailed in 7.5. After homogenization, the cell 
suspension was sonicated as outlined in the methods. The lysed cell suspension was centrifuged and 
the supernatant was removed from the cell pellet. 20g of cell pellet was obtained following the lysis, 
sonication and centrifugation steps. This cell pellet was then resuspended in 100ml of wash buffer until 
completely homogenized before being centrifuged and supernatant removed and pellet retained. This 
wash step was repeated a total of 3 times with 2 additional washes without any GdnHCl, Triton X-100 
and EDTA for the reasons previously discussed in section 7.5 and exclusion of EDTA per reasoning 
discussed above. Washes 4 and 5 were observed to have colourless and clear supernatant which is 
indicative of removal of most cellular components, lipids and membrane associate components. A 
white pellet indicative of successful exclusion bodies isolation was obtained at the end of the wash 
stages. This pellet was then homogenized into extraction buffer which was added as 1 ml per wet pellet 
weight of original cells (26g). 30ml of extraction buffer was used with the changes made as discussed 
at the start of this section.  
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The components of the original extraction buffer as outlined in section 7.5 are as follows: 
 100mM HEPES pH 7.5 
 5mM EDTA 
 6M GdnHCl  
 5mM DTT 
 
The changes made during this attempt were the exclusion of EDTA to avoid chelation of the nickel 
during binding with Ni-NTA and the replacement of DTT with β-mercaptoethanol for the reasoning 
outlined in section 7.5. The inclusion bodies pellet following the wash steps was homogenized with 
30ml of the amended extraction buffer and bound with 10ml of Ni-NTA overnight at room 
temperature. Following this, the suspension was transferred into a polypropylene column and flow 
through was collected. The Ni-NTA resin was then washed through with 200ml of 100mM HEPES pH 
7.5, 10% glycerol, 50mM MgCl2 buffer before eluting off any bound AIDH with 2x 100mM HEPES pH 
7.5, 10% glycerol, 200mM MgCl2, 500mM imidazole elutions. As discussed previously during the 
purification strategies of GDH and DHAD in chapters 4 and 5 respectively, EDTA has been successfully 
used to improve dialysis efficiency of soluble proteins as protein precipitation was significantly reduced 
via addition of 100mM final concentration of EDTA to collection tubes during protein elutions when 
performing Ni-NTA affinity chromatography. The concept behind this strategy was that leached nickel 
from the column enhances protein-protein self-interactions which were then contributing to protein 
precipitation during dialysis. For this reasoning, 100mM final concentration of EDTA was added to the 
collection tubes for the HEPES buffer imidazole elutions. All elutions obtained from the Ni-NTA affinity 





Figure 7.16. SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies following extraction with 
GdnHCl. Samples in all lanes are from elutions obtained from the column following Ni-NTA affinity 
chromatography. Lane 2 contains flow through of extraction buffer. Lanes 3 and 4 contain samples from HEPES 
buffer washes (100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2). Lanes 5 and 6 contain HEPES buffer (100mM 
HEPES pH 7.5, 10% glycerol, 200mM MgCl2) imidazole elutions with 500mM imidazole and lane 7 with 1M 
imidazole respectively. 
 
From Figure 7.16 lane 2, which contains the flow through of the extraction buffer suspension bound 
with Ni-NTA, it is evident that a lot of the AIDH has been lost in the flow through. This sample was 30ml 
in volume and this flow through was attempted to be dialysed into 100mM HEPES pH 7.5, 10% glycerol, 
50mM MgCl2 buffer to try and salvage the unbound AIDH, however protein sample was seen to be 
aggregating soon in the dialysis tubing. Lanes 5 and 6 from Figure 7.16 containing the 100mM HEPES 
pH 7.5, 10% glycerol, 200mM MgCl2, 500mM imidazole elutions show bands corresponding to AIDH, 
albeit the bands are not high intensity indicating low protein recovery, the elutions were pooled and 
dialysed to remove the imidazole and EDTA added during collection of elutions. 
3 cycles of dialysis were performed: 
3- 30ml elution dialysed in 1L of 100mM HEPES pH 7.5, 10% glycerol, 100mM MgCl2 buffer at a 
dilution factor of 33. 
4- 30ml elution dialysed in 1L of 100mM HEPES pH 7.5, 10% glycerol, 100mM MgCl2 buffer at a 
dilution factor of 33. 
5- 30ml elution dialysed in 1L of 100mM HEPES pH 7.5, 10% glycerol, 50mM MgCl2 buffer at a 
dilution factor of 33. 
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All 3 cycles of dialysis were successful with no signs of protein aggregation seen in the dialysis tubing, 
the presence of 100mM EDTA in the 30ml elutions containing the eluted AIDH presumably contributed 
to this as previously demonstrated with GDH and DHAD. The 3 cycles of dialysis sufficiently diluted 
EDTA and imidazole present in the fraction to negligible concentrations and the MgCl2 concentration 
was gradually lowered to 50mM as well. Following dialysis, the sample was concentrated down to a 
final volume of 4ml with a concentration of 1mg/ml as determined via BCA. However, during the final 
concentration stages, the sample started to display signs of aggregation so protein stability was an 
issue that required addressing. It could be possible that 50mM of MgCl2 was too low for the protein 
stability over time and an increased concentration was required for protein stability.  The insufficient 
binding of the AIDH to the Ni-NTA and its subsequent loss through the flow through is also of concern 
and binding efficiency was explored in the next attempt.  
7.9 Attempt 4 at extraction and purification of soluble AIDH from AIDH inclusion bodies using Ni-
NTA via changes in buffer components  
Following on from the findings of the previous section, the key issue of loss of unbound protein (AIDH) 
through the flow through of Ni-NTA affinity chromatography was explored. The changes made to the 
wash buffer and extraction buffer in section 7.8 were maintained in this attempt as well. An additional 
change was made to the wash buffer; in the previous section, GdnHCl, Triton X-100, and EDTA were 
excluded from the final 2 washes to ensure no residual EDTA remained to interfere with binding of 
protein with Ni-NTA. Additionally, in this attempt, DTT was also removed from the final 2 washes as it 
is a strong reducing agent and will reduce the nickel ions in the Ni-NTA resin. This was done to test if 
the Ni-NTA efficiency is being reduced by any trace components involved in the wash or extraction 
buffers. So, the wash buffer for the final 2 washes consisted only of 100mM HEPES pH 7.5 and 10% 
glycerol. The volume of Ni-NTA used was also doubled from 10ml used in the last attempt to 20ml in 
this attempt as there was a lot of unbound protein, so here it was tested to see if increased amount of 
Ni-NTA solves the issue.  
26.8g of AIDH cell pellet was obtained following expression of AIDH in 4L of AI media. The cell pellet 
was resuspended in 130ml of lysis buffer made up as detailed in 7.5. After homogenization, the cell 
suspension was sonicated as outlined in the methods. The lysed cell suspension was centrifuged and 
the supernatant was removed from the cell pellet. 19g of cell pellet was obtained following the lysis, 
sonication and centrifugation steps. This cell pellet was then resuspended in 100ml of wash buffer until 
completely homogenized before being centrifuged and supernatant removed and pellet retained. This 
wash step was repeated a total of 3 times with 2 additional washes without any GdnHCl, Triton X-100, 
EDTA and DTT for the reasons previously discussed in section 7.5, 7.8 and exclusion of DTT as discussed 
154 
 
above. Washes 4 and 5 were observed to have colourless and clear supernatant which is indicative of 
removal of most cellular components, lipids and membrane associate components. A white pellet 
indicative of successful exclusion bodies isolation was obtained at the end of the wash stages. This 
pellet was then homogenized into extraction buffer which was added as 1 ml per wet pellet weight of 
original cells (26.8g). 30ml of extraction buffer was used with the changes made as discussed at the 
start of section 7.8 (replacement of DTT with β-mercaptoethanol for the reasoning outlined in 7.5).  
The inclusion bodies pellet following the wash steps was homogenized with 30ml of the amended 
extraction buffer and bound with 20ml of Ni-NTA overnight at room temperature. Following this, the 
suspension was transferred into 4 polypropylene columns (for ease of handling) and flow through was 
collected. Each column containing 5ml of Ni-NTA resin was then washed through with 200ml of 100mM 
HEPES pH 7.5, 10% glycerol, 100mM MgCl2 buffer before eluting off any bound AIDH with 100mM 
HEPES pH 7.5, 10% glycerol, 100mM MgCl2, 600mM imidazole elutions. Final concentration of 100mM 
EDTA was added to the collection tubes as discussed in section 7.8 (it has been demonstrated to 
decrease the instances of protein aggregation in dialysis tubing). All elutions obtained from the Ni-NTA 
affinity chromatography were analysed via SDS-PAGE (Figure 7.17). 
 
Figure 7.17. SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies following extraction with 
GdnHCl. Samples in all lanes are from elutions obtained from the column following Ni-NTA affinity 
chromatography. Lane 2 contains flow through of extraction buffer. Lane 3 contains samples from HEPES buffer 
wash (100mM HEPES pH 7.5, 10% glycerol, 100mM MgCl2). Lanes 4 and 5 contain HEPES buffer (100mM HEPES 





As seen previously with the attempt in section 7.8 Figure 7.16, Figure 7.17 Lane 2 also contains 
evidence of unbound AIDH which is subsequently being lost in the flow through. In comparison to 
Figure 7.16, very little soluble AIDH has been obtained from the imidazole elutions indicating that very 
little protein has actually bound to the Ni-NTA in the first instance. Due to poor soluble AIDH recovery 
from the Ni-NTA affinity purification, no fractions were pooled as the amount of protein concentrated 
would be very small. This attempt had twice the amount of Ni-NTA as the previous attempt hence it 
was deduced that binding possibly is not the issue, poor expression might be the root cause of the 
issue leading to poor protein recovery in this instance. The pH of the extraction buffer was checked 
through the flow through (pH 7.84) as one of the potential causes of insufficient binding of protein to 
Ni-NTA could be the protonation of histidine which occurs at pH below 6 rendering the His tag non-
functional, however as the pH of the extraction buffer was confirmed to be above 6, this was not the 
cause of the insufficient binding.  
The flow through with the unbound AIDH was then thought to be diluted before attempting dialysis 
again as the fast dilution of the extraction buffer components was thought to be the main factor 
contributing towards the failure of dialysis. 30ml of flow through with unbound AIDH was obtained 
from the Ni-NTA affinity chromatography in extraction buffer (100mM HEPES pH 7.5, 6M GdnHCl, 2mM 
β-mercaptoethanol). This 30ml was diluted into 100mM HEPES pH 7.5, 10% glycerol, 35mM EDTA and 
50mM MgCl2 (EDTA added to chelate any leached nickel during Ni-NTA affinity chromatography and 
MgCl2 added to stabilise and promote refolding during dialysis).  During the dilution of the 30ml of flow 
through into 100ml, the suspension was noticed to immediately turn white, indicating protein 
precipitation. This lead to the conclusion that the protein is stable when unfolded under denaturing 
conditions and removal or dilution of denaturing environment and introduction of refolding conditions 
do not cooperate well, resulting in the protein precipitating. The 100ml suspension was centrifuged 
the AIDH aggregated protein pellet was retained and pooled together with the aggregated protein 
pellet from section 7.7.  
7.10 Change of denaturant from GdnHCl to urea 
The aggregated protein pellets from previous attempts (7.7 and 7.9) were pooled and the denaturant 
was changed from GdnHCl to urea. No success had been achieved with dialysis of extraction buffer 
containing GdnHCl in the past attempts so the denaturant was changed to urea and glycerol was also 
added to the extraction buffer to aid protein stability. The extraction buffer used to resolubilise the 




 100mM HEPES pH 7.5 
 8M Urea 
 2mM β-mercaptoethanol 
 10% Glycerol 
 
40ml of the extraction buffer was prepared and the precipitated AIDH pellets were resuspended into 
this buffer until completely homogenized overnight at room temperature. Following this, the 
suspension was centrifuged to remove any insoluble fractions and obtain a clear suspension, and 
dialysis was attempted again to gradually dialyse out the urea and β-mercaptoethanol. 2 cycles of 
dialysis were carried out in 300ml buffer volumes at a dilution factor of 7.5 as outlined below: 
1- 40ml precipitated AIDH homogenized in extraction buffer dialysed in 300ml of 100mM HEPES 
pH 7.5, 10% glycerol, 5M urea buffer at a dilution factor of 7.5. 
2- 40ml precipitated AIDH homogenized in extraction buffer dialysed in 300ml of 100mM HEPES 
pH 7.5, 10% glycerol, 2M urea buffer at a dilution factor of 7.5. 
The composition of the dialysis buffer was kept the same with the exception of reducing the 
concentration of urea from 8M to 5M in the first cycle and then to 2M in the second cycle of dialysis. 
β-mercaptoethanol was also exempted from both cycles of dialysis buffer. The first cycle of dialysis 
was carried out at room temperature for 3 hours and displayed no signs of aggregation. Following this, 
when the dialysis tubing was transferred to the second cycle of dialysis buffer with 2M of urea, 30 
minutes into the planned 2 hours dialysis cycle, aggregation was seen inside of the dialysis tubing. 
Dialysis was terminated at this point, the aggregated protein suspension was centrifuged and the pellet 
retained at -80°C. Changing the denaturant from GdnHCl to urea did not made a significant difference 
to the success of dialysis as protein aggregates were still being observed during dialysis. The main issue 
still to be resolved is the binding of the denatured AIDH to the Ni-NTA. 
7.11 Western blots to confirm functionality of His10 tag  
After subsequent attempts of failure to efficiently bind AIDH in the denatured state to Ni-NTA, the 
binding issue was investigated via a western blot to determine if the His10 tag is actually accessible in 
the first place. 1mg/ml of soluble AIDH was successfully obtained following Ni-NTA affinity 
chromatography as outline in section 7.8. Sections 7.9 and 7.10 discuss the attempts to resolubilise 
aggregates of AIDH into GdnHCl and urea respectively. Samples from all 3 conditions were analysed 






Figure 7.18. SDS-PAGE analysis of AIDH samples obtained from 3 different conditions. Lane 2 contains AIDH 
aggregates homogenized in GdnHCl, Lane 3 contains AIDH aggregates homogenized in urea and Lane 4 contains 
soluble AIDH obtained during Ni-NTA affinity chromatography.  
 
 
Figure 7.19. Western blot analysis of AIDH samples obtained from 3 different conditions. Lane 2 contains AIDH 
aggregates homogenized in GdnHCl, Lane 3 contains AIDH aggregates homogenized in urea and Lane 4 contains 
soluble AIDH obtained during Ni-NTA affinity chromatography.  
158 
 
From the western blot analysis in Figure 7.19, it can be deduced that the His10 tag on AIDH is functional 
as there are clear bands seen in the SDS-PAGE followed by the western blot. The sample of AIDH loaded 
on both gels (Figure 7.18 and 19, Lanes 2) are from AIDH aggregates homogenized in GdnHCl, it is 
already known that SDS forms aggregates with GdnHCl so the samples were expected to give a smear 
as evident from the gels ran (Figure 7.18 and 19). Presence of a distinctive band can be clearly seen in 
lane 4 of the western blot (Figure 7.19) corresponding to the weight of AIDH (57kDa), and blots are 
seen at around the 50kDa in both of the samples where ADIH has been resolubilised with denaturants, 
confirming the presence of AIDH via the His10 tag. Having established the functionality of the His10 tag, 
the insufficient binding of the protein to the Ni-NTA could still not be explained and the original 
protocol was replicated to establish if the modified protocol has retarded the binding process.  
7.12 Replicating original attempt of AIDH inclusion bodies extraction and purification 
The most successful attempt to date with extraction of inclusion bodies and purification is as outlined 
in section 7.2.2. In this attempt, it was presumed that inclusion bodies were not extracted efficiently 
enough as the protocol developed for use in the preparation and extraction of the AIDH inclusion 
bodies was simplified at the time of attempt. However, this attempt gave the highest yield of AIDH to 
date and therefore an attempt was made to repeat the exact methodology employed during this 
attempt to determine if optimizing the extraction and purification protocol of soluble AIDH from AIDH 
inclusion bodies protocol and outlined and discussed in section 7.5 has reduced efficiency.  
Fresh transformation of AIDH vector was carried out into BL21-DE3 cells. Following successful 
transformation of AIDH vector DNA, protein expression for crude protein fraction preparation was 
carried out in a 4L final volume of AI media with a final concentration of kanamycin at 50µg/ml. An 
average OD600 of 11.4 was read across the 4 flasks.  The cell pellet obtained from the cultures was 
resuspended, sonicated and heat treated as outlined in the methods sections. All resuspension, 
sonication, heat treatment and centrifugation steps were carried out in a 100mM HEPES pH 7.5, 10% 
glycerol buffer unless otherwise stated. As previously discussed in section 7.5, this cell pellet was 
processed with the main goal of downstream processing of AIDH inclusion bodies, therefore no MgCl2 
was added to the buffer used for resuspension, sonication and heat treatment of the cell pellet as 
presence of salt promotes refolding and the inclusion bodies protocol was to be done under denaturing 
conditions to unfold and correctly refold the protein. The supernatant obtained from this step was 
previously used as the soluble fraction which was purified using Ni-NTA affinity chromatography as 
outlined in section 7.2.1, however since then, the focus has been on the inclusion bodies extraction 
from the pellet only, and the soluble fraction has not been used to check for presence and purification 
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of any soluble AIDH expressed as only a low protein yield was obtained previously. This supernatant 
was retained for analysis.  
The cell pellet obtained following the sonication, heat treatment and centrifugation was processed for 
AIDH inclusion bodies. The cell pellet was resuspended in 50ml of denaturation buffer consisting of 6M 
GdnHCl, 2mM DTT and 20mM HEPES pH 7.5 as outlined in the materials section and incubated to 
denature the protein and unfold it completely. The expectation after incubation of the cell pellet with 
denaturation buffer was to have the AIDH completely unfolded in solution which was followed by 
centrifugation to get rid of cellular debris. The 50ml suspension with AIDH in the denatured state was 
incubated with 7.5ml of Ni-NTA and bound overnight at room temperature. This was followed by 
affinity chromatography which gradually removes the GdnHCl and DTT in the flow through from the 
column, and the excess HEPES buffer (100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2) washes 
remove traces of GdnHCl and DTT from the Ni-NTA resin until their concentrations are negligible. 
Removing AIDH from GdnHCl solution promotes refolding and the introduction of MgCl2 and glycerol 
in the buffer further encourages protein refolding and stability. This was followed by imidazole elutions 
to elute any bound protein from the Ni-NTA. 3 different imidazole concentrations were used to elute 
any bound protein (Figure 7.20). 
  
Figure 7.20. SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies following extraction with 
GdnHCl. Samples in all lanes are from elutions obtained from the column following Ni-NTA affinity 
chromatography. Lane 2 contains flow through of denaturation buffer. Lanes 3 and 4 contain samples from HEPES 
buffer washes (100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2). Lanes 5, 6, 7 and 8 contain HEPES buffer 
imidazole elutions with 100, 500, 500 and 1000mM imidazole respectively. 
 
The precipitation of the flow through as seen in Lane 2 is expected as it is of the flow through which 
contains the denaturation buffer consisting of 6M of GdnHCl. A band is still visible at 57kDa indicating 
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presence of AIDH. In comparison to the attempt outlined in section 7.2.2, little protein has been 
recovered following binding of AIDH in the denatured state to Ni-NTA and eluting with imidazole 
(Figure 7.20, Lanes 6 and 7). The supernatant retained following the resuspension, sonication, heat 
treatment and centrifugation of the cell pellet obtained from AIDH cultures was treated as the soluble 
fraction. Any soluble AIDH expressed during the expression of AIDH in AI media should be present in 
this fraction. In the attempt made in section 7.2.1 to purify the soluble fraction of AIDH, some soluble 
AIDH expressed was purified and SDS-PAGE analysis of the soluble fraction obtained during this 
attempt was used to estimate the efficiency of expression (Figure 7.21).  
 
Figure 7.21. SDS-PAGE analysis of soluble fraction of AIDH in 100mM HEPES pH 7.5, 10% glycerol buffer obtained 
following the resuspension, sonication, heat treatment and centrifugation of the cell pellet obtained from AIDH 
cultures (Lane 2). 
 
The SDS-PAGE analysis of the soluble fraction of AIDH gives an indication that the expression of AIDH 
may not have been efficient enough leading to poor protein yield overall. There is very little protein in 
the soluble fraction in comparison to that seen in Figure 7.2. Considering this, the next step was to 
explore whether or not the protein expression of AIDH itself is optimal in the first place. The attempts 
so far have been focused on the binding of AIDH in its denatured state to Ni-NTA. Changes to the 
protocol were explored to test binding, however increasing the volume of Ni-NTA, changes to wash 
and extraction buffer components, change of denaturing agent from GdnHCl to urea and optimizing 
dialysis conditions did not alter the outcome of the inclusion bodies extraction and purification 
protocol. For these reasons, the expression methodology was explored and the details were examined 
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to determine if any small variations in protocol could have contributed to the successful attempt of 
AIDH purification as outlined in section 7.2.2.1 and the failure of all attempts since.  
7.13 Examining AIDH expression protocol to determine any contribution to successful protein yield 
Upon detailed examination of the methodology used to purify the soluble AIDH and extract and purify 
the AIDH from inclusion bodies, one difference was identified. The precultures used to inoculate the 
large scale media for expression and growth of AIDH were grown overnight before diluting the starter 
cultures to OD600 of 0.6 in larger volumes of fresh media. All large scale culture preparation done since  
the first attempt by utilising modified protocol for extraction and purification protocol of soluble AIDH 
from AIDH inclusion bodies as outlined in section 7.6, were done with precultures grown for 4 hours 
and added to the larger volume of media in mid-log phase. Therefore, the question arose of whether 
inducing expression with cells that are not fully saturated in growth possibly could be limiting the 
growth of large scale media and the quantity of protein expressed both as soluble AIDH and AIDH in 
inclusion bodies. The strategy going forward was to explore whether the actual protein expression was 
an issue and whether growth of precultures to full saturation before inoculation of large scale cultures 
was the key to obtaining a good yield of both soluble AIDH and AIDH inclusion bodies.  
For this attempt, AIDH precultures over grown overnight to lag phase before being diluted down to 
OD600 0.6 in the 1L large scale volumes. The large scale flasks were grown at room temperature 
overnight in 4L final volume of AI media with a final concentration of kanamycin at 50µg/ml. An 
average OD600 of 12.17 was read across the 4 flasks. The cell pellet (26.92g) obtained from the cultures 
was resuspended, sonicated and heat treated as outlined in the methods section. All resuspension, 
sonication, heat treatment and centrifugation steps were carried out in a 100mM HEPES pH 7.5, 10% 
glycerol buffer unless otherwise stated. No MgCl2 was added to the buffer used for resuspension, 
sonication and heat treatment of the cell pellet as presence of salt promotes refolding and the 
inclusion bodies protocol was to be done under denaturing conditions to unfold and correctly refold 
the protein.  
The cell pellet (19.26g) obtained following the sonication, heat treatment and centrifugation was 
processed for AIDH inclusion bodies. The cell pellet was resuspended in 50ml of denaturation buffer 
consisting of 6M GdnHCl, 2mM DTT and 20mM HEPES pH 7.5 as outlined in the materials section and 
incubated to denature the protein and unfold it completely. The expectation after incubation of the 
cell pellet with denaturation buffer was to have the AIDH completely unfolded in solution which was 
followed by centrifugation to get rid of cellular debris. The 50ml suspension with AIDH in the denatured 
state was incubated with 5ml of Ni-NTA and bound overnight at room temperature. This was followed 
by affinity chromatography which gradually removes the GdnHCl and DTT in the flow through from the 
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column, and the excess HEPES buffer (100mM HEPES pH 7.5, 10% glycerol, 200mM MgCl2) washes 
remove traces of GdnHCl and DTT from the Ni-NTA resin until their concentrations are negligible. This 
step proved problematic as during the buffer washes, heavy aggregate formation was seen in the 
column and in the washes as well. The suspension was attempted to be transferred to fresh 
polypropylene columns but the issue persisted and due to the clogging of multiple polypropylene 
columns, the experiment was abandoned.  
Section and attempt Protocol summary Outcomes 
7.6 Attempt 1 -Modified protocol (as described in section 
7.5) 
-Refolding via dialysis 
-Failure of dialysis 
7.7 Attempt 2 -Modified protocol 
-Refolding via binding with Ni-NTA resin 
-EDTA added in error to extraction buffer 
causing leaching of nickel ions 
-Unbound AIDH in flow through 
-AIDH recovered from Ni-NTA 
purification (low yield) 
-Failure of dialysis  
7.8 Attempt 3 -Modified protocol 
-Refolding via binding with Ni-NTA resin 
-No EDTA added to extraction buffer 
-Unbound AIDH in flow through 
-AIDH recovered from Ni-NTA 
purification (low yield) 
-Failure of dialysis during buffer 
exchange 
7.9 Attempt 4 -Modified protocol 
-Refolding via binding with Ni-NTA resin 
-No EDTA added to final wash buffer 
-Dilution of unbound protein in flow through  
-AIDH recovered from Ni-NTA 
purification (very low yield) 
-Failure of dilution leading to 
protein precipitation 
7.10 Attempt 5 -Modified protocol, GdnHCl replaced by Urea -Failure of dialysis 
Table 7.1. Summary of inclusion bodies extraction and purification attempts with modified protocol.  
 
This chapter has outlined the multiple issues faced during expression, purification and quantification 
for the production of AIDH. Initial positive activity of AIDH has been established with one batch only 
and multiple batches could not be tested due to failure of purification techniques. The activity assay 
established for testing AIDH activity has not given conclusive results due to uncertainty regarding false 
positives being obtained from the assay readings. There are outstanding issues of optimizing 
expression, extraction of inclusion bodies and their successful purification. Despite attempting 
multiple protocol changes to address issues regarding binding of denatured AIDH to Ni-NTA, this issue 
has persisted and unable to be solved, coupled with dialysis failures, isolation of soluble AIDH has 
proven to be a big challenge (Table 7.1). Multistep optimizations are required to be tackled before 
obtaining an improved outcome.  
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8. Engineered malate dehydrogenase for improved malate production 
 
The wildtype malate dehydrogenase (MDH) from the thermotolerant Thermococcus kodakarensis 
catalyses the reductive carboxylation of pyruvate to malate accompanied by bicarbonate independent 
reduction of pyruvate and produces lactate as a by-product. A triple mutant has been identified by 
Morimoto et al. with altered cofactor preference of the enzyme NADP(H) to NAD(H), furthermore the 
reaction specificity significantly shifted towards malate production and less lactate by-product than 
the wildtype (Morimoto et al. 2013). This triple mutant was utilized in the cascade design as the fifth 
and final enzyme to catalyse the conversion of pyruvate to malate. This chapter discusses the protein 
expression, purification and characterization of MDH. The key challenges faced in finding suitable assay 
protocols for optimization and detecting enzyme activity are also reviewed.    
8.1 Transformation of MDH vector DNA into BL21-DE3 competent cells 
Synthesised pET30a vectors containing the MDH sequence arrived as a concentrated miniprep of ~4µg 
of DNA from GenScript. The original vector sample was archived and transformation of vector into 
DH5α competent cells was done followed by a miniprep to obtain 50µl of quantified vector DNA. MDH 
DNA was transformed into BL21-DE3 cells and single colonies were used to initiate protein expression. 
LB agar kanamycin plates with the successful transformation of vector DNA into BL21-DE3 were also 
used to prepare glycerol stocks for storage at -80°C for future applications.  
 
Figure 8.1. Quantified vector DNA obtained following miniprep was transformed into competent BL21-DE3 cells, 




8.2 Small scale MDH protein expression and purification in AI media 
Following successful transformation of MDH vector DNA, protein expression and purification was 
initially carried out in a 2L final volume. Initial MDH expression was carried out in AI media with a final 
concentration of kanamycin at 50µg/ml. The cell pellets obtained from the cultures were resuspended, 
sonicated and heat treated as outlined in the methods sections. The crude protein fraction obtained 
from the prior steps was purified using 5 ml of Ni-NTA resin. All resuspension, sonication, heat 
treatment and purification steps were carried out in a 100mM HEPES pH 7.5, 200mM MgCl2, 10% 
glycerol buffer unless otherwise stated. 
 
Figure 8.2. SDS-PAGE analysis of MDH expressed in E. coli BL21-DE3 and AI media. Lane 2 contains flow through 
from the column and lanes 3 and 4 contain HEPES buffer washes. Lane 5, 6, and 7 contain HEPES buffer washes 
with 50, 100 and 200mM imidazole. Lanes 9, 10, 11 and 12 contain HEPES buffer washes with 400, 600, 800 and 
1000mM imidazole.  
 
Fractions from lanes 7 and 9 in Figure 8.2 were pooled, imidazole was removed by desalting using a 
PD-10 desalting column and the final fraction was concentrated. Its protein concentration was 
determined to be 1.5mg/ml by BCA. Prior to desalting, signs of protein aggregation were seen and the 
pooled fraction was centrifuged to separate the soluble fraction from the aggregates in an effort to 
minimise any further aggregation. Large scale expression of MDH was then attempted while 
addressing this issue.  
8.3 Large scale expression of MDH in AI media and purification with the aid of EDTA to minimize 
aggregation 
As previously attempted with proteins earlier in the cascade, EDTA was utilised with MDH large scale 
expression and purification to reduce protein aggregation. 4L of AI media were inoculated with 
precultures and a wet weight pellet of 19.72g was obtained. This was processed as per methodology 





Figure 8.3. SDS-PAGE analysis of MDH expressed in E. coli BL21-DE3 and AI media. Lane 2 contains crude protein 
prior to binding with Ni-NTA. Lane 3 contains flow through from the column and lane 4 contains HEPES buffer 
wash. Lanes 5, 6, 7, 8, 9 and 10 contain HEPES buffer washes with 50, 100, 200, 400, 600 and 1000mM imidazole 
respectively.  
 
The 200, 400 and 600mM imidazole elutions were pooled (30ml) with 100mM final concentration of 
EDTA. Three cycles of dialysis were performed as the pooled fraction size was too large to be processed 
using PD-10 columns. The repeated dialysis cycles were calculated to have diluted the imidazole and 
EDTA to a negligible amount (<0.01mM). No aggregation was noticed at any point during the dialysis 
cycles. On the last cycle of dialysis, the exchange buffer was altered to be 100mM MgCl2 instead of 
200mM Mgcl2 for final storage of MDH. Following dialysis, the fraction was split and both fractions 
were concentrated to different volumes and the protein concentration was determined via BCA to be 
3.7mg/ml and 8mg/ml.  
8.4 Size-exclusion chromatography and protein identification of MDH to determine presence of 
oligomers 
The small scale expression of MDH gave a single band on the SDS-PAGE matching the expected size of 
the MDH monomer (Figure 8.2, lane 9), however the large scale expression done in Figure 8.3 gave 
other non-specific bands of which some were suspected to be oligomers. To confirm the presence of 
oligomers and the positively identify the protein, the 8mg/ml MDH concentrated from section 8.3 was 
loaded onto the ÄKTA system and as size-exclusion chromatography separates molecules in solution 
based on their molecular weight, the peaks on a chromatogram are indicative of the different size 
proteins in the sample. The chromatogram obtained from size-exclusion chromatography of MDH 






Peak Retention (ml) Area (ml*mAU) Area % Fractions Volume (ml) 
a 10.63 36.41 14.85 B5-B10 3.0 
b 11.68 13.14 5.36 B12 0.5 
c 13.59 195.6 79.79 C2-D1 6.0 
Figure 8.4. Size exclusion chromatography of MDH. Figure 8.4A displays the chromatogram obtained from the 
software. The blue trace represents the UV absorbance at 280nm and the 3 peaks are indicative of the quantity 
of protein detected. The brown trace reflects the conductivity monitor which measures conductivity of buffer 
and samples for online monitoring of the true gradient. The green trace is applied if there is another buffer being 
used, since this sample was run in one buffer only, the trace has a value of 0. Figure 8.4B lists the retention time 
of each peak as well as the final volume collected of all fractions.  
 
Multiple samples from each identified peak, a, b and c, were loaded onto a SDS-PAGE gel in order to 
visualise their composition. The SDS-PAGE analysis of the samples (Figure 8.5) shows the composition 
is exactly the same in all samples loaded, confirming the presence of oligomers. Despite being 
identified as different peaks, the only difference among them is the quantity of protein present. A 
concentrated protein sample has been previously observed to elute off in multiple peaks in size-
exclusion chromatography and it would seem that this is the case here. In Figure 8.5, sample in lane 2 
is from peak a, sample in lane 3 is from peak b and lastly, sample in lane 4 is from peak c (Figure 8.4a). 
It is evident from the gel in Figure 8.5 that the same bands are constantly seen in all the samples, 
differing only in their intensities, which correlates with the different concentrations of protein present 
in the different fractions. Following the SDS-PAGE, as a further confirmation of oligomers, the MDH 
bands indicated in Figure 8.5 were excised from the gel and were analysed with mass spectrometry to 
confirm protein identification.  




Figure 8.5. SDS-PAGE analysis of MDH following size exclusion chromatography. Lane 2 contains samples from 
peak A, taken from fraction B9. Lane 3 contains sample from peak B, taken from fraction B12. Lane 4 contains 
sample from peak C, taken from fraction C5. The bands indicated in the figure were excised for mass 
spectrometry analysis. 
 
Mass spectrometry analysis of the bands shown in Figure 8.5 positively identified both as being MDH 
(data in appendix). Using ImageJ scientific image analysis, the confirmed MDH bands were calculated 
as a percentage of the total protein concentration. Using this method allowed for the actual 
concentration of MDH to be determined in a sample with other non-specific proteins purified during 
Ni-NTA purification in future experiments.  
8.5 Initial activity analysis of engineered MDH for malate production via IC 
Following on from the successful expression purification and positive protein identification of MDH, its 
activity for conversion of pyruvate to malate was analysed. The reaction conditions for this assay are 
required to be high in CO2 and low in O2. Due to equipment limitations at the time, this was done by 
equilibrating the container space of a sealed vial with CO2 before any given activity analysis. All assay 
conditions were analysed via the IC as well as pyruvate and malate standards (Figure 2.4 and 2.5), and 






After establishing successful standards of pyruvic and malic acid (Figure 2.4 and 2.5), an initial test of 
MDH activity was done with 30mM pyruvic acid as substrate and using 2 different enzyme 
concentrations of 0.003mg/ml and 0.024mg/ml MDH. 5mM NADH was added to the reaction as the 
cofactor. 5% CO2 was bubbled into each assay condition vials for 5 minutes followed by the addition 
of pyruvate and incubation of vials at 50°C for 3 hours. After the end of incubation period, assay 
conditions were analysed via IC. A control condition without any MDH was run alongside assay 
conditions.  
 
0.003mg/ml MDH 0.024mg/ml MDH 
Malic acid (mM) 2.19 1.40 
Table 8.1. IC activity analysis of 2 different MDH concentrations, 0.003 and 0.024mg/ml to monitor malic acid 
production. Standard deviation for all conditions= <0.045.  
 














Figure 8.6. IC chromatogram of the peaks obtained from MDH activity assays, top chromatogram is from activity 
assay with 5mM NADH and 0.003mg/ml MDH and bottom chromatogram is from activity assay with 5mM NADH 
and 0.024mg/ml MDH. The malic acid peak can be seen at around ~50 minutes.  
 
A control without any MDH was also tested on the IC. From Figure 8.6, there is a significant shift in the 
baseline from around the 50 minute point, following the malic acid peak. The reaction assay was tested 





Figure 8.7. Reaction control with 30mM pyruvic acid and 5mM NADH. 
 
From the reaction control in Figure 8.7, it is apparent that the reaction reagents are causing the shift 
in baseline at around the 50 minute mark. Since the malic acid retention time is also around 50 
minutes, the peak was selected and the shift in baseline did not affect the analysis.  
8.6 IC activity analysis of MDH assays at 2 different enzyme concentrations by equilibrating assay 
conditions in 5% CO2 incubator 
Following the IC activity analysis of MDH at 2 different enzyme concentrations by bubbling CO2 through 
samples, another method of equilibrating assay conditions with CO2 was attempted to determine 
which would be more successful to take forward. From Figure 8.6 and 8.7, it can be seen that malic 
acid was successfully produced from the 2 enzymatic assays tested. In this section, the assay conditions 
tested previously in section 8.5 were expanded while the CO2 equilibration method was changed to 
incubation of samples in a 5% CO2 incubator before analysis via IC. All other reaction components were 
the same as previously stated in section 8.5. Since the 0.024mg/ml assay condition was shown to give 
lower malic acid production than the 0.003mg/ml assay, the MDH concentration in assay was reduced 
along with a reduced NADH concentration. 4 assay conditions were set up, 0.003mg/ml MDH with 
1mM NADH, 0.003mg/ml MDH with 2mM NADH, 0.006mg/ml MADH with 1mM NADH, 0.006mg/ml 
MDH with 2mM NADH. Two reaction controls were also set up, one without any NADH and one without 
any MDH. After the 3 hour incubation period, all samples were analysed via IC. No peaks were seen at 
the expected retention time of malic acid for any of the reaction conditions. This ruled out equilibrating 
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samples in the 5% CO2 incubator and the method of equilibrating samples while bubbling through CO2 
was used for further experimentation. 
8.7 IC activity analysis of MDH assays at 4 different enzyme concentrations and 2 NADH 
concentrations by bubbling CO2 through samples 
Following the unsuccessful attempt of establishing enzyme activity by equilibrating assay conditions in 
a 5% CO2 incubator, further attempts moving forwards were only made with bubbling CO2 conditions. 
In an attempt to further explore the range of enzyme and cofactor concentrations and activity levels, 
8 reaction conditions were tested as outlined in section 8.5. 0.003mg/ml, 0.006mg/ml, 0.012mg/ml 
and 0.024mg/ml MDH assays were set up with both 5mM and 10mM NADH. All conditions were 
analysed via IC and the concentration of malic acid was calculated using a standard curve (Figure 2.5). 
Malic acid production from all 8 assay conditions is shown in Table 8.2.  
 































1.68 1.28 1.17 0.86 1.82 1.57 1.13 1.28 
Table 8.2. IC activity analysis of malic acid production from 4 MDH enzyme concentrations, each MDH 
concentration was tested with both 5mM and 10mM NADH. Standard deviation for all conditions= <0.2.  
 
The reaction controls gave the same chromatogram profile as that shown in Figure 8.7. Additionally, 
further reaction controls were run to confirm that the pyruvic and malic acid standard curves obtained 
were accurate. 30mM of pyruvic acid was run without addition of any MDH assay buffers. The 
retention time obtained from the chromatogram was 5.72 minutes as expected, the peak area 
(µS*min) was 65.297 and using the standard curve, the calculated pyruvic acid amount added to 
sample was 29.74mM. This is only underestimated by 0.26mM and fits within the expected outcome. 







Figure 8.8. Reaction control with 30mM pyruvic acid without any assay reagents.  
 
1mM of malic acid was also loaded as another control in 2 different conditions, the first being without 
any assay reagents like the pyruvic acid control in Figure 8.8, and secondly 1mM of malic acid with all 
the assay reagents (Figure 8.11 and 8.12). 
 




For the malic acid control without any assay reagents (Figure 8.9), the retention time obtained from 
the chromatogram was 55.36 minutes, as expected. The peak area (µS*min) was 4.03 and using the 
standard curve, the calculated malic acid amount added to sample was 1.48mM which is an 
overestimation by 0.48mM. 1mM of malic acid was also analysed via IC under the addition of MDH 
assay reagents. For this control of 1mM malic acid with MDH assay reagents (Figure 8.10) the retention 
time obtained from the chromatogram was 49.62 minutes as expected. The peak area (µS*min) was 
4.687 and using the standard curve, the calculated malic acid amount added to sample was 1.72mM 
which is an overestimation by 0.72mM.  
 
Figure 8.10. Reaction control with 1mM malic acid with assay reagents.  
 
Given that the malic acid is being over estimated in both controls, even more so under assay conditions 
with assay reagents, a different approach to measuring MDH activity was explored. 
 
8.8 MDH 0.003mg/ml activity analysis with 0.5 and 1mM NADH at 340nm 
Equilibrating the headspace of the reaction containers with CO2 was done as previously established in 
section 8.7. Reaction conditions were tested with 0.003mg/ml MDH; 0.5 and 1mM NADH (Figure 8.11), 
with the consumption of NADH, as indicated by decreased 340nm absorbance values, indicative of 




Figure 8.11. Testing 0.003mg/ml MDH activity with 0.5 and 1mM of NADH, both shown with individual controls. 
Standard deviation for 0.5mM NADH assay and control= <0.06, and standard deviation for 1mM NADH assay and 
control= <0.17.  
 
This assay was done by equilibrating the headspace of the reaction container with CO2 for 5 minutes 
before transferring samples to a 96 well plate for absorbance readings over a 4 hour period. As evident 
from Figure 8.11, the absorbance values from the assay and their respective controls with MDH follow 
a similar absorbance pattern, meaning there was no activity displayed by the enzyme. To explore this 
further, the assay components were investigated. 
8.9 Investigating MDH assay components 
Following the MDH activity assay with 2 different cofactor concentrations in section 8.8, the assay 
components in the assay were tested with CO2 bubbling and without to determine if pushing reaction 
equilibrium towards carbonate was the cause of the unexpected curve shape. The reaction 
components are outlined in the materials and methods section and for the purpose of this experiment, 
they were isolated individually or into certain combinations (Figure 8.12 and 8.13). CO2 was bubbled 
into each sample for 5 minutes and then measured for absorbance at 340nm at 50°C whereas the 
conditions without CO2 were left to equilibrate at room temperature for 5 minutes before being 

























Figure 8.12. Analysis of assay components without bubbling through CO2. Standard deviations for all 8 
conditions are as follows: 500mM HEPES <0.1; 5mM Ammonium chloride <0.08; 0.5mM Manganese chloride 
<0.033; 30mM Pyruvate <0.055; 85mM Sodium bicarbonate <0.006; 1mM NADH <0.12; Ammonium chloride, 
Sodium bicarbonate, Pyruvate, NADH <0.096; and Sodium bicarbonate, Pyruvate, NADH <0.097.  
 
Figure 8.13. Analysis of assay components with bubbling through CO2. Standard deviations for all 8 conditions 
are as follows: 500mM HEPES <0.174; 5mM Ammonium chloride <0.028; 0.5mM Manganese chloride <0.041; 
30mM Pyruvate <0.069; 85mM Sodium bicarbonate <0.023; 1mM NADH <0.146; Ammonium chloride, Sodium 

































































Comparing the two conditions, degradation of NADH occurred much faster in the condition where 
equilibrium was shifted towards carbonate, the remainder of the assay reagents displayed similar 
absorbance profiles. Conditions of ammonium chloride, sodium bicarbonate, pyruvate, NADH and 
sodium bicarbonate, pyruvate, NADH displayed a higher decrease in absorbance under the carbonate 
rich condition in comparison to that without. This could be due to the presence of NADH and its 
increased degradation in the carbonate rich condition as all other components in the two conditions 
mentioned display a somewhat linear absorbance individually.  
8.10 Sixteen hour MDH activity test 
Having tested MDH activity via absorbance at 340nm as in section 8.8, a key change was made before 
attempting another activity test. In the experiment done in section 8.8, CO2 was bubbled through the 
assay reagents including the substrate, pyruvate, for 5 minutes before starting absorbance readings, 
therefore initial changes in absorbance were missed. This was addressed by equilibrating the 
headspace of reaction container with all assay reagents except pyruvate and adding it immediately 
prior to starting absorbance readings. This allowed for the initial absorbance readings to be recorded 
(Figure 8.14). 
 
Figure 8.14. 16 hour activity analysis of 0.003mg/ml MDH with 1mM NADH. Standard deviation for control 



























The following work was done in collaboration with Dr Pinar Karagoz. 
8.11 Utilization of atmospheric control unit to measure activity of MDH 
All MDH enzymatic assays analysed as outlined in sections prior to this point were done using the 
technique of bubbling through CO2 before measuring any potential activity. However, it was apparent 
that a tight monitoring of atmospheric conditions is essential to be able to determine the activity 
parameters of MDH with certainty. An atmospheric control unit was sourced with the capability to fully 
and independently regulate both O2 and CO2 levels within the microplate reader chamber. This 
provided the opportunity for analysis of real time reaction parameters via absorbance at 340nm.  
8.12 Effect of atmospheric conditions on the activity of purified MDH enzyme 
To determine the effects of various atmospheric conditions on the activity of MDH followed by 
subsequent optimization, the activity of MDH was tested under different O2 and CO2 ratios. Box-
Behnken design and Response Surface Methodology were applied to find optimum conditions 
followed by application of mathematical software, MATLAB 2019a, to develop a model. The three 
variables and their tested values are outlined in Table 8.3. 
  - 0 + 
O2,                      (x1) 2.5 5 7.5 
CO2,                   (x2) 5 10 15 
Temperature,  (x3) 45 55 65 
Table 8.3. Atmospheric conditions independent variables and their values. O2 and CO2 are in % and temperature 
is in °C.  
 
15 independent experiments were performed, whereby the effect of the experimental variables on 
the initial rate of MDH was calculated. The initial rate was calculated via the decrease in the NADH 










O2 (x1) CO2 (x2) Temperature 
(x3) 
1 - - 0 
2 + - 0 
3 - + 0 
4 + + 0 
5 - 0 - 
6 + 0 - 
7 - 0 + 
8 + 0 + 
9 0 - - 
10 0 + - 
11 0 - + 
12 0 + + 
13 0 0 0 
14 0 0 0 
15 0 0 0 
Table 8.4. Box-Behnken design for 3 factors with 3 centre points. O2 and CO2 are in % and temperature is in °C.  
 
 
The full data set from all 15 conditions with experimentally obtained values are shown in Table 8.5. 
The highest initial rate, 0.103 mM/min, was detected at 65°C, with atmospheric conditions set as 7.5% 
O2 and 10% CO2 (Table 8.5, Experiment number 8). The highest initial rate value as calculated by the 
model was 0.102 mM/min with temperature, O2 and CO2 values accepted as 65°C, 5.625% and 12.5%, 
respectively. The experimentally obtained value and the value calculated by the model are in very close 













1 2.5 5 55 0.068 
2 7.5 5 55 0.061 
3 2.5 15 55 0.067 
4 7.5 15 55 0.086 
5 2.5 10 45 0.030 
6 7.5 10 45 0.059 
7 2.5 10 65 0.098 
8 7.5 10 65 0.103 
9 5 5 45 0.052 
10 5 15 45 0.054 
11 5 5 65 0.076 
12 5 15 65 0.092 
13 5 10 55 0.078 
14 5 10 55 0.092 
15 5 10 55 0.088 
Table 8.5. Experimental conditions and initial rates of MDH as experimentally obtained following the 
experimental conditions as outlined in Table 8.4.  
 
The accuracy of the model was experimentally tested at the model calculated optimum conditions. 
Atmospheric control unit was set to 5.6% O2 and 12.5% CO2 which is the closest matching values 
achievable to the calculated optimum atmosphere conditions via the model (5.625% O2 and 12.5% 
CO2) and the activity of MDH was tested at 65°C. Due to technically related issues with the equipment 
required for this experiment, this experiment was carried out after a lag of 2 weeks. During this time, 
MDH enzyme stock was stored at 4°C. Possible activity loss due to enzyme degradation was anticipated 
and this was experimentally confirmed by repeating some of the experiments listed in Table 8.5. 
Experiment number 7, 13, 14 and 15 were repeated to detect possible activity loss caused by enzyme 
storage. As can be seen from Table 8.6, the observed initial rate at optimum conditions was 
0.092mM/min which is 9.6% lower than the calculated maximum initial rate. However, similar to this 
result, when the experimental conditions (Experiment number 7, 13, 14 and 15) were repeated with 
MDH stock that had been stored at 4°C for 2 weeks, the initial rate of the MDH was approximately 10% 
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lower than the previous results. Thereby, the 9.6% difference was theorised to be caused by the long 
storage of the MDH at 4°C. This data further goes to display the accuracy of the model. 
 O2 (%) CO2 (%) Temp (°C) Initial rate (mM/min) 
Optimum conditions as 
calculated by model 
5.6 12.5 65 0.09 
Experiment number 7 2.5 10 65 0.08 
Experiment number 13, 14 
and 15 
5 10 55 0.08 
Table 8.6. Initial rate of MDH experimentally calculated under optimum conditions by the model and the 
repeated experiments from Table 8.5 with MDH stock from 2 weeks at 4°C. 
 
The results obtained from the model are shown in Figure 8.15. Figure 8.15A shows the effect of the 
temperature and CO2 concentration on initial NADH consumption rate of MDH, initial velocity (Vi), at 
constant oxygen levels (5%). Increasing temperature from 45°C to 65°C increased the Vi by 2-fold. 
However, increasing the CO2 level from 5% to 10% caused approximately 20% increase in Vi. The effect 
of CO2 on the Vi was less significant when CO2 level was between 10% to 15%. This might be because 
of the maximum solubility of CO2 in water. After it reaches its maximum solubility, adding excessive 
amount of CO2 does not change the amount of soluble CO2.  
Figure 8.15B shows the effect of the reaction temperatures and the O2 levels on the Vi. Similarly to 
Figure 8.15A, temperature change affected the Vi most significantly. The effect of O2 was more visible 
at low temperatures. At 45°C, increasing the O2 level from 2.5% to 5% increased the Vi from 0.4 to 0.56 
mM/min. The similar change in the O2 levels did not show a visible effect on the reaction rate at 65°C. 
Solubility of oxygen is strongly dependant on temperature and it decreases at high temperatures. It 
was theorized that at 65°C the amount of soluble oxygen was not significantly affected by the addition 
of excessive oxygen, since it was already at the equilibrium.  
Figure 8.15C shows the effect of the atmospheric conditions on the initial reaction rate at 55 °C. Similar 
to previous results, higher reaction rates were achieved when the O2 and CO2 concentrations were 












8.13 Establishing enzyme kinetics of MDH 
Following the establishment of optimum atmospheric and temperature conditions for reaction 
conditions, enzyme kinetics were determined at 55°C under 5% O2 and 15% CO2 at 340nm. MDH 
reaction mix was as previously  described in the methods section, with MDH being used at 0.3mg/ml 
final concentration. The substrate (pyruvate) concentration was  tested in the range of 0-75mM. Figure 
8.16A shows the initial activity of the MDH at different substrate concentrations. Figure 8.16B shows 
the Lineweaver-Burk plot for the kinetic calculations. Based on the equation of the linear function, Km 
and Vmax were calculated as 5.33mM and 0.041 mM/min, respectively. 
 
 
Figure 8.16. Initial activity of the MDH at different pyruvate concentrations (A), Lineweaver-Burk plot for the 
kinetic analysis of MDH at different substrate levels (B). 
 
































8.14 Coupling MDH with GDH for cofactor recycling 
The first enzyme (GDH) of the cascade design utilizes NAD+ as cofactor forming NADH along with the 
product gluconate. GDH presents itself to be an optimal pairing partner with MDH for testing cofactor 
recycling as MDH utilizes NADH, thereby sets up a well-balanced cofactor recycling opportunity.  
8.14.1 Effect of buffer components of GDH on the activity of MDH 
The assay reagents utilized in GDH and MDH vary with some being added at different concentrations 
whilst others only being utilized in one assay and not required for the other. MDH has higher assay 
condition requirements with additional assay reagents required in comparison to GDH, as well as the 
additional atmospheric condition requirements (Table 8.7). Thereby the effect of GDH assay 
components was tested on the relative activity of MDH. 
GDH standard assay conditions MDH standard assay conditions 
No atmospheric control required 
100 mM HEPES pH 7.5  
2.5% glycerol 
30mM MgCl2  
100mM glucose 
5mM NAD+ 
15% CO2 and 5% O2 






Table 8.7. Standard assay conditions for GDH and MDH.  
 
All experiments were done with 15% CO2 and 5% O2. Initial pyruvate concentration was adjusted to 
30mM. To detect the effect of the reaction components of GDH on the activity of the MDH, only one 
component of the GDH assay buffer was added to the MDH reaction mixture at one time. The final 
concentration of each chemical was the same as their concentration in the GDH assay buffer. Every 
component in the MDH reaction mixture (NH4Cl, MnCl2, NaHCO3, Pyruvate, NADH) was kept constant.  
The most significant effect was seen when the HEPES concentration of the reaction mixture reduced 
from 500mM to 100 mM, which is the concentration of the GDH buffer (Figure 8.17). As a result of 
reduced HEPES concentration, the activity of MDH reduced by 20%. Addition of glycerol, glucose and 
MgCl2 into MDH reaction mixture did not affect the activity of the MDH significantly. However, to 
successfully couple MDH and GDH in the same environment, a similar study was to be done for the 




Figure 8.17. Effect of GDH assay components on the activity of MDH.  
 
8.14.2 Effect of atmospheric conditions required by MDH on the activity of GDH 
The activity of GDH was tested at 55°C under 15% CO2 and 5% O2 atmospheric conditions in a standard 
GDH reaction mix. The activity of the GDH under these conditions was compared with the activity of 
GDH under its standard aerobic (without atmospheric control) assay conditions. As outlined in Figure 
8.18, activity of GDH was determined not to be affected by the atmospheric conditions required by 
MDH. 
 
Figure 8.18. Activity of GDH under aerobic and 15% CO2 and 5% O2 atmospheric condition (results are the 
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8.14.3  Effect of MDH assay buffer components on the activity of GDH 
As MDH requires a variety of assay components, any effect of MDH buffer components on the activity 
of GDH was tested under 15% CO2 and 5% O2 atmospheric condition. Initial glucose concentration was 
100mM. Similarly to the MDH experiment in section 8.14.1, only one component of the MDH buffer 
was added to the GDH reaction mixture at any one time, and all components of the GDH reaction 
mixture (MgCl2, glycerol, glucose, NAD+) were kept constant in their standard reaction concentrations. 
Figure 8.19 shows the effect of each buffer component on the activity of GDH. As evident from Figure 
8.19, pyruvate has a significant effect on the activity of GDH. Presence of 30mM final pyruvate 
concentration in the buffer decreased the activity of GDH about 96.7%. Increasing final concentration 
of HEPES from 100 mM to 500 mM, decreased the activity of GDH about 15.5%. When MnCl2 and 
NaHCO3 were added into the buffer, the activity of the GDH was slightly increased about 6.9 and 8.2%, 
respectively. 
 
Figure 8.19. Effect of MDH assay components on the activity of GDH. 
 
As pyruvate displayed a significant negative effect on the activity of GDH (Figure 8.19), this was 
explored further. To investigate the effect of the pyruvate concentration on the activity of GDH, 
different concentrations of pyruvate were tested by addition into the standard GDH reaction mixture 
and the NADH formation was detected for 2.5 hours. Based on the accumulated NADH concentration 
at the end of 2.5 hour reaction period, the relative activity of GDH was calculated as shown in Figure 
8.20. As can be seen from Figure 8.20, pyruvate concentrations above 10mM, have significant effect 
on the activity of GDH and reducing the activity of GDH more than 50%. Figure 8.21 shows the effect 

























Figure 8.20. Effect of pyruvate concentration on activity of GDH. 
 
 
Figure 8.21. Effect of pyruvate concentration on the NADH production profile of GDH using 100mM glucose as 
substrate (results are the average of 3 different readings, standard deviation for all conditions = <0.03). 
 
8.14.4 Exploring pyruvate inhibition 
To understand the cause of the pyruvate inhibition, activity of GDH was monitored at different 
substrate levels, between 2.5-100mM, in the presence of inhibitor (pyruvate). Due to the amount of 
GDH required for this set of experiments, a new batch of GDH was purified and this new batch was 
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Table 8.8. The Vmax value of the GDH from this batch was calculated to be 1.5U/mg which is lower than 
the previous batch (5.911U/mg). Table 8.8 shows the change of the kinetics values of the GDH (new 
batch) at different inhibitor concentrations. Even though the Vi is not significantly changed by the 
increase of the inhibitor, the Km value was significantly increased by the increase in pyruvate 
concentrations. This suggests that the inhibitor, pyruvate, is affecting the binding of the enzyme to 
substrate which was concluded to be competitive inhibition. 
 
Figure 8.22. Lineweaver-Burk plot for the kinetic analysis of MDH at different substrate and pyruvate levels. 
 
Kinetic parameters  Pyruvate concentration (mM) 
0 10 15 20 
Km (mM) 0.42 0.41 0.95 2.55 
Vmax (mM/min) 0.04 0.03 0.02 0.03 
Table 8.8. Change in kinetic parameters of MDH in the presence of different pyruvate concentrations. 
 
8.14.5 Coupling MDH and GDH for cofactor recycling enzyme system 
Despite the inhibitory effect of pyruvate on the activity of GDH, purified MDH and GDH enzymes were 
placed in the same assay condition to investigate their simultaneous activities and co-factor recycling 
capabilities. The final pyruvate and glucose concentrations in the reaction mixture were adjusted to 


















reaction mixture contained the same amount of other reagents as specified in their standard reaction 
mixtures. Two different scenarios were used to detect the success of the process.  In the first scenario, 
the rapid reduction of pyruvate concentration was aimed for. In this case, NADH would be utilized as 
a co-factor and MDH would catalyse its conversion to NAD+ while simultaneously converting pyruvate 
to malate. The reaction was tested at 55°C, under atmospheric conditions described previously, by the 
addition of NADH.  
In the second scenario, the same reaction mixture and condition was used but the reaction was started 
by the addition of NAD+ to the reaction mixture. Change in the NADH concentration was observed 
during 2 hours via plate reader. The final NADH concentrations were compared with an enzyme-free 
reaction control containing same amount of initial NADH concentration with the first scenario (Table 
8.9). Despite the presence of pyruvate, GDH enzyme still displayed activity (Scenario 2). Furthermore, 
the NADH consumption in the first scenario shows the activity of MDH. However, these results are not 
sufficient to discuss the success of the co-factor recycling, since they are only showing the activity of 
only one side of reaction. Hence, the amount of produced malate and gluconate must be detected. 
Samples taken from the reaction mixtures were deproteinized, diluted 10-fold and analysed via IC. Due 
to high dilution factor, malate peaks were under the detection limit. However, gluconic acid production 
was detected in both cases. Hence, we can conclude that co-factor recycling was successfully done 
through both scenarios. 
 Scenario 1: Presence of 
both enzyme (GDH and 
MDH), NADH as a co-
factor 
Scenario 2: Presence of 
both enzyme (GDH and 
MDH), NAD+ as a co-
factor 
Control: No enzyme, 
Contains same amount 
of NADH with Scenario 1 
Final NADH 
concentration, mM 
1.21 ±0.06 1.31 ±0.01 1.74 ±0.04 
Gluconic acid 
concentration, mM 
8.81 10.45 0 
Table 8.9. Coupling GDH and MDH for co-factor recycling. 
 
This chapter has discussed the production of recombinant MDH from T. kodakarensis and its successful 
purification and characterization. Atmospheric condition requirements for MDH have also been 
optimized and successful analysis methods were also determined. The cofactor recycling was also 
explored via coupling MDH with GDH, and demonstrated to be successful. Coupled enzyme reactions 
display great potential and we have demonstrated the utilization of engineered MDH and GDH for the 





9.1 Enzymatic cascade design for the conversion of glucose to malate 
The overall aim of the project described in this thesis was to enzymatically convert glucose to malate 
as shown in Chapter 3, Figure 3.1. A summary of experimental work carried out with each protein is 
shown in Table 9.1. 
Enzyme Experimental summary 
Glucose dehydrogenase (GDH) -Transformation, expression, protein purification 
-Positive enzymatic activity 
-Immobilization onto novel supports 
-Thermal stability, storage stability and reusability 
determined 
-Enzyme kinetics determined 
Dihydroxy-acid dehydratase (DHAD) -Transformation, expression and purification 
-Positive enzymatic activity (crude only) 
-Storage stability determined 
-Enzyme kinetics determined 
2-Keto-3-deoxygluconate aldolase (KDGA) -Transformation, expression, protein purification 
-Positive enzyme activity (reverse) 
-Enzyme kinetics determined 
Glyceraldehyde dehydrogenase (AIDH) -Transformation, expression  
-Partially successful protein purification 
-Analysis of several protein refolding strategies 
Malate dehydrogenase (MDH) -Transformation, expression, protein purification 
-Positive enzymatic activity 
-Atmospheric conditions optimized for assay 
-Coupling of GDH with MDH 
Table 9.1. Summary of experimental achievements with each protein in the cascade. 
 
The cascade constructed for the production of malate from glucose was achieved via utilization of 4 
thermophilic enzymes from the non-phosphorylative Entner-Doudoroff pathway (Ahmed et al. 2005). 
In this system design, a single mole of glucose is converted into 2 moles pyruvate with the concomitant 
reduction of two NAD+, followed by the use of an engineered enzyme with altered cofactor preference 
(Morimoto et al. 2013) to utilize the NADH formed and catalyse the conversion of pyruvate to malate 
maintaining redox neutrality (Guterl et al. 2012). Phosphorylation/dephosphorylation steps have been 
eliminated from the cascade design by employing an archaeal dihydroxy-acid dehydratase which has 
been reported to display substrate promiscuity and catalyse conversion of gluconate to 2-keto-3-
deoxygluconate along with the conversion of glycerate to pyruvate (Kim and Lee 2006), with the latter 
step improving reaction efficiency as it redirects the transformation of unwanted glycerate into the 
key substrate, pyruvate. The cascade was designed to be redox balanced and utilizing enzymes from 
the Entner-Doudoroff pathway provided a feasible solution for enzyme stability and ease of 
purification. In a novel approach, an engineered malate dehydrogenase was utilized to convert glucose 
to malate in just 5 enzymes.  
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The enzymes in the cascade design were chosen keeping in mind the challenges associated with cell-
free cascade systems. Enzyme stability is a key challenge hindering large scale implementation of in 
vitro synthetic biosystems for biomanufacturing, and 3 strategies can be scrutinized to meet this 
challenge: immobilization, thermostable enzymes and enzyme engineering (Zhang 2015). In the design 
of the cascade discussed here, the criteria required for efficient design were met; firstly, recombinant 
glucose dehydrogenase (GDH) from S. solfataricus was successfully purified and immobilized onto 
different supports. GDH immobilized onto a novel, hierarchically-structured macroporous-
mesoporous silica support showed great potential for gluconic acid production and excellent 
reusability. Secondly, thermostable enzymes were selected in the cascade design as they can 
withstand higher solvent concentrations and tolerate higher process conditions (Cowan 1997, Iyer and 
Ananthanarayan 2008) leading to higher rates of reaction, substrate diffusion, lower viscosities, 
improved phase separation and decreased bacterial contamination (Guterl et al. 2012). Enzyme 
purification costs can also be reduced by employing thermostable enzymes as these are stable at 
higher temperatures, and heat treatment at higher temperatures can deactivate endogenous 
mesophilic host proteins and following centrifugation, thermostable soluble proteins can be found in 
the supernatant (Zhang 2015). Lastly, the use of engineered malate dehydrogenase allowed for the 
redox neutrality of the cascade to be in place as the wildtype enzyme has a different cofactor 
preference (Morimoto et al. 2013). Overall, objective 1 as outlined for the project was completed.  
9.2 Production, purification, characterization and immobilization of GDH 
GDH from Sulfolobus solfataricus was successfully purified and immobilized as outlined in Chapter 4. 
Effective enzyme immobilization is known to be critically-dependent on the choice of support material 
(dos Santos et al. 2015) and the purity of the enzyme being immobilized: the presence of other, 
contaminating proteins in an enzyme preparation reduces both enzyme loading and the apparent 
biocatalytic performance of the enzyme. The high purity of the GDH preparation (99.83%) achieved as 
outlined in Chapter 4, is therefore a substantial benefit to further studies (Figure 4.3). For applications 
outside of immobilization, crude preparations of recombinant thermophilic proteins such as GDH, offer 
multiple advantages. Costly purification protocols can be avoided involving resins or columns, which 
while manageable on the lab scale and for analytical purposes, scale up on an industrial scale may not 
be desirable due to costs involved and have difficulties to compete economically with petroleum 
derived equivalents (Guterl et al. 2012). Thermophilic proteins offer an advantage in comparison to 
mesophiles due to increased stability at higher temperatures. This allowed for the 5 thermophilic 
proteins characterized in this thesis to use heat treatment as a primary purification step. Following cell 
lysis, lysates can be heated to temperatures in the range of 60-80°C for 30-60 minutes, resulting in the 
denaturation and precipitation of most endogenous E.coli proteins followed by centrifugation to 
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remove host cellular debris. This method can be used to achieve a rapid and simple partial purification 
of thermostable proteins free of contaminating activities (Patchett et al. 1986, Xu et al. 2015).  
In earlier attempts of Ni-NTA affinity chromatography of GDH, multiple large preparations of GDH were 
lost to protein aggregation during the dialysis stages. This is a wide issue faced by many researchers 
when using proteins for in vitro studies or as therapeutic agents. There are a large number of protein 
stabilizers available, however determining the most appropriate one is a time consuming task (Bondos 
and Bicknell, 2003). Large scale preparation of purified GDH posed an issue when attempting to 
remove the imidazole used to elute the protein from the affinity column. As the protein sample 
volumes were large, buffer exchanging the elutions into imidazole-free buffer using spin columns was 
an inefficiently laborious and time-consuming process. Dialysis was the best option, however, despite 
multiple attempts at variation of dialysis protocol to optimize dialysis ratios, step-wise reduction in 
buffer components (namely imidazole), the aggregation issue persisted. To overcome this issue, 
addition of EDTA to the protein sample was explored as a solution. The elution of bound protein with 
imidazole also leads to leached nickel ions from the column and into the collection tubing. During Ni-
NTA affinity chromatography, both imidazole the His10 tag chelate the nickel, and the removal of just 
imidazole during dialysis could have resulted in the sample being insoluble. The addition of 100mM 
EDTA aided successful dialysis as it was assuming to be chelating the nickel ions and thereby prevents 
protein-protein self-interactions and a successful dialysis cycle (section 4.4). Protein aggregation was 
not observed in any dialysis samples onwards after the addition of EDTA. EDTA was thereby 
successfully removed along with the imidazole in subsequent dialysis cycles as well. Maximum GDH 
activity has previously been established at Mg2+, Mn2+ or Ca2+ concentrations of 20mM, however the 
presence of 50mM EDTA in the standard reaction mixture reduces the enzyme activity to about 5%; 
which is restored upon the excess addition of Mg2+ (Giardina et al. 1986). 200mM of MgCl2 was used 
for the initial cycle of dialysis to provide the excess of Mg2+ required to restore activity of GDH following 
addition of EDTA to elutions. The concentration of Mg2+ in subsequent cycles of dialysis was reduced 
to 100mM and finally 50mM for storage and assay conditions. Despite 20mM Mg2+ identified as 
providing maximum activity, for storage stability 50mM of Mg2+ was adapted as being the standard.  
Due to the presence of hydroxyl groups that facilitate enzyme binding, silica-based materials are 
efficient and attractive supports for enzyme immobilization (Zdarta et al. 2018) and were therefore 
the subject of immobilization as outlined in Chapter 4. The surface area and pore diameter of an 
immobilization support determines its loading capacity and the size of protein that can be immobilized 
(Mohamad et al. 2015). Small pore sizes may limit diffusion and increase the risk of pore blockage. 
Furthermore, immobilization can only be achieved on the external surface of a support if the pore size 
is too small (Mohamad et al. 2015) desorption is also more likely to occur as the operating temperature 
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is increased (Li et al. 2010). It has therefore been suggested that the pore diameter should be at least 
4-5 fold larger than the equivalent dimension of the enzyme to be immobilized, but not so large such 
that it affects the mechanical properties of the support material (dos Santos et al. 2015). In this study, 
the immobilization efficiency of GDH was significantly higher on the novel MM-SBA-15 silica support 
materials with macro-meso structured hierarchical pores than on commercially-available silica 
supports. As a result of its smaller pore diameter, and consistent with the observations above, more 
immobilized enzyme was visible on the surface of MM-SBA-15-200 than MM-SBA-15-300 (Figure 4.6).  
The activity of an enzyme under different physicochemical conditions is a function of its stability 
(Poorakbar et al. 2018). Immobilization often increases enzyme thermostability (Kumar et al. 2017, 
Mission et al. 2015). The chemistry of a support material, including the nature of its functional groups 
and the length of the matrix-enzyme spacer all affect thermostability (Zdarta et al. 2018). The 
thermostability of immobilized GDH on commercial supports and the novel hierarchically-structured 
MM-SBA-15 was explored (section 4.10). Thermal shocks were carried out on immobilized and free-
state GDH at 55, 65, and 80°C overnight; no significant activity loss was detected at 55 and 65°C.  
However, when the temperature was increased to 80°C, all immobilized and free-state GDH lost 
activity (Figure 4.7). To understand the robustness of immobilized  GDH on different supports, heat 
shocks at 80°C were carried out for shorter periods. Compared to free-state GDH, the thermostability 
of GDH immobilized on ECR8309F was significantly improved. The activity of immobilized GDH on other 
commercial supports had similar activities to free-state GDH. Unexpectedly, GDH immobilized on MM-
SBA-15 showed reduced thermostability. This may be caused by the thermal conductance properties 
of silica. Similar observations have been reported in previous studies using silica-based support 
materials at very high temperatures (Masuda et al. 2013).  
Free-state enzymes are difficult to recover and re-use (Li et al. 2018), while immobilization of enzymes 
allows their cost-effective re-use in repeated batch or continuously-running processes (Yu et al. 2017). 
As outlined in section 4.11, immobilized GDH was used 10 times. At the end of the 5th cycle, GDH 
immobilized on commercial supports had lost more than 65% of its initial activity. However, GDH 
immobilized on MM-SBA-15-300 and MM-SBA-15-200 had lost 41% and 51% of their initial activities, 
respectively (Figure 4.8). In previous studies, GDH immobilized on nanoSiO2 and SBA-15 retained 50% 
and 43% of its initial activity, respectively (Zdarta et al. 2018), while glucose-6-phosphate 
dehydrogenase (G6PD) immobilized on silanized silicon retained 38% of its initial activity after 6 cycles 
(Aissaoui et al. 2013). Improved storage stability of immobilized enzymes is another advantage over 
the corresponding free-state preparations (Kunjukunju et al. 2018). The activity of GDH immobilized 




Despite the reduced thermostability of GDH on MM-SBA-15 supports at 80°C (Figure 4.7), the data 
demonstrated substantial enzyme activity at normal working temperatures, long term enzyme re-
usability and improved storability. To further improve the activity of GDH immobilized on MM-SBA-15, 
the effects of temperature and pH on the activity of free and immobilized GDH were tested (section 
4.14). It was noted that immobilization on MM-SBA-15 did not shift the optimum working temperature 
of GDH. The activity of the free-state enzyme was slightly decreased when the temperature increased 
from 50°C to 60 °C, while the activity of the immobilized enzyme was not affected (Figure 4.10a). The 
optimum pH of an immobilized enzyme depends upon the particular enzyme and the chemistry of the 
support (Sahin and Ozmen 2016). In this study, the activity of GDH was tested over a range of pH. At 
pH greater than 7.5, the activity of immobilized GDH on MM-SBA-15 supports was significantly higher 
than free-state GDH (Figure 4.10b). Usefully, at high pH, above the pKa of gluconic acid, gluconic acid 
can be separated from the reaction mixture by simple separation methods, such as membrane 
filtration (Zdarta et al. 2018).  
Specific area determines the loading capacity of a support and the ratio of enzyme to support material 
is a crucial immobilization parameter for achieving high efficiency and high reaction rates (Patel et al. 
2014). Immobilizing high concentrations of enzyme is preferable from an economical point of view 
(dos Santos et al. 2015), but increasing enzyme concentrations on the support material can also 
increase the cost of the process (Fernandez-Lopez et al. 2017). Furthermore, excessive loading may 
have an effect on enzyme leakage, pore blockage and mass transfer between liquid and solid (Sahin 
and Ozmen 2016). Hence, working at a reasonable enzyme/support ratio is important in developing 
catalytic bioprocesses. Different enzyme/support ratios were tested and immobilization efficiencies 
and GDH activity were quantified (Table 4.9). At enzyme loading ratios  between 1/1 and 10/1 (mg/g), 
almost all of the GDH was immobilized onto the MM-SBA-15 supports. However, enzyme activity was 
reduced at decreased enzyme loading ratios, which might be a result of diffusional constraints. The 
highest GDH/support ratio tested in this study was 25/1 (mg/g) where more than 80% of the enzyme 
was successfully immobilized on MM-SBA-15-200. Under the same conditions, 98% of the enzyme was 
immobilized on MM-SBA-15-300, probably due to its higher surface area and pore diameter.  
The kinetic parameters of free-state GDH and GDH immobilized on MM-SBA-15 supports showed that 
immobilization leads to drop in the Vmax. This expected result might be caused by mass transfer 
limitations (Patel et al. 2014). As a result of enzyme attachment, some of the active sites of GDH could 
be blocked, which would reduce the reaction rate and Vmax (Zdarta et al. 2018). Similar observations 
have been made when GDH from Bacillus megaterium was immobilized on DEAE-Sephadex (Baron et 
al. 1997). Diffusional limitations caused by immobilization also lead to an increase in Km values for 
GDH immobilized on MM-SBA-15 supports. As shown in Figure 4.6, while GDH was mainly immobilized 
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on the surface of MM-SBA200, GDH was predominantly immobilized inside of the pores of MM-SBA-
15-300. Similarly, after immobilization of commercial GDH onto silica supports, depending of the pore 
structure of the supports, a reduction in Vmax of up to 1.87-fold, and an increase in Km of up to 1.78-
fold were reported (Zdarta et al. 2018). 
Increasing generation rates and quantities of food waste are a global concern (Dahiya et al. 2018).  
Bread waste contains high amounts of carbohydrate that can be used as a potential feedstock in 
bioprocesses for the generation of various biobased products, replacing those from fossil resources 
with their associated economic and environmental concerns (Mirabella et al. 2014).  As outlined in 
section 4.15, bread waste was converted to gluconic acid, a potential platform chemical, by using free-
state and immobilized GDH. Immobilized GDH was reused 10 times in reaction mixtures containing 
BWH (bread waste hydrolysate) as a substrate (Figure 4.11). After the 7th cycle, the activity of GDH 
immobilized on MM-SBA-15 was above 50% of its initial activity. The gluconic acid yield from GDH 
immobilized on MM-SBA-15-300 was higher than that on MM-SBA-15-200, in each cycle. Further 
investigations such as the effect of substrate levels and BWH/enzyme loading ratios on the gluconic 
acid production yield are needed. To develop a more effective and economic bioprocess, GDH could 
be coupled with an additional enzyme for co-factor recycling. In a previous study, commercial GDH 
was successfully co-immobilized with xylose dehydrogenase (XDH) on a silica surface for co-factor 
recycling (Zdarta et al. 2018). Co-enzyme re-cycling as a part of multi-enzyme cascades could be an 
attractive route for green chemical production from waste. 
9.3 Production, purification and characterization of DHAD 
Following the oxidation of glucose to gluconate by GDH, gluconate is further dehydrated via dihydroxy-
acid dehydratase (DHAD) to 2-keto-3-deoxygluconate (Kim and Lee 2006, Lamble et al. 2004). DHAD 
utilised for the purpose of studies carried out in this thesis was sourced from the hyperthermophilic 
archaea, S. solfataricus. Biochemical studies suggest that the metabolic conversion of glucose in 
hyperthermophilic archaea occurs via the non-phosphorylative branch of the Entner-Doudoroff 
pathway (Ahmed et al. 2005). DHAD has previously been identified as a key enzyme in the non-
phosphorylative branch of the Entner-Doudoroff pathway. Its expression and purification was 
successfully established following heat treatment of crude lysates followed by Ni-NTA affinity 
chromatography in the earlier attempts. Large scale protein production was aided by dialysis carried 
out following the addition of EDTA to the eluted protein fractions as previously done with GDH (Figure 
5.9).  
Previous studies performed with DHAD from multiple hyperthermophilic sources have utilised 
separation and quantification techniques such HPLC and LC-MS for enzymatic analysis of DHAD 
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(Carsten et al. 2015, Guterl et al. 2012, Matsubara et al. 2004). DHAD activity was analysed using HPIC 
for the purpose of activity analysis, however a few challenges were encountered. The retention times 
for the substrate and product of the reaction were close in values (typically around 3.5 minutes for 
gluconic acid and 3.8 minutes for 2-keto-3-deoxygluconate respectively). The enzymatic activity was 
analysed under standard reaction conditions and combinations, such as high/low enzyme 
concentration and high/low substrate concentrations. As concentrations of the substrate were 
increased in the assay, the area of the peak also widened leading to a less sharp peak with a wider 
base on the chromatogram. If little product was obtained during the assay, then the gluconic acid peak 
overshadowed the peak corresponding to 2-keto-3-deoxygluconate leading to the start of the peak not 
being visible clearly and therefore the concentrations of 2-keto-3-deoxyglucunate being inaccurately 
calculated. This issue was somewhat resolved by limiting the concentrations of gluconic acid used in 
assay conditions to those forming sharp distinguishable peaks under the same dilution factors. 
Overlaying control chromatograms were also used to identify the 2-keto-3-deoxygluconate peaks in 
assay conditions where product yields were low. Positive DHAD activity was established with freshly-
purified DHAD (Ni-NTA affinity chromatography) samples that had not undergone long term storage 
either at 4 or -80°C (Table 5.1), where 10mM gluconic acid was used as substrate with 0.1mg of DHAD 
and on average, 4.14mM of 2-keto-3-deoxygluconate was obtained following incubation for 20 hours 
at 60°C. After solving the issue of protein aggregation by employing EDTA before dialysis of large-scale 
preparations of DHAD (Figure 5.9), further DHAD samples that had not undergone long term storage 
at either 4 or -80°C were tested for activity using 50mM gluconic acid as substrate (Table 5.3). Due to 
technical issues with the range of values in the standard curve for 2-keto-3-deoxygluconic acid, the 
analysis from these assay conditions was only done by assaying the consumption of gluconic acid. 
Positive confirmation of DHAD activity was established through these experiments by deducting the 
gluconic acid concentrations from the assay condition from those of the control condition. Higher 
DHAD concentration containing assays were shown to be consuming more gluconic acid, thereby 
presumably producing more 2-keto-3-deoxygluconic acid. 
To confidently identify the consumption of gluconic acid under assay condition, gluconic acid assay kits 
were employed. This method provided the sensitivity required that could not be achieved with the IC 
analysis. Section 5.8.1 discussed how a suitable dilution factor was determined to be around 200 as it 
fit within the range of the gluconic acid standards run alongside each assay. Since the detection limit 
for the gluconate present inside a sample had to be <2µM, the samples had to be diluted x200 to fit 
within the range of the standard curve. With a high dilution factor, a considerable error factor was also 
introduced considering sizeable pipetting errors that come with handling very low volumes of liquid. 
Fresh gluconate standards were run alongside each assay, however the same pipetting errors applied 
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and the low R2 values obtained during a few experiments are testament to this. Despite the assay’s 
shortcomings, repeated checks were performed when carrying out the assay at each stage and it was 
the best method to confirm DHAD activity at low levels. 0.01mg/ml of DHAD was tested for activity 
with 20mM of gluconic acid via the gluconate assay kit (Table 5.5) . The 450nm absorbance values for 
the control condition and the 0.01mg/ml DHAD 120 minute assay condition were 0.406 and 0.405 
respectively. As the values only varied by 0.001, an apparent lack of activity was attributed to possible 
batch degradation because the set of experiments carried out in section 5.8 were performed with snap 
frozen DHAD stored at -80°C, and it was evident that DHAD cannot be frozen and retain high activity.  
DHAD from S. solfataricus displays substrate promiscuity and is furthermore able to convert glycerate 
to pyruvate in a reaction which does not occur in natural metabolic pathways (Carsten et al. 2015, 
Guterl et al. 2012, Kim and Lee 2006). DHAD catalyses the conversion of gluconate to 2-keto-3-
deoxygluconate, the latter then undergoes a reversible aldol cleavage catalysed by 2-keto-3-
deoxygluconate aldolase (KDGA) to give pyruvate and glyceraldehyde. Glyceraldehyde is an unwanted 
intermediate in the cascade design which can be converted to glycerate via glyceraldehyde 
dehydrogenase. The glycerate can be then utilised by DHAD and converted into pyruvate reducing 
unwanted intermediates in the overall cascade design. The previous set of experiments outlined in the 
last paragraph discussed the apparent lack of activity displayed by thawed DHAD stored at -80°C when 
assayed for activity with gluconic acid as substrate for formation of 2-keto-3-deoxygluconate. 
Following inconclusive data about activity displayed by DHAD, its substrate promiscuity was exploited 
to confirm or deny activity. As DHAD also facilitates the conversion of glyceric acid to pyruvic acid, 
accumulation of pyruvate was monitored (section 5.9). Multiple batches of DHAD were tested to 
ensure the results obtained in section 5.8.2 were not due to a single batch anomaly. 2 batches of DHAD 
were tested, DHAD batch 1, which was snap frozen and stored at -80°C, DHAD from the same batch 
hereby referred to as batch 1a, which was stored at 4°C and DHAD batch 2 snap frozen and stored at -
80°C. 2 concentrations of DHAD were tested, 0.01mg/ml and 0.1mg/ml with 20mM glyceric acid as 
substrate at a reaction time of 1 hour. DHAD batch 1 and 1a were from the same original batch with 
the notable difference being their final storage conditions after protein purification and concentration. 
The highest pyruvate concentration was detected in 0.1mg/ml of DHAD from batch 1 (snap frozen and 
stored at -80°C for 5 months) which gave 9.55ng/µl of pyruvate. The same batch of DHAD stored at 
4°C for 5 months (DHAD batch 1a) assayed under identical assay conditions with 0.1mg/ml DHAD 






DHAD batch 1 DHAD batch 1a DHAD batch 2 Control 
no DHAD 
DHAD mg/ml 0.01 0.1 0.01 0.1 0.01 0.1 N/A 
Absorbance 570nm 0.06 0.6 0.01 0.13 0.01 0.09 0.00 
Pyruvate ng/µl 0.93 9.55 0.21 2.04 0.13 1.46 0.05 
Table 5.6. Analysis of pyruvate production using pyruvic acid assay kit from 2 different batches of DHAD and 
storage conditions. Standard deviation for all conditions= <0.02.  
 
This results in a 78% loss in relative activity of DHAD with the storage at 4°C in comparison to snap 
freezing and storage at -80°C. Similar observations were made by Carsten et al. 2015, who recommend 
that storage at -80°C is best only if DHAD cannot be prepared fresh and used immediately, as activity 
degradation was noted with prolonged storage at -80°C as well. This would explain the low pyruvate 
production seen in the assays performed with this batch (1.46ng/µl pyruvate), as the DHAD stored at 
-80°C in batch 2 was an even older sample and prolonged storage over time could have led to 
diminished activity.  
Using the gluconate and pyruvate detection kits confirmed the DHAD displaying activity, albeit poor 
levels of activity but enzyme functionality was established. Following on from this, the reasons for poor 
activity and ways to improve it were explored. Carsten et al. 2015 reported the purification of His-
tagged DHAD decreased the total enzyme activity to 43% of the crude extract and even further to 17% 
when stored at -80°C for one day. Ni-NTA purification is reported to severely diminish enzyme activity, 
imidazole elutions reported no measurable activity, leading to a complete elimination of DHAD activity 
towards gluconate. Buffer exchange of protein into another buffer would then be required to restore 
any % of initial activity. Nickel has been reported to strongly inhibit DHAD and reduce residual activity 
to 3% so diminished enzyme activity within the imidazole fraction could be due to the Ni-NTA 
purification associated with the entire protocol (Carsten et al. 2015, Kim and Lee 2006). Nickel ion 
leakage during Ni-NTA affinity chromatography and the higher concentrations of imidazole present in 
samples during purifications can be presumed to be the main contributor to diminished activity of His-
tag purified protein fractions.  
Carsten et al utilised a wildtype variant of DHAD without His-tag and employed heat treatment at 80°C 
as the only purification method. This methodology was adapted and crude DHAD lysate was purified 
using heat treatment only followed by centrifugation to remove host protein precipitates. Crude lysate 
was quantified using ImageJ scientific image analysis, the DHAD monomer and confirmed oligomers 
were calculated as a total % of the total sample giving % of DHAD in the crude lysate. This was an 
efficient method at isolating % protein present in the crude as image J was used to select entire lanes 
of samples run on SDS-PAGE and there was no subjective selection error associated with the analysis. 
Carsten et al reported the 2 methods of purification (Ni-NTA and heat treatment) and reported their 
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specific activities, which were 0.13 and 0.54U/mg for Ni-NTA and heat treated DHAD respectively. This 
leads to the conclusion that as the number of purification steps is increased, the activity levels 
decrease, as supported by Flint and Allen who describes an increased leakage of [Fe-S] cluster when 
more purification steps are performed (Flint and Allen 1996). Originally studied with DHAD isolated 
from spinach, a [2Fe-2S] cluster was suggested to be directly involved in catalysis as the reduction of 
the [2Fe-2S] cluster led to decreased enzyme activity by 6 fold (Flint and Emptage 1988), furthermore, 
DHAD has also been purified from Escherichia coli which contains a [4Fe-4S] cluster (Flint et al. 1993). 
Flint et al found an amino acid pattern that is unique for [2Fe-2S] cluster containing DHAD enzymes 
and based on the homology of the sequence, the same pattern was found within the S. solfataricus 
DHAD, leading to the assumption that the latter also contains a [2Fe-2S] cluster. Similarly to the results 
seen with DHAD when assayed for activity with gluconate and pyruvate (section 5.7-5.10), Carsten et 
al also reported low levels of DHAD activity. As the [2Fe-2S] has previously been suggested to have a 
direct catalytic role within DHAD purified from spinach, extending the same principle to DHAD from S. 
solfataricus utilised in this thesis, the problem of low activity levels could be due to an ineffective [2Fe-
2S] cluster supply during the expression of DHAD in E. coli. This however is most likely not the case as 
DHAD activity yield was attempted to be enhanced by the addition of additional FeSO4 (1-20mg/L)  to 
the expression medium to ensure excess ions are available to supplement DHAD active sites with [Fe-
S] clusters (Carsten et al. 2015). Excess ions availability in expression media did not affect overall 
expression or specific activity of DHAD expressed in in E. coli. From this it was concluded that there are 
either sufficient ferrous ions to load the catalytic sites of DHAD with an [Fe-S] cluster or the cluster 
assembly in E. coli works at its maximum efficiency and DHAD catalytic sites cannot be loaded with 
more functional [Fe-S] clusters.  
A reducing agent has been previously employed as an activation method to increase activity of other 
DHAD via possible [Fe-S] cluster repair, activation and/or stabilization following enzyme purification. 
The mechanism behind this activation is unknown but it is assumed that a reducing agent such as β-
mercaptoethanol is able to alter the [Fe-S] cluster’s oxidative state culminating in the active form of 
the cluster followed by removal of the reducing agent (Gottschalk and Bender 1982, Carsten et al. 
2015). Carsten et al studied apparent activation of [Fe-S] cluster with β-mercaptoethanol with S. 
solfataricus DHAD and reported an increased DHAD activity towards gluconate. This was only done 
with native DHAD without a His-tag, and Ni-NTA purified DHAD was not subjected to an activation 
protocol in the cited literature. The activation protocol was tested with Ni-NTA purified DHAD as 
outlined in section 5.11. Gluconic acid assay kits were utilised to monitor the depletion of gluconic acid 
in activated and non-activated DHAD assay conditions (control). Under the circumstances that the 
activation protocol indeed increased the DHAD activity towards gluconate, lower corresponding 
199 
 
450nm absorbance values would be recorded for the condition displaying the highest DHAD activity. 
The control for this assay were not sufficiently in range of the gluconate standards, however the 
absorbance values for the activated DHAD non-activated DHAD 0.1mg/ml assay conditions gave 
absorbance 450nm values of 0.438 and 0.456 leading to the conclusion that activation of DHAD using 
β-mercaptoethanol has no significant effect on improving activity within fractions of Ni-NTA purified 
DHAD. Nickel and imidazole could be irreversibly diminishing activity of Ni-NTA purified DHAD leading 
to the activation protocol being ineffective. 
Following unsuccessful experiments to establish higher levels of activity from the purified DHAD even 
after using an activation protocol, an approach was devised to use crude DHAD in an attempt to 
establish activity instead. As previously mentioned, Ni-NTA purification diminishes the activity of DHAD 
thereby cited literature protocols utilised heat treatment of crude DHAD as a method of purification. 
The activation protocol was repeated with crude heat treatment purified DHAD to establish if a DHAD 
sample not having undergone Ni-NTA purification is more susceptible to activation to give improved 
enzyme activity. The gluconic acid consumption in the activated crude DHAD and non-activated crude 
DHAD 0.1mg/ml were 8.506 and 7.804mM respectively (Table 5.9). In comparison, the most successful 
activation condition tested by Carsten et al reported an 2.5 fold increase in enzyme activity following 
activation with β-mercaptoethanol. To confirm the analysis obtained by gluconic acid assay, the 
samples were analysed via IC as well and the actual concentration of 2-keto-3-deoxygluconate was 
calculated from a standard curve. IC analysis confirmed the findings of the gluconic acid assay kit, 
whereby 6.772mM and 6.545mM of 2-keto-3-deoxyglcuonate was obtained from the activated crude 
DHAD and the non-activated crude DHAD respectively. With both analysis methods showing no 
significant difference between the activated and non-activated enzyme activity, this contradicts to 
what is reported in the literature. Due to differences in expression and possible media preferences 
(Auto-induction media), [Fe-S] clusters in our samples did not require or respond to 
repair/activation/stabilization. The batch to batch variation in crude DHAD preparations could also 
have led to improperly folded DHAD proteins causing the activation process to have a more significant 
effect on enzyme activity in some batches compared to others. 
As previously established, Ni-NTA-purified DHAD displays poor enzyme activity and the activation 
protocol with β-mercaptoethanol had no significant effect on the improvement of enzyme activity. It 
was also shown than activation protocol did not significantly affect crude DHAD activity either. 
Thereby, crude DHAD without any activation protocol was used to establish DHAD activity with any 
subsequent assays and kinetics analysis. Crude DHAD was used to analyse enzyme activity as outlined 
in section 5.13. 2 and 20mM of gluconic acid were tested with various DHAD concentrations at 3 time 
points, all end reactions were deproteinized and analysed for gluconic acid depletion with gluconic 
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acid assay kit. The data for both substrate conditions indicated positive DHAD activity, 2mM of gluconic 
acid was all consumed when analysed at 30 minutes at all DHAD concentrations tested (1, 2.5 and 
5mg/ml). 20mM gluconic acid condition showed increased gluconic consumption with the higher 
DHAD concentration consuming more gluconic acid with increasing time. The gluconic acid assay kit 
application became difficult to utilise with higher concentrations of gluconic acid under assay 
conditions, given the high error factors involved with dilution of samples. In the gluconate detection 
kit, gluconate is utilized by gluconokinase to form gluconate-6-phosphate and ADP, producing a 
coupled enzyme reaction that generates a colorimetric signal  at 450 nm, proportional to the amount 
of gluconate present and the assay is sensitive to less than 2 µM of gluconate. As it is a coupled enzyme 
reaction, assay components could potentially be contributing to absorbance readings, also it does not 
give a direct measure of the amount of 2-keto-3-deoxygluconate produced during the reaction. Using 
the IC mitigates these issues and allows for direct visualization of product formed and its subsequent 
quantification. Although both methods of activity analysis for DHAD have their own advantages and 
disadvantages, ultimately, IC analysis is a better option as it offers analysis of a wider range of gluconic 
acid concentrations and direct detection and quantification of 2-keto-3-deoxygluconate.  
Kim and Lee have reported DHAD activity towards its natural substrate to be 47U/mg (Kim and Lee 
2006), and this is very high compared to other DHAD’s. A possible reason for this could be in the 
detection method employed by Kim and Lee, whereby a semicarbazide based method was employed 
where the dehydration reaction is quantified by measuring the absorption of semicarbazone with a 
ketoacid at 250nm. The issue is that at this wavelength, crude cell extract components such as DNA 
and proteins show high absorption, therefore there is a high likelihood of quantifying false positives 
leading to a high specific activity determination (Carsten et al. 2015). Km values in the range of 2.42mM 
(determined at 80°C)  and 7.8mM (determined at 50°C) by DHAD have been reported towards D-
gluconate by Kim and Lee and Carsten et al, respectively. Kim and Lee have reported the highest Km to 
be at 80°C which falls in the optimal range for the native organism, S. solfataricus. The DHAD employed 
by Kim and Lee underwent Ni-NTA affinity chromatography followed by size exclusion 
chromatography. As Ni-NTA purification was later reported to lower enzyme activity, this could 
potentially be increasing the Km value due to lowered substrate affinity caused by catalytic site 
inefficiency. Without the activation protocol, Carsten et al reported specific activity of 0.13U/mg for 
Ni-NTA purified DHAD, increasing to 0.54U/mg for heat treatment purified DHAD. The enzyme 
preparation used by Carsten et al was desalted into reaction buffer using an ÄKTA system, presumably 
the impurities present in that sample were reduced in comparison to the crude enzyme preparation 




9.4 Production, purification and characterization of KDGA 
Archaea exhibit a complex carbohydrate metabolism in which glucose is utilized through several 
branches of the Entner-Doudoroff pathway and KDGA is a unique enzyme in the pathway. In the 
common part of the branches Entner-Doudoroff pathway, glucose is first oxidized to gluconate by GDH 
followed by the dehydration of gluconate to 2-keto-3-deoxygluconate by DHAD. In the non-
phosphorylative branch of the Entner-Doudoroff pathway, 2-keto-3-deoxygluconate is then reversibly 
cleaved by KDGA into pyruvate and glyceraldehyde (Kouril et al. 2012). KDGAs from thermophilic 
sources showcase high thermostability and activity on non-phosphorylated substrates which makes 
them high potential candidates for biocatalysts in the industrial applications (Schurink et al. 2014). 
GDH, DHAD and KDGA utilised as the first 3 enzyme in the cascade featured in this thesis have been 
modelled on the non-phosphorylative branch of the Entner-Doudoroff pathway. This pathway has 
been reported for the hyperthermophilic archaea S. solfataricus, Sulfolobus acidocaldarius and 
Thermoproteus tenax amongst others (Ahmed et al. 2005, Selig et al. 1997). The GDH and DHAD utilized 
in the cascade are from S. solfataricus, however KDGA has been sourced from S. acidocaldarius. A 
minimized reaction cascade as reported by Guterl et al. 2012, utilized the enzymes derived from 
hyperthermophilic archaea from a modified non-phosphorylative Entner-Doudoroff pathway, 
whereby GDH and DHAD were sourced from S. solfataricus and KDGA from S. acidocaldarius. Noting 
that both of these organisms are hyperthermophilic and from the Sulfolobus family, the reasoning for 
this change was not commented upon by Guterl et al. As the cascade reported by Guterl et al was a 
huge step forward in the development of minimized cascades, the same experimental strategy as 
Guterl et al was adapted for the cascade design outlined in this thesis.  
Glyceraldehyde-3-phosphate has been reported to be the best reacting substrate for S. solfataricus 
KDGA, with the non-phosphorylated analogue of glyceraldehyde-3-phosphate having a 38% reaction 
as that of phosphorylated analogue (Ahmed et al. 2005). BLAST analysis with the KDGA of S. 
solfataricus showed high homology with KDGA from S. acidocaldarius, on the basis of which KDGA 
from S. acidocaldarius was expected to have similar activity with pyruvate and glyceraldehyde as KDGA 
from S. solfataricus (Wolterink-van Loo et al. 2007). Wolterink-van Loo et al. 2007 tested 2 KDGAs from 
the Sulfolobus family (S. solfataricus and S. tokodaii) and compared their characteristics to the KDGA 
from S. solfataricus. Activity of KDGAs was assayed in the synthesis direction of 2-keto-3-
deoxygluconate, utilizing pyruvate and glyceraldehyde and it was reported that the 2 tested KDGAs 
had activity in the same range as that of S. solfataricus. Biochemical data comparisons between the 
three KDGAs from the Sulfolobus family highlighted the differences between them. KDGA from S. 
acidocaldarius displays higher specific activity towards both reaction substrates (pyruvate 26.3U/mg 
and glyceraldehyde 33.1U/mg) when compared to KDGAs from S. solfataricus (pyruvate 15.7U/mg and 
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glyceraldehyde 17.1U/mg) and S. tokodaii (pyruvate 17.8U/mg and glyceraldehyde 20.3U/mg) 
(Buchanan et al. 1999, Wolterink-van Loo et al. 2007). This could potential be reasoning for utilization 
of KDGA from S. solfataricus as the KDGA of choice for integration into the cascade by Guterl et al. 
2012. However, all biochemical data gathered on the activity of KDGA from various organisms of the 
Sulfolobus family is in the synthesis direction of 2-keto-3-deoxygluconate.  
At the time of writing, Guterl et al are alone to have reported KDGA activity analysis followed in the 
cleavage direction using 2-keto-3-deoxygluconate as substrate, however this only seems to have been 
achievable with the addition of pyruvate decarboxylase to the activity assay which catalyses the 
conversion of pyruvate to acetaldehyde. As pyruvate is one of the two products obtained from the 
cleavage of 2-keto-3-deoxygluconate, its removal from the reaction equilibrium should theoretically 
be pushing the reaction forward towards the cleavage direction. From the KDGA activity experiment 
performed in section 6.6, there was no secondary enzyme or removal method to facilitate the removal 
of either pyruvate or glyceraldehyde formed from the cleavage reaction, thereby the reaction 
equilibrium seems to have stayed at its preferred equilibrium with the control and assay conditions 
showing no significant differences in concentrations when analysed via IC (Figure 6.5). This activity 
assay was not run at optimal reaction conditions, due to reasons discussed in section 6.5, commercial 
2-keto-3-deoxygluconate was not utilized for activity analysis of KDGA as it is not commercially 
favourable due to limited quantities available for purchase. 2-Keto-3-deoxygluconate was instead 
synthesised in the lab with the utilization of DHAD which catalyses the conversion of gluconate to 2-
keto-3-deoxygluconate. However, due to protein degradation issues resulting from storage of the 
batch of DHAD utilized in the large scale reaction to produce 2-keto-3-deoxygluconate, the resulting 
reaction mixture consisted of a 50/50 split of the substrate, gluconic acid and product, 2-keto-3-
deoxygluconate. The presence of gluconic acid in the reaction mix could potentially have inhibitory 
effects on the cleavage of 2-keto-3-deoxygluconate, however this has not been reported in related 
literature of minimized cascades which have utilized similar enzymes.  
Characterization of KDGA activity analysis has been reported to be done with 20mM glyceraldehyde 
and 50mM pyruvate (Buchanan et al. 1999, Wolterink-van Loo et al. 2007) and as the theoretical 
reaction ratios are 1:1, the effect of altered substrate ratios were explored on the final product yield 
and also to understand the rationale behind using said ratios for activity analysis. The standard 
substrate concentrations modelled on the KDGA activity assays run in previous literature were 
modified to be 10mM glyceraldehyde and 20mM pyruvate as tested in section 6.8.2. Substrate ratios 
of 10mM glyceraldehyde and 20mM pyruvate were used as assay control and a further 2 substrate 
ratios were tested; 20mM glyceraldehyde + 20mM pyruvate (1:1 substrate ratio) and 20mM 
glyceraldehyde + 10mM pyruvate (reverse ratio of the standard assay condition). Analysis of the 
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product formed (2-keto-3-deoxygluconate) showed that the product yield is in similar concentrations 
to the conditions where the substrate concentration ratio is 1:2 (10mM:20mM) with respect to either 
pyruvate or glyceraldehyde. Either one or the other is not required to be in excess and is not capable 
of giving a higher final yield of product (Table 6.5). Assay condition with 10mM glyceraldehyde + 20mM 
pyruvate gave a final yield of 8.34mM of 2-keto-3-deoxygluconate whereas assay condition with 20mM 
glyceraldehyde + 10mM pyruvate gave a final yield of 7.9mM of 2-keto-3-deoxygluconate. The 
experimental condition where the concentration of both glyceraldehyde and pyruvate was the same 
(20mM glyceraldehyde + 20mM pyruvate) gave a final yield of 13.1mM under the same assay 
conditions as previously mentioned. Given the theoretical yield maximum has not doubled as 
calculated when compared to the previous conditions, increasing the substrate concentrations ratios 
to be equal was determined to be waste of resources and therefore was not adapted for any further 
assays performed.  
KDGA from thermophilic sources is a unique enzyme with the potential of large industry applications. 
Its unique metabolic properties and substrate promiscuity make it ideal for applications in catalysis of 
phosphorylated and non-phosphorylated chemicals. Paired with its wildtype preceding enzymes GDH 
and DHAD from the Entner-Doudoroff pathway, KDGA forms the industrially valuable platform 
chemical pyruvate which can be paired with further downstream artificial enzyme cascades to obtain 
higher value chemicals.  
9.5 Improving yields of refolded AIDH from inclusion bodies 
GDH, DHAD and KDGA are enzymes derived from the naturally occurring non-phosphorylating branch 
of the Entner-Doudoroff pathway functioning in multiple thermophilic archaea (Ahmed et al. 2005). 
The next enzyme to follow in the non-phosphorylating branch of the pathway is glyceraldehyde 
dehydrogenase (AIDH) (Ahmed et al. 2005, Ettema et al. 2007, Reher and Schönheit 2006) . KDGA 
cleaves 2-keto-3-deoxygluconate into pyruvate and glyceraldehyde, and while pyruvate is a key 
intermediate in the cascade design outlined in this thesis, the second product of cleavage, 
glyceraldehyde, is not. Guterl et al proposed a solution to this by utilizing the natural fourth enzyme 
to redirect the glyceraldehyde towards pyruvate formation. This was achieved by the addition of a 
thermophilic AIDH from Thermoplasma acidophilum, which facilitates the conversion of 
glyceraldehyde to glycerate, the latter is then redirected towards pyruvate formation courtesy of the 
substrate promiscuity displayed by DHAD. The removal of glyceraldehyde from the reaction 
equilibrium of DHAD also pushes reaction equilibrium forward in the direction of pyruvate formation. 
Previous literature has established protein characterization and biochemical properties of AIDH from 
multiple hyperthermophilic sources including Picrophilus torridus, S. solfataricus and T. acidophilum. 
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The analysis from these has shown inconsistencies between findings relating to the same protein. 
AIDHs purified from P. torridus, T. acidophilum and S. solfataricus have all been reported to display 
negligible activity with NAD+ (Ettema et al. 2007, Reher and Schönheit 2006). The design of the cascade 
outlined in this thesis is dependent on the usage of NAD+ as cofactor as the other enzymes in the 
cascade were designed to be NAD+/NADH dependent, thereby the AIDH to be utilized in the cascade 
was required to accept NAD+/NADH as a cofactor. On the contrary, it has been reported that the AIDH 
from T. acidophilum to accept NAD+ as a cofactor under technically relevant conditions whereby the 
cofactor concentration is <1mM (Steffler and Sieber 2013), this supports the utilization of AIDH in the 
current cascade design for the production of malic acid where NAD+/NADH are the only utilized 
cofactors. Albeit, all three AIDHs from P. torridus, T. acidophilum and S. solfataricus are reported to 
show strong substrate specificity for glyceraldehyde (Ettema et al. 2007, Reher and Schönheit 2006, 
Steffler and Sieber 2013) which makes them attractive for utilization in minimized cascades in case 
there are other aldehydes intermediates, which must not be the target for oxidation by AIDH.  
Previously, expression and purification of AIDH from T. acidophilum has been reported as standard. 
Recombinant T. acidophilum was obtained as a His-tagged protein after expression in LB broth using 
IPTG. Crude AIDH lysate was purified via Ni-NTA affinity chromatography and the protein was eluted 
via an imidazole gradient however no yield information was provided (Reher and Schönheit 2006). On 
an attempt to replicate Ni-NTA purified AIDH, we were also able to recover some soluble protein 
(Figure 7.2), which was further positively identified as the protein of interest via mass spectrometry 
analysis. However, before any positive confirmation of activity could be attempted, the protein 
fraction aggregated following imidazole removal during the protein concentration process. Contrary 
to soluble protein recovery of the other proteins featured in the cascade design, the amount of AIDH 
soluble protein recovered was low. The efficiency of AIDH soluble protein recovery could not be 
compared to that reported by Reher and Schönheit (2006) as no yield information was provided. Our 
findings are consistent with those reported by Steffler and Sieber, who also reported very small 
amounts of AIDH in the soluble form. Based on our observations and experimental data, band 
intensities around the size of AIDH were low in comparison to  supported by the report of Steffler and 
Sieber, we concluded that the majority of the protein produced was formed as inclusion bodies. A 
protocol was developed for the refolding of AIDH found in the inclusion bodies whereby guanidine 
hydrochloride (GdnHCl) and dithiothreitol (DTT) were utilized in a simplified denaturation buffer 
methodology (section 7.2.2.1). The cell pellet obtained following the sonication, heat treatment and 
centrifugation during the soluble fraction preparation was processed downstream for AIDH inclusion 
bodies so both of the soluble and insoluble purifications were carried out on the same batch of culture. 
The simplified denaturation buffer consisting only of GdnHCl and DTT was used to unfold the protein 
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and 2 methods of refolding the protein were explored. Firstly, while in its denatured state, AIDH was 
bound to Ni-NTA resin, followed by standard column affinity chromatography, and secondly the 
denatured AIDH solution was dialysed against buffer. With the first strategy, the gradual removal of 
denaturation buffer during the washing of the Ni-NTA resin and reintroduction of standard buffer 
conditions during washes and imidazole elutions promotes refolding of the protein to its native 
structure, while the salt promotes proteins stability. This was successfully achieved as demonstrated 
by SDS-PAGE analysis of Ni-NTA purification attempt of AIDH inclusion bodies following extraction with 
GdnHCl (Figure 7.3). The recovery of some soluble AIDH mentioned earlier and insoluble AIDH were 
both analysed via SDS-PAGE and the suspected oligomers were all positively confirmed to be AIDH 
from T. acidophilum via mass spectrometry analysis.  
Refolding insoluble AIDH on the affinity column proved to be a more successful strategy in comparison 
to utilizing dialysis for the same purpose. Heavy aggregation was observed in the first cycle of dialysis 
(Figure 7.4) carried out to remove the GdnHCl and DTT from the protein solution, again with the 
understanding the removal of the denaturation components would promote refolding of the extracted 
protein to its native state. Following the heavy aggregation seen in the dialysis tubing, the aggregated 
suspension was centrifuged to isolate aggregates from solution. A subsequent SDS-PAGE analysis of 
the supernatant displayed a significant band matching the size of AIDH (Figure 7.5), indicating very low 
quantities of soluble protein salvaged. However, in comparison to the method of refolding denatured 
AIDH with Ni-NTA affinity chromatography, the dialysis method is prone to containing a lot of non-
specific host proteins. Given the dialysis protocol could be optimized and protein aggregation during 
refolding of denatured AIDH could be prevented, the non-specific proteins would still require removal 
via Ni-NTA affinity chromatography. This concludes the dialysis step to be moot as binding denatured 
AIDH to Ni-NTA facilitates the refolding of AIDH and the removal of non-specific protein in one single 
step.  
The failure of dialysis has multiple contributing factors and a combination of these have presumably 
contributed to the multiple failures observed. The presence of cysteines in protein sequence has been 
reported to contribute towards aggregation of proteins (Ramkumar et al. 2018) and require the 
additions of reductants such as DTT to compensate. The denaturation buffer containing AIDH in its 
denatured state was supplemented with DTT and thereby this theoretically should have mitigated any 
aggregation due to cysteine residues. Depending on the concentration of the protein present in the 
sample, high salt is another requirement for the protein to remain in solution. 200mM of MgCl2 was 
added to the dialysis buffer and this was not sufficient as heavy aggregation was seen in the dialysis 
tubing. Possibly higher concentrations of MgCl2 could be experimentally tested to determine if 
aggregation levels can be reduced. The temperature of dialysis conditions can also contribute towards 
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protein aggregation (Yamaguchi and Miyazaki 2014) as some proteins, during refolding, can aggregate 
if the dialysis buffer is exchanged too quickly. Low temperatures can be utilized to slow down the 
dialysis process and prevent aggregation. This was testing by repeating the dialysis process at different 
temperatures (room temperature and 4°C), however it failed to prevent aggregation and visually there 
was no difference in the amount of aggregates observed in both conditions. Some success was 
achieved with step wise dialysis but only with protein fractions with low concentrations. Given that we 
had previously successfully displayed recovery of insoluble AIDH via binding to Ni-NTA and elution with 
imidazole, removal of denaturing buffer via dialysis and attempted refolding of AIDH was not trouble-
shot any further.  
Further attempts at refolding denatured AIDH extracted from inclusion bodies was optimized for yield 
purposes. Inclusion bodies contain very little host protein and are a potential pure source of the 
desired recombinant protein (Ramon et al. 2014). However the inclusion bodies need to extracted 
from the cell lysates as they are heavily contaminated with host cellular components, which can be 
removed by selectively extracting with detergents and low concentrations of chaotropic agents. 
Following the proper extraction of inclusion bodies from cell lysates results in a significant purification 
of the recombinant protein (Palmer and Wingfield 2004). The recombinant protein in the inclusion 
bodies can thereby be solubilised and refolded into native structure proteins and optimistically be 
biologically active. We adapted these strategies into our resolubilisation protocol and achieved the 
typical white inclusion bodies pellet indicative of a pure inclusion bodies pellet free of any host cellular 
components (Figure 7.12). The biggest issue faced during the modified attempts to increase recovery 
yield of AIDH was the AIDH not binding sufficiently to the Ni-NTA. Through consistent attempts, a high 
intensity band was observed at the expected size of AIDH in SDS-PAGE analysis while unsuccessfully 
attempting to bind and later elute protein via imidazole. During these failed attempts of binding AIDH 
to Ni-NTA, dialysis was explored again as an option. AIDH aggregates from unsuccessful dialysis 
attempts were attempted to be dialysed into urea to evaluate if the change in chaotropic agents makes 
dialysis more likely to succeed. Step-wise dialysis was explored where the concentration of urea was 
reduced to 5M from the original 8M which this was a successful cycle with no aggregation seen in the 
dialysis tubing. The second cycle of dialysis whereby the concentration of urea was reduced to 2M 
from 5M was not successful and protein aggregates were observed in the dialysis tubing.  
The unsuccessful binding of AIDH in its denatured state to Ni-NTA was a persistent issue as a lot of 
AIDH recovered from the inclusion bodies was being lost in the flow through during Ni-NTA affinity 
chromatography leading to very low yields in terms of soluble protein recovery. Primary factors 
suspected of decreasing binding efficiency were tested to rule them out, different batches of Ni-NTA 
resin were used to ensure the resin was fully charged for successful binding; resin amount, binding 
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times and binding temperatures were explored and after concluding there was no significant 
difference made to the binding efficiency, further troubleshooting was attempted. A main reason for 
His-tagged fusion proteins not binding to metal affinity chromatography resin is the inaccessibility of 
the tag as it could potentially be buried inside the protein’s three-dimensional confirmation in its 
native folded state. The inaccessibility of the tag can be experimentally determined via binding the 
protein in the presence of denaturants such as GdnHCl or urea (Clark 1998) and if the binding is 
successful, then it indicates that the protein folding is to blame.  As we were trying to bind our protein 
to Ni-NTA resin under denaturing conditions already, a western blot was performed to analyse the 
efficiency of the His-tag which confirmed the presence of a functional His-tag (Figure 7.19). Standard 
protocols and general lab practices are known to utilize the addition of a small amount of imidazole to 
the binding buffer in order to inhibit binding of non-specific proteins, however an excess amount can 
inhibit binding  as the imidazole could potentially outcompete the tag for metal binding. This was also 
ruled out as a potential cause of unsuccessful binding of denatured AIDH to Ni-NTA as no imidazole 
was added to the binding buffers in any attempts. The AIDH protein construct was also designed to 
contain a serine-glycine linker to separate the tag from the protein, which thereby essentially exposes 
the tag and prevents it being buried (Chen et al. 2013). The ability of the His-tag to bind coordinate 
with the Ni-NTA was also explored as a probable cause for impaired binding, as at low buffer pH, 
protonation of the histidine side chains can impair the binding of histidine to nickel (Bornhorst and 
Falke 2000). This was examined and the pH of the buffer was monitored to ensure it stayed within 
buffering range. Imidazole can also lower the pH of a buffer, therefore a buffered stock of imidazole 
was used as well, ruling it out as the probable cause for unsuccessful binding of AIDH in its denatured 
state to Ni-NTA. Following several attempts of optimizing the washing, extraction and purification of 
AIDH from inclusion bodies, the overall soluble protein recovery yield was not significantly improved, 
the issues with unsuccessful binding of AIDH in the denatured state and aggregation of any recovered 
AIDH remained unsolved.  
It was hypothesised that the success of soluble AIDH recovery in the original attempt (section 7.2.2.1) 
could potentially be due to the simplified nature of the extraction and purification of inclusion bodies. 
The extraction of the inclusion bodies in the initial attempt was not accompanied by extensive washing 
of the pellet with detergent, reducing agent, chelating agent and denaturant, thereby the eventual 
inclusion bodies pellet exposed to high denaturing conditions did not exclusively consist of pure 
inclusion bodies, but also contained host cellular components. The presence of these components cold 
have potentially prevented protein-protein self-interactions and reduced the chance of aggregation. 
Impartial extraction of AIDH from the inclusion bodies could have led to lower concentrations of AIDH 
binding to Ni-NTA. Moreover, Ni-NTA affinity chromatography is high capacity but low specificity, so, 
208 
 
often using nickel to purify His-tagged proteins leads to the co-purification of contaminants (Porath 
1992). The inclusion bodies protocols were modified and optimized based on multiple 
recommendations in literature and was trouble shot to identify and rectify the potential issues casing 
the problem. However, no significant advances were achieved. Further experimental work with 
modified purification strategies could provide a potential solution to the issue at hand. There are a 
variety of affinity tags available for protein purification purposes and individually they can vary 
significantly in purity, yield and cost (Lichty et al. 2005), a change in tag could offer more success in the 
purification and subsequent soluble protein recovery. 
The initial attempt made at refolding unfolded AIDH on the Ni-NTA affinity column was successful and 
AIDH recovered from inclusion bodies was successfully buffer exchanged to remove imidazole, GdnHCl 
and DTT to negligible amounts. 1.27mg/ml of AIDH was obtained in 100mM HEPES pH 7.5, 10% 
glycerol, 200mM MgCl2 buffer. The enzymatic assay for confirmation of positive enzymatic activity 
highlighted an issue with the control condition. Without the presence of AIDH, an increase in the 
absorbance values at 340nm was absorbed over time which indicates the formation of NADH.  Further 
experimentation with the control reagents and isolation suggested the breakdown of the substrate 
aldehyde to carboxylic acid providing the required electrons for the formation of the carboxylic acid. 
Activity measurements via analysis at 340nm was not an efficient method to follow the reaction as it 
is an indirect measurement by following the concomitant reduction of NAD+ to NADH. Due to 
unavailability of IC analysis at the time of the experiment this could not be done. Ideally this reaction 
would be efficiently analysed via IC, whereby the product formation can be monitored and quantified 
by subsequent peak selection. However, there was a substantial difference in absorbance values 
between the assay and control conditions which was taken as confirmation of functional activity. AIDH 
offers a valuable addition to the overall design of the cascade as it facilitates the conversion of an 
unwanted intermediate towards a central valuable intermediate. Possible change of tag and/or 
expression vector could be explored further to either optimize soluble expression of AIDH or to 
improve purification of AIDH from inclusion bodies.  
9.6 Production, purification and characterization of MDH, coupled with GDH 
Wildtype NADP(H)-dependent malate dehydrogenase (MDHwt) from the thermophilic archaeon 
Thermococcus kodakarensis, catalyses the HCO3- independent reductive carboxylation of pyruvate to 
malate with lactate as a by-product, presenting itself suitable for application as the final enzyme in our 
cascade design. A suitable enzyme for application in the cascade design was presented in the form of 
engineered MDH from T. kodakarensis whereby a triple mutant was identified via directed evolution 
(Morimoto et al. 2013). Directed evolution was carried out with the MDH in reference to alter its 
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cofactor preference from NADP(H) to NAD(H). A triple mutant was thereby identified which exhibited 
the desired properties; it exhibited a 6-fold higher kcat/km with NAD+ than the wildtype and in addition 
to the change in cofactor preference, it was also serendipitously reported that the reaction specificity 
of the mutant was significantly shifted towards malate production and it also gave less by-product in 
comparison to the wildtype. Using the triple mutant MDH (hereby referred to as MDH) to catalyse 
pyruvate carboxylation with NADH, 1.2 times higher malate concentrations were achieved than the 
wildtype MDH with NADPH (Morimoto et al. 2013). This MDH was therefore the ideal candidate to 
catalyse the conversion of pyruvate to malate as due to the altered cofactor preference from NADPH 
to NADH, the cofactor recycling is possible within the closed reaction environment. 
Activity analysis of MDH via equilibrating reaction components with CO2 prior to addition of substrate 
was not a well-designed experiment, the dissolved CO2 was only equilibrated at the start of the 
reactions, followed by incubation of the sealed reaction vials at the reaction temperature. This method 
of activity analysis did not provide an efficient method for this as the reaction vials were not leak-proof 
and without constant regulation of CO2 levels, eventually the carbonate levels in the assay mixture 
would reach equilibrium. Furthermore, the solubility of CO2 in water decreases with increases in 
temperature (Carroll et al. 1992, Crovetto 1991, Prini and Crovetto 1989), thereby the decrease in 
carbonate levels dissolved in liquid is accelerated. Given that the experimental parameters could not 
be controlled, the series of MDH activity analysis experiments performed in section 8.5-8.10, were not 
taken under consideration, given the nature of the flawed experimental designs.  
The atmospheric control unit provided an excellent solution to the problems faced in experimental 
design prior to its use. There are 3 independent variables affecting reaction parameters of MDH, % of 
O2, % of CO2 and temperature. The earlier experiments (section 8.5-8.10) were performed in 5ml glass 
vials with seal caps. Given the container used, the suitable incubation methods for reaction duration 
included either a water bath or an incubator, both of which vary in their incubation efficiencies due to 
one offering an option to shake the containers while the other not having that option. As discussed in 
the last paragraph, the issues with CO2 level control occur in both incubatory conditions. As the 
atmospheric control unit is designed to be utilized with the plate reader, which itself is fitted with 
temperature control in the chamber with ability to incubate up to 65°C, all variables of the assay could 
be controlled and monitored. Real time absorbance readings also allowed for the reaction progression 
to be monitored and the indirect product formation to be followed. All reaction variables could then 
be objectively controlled and their monitoring was done under high levels of confidence, the reaction 
parameters were optimized to identify the optimum reaction conditions. The optimization was done 
via Box-Behnken design (Table 8.4) and response methodology (Figure 8.15), Box-Behnken is good 
design for response surface methodology as it permits the estimation of the quadric model 
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parameters, sequential design building, detection of the lack of lack of fit of the model and finally, the 
use of blocks (Bezerra et al. 2008, Ferreira et al. 2007). The application of Box-Behnken designs for 
optimization of analytical methods has wide applications and has been utilized for optimizations for 
industrial to pharmaceutical applications (Campone et al. 2018, Diaz-Dinamarca et al. 2018, GilPavas 
et al. 2018).  
Biocatalysis contributes to global goals of sustainable chemical processing however its practical 
application can be limited due to dependence on cofactors, which can be expensive (Wang et al. 2017). 
Many enzymatic redox reactions require the use of one or more cofactors that are utilized during the 
reaction (Bornscheuer et al. 2012) and their supply is not economically favourable, thereby an effective 
system of cofactor regeneration is required of practical large-scale application of enzymatic reactions 
(Wang et al. 2017). GDH along with formate dehydrogenase (FDH) are the two most widely used 
enzymes for cofactor recycling in industrial/commercial processes, with GDH from the Bacillus species 
showing the highest activity and stability, leading to its wide applications in industry (Hollmann et al. 
2011). Consequently, the pairing of MDH with GDH to test cofactor recycling was anticipated to be an 
efficient system and utilizing GDH as the cofactor recycling system mimicked commercial processes 
whereby this class of enzymes are the optimal choice for the purpose of cofactor recycling. Although 
there are other methods of cofactor NAD(P)H regeneration, for example, chemical regeneration, 
homogeneous catalytic regeneration and electrochemical regeneration; cofactor regeneration using 
enzymes is the only method industrially employed despite it also having setbacks. Water soluble by-
products formed require costly downstream processing and can cause deactivation of enzymes, 
enzyme instability and can involve complex product separation and purification (Wang et al. 2017). 
Use of thermophilic enzymes has the potential to alleviate some of these setbacks, notably those 
relating to enzyme instability and costly enzyme production/purification as thermophilic proteins offer 
the advantage of single step heat purification as we have demonstrated.  
For a successful coupled reaction system, any potential effects of the reaction reagents of GDH (acting 
as the regeneration enzyme) on the activity of MDH (the production enzyme) were tested. The highest 
reduction in MDH enzymatic activity was caused by the decrease in HEPES buffer concentration from 
the standard 500Mm HEPES in MDH assays to 100Mm HEPES in GDH assays, where the activity of MDH 
was reduced by 20% (Figure 8.17). Higher stabilization capacity is offered by higher concentrated 
buffer system, but majority of enzymes accept only moderate ionic strength, ranging commonly 
between 50-200Mm. This is not the case for thermophilic enzymes which prefer higher buffer 
concentration up to 1M (Vieille and Zeikus 2001), the decrease in activity can be attributed to the 
reduction in buffer strength, which along with any added components can reduce obligatory enzyme 
activity (Bisswanger 2014). Aside from HEPES, the addition of other GDH assay components such as 
211 
 
MgCl2, glycerol and GDH substrate glucose, did not reduce MDH activity by any more than 10% (Figure 
8.17). MDH activity assay are required to be carried out under 15% CO2 and 5% O2 atmospheric 
conditions, therefore GDH activity was assayed under atmospheric conditions required by MDH and 
activity levels of GHD were measured by the concomitant production of NADH from the oxidation of 
glucose to gluconate. After 60 minutes, there was no significant difference between the amount of 
NADH produced by GDH assayed under aerobic conditions and GDH assayed under atmospheric 
control (Figure 8.18). From these findings, it was concluded that GDH is a suitable cofactor recycling 
partner and its reaction components do not drastically inhibit the activity of MDH and GDH is capable 
of its role under altered atmospheric conditions as per the requirements of MDH. 
For a fully feasible cofactor recycling coupling, the assay components of MDH were also tested on the 
activity of the GDH under atmospheric conditions. This experiment demonstrated the drastic effect of 
pyruvate on the activity of GDH where it was almost completely diminished at only retained 3.3% of 
its relative activity (Figure 8.19). This loss of activity was determined to be due to competitive inhibition 
of GDH by pyruvate as concentrations of +10mM pyruvate reduce GDH activity by ~60% and a 2-fold 
increase in pyruvate concentration increased the km value 6-fold (Table 8.8). 30mM of pyruvate and 
30mM of glucose were then employed as compromised concentrations to mitigate the issue of GDH 
inhibition by pyruvate. Considering all the optimizations and substrate inhibition issues, cofactor 
recycling was successfully displayed when using NAD+ or NADH as cofactor in the presence of both GDH 
and MDH (Table 8.9). Further optimization regarding the separation of the products can be explored 
further in an attempt at potentially commercializing this process. As outlined earlier, there are 
numerous pitfalls of enzymatic cofactor regeneration system including costs associated with enzymes 
(Wang et al. 2017). However, in large scale industrial operations, enzymatic cofactor regeneration is 
still preferred as it offers high activity and mild operating conditions (Presecki et al. 2007). 
Immobilization of the coupled enzymes provides a possible solution to the issues linked with enzyme 
cost, recyclability and stability (Kumar et al. 2017, Mission et al. 2015), thereby immobilized enzymes 
are utilized in industry for catalyst recycling (Sheldon and van Pelt 2013) and offer advantages of both 
economy and sustainability.  
9.7 Overall conclusions 
This thesis has described a cofactor balanced, cell-free, 5 enzyme biosystem for the sustainable 
production of malic acid from glucose. All 4 objectives of this project have been fulfilled whereby: (i) 
an enzymatic cascade was designed to convert glucose to malic acid, (ii) With the exception of AIDH 
which was obtained in low yields, GDH, DHAD, KDGA and MDH were successfully produced and 
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purified, (iii) the successfully produced enzymes were characterized and finally, (iv) enzyme 
immobilization was investigated in detailed with GDH and a novel support.   
GDH immobilized onto a novel, hierarchically-structured macroporous-mesoporous silica support 
showed great potential for gluconic acid production from glucose as well as bread waste hydrolysate. 
Hierarchically porous MM-SBA-15 showed better immobilization efficiency than commercial supports. 
Moreover, GDH immobilized onto these materials showed excellent reusability. The use of GDH 
immobilized onto hierarchically-structured supports has the potential to be incorporated into next 
generation bio-refineries and waste valorization studies. GDH and MDH were also successfully coupled 
together and demonstrated cofactor recycling, showing potential for applications into a feasible cell-
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11. Chemoxy placement report 
Being supported by a BBSRC iCASE studentship which is co-sponsored by Chemoxy, as part of my 
studentship, I was to spend some time of my PhD at Chemoxy. 
The aim of this placement was to become familiar with industrial processes, their setup, planning and 
execution on a larger scale in comparison to academic research. Since Chemoxy mainly serves as a 
contract manufacturer, the projects coming into the research and development department vary in 
their nature, duration, and analysis techniques etc. Customers could have requested a certain amount 
of a chemical and R&D would then carry out the reaction on a smaller scale, identify and optimize any 
productivity issues before the reaction can be approved for production on a plant scale. Chemoxy also 
have their own line of performance products which are also developed and optimized for large scale 
production by the R&D department. Occasionally there is developmental analysis carried out on 
established products to serve either as further optimization or when the product faces external 
analysis. During this placement, 2 custom products were produced via esterification followed by 
distillation on a small scale to optimize production conditions and carry out yield analysis for 
production on plant scale. These two products are n-butyl propionate and di-n-propyl malate. Both of 
these esters are chemically valuable to industry due to their varied uses as platform chemicals and 
subsequent applications into a range of industries.  A Chemoxy performance product was also 
separated into its 3 main components for new blending analysis in another project (data not shown as 
it is a straight forward distillation to separate components and then blend them in different ratios for 
external testing).  
11.1 Introduction 
Chemoxy is a large independent contract manufactures based at two sites in the UK, with the 
Middlesbrough site carrying out distillations since 1868 and the Billingham site added in 1994. The 
company has 3 main activities, custom processing solutions, solvent recovery and performance 
products. They manufacture a range of environmentally friendly solvents which are used in the latest 
generation of paints and cleaning products. They serve a diverse range of industries to include specialty 
chemicals, petrochemicals, oil and gas, fuel and lube additives, household and personal care, flavour 
and fragrance, agricultural chemicals and surface coatings (Chemoxy 2018).  
11.1.1 Custom Processing  
Chemoxy’s core activity is custom processing which allows them to combine their versatile reactors 
with the distillation capabilities. Efficiency can further be improved by adding increased value to by-
224 
 
product or recycle streams via the solvent recovery service. The approach towards custom processing 
consists of initial feasibility studies to include environmental and health and safety and also equipment 
evaluation. This is followed by computerised process simulation and cost estimate. A suitable process 
can then be developed by the R&D lab which includes sample analysis methods and anticipated yields. 
This is then experimentally tested using the R&D pilot equipment, which serves as an indication of 
actual yields and any contamination issues. The product is then developed to the specification 
required, followed by quality control. A product sample can then be submitted to customer for 
approval or it can be processed on a large scale, using plant equipment. Any required plant 
modification are accounted for, final costing is done and then as before, sample can be submitted to 






chemistries available  
Typical raw materials 
handled 
Adsorption Esterification Acetal formation Acetic acid/Anhydride 
Batch reactions Etherification Acetylation Acrylonitrile 
Batch-to-continuous Epoxidation Aldol condensation Epichlorohydrin 
Catalyst regeneration Methylation/Methyl 
capping 
Alkylation Ethyl chloride 
Distillation Quaternization Amination Hydrogen peroxide 
Reactive distillation Transesterification Borationn Methyl chloride 
Extractions  Dehydration Phenol 
Filtration  Diels-Alder Toluene diisocyanate 
Fixed-bed reaction  Epoxidation  
Molecular sieve 
treatment 
 Hydrolysis  
Solvent recovery  Isomerization  
  Oligomerization  
  Oxidation  
  Phase transfer catalysis  
  Polymerization  
Table 11.1. Custom processing options available to customers by Chemoxy (Chemoxy Custom Processing 2018). 
11.1.2 Solvent recovery 
Chemoxy offer a wide range of solvent recovery solutions, they have expertise in the recovery and 
recycling of a wide range of streams and by-products from across multiple manufacturing sectors. 
Solvent recovery can be defined as the process of extracting useful products from waste/by-product 
solvents generated during the manufacture of a desired product. If extracted, these chemicals can be 
recycled back into processes, reducing the need to generate new solvents, while also reducing waste 
and extracting potentially hazardous substances. Solvent recovery can be achieved using a few 
methods, which include fractionation, azeotropic distillation and extractive distillation (Chemoxy 




Figure 11.1. Solvent recovery process summary showing potential outcomes as employed by Chemoxy (Chemoxy 
Solvent Recovery 2018). 
 
There are multiples types of solvents that can be recovered on site by Chemoxy. These include: 
• Alcohols 
• Hydrocarbons 
• Aromatic solvents 
• Halogenated solvents 
• Ketones 
• Esters 
• Organic acids 
• Amines 
 
11.1.3 Performance products  
Chemoxy also has a line of their own performance products which feature low toxicity, 
environmentally-friendly solvents. These have a variety of applications in adhesives, architectural 
coatings, automotive coatings, cleaners, coatings, coil coatings, compact discs, fragrance and 
flavouring, home care, inks, leather and soil stabilisation and oilfield chemicals.  
11.1.4 Distillation 
One of the most routinely done processes in the department is distillations. Distillation is the main 
process used to separate liquid mixtures and it is based on the differences in the boiling points or 
relative volatility of the components. The mixture of liquids can be heated which forces the different 
components of different boiling points into the gaseous state. The vapour can then be channelled into 
a condenser. There are various types of distillations used on the basis of the properties of the 
reactants/products. These include but are not limited to: fractional distillation, steam distillation, 
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vacuum distillation, air-sensitive vacuum distillation, short path distillation, zone distillation, 
azeotropic distillation, membrane distillation and reactive distillation (Kiss 2013).  
11.1.4.1 Reactive distillation 
Reactive distillation is a technique in which the catalytic chemical reaction and distillation 
(fractionation of products and reactants) occurs simultaneously in a single apparatus. This technique 
can be classified as a process intensification technology and in the literature this integrated technique 
can be referred to as catalytic distillation or reaction with distillation. Catalytic distillation can be 
defined as a process in which a heterogeneous catalyst is localised at a particular position in a 
distillation column. Reactive distillation is an umbrella term for catalytic distillation as under reactive 
distillations, the catalyst being homogenous or heterogeneous is not distinguished (Sakuth 2012). The 
focus of this report is catalytic distillation because it is the main established method at Chemoxy. 
Catalytic distillations offer a major advantage in the way of eliminating equilibrium limitations of 
conversion by continuous removal of product from the reaction mix. Le Chatelier’s principle states that 
if a dynamic equilibrium is disturbed by changing conditions, the position of the equilibrium will shift 
to counteract said change. The application of Le Chatelier’s principle here drives the reaction forward 
by increasing the concentration of reactants on one side and decreasing the product concentration of 
the other side owing to its continuous removal.  
 
Alongside increased conversion, the following benefits arise from the use of catalytic distillations 
(Podrebarac et al. 1997): 
• Low capital investment as 2 process steps are combined and carried out in the same 
equipment.  
• Catalytic distillation with exothermic reactions offer their own subset of advantages, the 
reaction heat can be used to vaporise the surrounding liquid which offers simple and reliable 
temperature control and also the integration of reaction heat in the distillation process 
reduces boiler duty by saving energy. 
• Product selectivity improved due to removal of desired component as the probability of 
consecutive reactions is lowered.  
 
As with any process, there are certain drawbacks to the catalytic distillations technologies: 
• Catalytic distillations can only be employed in circumstances where the temperature window 
of the vapour-liquid equilibrium is equivalent to the reaction temperature. This can be altered 
by changing the column operating pressure.  
• The thermal stability of the catalyst can limit the upper operating temperature. 
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• Wet catalyst pellets are required, hence the reaction is entirely limited to being performed in 
the liquid phase only.  
• Since a catalytic distillation column is packed, it can be very expensive to change the catalyst 
and hence the requirement for the catalyst to have a long lifetime is critical.  
• Catalytic distillation technologies can be mathematically difficult to model which can 
complicate the scale up from the research lab to full plant production. 
 
Industrial application of reactive distillations has rapidly developed in the last 25 years. In 2007, there 
were more than 150 industrial scale reactive distillations operated worldwide at capacities varying 
from 100 to 3000 kilo tonnes per year (Harmsen 2007). Since their development, reactive distillations 
have been favoured by industry and there are key business interests behind it being the case. Variable 
cost, capital expenditure and reduced energy requirement all favour use of reactive distillations as the 
above mentioned factors are reduced by 20% or more in comparison to the set-up of a reactor and 
then distillation. There are also environmental factors to consider such as lower emissions and also 
social factors, such as improvements on health and safety (Harmsen 2007).  
 
11.1.4.2 Membrane distillation 
Membrane distillation refers to a thermally driven separation process in which only vapour molecules 
transfer through a microporous hydrophobic membrane. The driving principle behind this distillation 
technique is that the hydrophobic membrane temperature difference induces a vapour pressure 
difference. This process is of great interest to industry as it has multiple applications across fields such 
as desalination, wastewater treatment and in the food industry. Membrane distillation applications in 
desalination are of obvious interest as they contribute towards tackling the global issue of increased 
supply and demand of fresh water. As mentioned earlier, this separation process is driven by the 
vapour pressure difference existing between the porous hydrophobic membrane surfaces. Use of 
membrane distillation has many advantages, the operating temperatures are not high compared to 
those seen in conventional processes. Membrane distillation systems also have the feasibility to be 
combined with other separation processes to create an integrated separation system such as 
ultrafiltration. Further enhancing the appeal is the ability of membrane distillation to utilise alternative 
energy resources such as solar energy. The main competitive application of membrane distillation is 
desalination of sea water and it also has effective applications for removing organic and heavy metals 
from waste water. A further example of application is using membrane distillation to treat radioactive 
waste where the product is considered safe to be discharged into the environment after treatment 




One of the routine techniques done in the R&D department at Chemoxy is esterification. Esters are a 
functional group commonly found in organic chemistry. It is characterized by a carbon bound to three 
other atoms of which a single bond is to a carbon, a double bond to an oxygen and a single bond to 
another oxygen. The single oxygen is bound to another carbon (RCOOR’). Esters are most commonly 
derived by reacting together carboxylic acids with alcohols in most cases under acid catalysis which 
also forms water as a by-product. 
K= [Ester] [water] / [acid] [alcohol] 
Their names are derived from the parent alcohol and acid based on the name of the acid followed by 
the suffix ‘-oate’. For example, an ester derived from butanol and propionic acid is butyl propionate. 
 
With respect to bulk productions, ethylene terephthalate manufacture is the most important ester 
producing process. It’s produced either by direct esterification of the terephthalic acid and ethylene 
glycol or by the transesterification of dimethyl terephthalate with ethylene glycol, the former being 
produced by direct esterification of terephthalic acid and methanol (Chem Eng News 1991). Other 
esters of bulk production interest are vinyl acetate, methyl methacrylate and dioctyl phthalate. The 
acetates of common alcohols are readily available commercially and are used in diverse industries such 
as coatings, flavouring components and additives in perfumes (Kirk and Othmer 2000).  
 
As mentioned previously, esters are most commonly derived by reacting together carboxylic acids with 
alcohols in most cases under acid catalysis which also forms water as a by-product. In many cases this 
equilibrium is affected by the proportion of reactants, the temperature and any salt presence may also 
affect it (Trimble and Richardson 1932). As there is an equilibrium present, usually esterification 
reactions do not go to completion. To achieve conversions close to 100%, the equilibrium has be 
shifted in favour of product formation and this can be done by either removing the formed ester or 
water via a variety of distillation methods providing that the reaction is equilibrium limited and not 
rate limited. There are other methods of removing the distillation products such as reactive extraction 
and reverse osmosis (Hirata et al. 1987). The ease at which the esters formed can be removed from 
the reaction mix via distillation depends on their volatility. High volatility esters have a lower boiling 
point than those of corresponding alcohols, therefore can be easily separated from reaction mix using 
distillation. Medium volatility esters are capable of removing the water formed by distillation and low 
volatility esters can be extracted by the removal of water as a binary azeotrope mixture with the 
alcohol. It is to be noted here than an azeotrope, also known as a constant boiling point mixture, is a 
mixture of two or more liquids whose proportions cannot be altered or changed by simple distillation 
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as it has the same proportions of constituents as the reaction mixture. Binary azeotropes may form 
between the alcohol and water, the alcohol and ester, and the ester and water. Ternary azeotropes 
are also possible with the alcohol, ester and water and these generally have the lowest boiling points. 
Azeotropes can exist as homogeneous, where the liquids are miscible and form a solution, or as 
heterogeneous where the liquids are immiscible and form two liquid phases. An entrainer in the form 
of a water-insoluble solvent might also be necessary to increase the amount of distilled water in case 
of immiscible azeotropes (Kirk and Othmer 2000). 
The process of esterification is carried out by refluxing the reaction mixture until the majority of the 
carboxylic acid has reacted with the alcohol and the water has been separated off. Either the water or 
ester can be removed via distillation depending on the properties mentioned above. There is no 
universally applicable process for a given esterification, in order to obtain maximum yield, it has be 
optimized based on multiple factors dependent on reaction components.  
 
11.1.5.1 Enzymatic esterification 
Multiple sectors of industry have increased their interest in esters owing to their flavour properties. 
Flavour esters are versatile and serve as important ingredients in food, beverages, cosmetics, 
pharmaceuticals, chemicals and personal care products (Akacha and Gargouri 2015).  Flavour esters 
contain an aromatic ring are known as aromatic esters. These are widely naturally occurring and can 
be extracted via natural routes directly from plants or synthetically made in the lab. However, natural 
extraction is not fit for industrial applications as source is dependent on season and climatic factors 
(Badgujar et al. 2015). Chemical production of aromatic esters also has several disadvantages such as 
use of hazardous chemicals, toxic solvents, high temperatures and pressure, high costs, excessive 
consumption of energy, by product removal and possible corrosion of equipment. Moreover, the final 
products cannot be legally labelled as natural and may contain trace toxic impurities which may result 
in it being unsuitable for human consumption, and therefore the process can be industrially 
disadvantageous (Khan and Rathod 2015).  
 
A combination of the factors above makes a biotechnological (microbial and enzymatic) approach to 
the production of esters very appealing. It is a useful sustainable approach with several offered 
advantages such as high specificity, high yields in mild reaction conditions, reduced by-product 
formation, biocatalyst recycling and overall reduced production costs (Ferraz et al. 2015). Additionally, 
esters produced biotechnologically are identified as natural thereby attracting certain industries and 
satisfying consumer interests (Tomke and Rathod 2015). Furthermore, Chemoxy and Proteus are two 
companies under management by Novacap, with Proteus’s main interest being biocatalysis and 
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industrial biotechnology. Under their shared parent company, Chemoxy and Proteus are looking to 
develop partnerships to set up large scale biobased productions of commodities.   
 
11.2 Methods and Materials 
11.2.1 Materials    
All materials were provided by Chemoxy including propionic acid, n-butanol, pTSA, malic acid, n-




Starting materials were placed into a 3-necked round bottomed flask (3L) along with metal coupons 
identical to the internal lining of the industrial plant where the eventual large scale production would 
occur. This allows to check for any out of normal range corrosion directly stemming from the reaction 
procedure. The contents of the round bottomed flask were then placed into the base mantle, heat 
applied and brought to boil gently. The reactants in the base react together to form product and water 
as a by-product. The reaction can be driven to completion by removing the water from the reaction 
mixture. The system is closed off with a condenser so the boil up in the column condenses at the top 
and drains back into the base ensuring any unreacted materials are constantly being fed back into the 
reaction mixture (Figure 11.2). The Dean & Stark (D&S) (removable glassware fitted onto column, used 




Figure 11.2. Distillation column in its typical setup, heat is applied to the 3 necked flask via the mantle it is placed 
in (2a). 2 temperature probes set up, one typically measuring the base temperature and the other measuring the 
temperature at the top of the column. For the first pass of the reaction, which involves an esterification, the 
overheads are fitted with a D&S (2b, circled) to collect water from the esterification reaction. (Overheads here 
refer to the glass equipment fitted on top the column which differs depending on the type of reaction being 
carried out e.g. D&S.) 
 
11.2.2.2 Distillation 
After the esterification has been terminated, the flask and its contents were placed onto the base 
mantle and heat applied again. The distillation protocol uses the same column as shown in Figure 11.2, 
however the overheads were changed as shown in Figure 11.3. The condenser was fit with a reflux 
head which allows for the reflux ratio to be adjusted either to total, meaning all condensed 
components are drained straight back down the column into the base, or the reflux controller can be 
opened to allow a certain ratio of components to go into the collection flask. A Perkin triangle was also 
added onto the system. By the use of taps, this specialised piece of equipment allows for the isolation 
and collection of fractions under vacuum distillation without disturbing the vacuum being applied to 
the main distillation column.  




Figure 11.3. Standard distillation setup with a reflux condenser, Perkin triangle and collection flask for collecting 
fractions. The column is the same for carrying out all reactions with just the overheads being altered depending 
on the type of reaction. 
11.2.2.3 Gas Chromatography (GC) 
All fractions distilled off the column and some base samples were put through the GC to isolate 
components and determine their % in the fraction. Individual methods were set up for the 2 
esterification products as follows. n-Butyl propionate samples were analysed using hydrogen at a 
pressure of 5.0 psig.  The injector and detector temperature was set to 240°C and 260°C respectively. 
A standard sample size of 0.1µl was loaded into the GC for all fractions analysed. The programme 
temperature increased from 60°C (isolated for 2 mins) to 240°C (isolated for 6 mins) at an increase of 
15°C/min. The total run time for one sample was 20 minutes. 
Di-n-propyl malate samples were analysed using hydrogen at a pressure of 5.0 psig.  The injector and 
detector temperature was 260°C. A standard sample size of 0.1µl was loaded into the GC for all 
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fractions analysed. The run temperature ranged from 50°C to 260°C at an increase of 15°C/min with a 
final isolated hold of 19.5 minutes at 260°C. The total run time for one sample was 30 minutes. 
11.2.2.4 Acid number 
Reaction mixtures are also analysed throughout to check progress of product formation via acid 
number. As one of the reactants in both esterifications is an acid, a low acid number is a good indication 
of reaction completion. Acid numbers are also tightly monitored to ensure customer specifications are 
met for the final product. An automated titration system was used to determine all acid numbers, this 
is the mass of potassium hydroxide (KOH) in milligrams that is required to neutralise one gram of 
chemical substance. This acid number could then be converted into % acid present in sample and 
further distillation steps could be determined dependent of whether or not the % acid present in 
sample is within acceptable range.  
 
11.3. Results and Discussion 
The overall objective for the placement was to synthesise 2 industrially important products as 
mentioned earlier, n-butyl propionate and di-n-propyl malate. The experimental approach for was an 
esterification followed by a distillation, the details of which are in the previous section.  
11.3.1 Synthesis of n-Butyl Propionate 
n-Butyl propionate is a water-white (approaching water in colourlessness and clarity) liquid with an 
apple-like odour, its main industrial application lies in making perfumes, flavourings. Previously, similar 
esters had been successfully produced in the R&D lab before production on a large scale therefore no 
major issues were expected during manufacture. n-Butyl propionate is produced by various industries 
and depending on the final application, there is a product specification which the product has to 
adhere to. The following specification is from Eastman which is a specialist chemical manufacturer. 
The final product reported here is produced and analysed keeping in mind the following specification. 
Chemoxy did not have a product specification for this product, hence a specification available in the 
public domain by Eastman was used as a guide (Table 11.2).  
Property Limits 
n-Butyl propionate % 99.5 minimum 
n-Butanol % 0.5 maximum 
Water % 0.05 maximum 
Acid as Propionic % 0.01 maximum 
Visual colour, pcs 10 maximum 
Appearance  Clear and free of suspended matter 
Table 11.2. Product specification for n-butyl propionate.  
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A standard protocol was used with 2 part reactions, the first being esterification and the second being 
distillation of pure product. The esterification reaction is as follows: 
Propionic acid + n-butanol (in excess)  n-butyl propionate + water 
Prior to charging the reactants to the flask and commencing the reaction, the azeotropes in the 
reaction mix needed to be identified. As mentioned in the introduction, this information is needed to 
determine if an entrainer needs to be added to the reaction mix. Azeotrope data was obtained from 
databases online and there were 2 azeotropes identified, the details of which are listed below.  








n-Butanol 117.7 93 55.5         79.9            7.7 
Water 100 44.5 20.1 92.3 
 








Propionic acid 141.6 99.9 17.7 Miscible 
Water 100 82.3 
Table 11.3. 2 azeotropes identified in the reaction mixture, one consisting of n-butanol and water and second of 
propionic acid and water. The boiling points of both azeotropes are relatively close with the former being 93° C 
and the latter being 99.9° C.  
 
11.3.1.1 Preparation of crude n-Butyl Propionate 
 
n-Butanol (1208g), propionic acid (1051.6g), pTSA (4.531g) and 1.6g of corrosion inhibitors were 
charged into a 3L three necked flask and placed under a 30 theoretical plate column fitted with a D&S. 
Heat was applied and the mixture was heated to total reflux. Water formed in the reaction was 
removed as a lower layer from the D&S. The reaction was continued and the overheads appearance 
and temperature were monitored. Once the system appeared dry at the top of the column, the 
reaction was continued for a further 2 hours and then heat was turned off. Upon cooling, the base was 
analysed for acidity. At this point sodium carbonate (powder, 3g, in excess) was added to neutralise 
the acidity present. The neutralisation was effective at neutralising the pTSA strong acid but not the 








Time Base T (°C) Top T (°C) D&S lower layer Action/Observations 
13-09-18 12:04    Heat turned on 6 
13:20 104   Boiling in base 
13:32 102.3 92.9  Refluxing 
15:24 110.1 93 D&S LL 97g  
16:24 132.8 93 D&S LL 88g  
17:04 143.1 93  Heat off 
Cloudy light yellow 
in base 
14-09-18 08:36    Heat turned on 6 
11:10 144.2 113.7  Overheads appear 
dry 
11:50 144.9 112.9   
12:30 145.1 111.6   
13:00 145.1 111.2  Heat off 
17-09-18 14:11   D&S LL 79.2g 
D&S UL 44.55g 
Base sample taken 
Acidity 0.055% as 
propionic acid 
Table 11.4. Timeline of esterification reaction.  
 
As mentioned previously, there are 2 azeotrope identified (Table 11.4) which is of butanol and water 
(bp of 93° C) and propionic acid and water (bp of 99° C). As the reaction proceeded, water was formed 
as the by-product as well as the desired ester as it is a condensation reaction. This water formed an 
azeotrope with the reactant n-butanol which had been added in excess to drive the reaction forward. 
This water and n-butanol azeotrope boiled up through the column before any other component. The 
water also formed an azeotrope with the propionic acid but this had a higher boiling point than that 
of the butanol-water azeotrope so it moved up the column after the butanol-water azeotrope. The 
experimental strategy employed here was to drain the D&S less often as the butanol-water azeotrope 
is non miscible so it split into an upper layer of butanol and lower layer of water. By keeping the D&S 
full, the butanol in the upper layer was drained back into the base containing the catalyst, thus forcing 
the reaction forward. There were advantages to this as the excess butanol was kept feeding back into 
base, moreover the butanol-water azeotrope also occupied the space in the middle and top of the 
column which stopped the propionic acid-water azeotrope from being pulled into the D&S. This was 
an added advantage as the propionic acid and water azeotrope is miscible so it would have required 
additional processing to strip any carried over propionic acid and feed it back into the base rather than 
easy separation via upper and lower layers. 
  
The boiling points of all the individual reaction components are much higher, butanol boils at 117.7°C, 
propionic acid at 141.6°C and the product of butyl propionate, boils at 146°C and by-product of water 
boils at 100°C. Given the molar ratio of reaction is 1 mole of reactants give 1 mole of product then 
using Mass = moles x Mr, the amount of water expected if reaction has gone to completion was 
calculated. Another good indication for the reaction to have gone to completion was the base 
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temperature reaching around the boiling point of the ester (146°C). The temperature at the top of the 
column was higher than both of the azeotropes which concluded that majority of the azeotropes have 
been pulled out of the system. There were no 2 phase liquid droplets seen in the overheads, as these 
are indicative of water in the system, the system was declared as being dry and all in 1 phase. At this 
stage, the reaction mix was left to react for another 2 hours. 
  
After the base had cooled down, a base sample was removed to determine its acid number. There was 
a strong acid catalyst in the base but all the propionic acid was expected to have been consumed during 
the esterification. The acid number showed that this was not the case as there was still 0.055% acidity 
left as propionic acid (Table 11.4). This posed a slight problem as this propionic acid was now to be 
removed during the distillation before the pure product can be distilled off. This acid number was done 
with the main purpose of checking how much neutralising agent was needed to neutralise it before 
the distillation to get off pure product. After determining the acid number, the amount of carbonate 
required to neutralise it was calculated and added and the distillation was carried out. 
 
11.3.1.2 Distillation of crude n-butyl propionate 
The distillation was carried out in a 3L three necked flask under a 30 theoretical plate column fitted 
with a reflux controller as the overheads. The reflux controller was set to total reflux as the system was 
brought to boil. At this point, it was allowed to reflux in the overheads for around 30 minutes. The first 
part of the distillation focused on the removal of the excess n-butanol and any unreacted propionic 
acid. The butanol was removed without much issue at a reflux ratio of 7:1, however the acid number 
tests showed the propionic acid was being removed from the reaction at a very slow rate due to the 
close boiling points.  Removing the unreacted propionic acid was slightly more difficult, this was carried 
out at a reflux ratio of 10:1. When the distillate was in specification the reflux ratio was adjusted to 1:1 
and high purity n-butyl propionate was collected down to a small heel.  
Time  Base T (°C) Top T (°C) Reflux ratio Fraction/Mass 
(g) 
Action/Observation 
18-09-18 8:55   Total  Heat turned on 5 
10:38 141.6 21.1 Total  Boiling in base 
11:24 143.2 22.0 Total  Column heat on 3 
12:00 144.7 100.3 Total  Heat 6 column heat 5 
Refluxing 
12:15   7:1   
12:38 145.2 115.2 5:1   
13.00 146 117.2 3:1   
14:34 147.8 132.3 10:1 F1 109.83g 0.14% Propionic acid 
15:52 147.9 133.7 10:1 F2 20.85g 0.49% Propionic acid 
16:54 148 138.3 10:1 F3 19.10g 0.26% Propionic acid 
17:19 148  Total  Heat off 
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Time Base T (°C) Top T (°C) Reflux ratio Fraction/Mass 
(g) 
Action/Observation 
19-09-18 8:30   Total   Heat turned on 6 
column heat 5 
9:40 147.6 23 Total  Boiling in base 
10:30  147.8 49.9 Total  Refluxing 
11.00  147.8 96 10:1   
11.17 147.9 138.7 10:1 F4 14.06g 0.2% Propionic acid 
11:45 147.8 142 10:1   
12:05 147.8 143.5 10:1 F5 16.09g 0.14% Propionic acid 
12:28 147.8 144.2 Total   
13:04 147.8 143.9 10:1   
13:40 147.9 144.5 10:1 F6 17.01g 0.27% Propionic acid 
14:48 147.9 144.2 10:1 F7 16.86g 0.047% Propionic acid 
15:48 147.9 144.3 10:1 F8 14.89g 0.037% Propionic acid 
16.42 148 144.5 10:1 F9 13.94g 0.033% Propionic acid 
16:45 148 144.5 Total  Heat off 




8:55   Total  Heat turned on 6 
column heat 5 
10:07 148.2 22.3 Total  Boiling in base 
10:45 148.3 115 Total  Refluxing 
11.00  148.4 140 10:1   
11:40 148.4 144.4 10:1 F10 13.63g 0.037% Propionic acid 
12:44 148.3 145.3 10:1 F11 18.93g 0.023% Propionic acid 
12:53 148.2 145.4 1:1   
13:09 148.3 145.8 1:1 F12 74.41g 0.011% Propionic acid 
14:12 148.3 146 1:1 F13 188.62g 0.0087% Propionic 
acid 
14:42 148.3 146.1 1:1 F14 105.83g 0.0054% Propionic 
acid 
 
15:50  148.3 145.8 1:1 F15 252.38g 0.0054% Propionic 
acid 
16:40 148.4 146.3 1:1 F16 237.93g 0.005% Propionic acid 
17:10 148.4 146.2 1:1 F17 160.65g 0.006% Propionic acid 
17:18 148.3 145.9 Total  Heat off 
21-09-18 8:20   Total  Heat turned on 6 
column 5 
9:02 148 17 Total  Boiling in base 
9:44 148 79.5 Total  Refluxing 
10:10 148.1 140.4 3:1   
10:27 148.1 143.3 1:1 F18 14.64g 0.0245% Propionic 
acid 
11:35 147.7 145.2 1:1 F19 225.45g 0.005% Propionic acid 
12:30 147 145.3 1:1 F20 229.89g 0.004% Propionic acid 
Table 11.5. Timeline of distillation reaction, pass 2 to obtain pure product of n-butyl propionate. The reflux ratio 
is kept high and smaller fractions are collected to monitor the acidity. Once the acidity is low enough, the reflux 







11.3.1.3 GC analysis of distilled fractions 
All fractions obtained from the distillation were put through the GC for analysis. All the samples were 
checked for acidity to monitor the propionic acid levels, butanol and n-butyl propionate were 
monitored via GC. 
Fraction  Mass (g) % n-butanol % n-butyl 
propionate 
% GC lights % GC heavies 
1 109.83 90.29 7.1 92 n/d 
2 20.85 12.16 85.79 14.21 n/d 
3 19.10 1.5 97.1 2.84 n/d 
4 14.06 0.46 98.4 1.56 n/d 
5 16.09 0.06 99.4 0.59 n/d 
6 17.01 0.037 99.5 0.46 n/d 
7 16.86 0.02 99.7 0.3 n/d 
8 14.89 0.018 99.79 0.21 n/d 
9 13.94 0.016 99.83 0.16 n/d 
10 13.63 0.00997 99.7   
11 18.93 0.0178 99.91   
12 74.41 <0.01 99.73   
13 188.62 <0.01 99.98 0.02 n/d 
14 105.83 <0.01 99.99 0.006 n/d 
15 252.38 <0.01 99.99 0.003 n/d 
16 237.93 <0.01 99.98 0.002 0.02 
17 160.65 <0.01 99.98 0.0027 0.02 
18 14.64 0.0469 99.9   
19 225.45 <0.01 99.99 n/d 0.004 
20 229.89 <0.01 99.94 0.0034 0.061 
Table 11.6. Each fraction from the distillation of crude n-butyl propionate was analysed via GC. GC lights refer to 
any components coming off before the main product of interest, in this case n-butyl propionate (this also includes 
any unreacted reactant such as butanol in this case). GC heavies refer to any components coming off after the 
product of interest. 
 
After the product was on specification in all the analysis (acidity, %purity), the final fractions were 
collected in larger amounts and analysed to confirm all samples were still on specification. After 
confirmation of this, the fractions which fall under the specification were pooled together and a 
composite sample was made and analysed for acidity and purity by GC as well checking the colour and 
water content as well. 
11.3.1.4 Composite sample 
A sample was made by combining fractions 7-17, 19 and 20 (1553.42g). The analysis was as follows: 
Test Specification Result 
Water % 0.0500 Maximum 0.01 
Acid as propionic % 0.0100 Maximum 0.005 
n-Butanol % 0.50 Maximum <0.01 
n-Butyl Propionate % 99.50 Minimum 99.97 
Visual colour, pcs 10 Maximum 3 
Appearance Clear and Free of Suspended 
Matter 
Pass 
Table 11.7. Analysis of n-butyl propionate in comparison to specification.  
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The final product fell well within the specification range, the composite could now be sent off to 
potential customers for analysis and then be scaled up as required on the plant.  
 
11.3.2 Synthesis of Di-n-propyl malate 
Previously, the following esters had already been made by the R&D department at Chemoxy: 
• Di-isopropyl malate 
• Di-isobutyl malate 
• Di-n-butyl malate 
The latter proved rather difficult to synthesise due to product breakdown and the need for a second 
pass of the distilled product. It was decided that a previously unattempted malate ester could be 
attempted, di-n-propyl malate (DnPM), the reaction for which is as follows. 
Malic acid + n-propanol (in excess)  Di-n-propyl malate + water 
It is to be noted here that toluene was added into the reaction with malic acid and n-propanol as the 
entrainer to separate out the water into layers in the D&S as the azeotropes are immiscible. 
As with the n-butyl propionate, before all the reactants are charged to the flask and the reaction is 
started, the azeotropes in the reaction mix needed to be identified. This information was found in 
databases online and is detailed below. 
Compound Boiling point/°C Azeotrope 
b.p./°C 




Compound Boiling point/°C Azeotrope 
b.p./°C 
Toluene 110.6 85 
Water 100 
 
Compound Boiling point/°C Azeotrope 
b.p./°C 
n-Propanol 97 88.1 
Water 100 
 
Compound Boiling point/°C Azeotrope 
b.p./°C 
n-Propanol 97 92.6 
Toluene 110.6 
Table 11.8. 4 azeotropes were identified from the reaction mix. There was no information on the existence of an 
azeotrope between malic acid and di-propyl malate. 
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The azeotropes were identified as listed in Table 11.8, however not all azeotropes are available in 
databases. Information could not be sourced about the presence of an azeotrope between the 
reactant, malic acid and the product formed, di-n-propyl malate. This does not necessarily mean that 
it does not exist, it just has not been reported at that given time. Only if experimental analysis has 
shown that an azeotrope doesn’t form, it can be reported as ‘non azeotrope’.  
11.3.2.1 Preparation of crude di-n-propyl malate 
n-Propanol (1271.8g), malic acid (975.90g), toluene (185.160g) and XSA (8.185g) as the catalyst were 
charged into a 3L three necked flask and placed under a 30 theoretical plate column fitted with a D&S. 
Since the malic acid was added as a powder, heat was applied and the mixture was gently heated to 
avoid any bumping and to allow the reagents to form a homogenous solution. Until all the reactant in 
powder form had dissolved into solution, gentle heating in the base was essential as too much heat 
could cause heat spots in the base of the flask which on occasion could have shot up the length of the 
column and potentially damage equipment. When all of the solids had been dissolved/partially 
reacted, the heat source was increased and the water formed in the reaction was removed by the D&S. 
The reaction was to be continued until the acid no. in the base was <2mgKOH/g. Actual acid number 
at termination of reaction, base sample 3 (BS3), (Table 11.9) was 2.22mgKOH/g. The reaction was 
deemed complete once no more water was collecting in the D&S. A total of 605.71g (D&S and base 
samples) was removed from the system. At this point, neutralising agent (25% molar excess) was added 














Time Base T (°C) Top T (°C) D&S lower layer Action/Observations 
23-10 9:30    Heat on 2 
14:54 125 21.2  Heat 3 
15:10 141.4 21.1  Malic acid in solution 
15:30    Heat 5 column 3 
15:45 98.5 80.8  Boiling, Refluxing 
16:25 99.7 80.9  D&S full, cloudy with 
no distinct layers 
16:40 99.8 80.9  D&S not drained, heat 
off, straw yellow base 
24-10 8:50   BS1 29.07g Heat 4 column 3 
9:25 41.5 20.5 D&S1 22.52g  
11:00    Boiling in base, small 
solids of Malic acid 
11:20 98 80.9  Refluxing 
13:10 106.5 80.9 D&S2 59.28g  
13:52 109.8 81 D&S3 50.57g  
14:30 114.3 84.7  Dry overheads 
15:30 117.4 80.9 D&S4 91.34g Droplets seen in O/H 
16:07 120.7 91.4 D&S5 50.36g Dry overheads again, 
Layers seen in D&S 
16:30 122.8 87.8  D&S layers cloudy 
Heat off, D&S not 
drained 
25-10 9:00   BS2 24.25g 
D&S6 23.22g 
D&S7 90.09g 
2 layers in the D&S, 
drained 
14:50    Heat on 5 column 3 
16:00 121.6 79.8  Boiling in base 
16:18 127.8 83.4  Refluxing 
17:05 132 94.4 D&S8 34.26g  
18:35 132.7 70.6  Heat off 




Table 11.9. Timeline of esterification reaction. 
11.3.2.2 Distillation of crude di-n-propyl malate (Pass 1) 
 
After adding neutralising agent into the base to neutralise all acidic species, the flask was placed under 
a 30 theoretical plate column fitted with a reflux controller and a Perkin triangle as the overheads. The 
first part of the distillation was to strip off the excess n-propanol and toluene. This was done at 
atmospheric pressure while gradually pulling in the vacuum to a final pressure of 50 mm Hg at a reflux 
ratio of 10:1. The distillation was done under vacuum as the boiling point of the product is too high to 
safely carry out distillation at atmospheric pressure. By doing the reaction under vacuum, the boiling 
points of the reaction components were decreased, thereby achievable under standard lab conditions. 
When the majority of n-propanol/toluene had been removed, the vacuum was pulled in further to a 
final pressure of 10 mm Hg to try and strip off any by-products formed, at a reflux ratio of 10:1 (Table 
11.10). However, product breakdown was suspected as indicated by the presence of fumarate and 
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other lighter boilers in the GC analysis of fractions (Table 11.9). The reflux ratio was changed to 1:3 








Fraction (g) Pressure 
(mm Hg) 
Action/observation 
29-10 12:15   Total  Atm Heat on 4 
14:45 128.2 73.6 Total  660 Refluxing 
15:05 128.5 73.4 10:1  660  
16:12 131.3 84.3 10:1 F1 26.55g 660 Heat off 
30-10 8:50   Total  660 Heat 4 column 2 
10:30 125.3 21.0 Total  660 Boiling in base 
10:36 131 72.1 Total  660 Refluxing 
11:15 133.4 81.9 10:1  660  
12:30 138.2 86 10:1 F2 26.39g 660  
13:50 146.3 86.5 10:1 F3 32.36g 660 Heat off 
14:20 101.5 58 Total  200 Heat 4 column 2 
14:55 104.2 59.9 1:1  200  
16:15 151.8 55.5 1:1 F4 132.09g 200 Heat off 
31-10 8:55   Total  200 Heat 4 column 3 
10:10 124.3 33 Total  200 Boiling 
10:30 158.8 49.3 1:1  50  
12:50 176.2 27.1 Total F5 36.87g 50 Heat off  
13:30     18 Heat on 
14:10 156.1 20.1 Total  18  
15:50 157.5 23.2 Total  8 Heat 6.5 column 6 
16:05 165.3 100 Total  8 Refluxing 
16:22 170.3 127.5 1:2  8  
16:38 171.6 127.2 1:1 F6 20.13 8 Solids in collection 
flask, Heat off 
1-11 8:45   Total BS4 9:35g   
9:00   Total  10 Heat 6.5 column 6 
9:45 135.5 19.8 Total  10 Boiling in base 
10:25 165.7 119.4 Total  10 Refluxing 
10:40 168.2 120.6 10:1  10  
11:35 172 121.5 10:1 F7 16.02g 10  
12:15 172.5 121.5 10:1 F8 16.7g 10  
13:45 171.1 129 10:1 F9 32.32g 10  
14:55 179.1 143.7 10:1 F10 15.49g 10  
15:10 176.9 145.1 5:1  10  
15:30 176.3 144.9 5:1 F11 22.19g 10  
16:20 176.1 145.2 5:1 F12 30.91g 10 Heat off 
2-11 8:20   Total  BS5 8.88g 10 Heat 7 column 6 
9:20 137.7 20.2 Total  10 Boiling in base 
10:20 170.2 126.3 Total  10 Refluxing 
10:30 172.3 132.5 5:1  8  
10:50 173.9 139.1 5:1 F13 13.48g 10  
11:45 175.2 145.7 5:1 F14 23.46g 10  
12:25 176.2 146.5 Total F15 27.4g  Atm Product breakdown, 
decided to flash over 
5-11 12:50   Total  12 Heat 7, column 6 
13.30 125.7 20.2 Total  10 Boiling in base 
14:10 169.8 124.6 Total  10 Refluxing 









Fraction (g) Pressure 
(mm Hg) 
Action/observation 
15:36 184.6 147.6 1:1 F15A 
247.14g 
10  
16:30 198.7 148.6 1:1 F15B 
264.50g 
10  
16:50 211 147.7 1:1 F15C 99.69g 10 Heat off 
Table 11.10. DnPM distillation pass 1, the first part of the distillation was to strip off the excess n-propanol and 
toluene. This was done at atmospheric pressure while gradually pulling in the vacuum to a final pressure of 50 
mm Hg at a reflux ratio of 10:1. After the removal of n-propanol/toluene, the vacuum was pulled in further to a 
final pressure of 10 mm Hg to try and strip off any by-products formed, at a reflux ratio of 10:1. 
 




% GC others 
1 26.55 36.45 63.28   0.27 
2 26.39 37.51 61.31   1.18 
3 32.36 41.89 57.94   0.17 
4 132.09 98.95 0.7   0.35 
5 36.87 99.15 0.06   0.79 
6 20.13 0.51 0.006 98.71  0.774 
7 16.02 0.85  98.41  0.74 
8 16.7 0.91  98.65  0.44 
9 32.32 0.99  96.15 2.35 0.51 
10 15.49 1.9  33.65 63.30 1.15 
11 22.19 1.97  8.66 88.71 0.66 
12 30.19 1.97  5.74 91.84 0.45 
13 13.48 1.93  19.36 77.17 1.54 
14 23.46 2.24  10.62 86.17 0.97 
15 27.4 1.86  7.16 90.54 0.44 
15ABC 611.33 1.34  3.69 94.14 0.83 
Table 11.11. GC analysis of all fractions collected during pass 1, the reaction was terminated and the reflux ratio 
was adjusted at 1:1 to collect large fractions of semi-pure DnPM so that it could be redistilled again. Fraction 6 
onwards, unwanted by product was collected as the majority of the fraction and fraction 10 onwards was when 
majority of the product was collected, however % of GC others started to increase from fraction 10 onwards and 
therefore the reaction was terminated. 
 
The product di-n-propyl malate can react with itself to form a dimer which can produce propanol again, 
it can also further dehydrate to form di-n-propyl fumarate which was the majority breakdown product 
as seen in fraction 6-9 (Table 11.11). Di-n-propyl malate can also cyclise to form maleic anhydride and 
it was discussed that if pass 1 of distillation had been continued, the next set of product breakdown 
would have included maleic anhydride which contributes to the increased acidity in the fraction 
collected. The acid numbers were therefore analysed for pass 1 fractions 12-14 and it showed the acid 
number increasing (data not shown) which was an indication of accelerated product breakdown, 
thereby the decision was made to flash over as much of the remaining product in the base and redistill 
it in distillation pass 2. The base temperature was cut off at 210°C and no more product was collected 
after the base had reached that temperature, this was for safety and product breakdown reasons. 
There was still a substantial amount of residues left in the base and these are suspected to be the 
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dimers and trimers formed during reaction. Before starting pass 2 of distillation to hopefully recover 
pure DnPM, a composite was made from fractions collected in pass 1.  
A composite was made by pooling together fractions 11-15 from the first pass; this was analysed by 
GC before starting the second pass. 




% GC others 
Composite 688.78 1.34 n/d 4.37 93.69 0.6 
Table 11.12. GC analysis of composite di-n-propyl malate.  
 
This composite had an acid number of 6.99 mgKOH/g and 0.17% water. 688.78g of the composite was 
charged to a 1.5L three necked flask and second pass of distillation carried out.  
 







Fraction (g) Pressure 
(mm Hg) 
Action/observation 
6-11 11:35   Total  8 Heat 5 column 3 
12:50 137 23 Total  8 Boiling in base 
13:30 146.7 70.8 Total  8 Refluxing 
14.00 152.8 98.8 10:1  8 Solids forming in 
condenser* 
14:15 153.3 107.7 10:1  8 System settled, 
collecting 
14:20 153.4 108.6 5:1  8  
16:30 158.9 133.5 5:1 F16 68.15g 8 Base straw yellow, 
Heat off 
7-11 9:00   Total  10 Heat 7 column 6 
9:55 142.9 21 Total  8 Boiling in base 
11:00 154 132 5:1  8 Refluxing 
11:50 164.5 134.4 5:1 F17 21.25g 8  
12:05 160.5 134.7 5:1 F18 12.82g 8  
12:45 165.7 134.7 5:1 F19 28.37g 8  
13:05 166 135.3 1:2  8  
14:05 161.9 135.5 1:2 F20 233.41g 8  
15:05 194.1 135.1 1:2 F21 227.45g 8 Small heel, base heat 
off, still collecting 
15:40 81.8 26.6 1:2 F22 27.59g 8 Vac off, heat off 
Table 11.13. Distillation pass 2 carried out as detailed above. *Solids formed suspected to be Maleic anhydride. 
 
During the second pass, as fraction 16 was being collected at a reflux ratio of 5:1, solids were observed 




Figure 11.4. Solids were observed being formed around the condenser, a heat gun was used to melt them and 
drain back into the base.  
 
The solids formed around the condenser were suspected of being maleic anhydride which was another 
breakdown product of the reaction. To confirm this, a sample was taken from fraction 16 and as well 
as doing the GC analysis as with all the other fractions, a GC-MS run was also done. This positively 
identified the sample to contain maleic anhydride. The distillation was continued with the expectation 
that majority of the maleic anhydride formed had been removed in fraction 16. Fractions were 
collected as standard and run through the GC for product % purity analysis (Table 11.14).  
 




% GC others 
16 68.15 0.088 43.12 52.4 4.392 
17 21.25 0.23 0.55 98.63 0.59 
18 12.82 0.2 0.22 99.29 0.29 
19 28.37 0.2 0.07 99.52 0.21 
20 233.41 0.07 0.02 99.89 0.02 
21 227.45 0.06 0.02 99.78 0.14 
22 27.59 0.05 0.05 99.77 0.13 
Table 11.14. GC analysis of all fraction collected during distillation pass 2. The highest % purity obtained for 
DnPM was in fraction 20 where 99.89% of the fraction collected was the product of interest. 
 
All the fractions collected during pass 2 were also analysed for acid number and water content as 
maleic anhydride contributes to acidity in the fractions, therefore acid numbers are a good indication 





Fraction Mass/g Acid number 
mgKOH/g 
% Water 
16 68.15 71.89 0.03 
17 21.25 7.62 0.04 
18 12.82 4.01 0.05 
19 28.37 2.96 0.05 
20 233.41 1.12 0.02 
21 227.45 2.07 0.02 
22 27.59 1.62 0.03 
Table 11.15. Fraction collected during pass 2 analysed for acid number and water content to monitor levels of 
product breakdown.  
 
A composite sample was made by combining fractions 17-22 (530.42g) for which the final analysis is 
as follows.  
Test Result 
Water % 0.02 
Acid number mgKOH/g 2.11 
 n-Propanol % 0.1 
Di-n-propyl fumarate % 0.04 
Di-n-propyl malate % 99.71 
Others % 0.15 
Colour, Hazen 2 
Table 11.16. Final analysis of di-n-propyl malate.  
 
The acid number is not ideal and is higher than desired but as with previously made similar esters, 
product breakdown is a big issue with malate esters.  
Malic acid is an expensive feedstock to start with and its addition to reactions in its solid form leads to 
a much long processing time. On a lab scale it is manageable but on a plant scale it can pose serious 
handling complications. In addition to this, product breakdown of malic esters means that specialised 
processes would have to be developed to make the ester more stable. Chemoxy mainly would use the 
malic esters as coalescing agents, however, the current feedstocks used to make their range of 
coalescing agents are much cheaper and stable than malic acid, and therefore there is no incentive to 
produce malic esters. If the feedstock (malic acid) could be obtained cheaply, then there may be an 
incentive there which is where biobased production strategies can be explored to give a sustainable 
solution.  
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12.1 pET30a Vector as supplied by GenScript 
 
 
12.2 GDH optimized sequence for expression in E. coli (Optimized Sequence Length:1158, GC%:53.82), with 























12.3 DHAD optimized sequence for expression in E. coli (Optimized Sequence Length: 1734, GC%:58.76), with 





























12.4 KDGA optimized sequence for expression in E. coli (Optimized Sequence Length: 924, GC%:53.27), with 






























12.5 AIDH optimized sequence for expression in E. coli (Optimized Sequence Length:1539, GC%:54.69) 



























12.6 MDH optimized sequence for expression in E.coli (Optimized Sequence Length:1335, GC%:57.29), with 






























12.7 Mass spectrometry protein identification of GDH, DHAD, KDGA, AIDH and MDH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
